
<html lang="en"     class="pb-page"  data-request-id="b9b53940-6144-4dbb-bd37-ca4717ffa3c8"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;article:article:10.1021/acs.jmedchem.0c00702;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text;issue:issue:10.1021/jmcmar.2020.63.issue-21"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Discovery of BIIB068: A Selective, Potent, Reversible Bruton’s Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases" /></meta><meta name="dc.Creator" content="Bin  Ma" /></meta><meta name="dc.Creator" content="Tonika  Bohnert" /></meta><meta name="dc.Creator" content="Kevin L.  Otipoby" /></meta><meta name="dc.Creator" content="Eric  Tien" /></meta><meta name="dc.Creator" content="Million  Arefayene" /></meta><meta name="dc.Creator" content="Judy  Bai" /></meta><meta name="dc.Creator" content="Bekim  Bajrami" /></meta><meta name="dc.Creator" content="Eris  Bame" /></meta><meta name="dc.Creator" content="Timothy R.  Chan" /></meta><meta name="dc.Creator" content="Michael  Humora" /></meta><meta name="dc.Creator" content="J. Michael  MacPhee" /></meta><meta name="dc.Creator" content="Douglas  Marcotte" /></meta><meta name="dc.Creator" content="Devangi  Mehta" /></meta><meta name="dc.Creator" content="Claire M.  Metrick" /></meta><meta name="dc.Creator" content="George  Moniz" /></meta><meta name="dc.Creator" content="Evelyne  Polack" /></meta><meta name="dc.Creator" content="Urjana  Poreci" /></meta><meta name="dc.Creator" content="Annick  Prefontaine" /></meta><meta name="dc.Creator" content="Sarah  Sheikh" /></meta><meta name="dc.Creator" content="Patricia  Schroeder" /></meta><meta name="dc.Creator" content="Karen  Smirnakis" /></meta><meta name="dc.Creator" content="Lei  Zhang" /></meta><meta name="dc.Creator" content="Fengmei  Zheng" /></meta><meta name="dc.Creator" content="Brian T.  Hopkins" /></meta><meta name="dc.Description" content="Autoreactive B cell-derived antibodies form immune complexes that likely play a pathogenic role in autoimmune diseases. In systemic lupus erythematosus (SLE), these antibodies bind Fc receptors on ..." /></meta><meta name="Description" content="Autoreactive B cell-derived antibodies form immune complexes that likely play a pathogenic role in autoimmune diseases. In systemic lupus erythematosus (SLE), these antibodies bind Fc receptors on ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="July 22, 2020" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.0c00702" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00702" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.0c00702" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.0c00702" /></link>
        
    
    

<title>Discovery of BIIB068: A Selective, Potent, Reversible Bruton’s Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.0c00702" /></meta><meta property="og:title" content="Discovery of BIIB068: A Selective, Potent, Reversible Bruton’s Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0017.jpeg" /></meta><meta property="og:description" content="Autoreactive B cell-derived antibodies form immune complexes that likely play a pathogenic role in autoimmune diseases. In systemic lupus erythematosus (SLE), these antibodies bind Fc receptors on myeloid cells and induce proinflammatory cytokine production by monocytes and NETosis by neutrophils. Bruton’s tyrosine kinase (BTK) is a non-receptor tyrosine kinase that signals downstream of Fc receptors and plays a transduction role in antibody expression following B cell activation. Given the roles of BTK in both the production and sensing of autoreactive antibodies, inhibitors of BTK kinase activity may provide therapeutic value to patients suffering from autoantibody-driven immune disorders. Starting from an in-house proprietary screening hit followed by structure-based rational design, we have identified a potent, reversible BTK inhibitor, BIIB068 (1), which demonstrated good kinome selectivity with good overall drug-like properties for oral dosing, was well tolerated across preclinical species at pharmacologically relevant doses with good ADME properties, and achieved &gt;90% inhibition of BTK phosphorylation (pBTK) in humans." /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta><meta name="twitter:description" content="Autoreactive B cell-derived antibodies form immune complexes that likely play a pathogenic role in autoimmune diseases. In systemic lupus erythematosus (SLE), these antibodies bind Fc receptors on myeloid cells and induce proinflammatory cytokine production by monocytes and NETosis by neutrophils. Bruton’s tyrosine kinase (BTK) is a non-receptor tyrosine kinase that signals downstream of Fc receptors and plays a transduction role in antibody expression following B cell activation. Given the roles of BTK in both the production and sensing of autoreactive antibodies, inhibitors of BTK kinase activity may provide therapeutic value to patients suffering from autoantibody-driven immune disorders. Starting from an in-house proprietary screening hit followed by structure-based rational design, we have identified a potent, reversible BTK inhibitor, BIIB068 (1), which demonstrated good kinome selectivity with good overall drug-like properties for oral dosing, was well tolerated across preclinical species at pharmacologically relevant doses with good ADME properties, and achieved &gt;90% inhibition of BTK phosphorylation (pBTK) in humans." /></meta><meta name="twitter:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0017.jpeg" /></meta><meta name="twitter:title" content="Discovery of BIIB068: A Selective, Potent, Reversible Bruton’s Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases" /></meta>
        
            <meta property="og:type" content="Article" /></meta>
        

        
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.0c00702"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/ke1q~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-6ee29527b3d8ff00a106.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00702">
            
        





































    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-12/achre4.2021.54.issue-12/20210615/achre4.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-6/amrcda.2021.2.issue-6/20210625/amrcda.2021.2.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-6/aabmcb.2021.4.issue-6/20210621/aabmcb.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-6/aaembp.2021.3.issue-6/20210622/aaembp.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-6/aaemcq.2021.4.issue-6/20210628/aaemcq.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-25/aamick.2021.13.issue-25/20210630/aamick.2021.13.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-6/aanmf6.2021.4.issue-6/20210625/aanmf6.2021.4.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-6/aapmcd.2021.3.issue-6/20210611/aapmcd.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-6/abseba.2021.7.issue-6/20210614/abseba.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-12/accacs.2021.11.issue-12/20210618/accacs.2021.11.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-6/acscii.2021.7.issue-6/20210623/acscii.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-6/acbcct.2021.16.issue-6/20210618/acbcct.2021.16.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-3/achsc5.2021.28.issue-3/20210524/achsc5.2021.28.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-12/acncdm.2021.12.issue-12/20210616/acncdm.2021.12.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-6/aesccq.2021.5.issue-6/20210617/aesccq.2021.5.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-6/aelccp.2021.6.issue-6/20210611/aelccp.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-6/aeecco.2021.1.issue-6/20210611/aeecco.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-6/aewcaa.2021.1.issue-6/20210611/aewcaa.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-5/afsthl.2021.1.issue-5/20210618/afsthl.2021.1.issue-5.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-6/aidcbc.2021.7.issue-6/20210611/aidcbc.2021.7.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-6/amlccd.2021.10.issue-6/20210615/amlccd.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-6/amlcef.2021.3.issue-6/20210607/amlcef.2021.3.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-6/amclct.2021.12.issue-6/20210610/amclct.2021.12.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-6/ancac3.2021.15.issue-6/20210622/ancac3.2021.15.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-25/acsodf.2021.6.issue-25/20210629/acsodf.2021.6.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-6/apchd5.2021.8.issue-6/20210616/apchd5.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-6/ascefj.2021.6.issue-6/20210625/ascefj.2021.6.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-25/ascecg.2021.9.issue-25/20210628/ascecg.2021.9.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-6/asbcd6.2021.10.issue-6/20210618/asbcd6.2021.10.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-25/ancham.2021.93.issue-25/20210629/ancham.2021.93.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-25/bichaw.2021.60.issue-25/20210629/bichaw.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-6/bcches.2021.32.issue-6/20210616/bcches.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-6/bomaf6.2021.22.issue-6/20210614/bomaf6.2021.22.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-24/cgeabj.2021.99.issue-24/20210628-01/cgeabj.2021.99.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-6/crtoec.2021.34.issue-6/20210621/crtoec.2021.34.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-12/chreay.2021.121.issue-12/20210623/chreay.2021.121.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-12/cmatex.2021.33.issue-12/20210622/cmatex.2021.33.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-6/cgdefu.2021.21.issue-6/20210602/cgdefu.2021.21.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-12/enfuem.2021.35.issue-12/20210617/enfuem.2021.35.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-12/esthag.2021.55.issue-12/20210615/esthag.2021.55.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-6/estlcu.2021.8.issue-6/20210608/estlcu.2021.8.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-25/iecred.2021.60.issue-25/20210630/iecred.2021.60.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-12/inocaj.2021.60.issue-12/20210621/inocaj.2021.60.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-6/jaaucr.2021.1.issue-6/20210628/jaaucr.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-25/jafcau.2021.69.issue-25/20210630/jafcau.2021.69.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-6/jceaax.2021.66.issue-6/20210610/jceaax.2021.66.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-6/jceda8.2021.98.issue-6/20210608/jceda8.2021.98.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-6/jcisd8.2021.61.issue-6/20210628/jcisd8.2021.61.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-6/jctcce.2021.17.issue-6/20210608/jctcce.2021.17.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-12/jmcmar.2021.64.issue-12/20210624/jmcmar.2021.64.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-6/jnprdf.2021.84.issue-6/20210625/jnprdf.2021.84.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-12/joceah.2021.86.issue-12/20210618/joceah.2021.86.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-24/jpcafh.2021.125.issue-24/20210624/jpcafh.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-24/jpcbfk.2021.125.issue-24/20210624/jpcbfk.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-24/jpccck.2021.125.issue-24/20210624/jpccck.2021.125.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-24/jpclcd.2021.12.issue-24/20210624/jpclcd.2021.12.issue-24.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-6/jprobs.2021.20.issue-6/20210604/jprobs.2021.20.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-25/jacsat.2021.143.issue-25/20210630/jacsat.2021.143.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-6/jamsef.2021.32.issue-6/20210602/jamsef.2021.32.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-25/langd5.2021.37.issue-25/20210629/langd5.2021.37.issue-25.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-12/mamobx.2021.54.issue-12/20210622/mamobx.2021.54.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-6/mpohbp.2021.18.issue-6/20210607/mpohbp.2021.18.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-12/nalefd.2021.21.issue-12/20210623/nalefd.2021.21.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-12/orlef7.2021.23.issue-12/20210618/orlef7.2021.23.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-6/oprdfk.2021.25.issue-6/20210618/oprdfk.2021.25.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-12/orgnd7.2021.40.issue-12/20210628/orgnd7.2021.40.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.0c00702&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.0c00702&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.0c00702&amp;href=/doi/10.1021/acs.jmedchem.0c00702" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 21</span><span class="cit-fg-pageRange">, 12526-12541</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/21" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.0c00579" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Drug Annotation</span><a href="/doi/10.1021/acs.jmedchem.0c01019" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of BIIB068: A Selective, Potent, Reversible Bruton’s Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Bin Ma</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bin Ma</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><span class="conrtib-corresp"><strong>*</strong>B.M.: email, <a href="/cdn-cgi/l/email-protection#caa8a3a4e4a7ab8aa8a3a5adafa4e4a9a5a7"><span class="__cf_email__" data-cfemail="2143484f0f4c406143484e46444f0f424e4c">[email protected]</span></a>; phone, 617-914-4955.</span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bin++Ma">Bin Ma</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3913-0545" title="Orcid link">http://orcid.org/0000-0002-3913-0545</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tonika Bohnert</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tonika Bohnert</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tonika++Bohnert">Tonika Bohnert</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Kevin L. Otipoby</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Kevin L. Otipoby</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Kevin+L.++Otipoby">Kevin L. Otipoby</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eric Tien</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eric Tien</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eric++Tien">Eric Tien</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Million Arefayene</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Million Arefayene</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Million++Arefayene">Million Arefayene</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Judy Bai</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Judy Bai</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Judy++Bai">Judy Bai</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Bekim Bajrami</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Bekim Bajrami</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Bekim++Bajrami">Bekim Bajrami</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eris Bame</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eris Bame</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eris++Bame">Eris Bame</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Timothy R. Chan</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Timothy R. Chan</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Timothy+R.++Chan">Timothy R. Chan</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael Humora</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Humora</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Humora">Michael Humora</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">J. Michael MacPhee</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">J. Michael MacPhee</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=J.+Michael++MacPhee">J. Michael MacPhee</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Douglas Marcotte</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Douglas Marcotte</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Douglas++Marcotte">Douglas Marcotte</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Devangi Mehta</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Devangi Mehta</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Devangi++Mehta">Devangi Mehta</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Claire M. Metrick</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Claire M. Metrick</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Claire+M.++Metrick">Claire M. Metrick</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">George Moniz</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">George Moniz</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=George++Moniz">George Moniz</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Evelyne Polack</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Evelyne Polack</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Evelyne++Polack">Evelyne Polack</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Urjana Poreci</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Urjana Poreci</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Urjana++Poreci">Urjana Poreci</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Annick Prefontaine</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Annick Prefontaine</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Annick++Prefontaine">Annick Prefontaine</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sarah Sheikh</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sarah Sheikh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sarah++Sheikh">Sarah Sheikh</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Patricia Schroeder</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Patricia Schroeder</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Patricia++Schroeder">Patricia Schroeder</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Karen Smirnakis</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Karen Smirnakis</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Karen++Smirnakis">Karen Smirnakis</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Lei Zhang</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Lei Zhang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Lei++Zhang">Lei Zhang</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Fengmei Zheng</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Fengmei Zheng</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Fengmei++Zheng">Fengmei Zheng</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Brian T. Hopkins</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Brian T. Hopkins</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Research & Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</div></div><span class="conrtib-corresp"><strong>*</strong>B.T.H.: email, <a href="/cdn-cgi/l/email-protection#4725352e2629692f28372c2e293407252e282022296924282a"><span class="__cf_email__" data-cfemail="583a2a313936763037283331362b183a31373f3d36763b3735">[email protected]</span></a></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Brian+T.++Hopkins">Brian T. Hopkins</a></span></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00702&amp;href=/doi/10.1021%2Facs.jmedchem.0c00702" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 21</span><span class="cit-pageRange">, 12526–12541</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">July 22, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>27 April 2020</li><li><span class="item_label"><b>Published</b> online</span>22 July 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 November 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.0c00702" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00702</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 <span class="NLM_copyright-holder">American Chemical Society</span></strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D12526%26pageCount%3D16%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DBin%2BMa%252C%2BTonika%2BBohnert%252C%2BKevin%2BL.%2BOtipoby%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D21%26contentID%3Dacs.jmedchem.0c00702%26title%3DDiscovery%2Bof%2BBIIB068%253A%2BA%2BSelective%252C%2BPotent%252C%2BReversible%2BBruton%25E2%2580%2599s%2BTyrosine%2BKinase%2BInhibitor%2Bas%2Ban%2BOrally%2BEfficacious%2BAgent%2Bfor%2BAutoimmune%2BDiseases%26numPages%3D16%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D12541%26publicationDate%3DNovember%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.0c00702"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3066</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">4</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.0c00702" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of BIIB068: A Selective, Potent, Reversible Bruton’s Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Bin&quot;,&quot;last_name&quot;:&quot;Ma&quot;},{&quot;first_name&quot;:&quot;Tonika&quot;,&quot;last_name&quot;:&quot;Bohnert&quot;},{&quot;first_name&quot;:&quot;Kevin&quot;,&quot;last_name&quot;:&quot;L. Otipoby&quot;},{&quot;first_name&quot;:&quot;Eric&quot;,&quot;last_name&quot;:&quot;Tien&quot;},{&quot;first_name&quot;:&quot;Million&quot;,&quot;last_name&quot;:&quot;Arefayene&quot;},{&quot;first_name&quot;:&quot;Judy&quot;,&quot;last_name&quot;:&quot;Bai&quot;},{&quot;first_name&quot;:&quot;Bekim&quot;,&quot;last_name&quot;:&quot;Bajrami&quot;},{&quot;first_name&quot;:&quot;Eris&quot;,&quot;last_name&quot;:&quot;Bame&quot;},{&quot;first_name&quot;:&quot;Timothy&quot;,&quot;last_name&quot;:&quot;R. Chan&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Humora&quot;},{&quot;first_name&quot;:&quot;J.&quot;,&quot;last_name&quot;:&quot;Michael MacPhee&quot;},{&quot;first_name&quot;:&quot;Douglas&quot;,&quot;last_name&quot;:&quot;Marcotte&quot;},{&quot;first_name&quot;:&quot;Devangi&quot;,&quot;last_name&quot;:&quot;Mehta&quot;},{&quot;first_name&quot;:&quot;Claire&quot;,&quot;last_name&quot;:&quot;M. Metrick&quot;},{&quot;first_name&quot;:&quot;George&quot;,&quot;last_name&quot;:&quot;Moniz&quot;},{&quot;first_name&quot;:&quot;Evelyne&quot;,&quot;last_name&quot;:&quot;Polack&quot;},{&quot;first_name&quot;:&quot;Urjana&quot;,&quot;last_name&quot;:&quot;Poreci&quot;},{&quot;first_name&quot;:&quot;Annick&quot;,&quot;last_name&quot;:&quot;Prefontaine&quot;},{&quot;first_name&quot;:&quot;Sarah&quot;,&quot;last_name&quot;:&quot;Sheikh&quot;},{&quot;first_name&quot;:&quot;Patricia&quot;,&quot;last_name&quot;:&quot;Schroeder&quot;},{&quot;first_name&quot;:&quot;Karen&quot;,&quot;last_name&quot;:&quot;Smirnakis&quot;},{&quot;first_name&quot;:&quot;Lei&quot;,&quot;last_name&quot;:&quot;Zhang&quot;},{&quot;first_name&quot;:&quot;Fengmei&quot;,&quot;last_name&quot;:&quot;Zheng&quot;},{&quot;first_name&quot;:&quot;Brian&quot;,&quot;last_name&quot;:&quot;T. Hopkins&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;07&quot;,&quot;day&quot;:&quot;22&quot;,&quot;issue&quot;:&quot;21&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;12526-12541&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.0c00702&quot;},&quot;abstract&quot;:&quot;Autoreactive B cell-derived antibodies form immune complexes that likely play a pathogenic role in autoimmune diseases. In systemic lupus erythematosus (SLE), these antibodies bind Fc receptors on myeloid cells and induce proinflammatory cytokine production by monocytes and NETosis by neutrophils. Bruton’s tyrosine kinase (BTK) is a non-receptor tyrosine kinase that signals downstream of Fc receptors and plays a transduction role in antibody expression following B cell activation. Given the roles of BTK in both the production and sensing of autoreactive antibodies, inhibitors of BTK kinase activity may provide therapeutic value to patients suffering from autoantibody-driven immune disorders. Starting from an in-house proprietary screening hit followed by structure-based rational design, we have identified a potent, reversible BTK inhibitor, BIIB068 (1), which demonstrated good kinome selectivity with good overall drug-like properties for oral dosing, was well tolerated across preclinical species at pharmacolo&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00702&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00702" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00702&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00702" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.0c00702&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00702" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.0c00702&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.0c00702&amp;href=/doi/10.1021/acs.jmedchem.0c00702" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.0c00702" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.0c00702" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (5 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00702&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.0c00702%26sid%3Dliteratum%253Aachs%26pmid%3D32696648%26genre%3Darticle%26aulast%3DMa%26date%3D2020%26atitle%3DDiscovery%2Bof%2BBIIB068%253A%2BA%2BSelective%252C%2BPotent%252C%2BReversible%2BBruton%25E2%2580%2599s%2BTyrosine%2BKinase%2BInhibitor%2Bas%2Ban%2BOrally%2BEfficacious%2BAgent%2Bfor%2BAutoimmune%2BDiseases%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D21%26spage%3D12526%26epage%3D12541%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291909" title="Immunology">Immunology</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=290975" title="Biopolymers">Biopolymers</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/21" title="Go to Volume 63, Issue 21"><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/jmcmar.2020.63.issue-21/20201112/jmcmar.2020.63.issue-21.largecover.jpg" alt="Go to Volume 63, Issue 21"/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00702&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Autoreactive B cell-derived antibodies form immune complexes that likely play a pathogenic role in autoimmune diseases. In systemic lupus erythematosus (SLE), these antibodies bind Fc receptors on myeloid cells and induce proinflammatory cytokine production by monocytes and NETosis by neutrophils. Bruton’s tyrosine kinase (BTK) is a non-receptor tyrosine kinase that signals downstream of Fc receptors and plays a transduction role in antibody expression following B cell activation. Given the roles of BTK in both the production and sensing of autoreactive antibodies, inhibitors of BTK kinase activity may provide therapeutic value to patients suffering from autoantibody-driven immune disorders. Starting from an in-house proprietary screening hit followed by structure-based rational design, we have identified a potent, reversible BTK inhibitor, BIIB068 (<b>1</b>), which demonstrated good kinome selectivity with good overall drug-like properties for oral dosing, was well tolerated across preclinical species at pharmacologically relevant doses with good ADME properties, and achieved >90% inhibition of BTK phosphorylation (pBTK) in humans.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_56114" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_56114" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Bruton’s tyrosine kinase (BTK) is a member of the Tec family of protein tyrosine kinases (TFK) that functions downstream of the B cell antigen receptor (BCR) in B cells and Fc receptors (FcRs) in myeloid cells such as neutrophils and basophils.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> BTK activation drives the activation of key BCR-signaling pathways, phospholipase C-γ (PLCγ), phosphatidalyinositol-3-kinase/Akt, and NF-κB, which eventually regulates B cell activation and expression of immunoglobulins (Ig). BTK plays a critical role in early B cell differentiation and mature B cell activation and is expressed throughout B cell development but is lost upon terminal differentiation to plasma cells.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> In 1952, Ogden Bruton<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> first reported a condition called X-linked agammaglobulinemia (XLA), manifested by lack of Igs and B cells,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> that affects approximately 1 in 200 000 males.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> Mutations in the X-linked BTK gene are responsible for the XLA phenotype.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Similarly, crippling mutations in the mouse BTK gene disrupt BTK expression and give rise to the X-linked immunodeficiency (xid) phenotype in mice, and those xid mice are resistant to acquiring lupus and collagen induced arthritis.<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> While BTK’s role in B cell biology has been best characterized, inhibition of kinase activity with either covalent<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> or reversible BTK inhibitors<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> additionally exhibits functional effects in myeloid cell populations,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> such as NETosis by neutrophils,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> inflammation by basophils,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> and cytokine production by monocytes.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a></div><div class="NLM_p">For the past 2 decades, the pharmaceutical community has directed significant resources to identify BTK inhibitors<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a> for potential therapeutic use in various oncology and autoimmune indications. Ibrutinib (<b>2</b>, <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>) is a first generation covalent BTK inhibitor that was approved by the FDA in 2013 to treat patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> Acalabrutinib (<b>3</b>), a second generation, more selective covalent BTK inhibitor, exhibited a considerably improved safety profile (reduced adverse events of skin rash, and bleeding risk<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a>) and was approved in 2017, followed in 2019 by the approval of zanubrutinib (<b>4</b>),<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> another covalent BTK inhibitor from the same generation. Despite clinical success in oncology, some characteristics of these covalent inhibitors preclude them from use in autoimmune diseases that are often chronic. For example, elevations in liver aminotransferase levels were reported<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> with these covalent BTK inhibitors; both inherent and acquired resistance to drug activity have been reported in various lymphomas,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> and an increased risk of idiosyncratic toxicity<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> is generally associated with covalent inhibitors. Therefore, the development of a reversible, selective BTK inhibitor may provide autoimmune patients a treatment with equivalent efficacy and a decreased risk profile.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0001.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of BTK inhibitors BIIB068 (<b>1</b>), ibrutinib (<b>2</b>), acalabrutinib (<b>3</b>), and zanubrutinib (<b>4</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00702&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although numerous clinical trials have been reported targeting BTK inhibition as a potential treatment for autoimmune diseases (spebrutinib<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> for rheumatoid arthritis (RA), poseltinib<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> for RA and lupus, BMS-986195<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> for RA, evobrutinib<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> for multiple sclerosis (MS), PRN1008<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> for pemphigus vulgaris, TAS5315 for RA,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> and remibrutinib for chronic spontaneous urticaria and Sjogren’s syndrome<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a>), only three reversible BTK inhibitors<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> (fenebrutinib, BMS-986142, and AS 1763) have been reported to be in clinic to date. The most advanced molecule is fenebrutinib, which was recently reported by Roche/Genentech to have achieved the primary end point of ACR50 response in a phase II RA study,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> thus validating that inhibition of BTK with a reversible small molecule can provide clinical efficacy for treatment of autoimmune indications such as RA when compared to covalent inhibitors.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a></div><div class="NLM_p last">Here we report the identification of a highly selective reversible BTK inhibitor compound <b>1</b> (BIIB068) in phase I clinical trial for Lupus, from an in-house proprietary screening hit followed by structure-based rational design.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50677" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50677" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> Hit Optimization</h3><div class="NLM_p">The initial hit pyrrolopyrimidine <b>5</b> (BTK IC<sub>50</sub> = 3700 nM, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) was identified from Biogen’s internal proprietary screening collection.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> It was cocrystallized with the BTK protein to obtain a structure to 1.4 Å resolution (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00702/suppl_file/jm0c00702_si_001.pdf" class="ext-link">Supplementary Table S-1</a>). Compound <b>5</b> is an orthosteric ATP-competitive inhibitor that binds to the BTK in a DFG-in conformation. In contrast to ibrutinib, which occupies the kinase back pocket behind the gatekeeper Tyr476 and interacts with Cys481,<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> compound <b>5</b> binds to the hinge region within the active site with the benzamide moiety reaching toward the pocket formed by Tyr551, Leu542, and Ser543 (termed as H3 pocket). Targeting the H3 pocket has been demonstrated to be essential for obtaining selectivity for BTK versus the other Tec family members.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Since this structure demonstrated ample room to grow into the H3 pocket toward Tyr551, the phenyl amide was augmented with a para <i>tert</i>-butyl group similar to CGI-1746.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> This modification led to compound <b>6</b> (BTK IC<sub>50</sub> = 142 ± 51 nM, <i>N</i> = 2), which exhibits more than 20-fold improvement in potency over compound <b>5</b>, though the ligand-lipophilicity efficiency (LLE = 1.8) remains low and comparable to that of compound <b>5</b> (LLE = 2.2). The kinase selectivity of compound <b>6</b> was profiled using the DiscoverX kinome panel, and it showed modest selectivity (15/403 kinase >80% inhibition at 10 μM, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00702/suppl_file/jm0c00702_si_001.pdf" class="ext-link">Supplementary Table S-2</a>), consistent with the <i>tert</i>-butyl group occupying the H3 pocket. An X-ray cocrystal structure of <b>6</b> was obtained to 1.6 Å resolution which confirmed this placement of the <i>tert</i>-butyl group (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>, <a href="/doi/suppl/10.1021/acs.jmedchem.0c00702/suppl_file/jm0c00702_si_001.pdf" class="ext-link">Supplementary Table S-1</a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0002.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of novel pyrrolopyrimidine BTK hit <b>5</b> and analogs <b>6</b> and <b>7</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00702&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0003.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. An overlay of BTK cocrystal structures with compound <b>5</b> (blue, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VXQ">6VXQ</a>) and compound <b>6</b> (green, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6W06">6W06</a>) bound in the ATP active site. H3 residues Y551, S543, and L542 are marked in orange, and structural features, binding interactions, and residues are labeled.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00702&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The cocrystal structure of <b>6</b> with BTK suggests that 2-substitution on the central phenyl core could reach toward the glycine rich P-loop and gain additional hydrophobic interactions (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00702/suppl_file/jm0c00702_si_001.pdf" class="ext-link">Supplementary Figure S-1</a>). Thus, the next effort was focused on modifying the 2-position of the central phenyl ring to improve potency and LLE. As summarized in <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>, adding a methyl group yielded compound <b>7</b> (BTK IC<sub>50</sub> = 5 ± 0.1 nM, <i>N</i> = 2) with a 30-fold increase in potency and improved LLE (2.8 for <b>7</b> vs 1.8 for <b>6</b>). Introducing larger hydrophobic substituents such as the ethyl or trifluoromethyl (<b>8</b> and <b>9</b>, BTK IC<sub>50</sub> = 15 nM and 94 nM, respectively) was detrimental to the biochemical potency. Introducing polar moieties such as the primary amide in <b>10</b> (BTK IC<sub>50</sub> = 3200 nM) led to a loss of activity. This is consistent with the in silico docking studies that suggested that small hydrophobic moieties were optimal for sitting in this pocket formed by lipophilic amino acid side chains.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Characteristics of Analogs of <b>6</b> Featuring 2-Substitution on the Central Phenyl Core</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0010.gif" alt="" id="fx1" /></img><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">R</th><th class="colsep0 rowsep0" align="center" char=".">BTK IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center" char=".">log <i>D</i> <a class="ref internalNav" href="#t1fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">LLE</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">142</td><td class="colsep0 rowsep0" align="char" char=".">4.95</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="char" char=".">5</td><td class="colsep0 rowsep0" align="char" char=".">5.18</td><td class="colsep0 rowsep0" align="char" char=".">2.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">Et</td><td class="colsep0 rowsep0" align="char" char=".">15</td><td class="colsep0 rowsep0" align="char" char=".">2.35</td><td class="colsep0 rowsep0" align="char" char=".">1.8</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="char" char=".">94</td><td class="colsep0 rowsep0" align="char" char=".">2.43</td><td class="colsep0 rowsep0" align="char" char=".">1.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" align="left">CONH<sub>2</sub></td><td class="colsep0 rowsep0" align="char" char=".">3200</td><td class="colsep0 rowsep0" align="char" char=".">1.99</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">IC<sub>50</sub> values were determined using nonphosphorylated BTK protein in a FRET assay in duplicates.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Measured using Analiza ELogD assay.</p></div></div></div><div class="NLM_p last">Compound <b>7</b> showed higher BTK potency and improved off target kinome selectivity (4/403 kinase >80% at 10 μM, FLT3, KIT, PDGFRB, and YSK4, with <i>K</i><sub>d</sub> = 82, 150, 53, and 160 nM, respectively) as compared to compound <b>6</b>. Despite the high lipophilicity with log <i>D</i> = 5.18, compound <b>7</b> exhibited cellular activity (<i>in vitro</i> whole blood (WB) pBTK IC<sub>50</sub> = 7.8 ± 0.2 μM, <i>N</i> = 2). Thus, compound <b>7</b> was selected to advance to the next stage to optimize drug-like properties.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Hit to Lead Optimization</h3><div class="NLM_p">With the achievement of good biochemical potency and kinase selectivity by compound <b>7</b>, the next challenge for this series was to improve the poor drug-like properties represented by high log <i>D</i> (5.18), poor aqueous solubility (kinetic solubility of <1 μg/mL at pH 6.8), weak WB cellular potency (IC<sub>50</sub> = 7.8 μM), and high <i>in vivo</i> rat clearance (CL %Q<sub>h</sub> > 90). To address these issues, our primary goals were to reduce the lipophilicity and improve the LLE of this chemical series. A series of compounds were synthesized in parallel to replace the distal 4-<i>tert</i>-butyl phenyl amide with various substituted five- and six-membered heteroaryl moieties. This effort led to the discovery of the isothiazole <b>11</b> which demonstrated comparable biochemical potency (BTK IC<sub>50</sub> = 3 nM) and improved LLE (3.9) when compared to compound <b>7</b> (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). Furthermore, compound <b>11</b> showed improved solubility (10 μg/mL at pH 6.8) and moderate <i>in vivo</i> clearance in rat iv PK (CL %Q<sub>h</sub> = 43). Although an initial disconnect between <i>in vivo</i> and <i>in vitro</i> clearance rates (IVIVC) of compound <b>11</b> (<i>in vitro</i> RLM CL %Q<sub>h</sub> > 90) was observed, correcting the <i>in vitro</i> clearance with plasma unbound fraction (fu)<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> (RLM CL %Q<sub>h</sub> = 33), brought these values more in line. To investigate the contribution of the hinge binding moiety on the potency and ADME properties, the pyrrolopyrimidine hinge binder was replaced with either the 4-aminopyrimidine <b>12</b> or the 2-aminopyrimidine <b>13</b>. Both changes brought a modest improvement in the <i>in vitro</i> rat metabolic stability (RLM CL %Q<sub>h</sub> = 72 and 65, respectively) and exhibited low clearance when dosed in the rat iv PK study (<b>12</b> CL %Q<sub>h</sub> = 6 and <b>13</b> CL %Q<sub>h</sub> = 11). The <i>in vivo</i> clearance values correlated with the fu-corrected <i>in vitro</i> rat clearance rates (<b>12</b> RLM CL %Q<sub>h</sub> = 10 and <b>13</b> RLM CL %Q<sub>h</sub> = 4).</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Characteristics of BTK Inhibitors <b>11</b>, <b>12</b>, and <b>13</b> Featuring Different Hinge Binders</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0011.gif" alt="" id="fx2" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0012.gif" alt="" id="fx3" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup><sup>a</sup></sup><p class="last">See notes from <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>.</p></div><div class="footnote" id="t2fn2"><sup><sup>b</sup></sup><p class="last">Measured using Analiza miniaturized shake flask.</p></div><div class="footnote" id="t2fn3"><sup><sup>c</sup></sup><p class="last">Unbound fraction was measured at a concentration of 2 μM for human plasma via rapid equilibrium dialysis (RED).</p></div><div class="footnote" id="t2fn4"><sup><sup>d</sup></sup><p class="last">Metabolic stability in human and rat liver microsome (%Q<sub>h</sub> hepatic blood flow (portal vein plus hepatic artery)).</p></div><div class="footnote" id="t2fn5"><sup><sup>e</sup></sup><p class="last">iv dosing in male SD rats, measured in triplicates.</p></div></div><div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Lead Optimization to Candidate</h3><div class="NLM_p">Having demonstrated the ability to attenuate the <i>in vivo</i> clearance while maintaining good biochemical potency and LLE, our efforts switched to further optimizing the biochemical potency and physicochemical properties of compound <b>13</b> in order to improve the WB cell activity (WB pBTK IC<sub>50</sub> = 1.8 μM). The crystal structure of compound <b>6</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00702/suppl_file/jm0c00702_si_001.pdf" class="ext-link">Supplementary Figure S-2</a>) indicated that substituents adjacent to the hinge and extending toward the solvent front could interact with the surrounding residues (Leu408, Tyr476, Ala478, and Gly480) and potentially improve the biochemical potency. Introducing various alkyl substitutions on the amino group including Et, Me, <i>i</i>-Pr, <i>t</i>-Bu, or cyclic alkyls decreased biochemical potency, but switching to aromatic substituents led to phenyl analog <b>14</b> which exhibited good biochemical potency (BTK IC<sub>50</sub> = 1.8 nM) but did not show cellular activity likely due to the high lipophilicity (log <i>D</i> = 3.44) and poor solubility (kinetic solubility of <1 μg/mL at pH 6.8) (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Introducing the 2-pyridine moiety <b>15</b> resulted in a loss in potency (BTK IC<sub>50</sub> = 32 nM). Including the 4-pyridine compound <b>16</b> increased biochemical potency (BTK IC<sub>50</sub> = 0.4 nM); however, like compound <b>14</b>, this improvement in biochemical potency was not paralleled by an improvement in the WB cell potency (WB pBTK IC<sub>50</sub> = 5.3 μM). To further probe the SAR within this region of the protein, a series of five-membered heteroaryl analogs were synthesized. Modulating the lipophilicity (log <i>D</i>) by introducing substituted thiadiazole (<b>17</b>), isoxazole (<b>18</b>), and triazole (<b>19</b>) moieties resulted in compounds that were active in the biochemical assay. Unfortunately, even the most potent analog <b>18</b> (BTK IC<sub>50</sub> = 1.7 nM) did not exhibit WB cellular activity. The most interesting SAR emerged with the synthesis of the 1,3 disubstituted pyrazole (<b>20</b>, BTK IC<sub>50</sub> = 2.1 nM), which exhibited comparable activity in the WB cellular assay (WB pBTK IC<sub>50</sub> = 4.7 μM) to pyridyl analog <b>16</b> but with increased log <i>D</i> (3.47). With appreciation of the impact of the nitrogen atom within pyridyl-containing analogs had on binding affinity, the 1,4-disubstituted pyrazole <b>21</b> was synthesized to mimic the placement of the pyridyl nitrogen. This adjustment provided a 10-fold improvement on both the biochemical potency and cellular activity (BTK IC<sub>50</sub> = 0.2 ± 0.12 nM (<i>N</i> = 5), human WB pBTK IC<sub>50</sub> = 0.43 ± 0.25 μM (<i>N</i> = 17)) and improved LLE (4.9) with higher LogD (4.76) (<a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a></a>). Compound <b>21</b> exhibited low <i>in vivo</i> clearance and modest oral bioavailability (CL %Q<sub>h</sub> = 6, iv 1 mg/kg, and <i>F</i> = 24% in CMC/Tween) when dosed in rat. However, to further evaluate this chemical series in preclinical efficacy models, it was necessary to address the physicochemical properties including high log <i>D</i> (4.76), low solubility (kinetic pH 6.8, <10 μg/mL), and high plasma protein binding (>99.5%).</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Characteristics of Analogs of <b>13</b> Featuring Amino Substitution off the Pyrimidine Hinge Binder</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0013.gif" alt="" id="fx4" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0014.gif" alt="" id="fx5" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup><sup>a</sup></sup><p class="last">See notes from <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>. ND, not determined.</p></div></div><div></div></div><div class="NLM_p">With the goal of reducing the lipophilicity of the lead series while maintaining the desirable biological and ADME properties of compound <b>21</b>, our attention moved to exploring the SAR around the amide moiety that occupies the H3 pocket. The thiadiazole analog <b>22</b> showed improved solubility but a notable loss in biochemical potency (0.2 nM vs 2 nM, <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>), and a similar trend was observed with a few other types of heterocycles (data not shown). In silico modeling studies suggested that sp<sup>3</sup> moieties such as five-membered aliphatic groups would be tolerated in place of the heteroaryl moiety, and that might improve the physicochemical properties of the series, including increasing solubility. To probe this hypothesis, the cyclopentyl analog <b>23</b> was synthesized. Compound <b>23</b> was less potent (BTK IC<sub>50</sub> = 2 nM, tested as a mixture of 4 isomers) than <b>21</b> in the biochemical assay; however, its activity nevertheless validated the rationale that nonplanar moieties might be tolerated in this position. Furthermore, the corresponding urea compound <b>24</b> showed significant improvement in both biochemical and cellular potency, as well as LLE (BTK IC<sub>50</sub> = 0.2 nM, human WB pBTK IC<sub>50</sub> = 0.35 μM, LLE = 5), though no improvement in solubility was observed. Additional attempts to enhance the solubility by reducing the lipophilicity led to the replacement of the pyrrolidine with the 3-substituted azetidine (<b>25</b>). This modification maintained good biological activity (BTK IC<sub>50</sub> = 0.4 nM, human WB pBTK IC<sub>50</sub> = 0.65 ± 0.79 μM (N = 3)) with lower log <i>D</i> (3.34), but still no improvement in solubility was observed. Introducing an oxygen linkage at the 3-position of azetidine led to the discovery of compound <b>1</b> (BTK IC<sub>50</sub> = 1 ± 1.1 nM, <i>N</i> = 5). This simple modification reduced lipophilicity (log <i>D</i> = 2.32) substantially, improved the solubility, and reduced the plasma protein binding which all contributed to improving the WB cell potency (human WB pBTK IC<sub>50</sub> = 0.12 ± 0.15 μM, <i>N</i> = 51).</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Characteristics of Analogs of <b>21</b> Featuring Modifications to the Distal H3 Pocket Region</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0015.gif" alt="" id="fx6" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0016.gif" alt="" id="fx7" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup><sup>a</sup></sup><p class="last">See notes from <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>.</p></div><div class="footnote" id="t4fn2"><sup><sup>b</sup></sup><p class="last">Measured in duplicates except those stated in the text.</p></div><div class="footnote" id="t4fn3"><sup><sup>c</sup></sup><p class="last">Unbound WB pBTK IC<sub>50</sub> = WB pBTK IC<sub>50</sub> × human PPB fu.</p></div></div><div></div></div><div class="NLM_p">To sum up, focusing the medicinal chemistry strategy on optimizing the physicochemical properties of the lead series resulted in the discovery of compound <b>1</b>. Compound <b>1</b> exhibited improvement in <i>in vitro</i> biological potency, as well as good drug-like properties (LLE = 5) which resulted in low <i>in vivo</i> clearance (CL %Q<sub>h</sub> = 6) and moderate oral bioavailability (<i>F</i> = 48%) when dosed in rats.</div><div class="NLM_p">A cocrystal structure (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>) of compound <b>1</b> bound in the active site of BTK confirmed that the 2-aminopyridimine moiety was acting as a dual hydrogen-bond acceptor/donor with residues in the hinge region of the protein. The methyl substituent on the phenyl core was positioned under the P-loop, and the benzyl urea linker oriented the azetidine into the H3 pocket which sequestered Tyr551 in an inactive conformation. Similar to the published literature whereby binding in the H3 pocket of the active site conferred excellent kinome selectivity,<a onclick="showRef(event, 'cit28a ref33'); return false;" href="javascript:void(0);" class="ref cit28a ref33">(28a,33)</a><b>1</b> hit only 10 kinases with >70% inhibition at 1 μM when screened against a panel of 395 kinases at DiscoverX (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00702/suppl_file/jm0c00702_si_001.pdf" class="ext-link">Supplementary Table S-3</a>). Affinity measurement (<i>K</i><sub>d</sub>) were subsequently determined for all 10 kinases (<a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a></a>),<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> which led to the conclusion that compound <b>1</b> yields >400-fold selectivity for BTK versus all the other kinases tested including the structurally similar Tec family members (BMX, ITK, TEC, TXK).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0004.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray cocrystal structure of compound <b>1</b> in BTK (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6W07">6W07</a>). The active site surface is shown semitransparent, and H3 residues Y551, S543, and L542 are marked in orange.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00702&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. <i>K</i><sub>d</sub> Values for Kinases Exhibiting >70% Affinity toward Compound <b>1</b> Relative to Control at 1 μM</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase name</th><th class="colsep0 rowsep0" align="center" char="."><i>K</i><sub>d</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">selectivity fold over BTK</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">adaptor-associated protein kinase 1 (AAK1)</td><td class="colsep0 rowsep0" align="char" char=".">430</td><td class="colsep0 rowsep0" align="char" char=".">1433</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BMP2-inducible kinase (BMP2K)</td><td class="colsep0 rowsep0" align="char" char=".">1100</td><td class="colsep0 rowsep0" align="char" char=".">3666</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BTK</td><td class="colsep0 rowsep0" align="char" char=".">0.3</td><td class="colsep0 rowsep0" align="char" char="."> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cyclin-dependent kinase-like 2 (CDKL2)</td><td class="colsep0 rowsep0" align="char" char=".">420</td><td class="colsep0 rowsep0" align="char" char=".">1400</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Janus kinase 2 (JAK2)</td><td class="colsep0 rowsep0" align="char" char=".">460</td><td class="colsep0 rowsep0" align="char" char=".">1533</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">phosphatidylinositol-4-phosphate 5-kinase type 1α (PIP5K1A)</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RIO kinase 1 (RIOK1)</td><td class="colsep0 rowsep0" align="char" char=".">1200</td><td class="colsep0 rowsep0" align="char" char=".">4000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">RIO kinase 2 (RIOK2)</td><td class="colsep0 rowsep0" align="char" char=".">2400</td><td class="colsep0 rowsep0" align="char" char=".">8000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">serine–threonine kinase (STK1)</td><td class="colsep0 rowsep0" align="char" char=".">880</td><td class="colsep0 rowsep0" align="char" char=".">2933</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mitogen-activated protein kinase kinase kinase 19 (YSK4)</td><td class="colsep0 rowsep0" align="char" char=".">130</td><td class="colsep0 rowsep0" align="char" char=".">433</td></tr></tbody></table></div></div><div class="NLM_p">To further evaluate the selectivity of compound <b>1</b>, it was tested <i>in vitro</i> at four concentrations (30, 10, 3.3, and 1.1 μM) in the BioMAP system developed by BioSeek/DiscoverX. This platform comprises 12 human primary cell-based assays that enable the assessment of both on- and off-target activity of a compound in a cellular system using pathway- and disease-relevant biomarkers.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> Compound <b>1</b> exhibited dose-dependent activity which was restricted to the culture systems that included hematopoietic cells that express BTK protein (LPS, SAg, BT, and Mphg). The predominant activity was observed in primary B cells and PBMCs (BT culture) and impacted biomarkers such as secreted IgG and sTNF-α (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). Furthermore, at 1.1 μM, the only culture system impacted by compound <b>1</b> was BT culture stimulated with anti-IgM and a subthreshold amount of anti-TCR. Compared to the BioSeek literature data<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> of a nonselective BTK inhibitor ibrutinib (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00702/suppl_file/jm0c00702_si_001.pdf" class="ext-link">Supplementary Table S-3</a>) at the same concentration, which showed activity in every cellular system, the BioSeek profile of compound <b>1</b> at 1.1 μM is consistent with its greater kinase selectivity.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0005.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Phenotypic BioSeek study data of compound <b>1</b> at 1.1, 3.3, 10, and 30 μM. The gray area shows the 95% confidence area of each biomarker response in the absence of drug. Data points that fall outside the gray area signify inhibition (below) or augmentation (above) of the biomarker response at the indicated concentration of compound <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00702&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In addition, compound <b>1</b> inhibited BCR mediated PLCγ2 phosphorylation in Ramos B cells (IC<sub>50</sub> = 0.4 μM), anti-IgD induced and anti-IgM BCR-induced B cell activation in human PBMCs (IC<sub>50</sub> = 0.11 μM and 0.21 μM, respectively) consistent with the activity on the BT culture system in the BioMAP study.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Drug Metabolism and Pharmacokinetics</h3><div class="NLM_p">Compound <b>1</b> exhibited low volume of distribution, low to moderate clearance in rat, dog, and cynomolgus monkey, moderate oral bioavailability (26–32% in dogs and cynomolgus monkeys and 48% in rats), and a short half-life across species (<a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a></a>). In <i>in vitro</i> ADME screening studies (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>), compound <b>1</b> exhibited high permeability and moderate efflux in the Caco-2 cell system. Tests for protein binding revealed a range across all preclinical species and humans, with fu<sub>rat</sub> (1.28%) < fu<sub>cyno</sub> (3.62%) < fu<sub>human</sub> (5.95%) < fu<sub>dog</sub> (11.3%). When evaluated for potential major human CYP-mediated drug–drug interactions, compound <b>1</b> did not inhibit any of the major CYP isoforms (1A2, 2C9, 2C19, 2D6, and 3A4) in human liver microsomes (IC<sub>50</sub> > 25 μM) and did not result in CYP (1A2, 2B6, and 3A4) induction in the sandwich cultured human hepatocyte assay at concentrations up to 50 μM. Compound <b>1</b> was stable in the plasma of mouse, rat, beagle dog, cynomolgus monkey, and human (>95% parent compound remaining after 6 h of incubation) and was not sequestered into the red blood cells of those species.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Pharmacokinetics Characteristics of Compound <b>1</b> in Preclinical Species</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">po, 5 mpk<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="4" align="center" char=".">iv, 1 mpk<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">PK</th><th class="colsep0 rowsep0" align="center" char=".">AUC (ng·h/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>C</i><sub>max</sub> (ng/mL)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th><th class="colsep0 rowsep0" align="center" char=".">CL (mL min<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char="."><i>t</i><sub>1/2</sub> (h)</th><th class="colsep0 rowsep0" align="center" char="."><i>V</i><sub>ss</sub> (L/kg)</th><th class="colsep0 rowsep0" align="center" char=".">%Q<sub>h</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">rat</td><td class="colsep0 rowsep0" align="char" char=".">11907</td><td class="colsep0 rowsep0" align="char" char=".">2920</td><td class="colsep0 rowsep0" align="char" char=".">48</td><td class="colsep0 rowsep0" align="char" char=".">3</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">0.2</td><td class="colsep0 rowsep0" align="char" char=".">6</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">dog</td><td class="colsep0 rowsep0" align="char" char=".">1938</td><td class="colsep0 rowsep0" align="char" char=".">652</td><td class="colsep0 rowsep0" align="char" char=".">26</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">37</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">cyno</td><td class="colsep0 rowsep0" align="char" char=".">2346</td><td class="colsep0 rowsep0" align="char" char=".">282</td><td class="colsep0 rowsep0" align="char" char=".">32</td><td class="colsep0 rowsep0" align="char" char=".">11</td><td class="colsep0 rowsep0" align="char" char=".">0.9</td><td class="colsep0 rowsep0" align="char" char=".">0.7</td><td class="colsep0 rowsep0" align="char" char=".">26</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup><sup>a</sup></sup><p class="last">Vehicle: 0.1% CMC/0.2% Tween-80.</p></div><div class="footnote" id="t6fn2"><sup><sup>b</sup></sup><p class="last">Vehicle: 40% NMP solution for rat and 70:30 PEG-400/H<sub>2</sub>O solution for dog and cyno.</p></div></div></div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Detailed <i>in Vitro</i> Profile of Compound <b>1</b></div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">assay</th><th class="colsep0 rowsep0" align="center">result</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BTK IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">1 ± 1.1 (<i>N</i> = 5)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BTK <i>K</i><sub>d</sub> (nM)</td><td class="colsep0 rowsep0" align="left">0.3 ± 0.2 (<i>N</i> = 2)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">human WB pBTK IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">0.12 ± 0.15 (<i>N</i> = 51)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">KINOMEscan at 1 μM (>90% control)<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">1/394, YSK4 (<i>K</i><sub>d</sub> = 130 nM)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Panlabs at 10 μM (>50% inhibition)<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">2/68, A<sub>3</sub>(IC<sub>50</sub> = 4.2 μM), H<sub>2</sub>(IC<sub>50</sub> = 26.5 μM)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP inhibition (1A2, 2C9, 2C19, 2D6, and 3A4) IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">all isoforms >25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">CYP 3A4 HLM time-dependent inhibition<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left"><i>K</i><sub>I</sub> = 50 μM, <i>k</i><sub>inact</sub> = 0.08 h<sup>–1</sup></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">LM (rat/dog/cyno/human) CL %Q<sub>h</sub> <a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">2/8/26/7</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">hERG inhibition IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t7fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">>50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">HepG2 cytotoxicity IC<sub>50</sub> (μM)<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">>20</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Caco2 (<i>P</i><sub>A–B</sub>/efflux ratio)<a class="ref internalNav" href="#t7fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">15.4/4.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PPB fu (%) (human)<a class="ref internalNav" href="#t7fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">5.95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">aq solubility (μg/mL, pH 7/2)<a class="ref internalNav" href="#t7fn4" aria-label="d">d</a></td><td class="colsep0 rowsep0" align="left">1/>100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">measured log <i>D</i><sub>7.4</sub> (shake flask method)</td><td class="colsep0 rowsep0" align="left">2.92 ± 0.17 (<i>N</i> = 2)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t7fn1"><div class="footnote" id="t7fn1"><sup><sup>a</sup></sup><p class="last">See notes from <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a></a>.</p></div><div class="footnote" id="t7fn2"><sup><sup>b</sup></sup><p class="last">See <a href="/doi/suppl/10.1021/acs.jmedchem.0c00702/suppl_file/jm0c00702_si_001.pdf" class="ext-link">Supporting Information</a>.</p></div><div class="footnote" id="t7fn3"><sup><sup>c</sup></sup><p class="last">In the automated patch-clamp assay.</p></div><div class="footnote" id="t7fn4"><sup><sup>d</sup></sup><p class="last">In simulated intestinal fluid (pH 7) and simulated gastric fluid (pH 2).</p></div></div></div><div class="NLM_p last">Compound <b>1</b> was extensively metabolized <i>in vitro</i> in liver microsomes and hepatocytes across all preclinical species (rat, dog, monkey) and humans. The primary biotransformation pathways of compound <b>1</b> in human liver microsomes were due to O-deisopropylation, oxidation at the pyrazole moiety, and N-demethylation. Oxidation of the isopropyl group appeared to be a minor pathway, with additional minor metabolites formed by combinations of these primary pathways. Multiple CYPs were responsible for the oxidative metabolism with major (66%) contribution by 3A4 (<i>K</i><sub>I</sub> = 50 μM, <i>k</i><sub>inact</sub> = 0.08 h<sup>–1</sup>). The metabolic pathways in liver microsomes and hepatocytes were similar across all four species with only quantitative differences detected. All metabolites detected in human liver microsomes and hepatocytes were also detected in more than one preclinical species, with no formation of unique human metabolites or any GSH or CN adducts. Overall, compound <b>1</b> showed acceptable ADME properties (<a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a></a>) to warrant further development.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Chemistry</h3><div class="NLM_p">Compound <b>1</b> was synthesized in seven steps starting with the commercially available 4-bromo-2-methylbenzonitrile <b>26</b> as shown in <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Reduction of the nitrile moiety followed by Boc protection gave aryl bromide <b>28</b>. To facilitate the aryl coupling to the pyrimidine moiety, it was necessary to first form the boronic ester <b>29</b>, followed by Suzuki coupling<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> to yield compound <b>30</b>. The 3-aminopyrazole moiety was installed via a palladium facilitated amination,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> and the Boc group was then removed upon treatment with HCl to produce the benzylamine hydrochloride salt <b>32</b>. Finally, a CDI-mediated urea formation provided compound <b>1</b>. With a viable synthetic route in hand to support the synthesis for preclinical toxicology studies, it was deemed necessary to identify a crystalline form for further development. After an extensive salt screening, the hemi-adipate salt was identified as a suitable crystalline form with the necessary physicochemical properties for use in clinic.</div><figure id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0009.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of BIIB068 (<b>1</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00702&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 3 equiv of BH<sub>3</sub>, THF, 0–80 °C, 16 h, 90%; (b) 1.1 equiv of Boc<sub>2</sub>O, 3 equiv of NEt<sub>3</sub>, THF, rt, 1 h, 95%; (c) 1.2 equiv of PinB-BPin, 0.1 equiv of Pd(dppf)Cl<sub>2</sub>, 3 equiv of KOAc, 1,4-dioxane, 100 °C, 2 h, 69%; (d) 0.1 equiv of Pd(dppf)Cl<sub>2</sub>, 2 equiv of K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O (4:1), 90 °C, 2 h, 80%; (e) 0.1 equiv of Pd<sub>2</sub>(dba)<sub>3</sub>, 0.2 equiv of S-Phos, 2 equiv of Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 120 °C, 2 h, 63%; (f) HCl/MeOH, rt, 6 h, 90%; (g) CDI, DIPEA, DMF, 30%.</p></p></figure></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Efficacy and Pharmacodynamic Measures</h3><div class="NLM_p">BIIB068 (compound <b>1</b>) inhibits B cell, neutrophil, and monocyte activation <i>in vitro</i> but not T cell responses (<a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a></a>). In an <i>in vitro</i> assay measuring total phosphorylated BTK (pBTK) in mouse WB, BIIB068 shows IC<sub>50</sub> = 0.17 μM.</div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. <i>In Vitro</i> Biological Profile of BIIB068 (<b>1</b>)</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">assay<a class="ref internalNav" href="#t8fn1" aria-label="a">a</a> (measured output, stimulus, cell type)</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> ± SD (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">B cell activation (CD69, anti-IgD/BCR, PBMC)</td><td class="colsep0 rowsep0" align="left">0.111 ± 0.087 (<i>N</i> = 10)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ROS generation (ROS, SLE IC/FcγR, neutrophils)</td><td class="colsep0 rowsep0" align="left">0.054 ± 0.057 (<i>N</i> = 4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">monocyte (PB IgG, IL-6, IL-1b, TNFα/FcγR, PBMC)</td><td class="colsep0 rowsep0" align="left">0.063 ± 0.034 (<i>N</i> = 4)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pBTK inhibition (pTyr, n/a, human WB)</td><td class="colsep0 rowsep0" align="left">0.12 ± 0.15 (<i>N</i> = 51)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">pBTK inhibition (pTyr, n/a, mouse WB)</td><td class="colsep0 rowsep0" align="left">0.17 ± 0.100 (<i>N</i> = 5)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">B cell activation (CD69, IL-4/anti-CD40/CD40, PBMC)</td><td class="colsep0 rowsep0" align="left">>10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">T cell activation (CD69, anti-CD3/CD28/TCR, PBMC)</td><td class="colsep0 rowsep0" align="left">>10</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t8fn1"><div class="footnote" id="t8fn1"><sup><sup>a</sup></sup><p class="last">See <a href="/doi/suppl/10.1021/acs.jmedchem.0c00702/suppl_file/jm0c00702_si_001.pdf" class="ext-link">Supporting Information</a> for assay conditions.</p></div></div></div><div class="NLM_p">In further biological profiling, BIIB068 demonstrated dampening of BCR-mediated B cell activation, as measured by CD69 expression after PBMC stimulation with anti-IgD (CD69 IC<sub>50</sub> = 0.111 μM). After factoring protein binding, this value correlates well with the compound’s ability to inhibit phosphorylation of BTK (IC<sub>50</sub> = 1 nM) in the biochemical assay. Similarly, BIIB068 was shown to inhibit FcγR-mediated ROS production when added to human neutrophils from healthy donors that were activated with immune complexes (IC) from SLE patients (SLE IC) (IC<sub>50</sub> = 0.054 μM). Blocking receptor access with antibodies to FcγRII (CD32) prevented SLE IC-mediated ROS production by neutrophils, demonstrating that the BIIB068 functional mechanism is dependent on FcγR signaling. Furthermore, to show that inhibition of BTK with BIIB068 selectively blocks B cell activation via BCR signaling, treatment of PBMCs with other receptor ligands including anti-CD40 and IL-4 in the presence of BIIB068 exhibited IC<sub>50</sub> ≥ 10 μM for induction of CD69 expression on CD19<sup>+</sup> B cells. Collectively, the biological profile observed for BIIB068 was consistent with a molecule that selectively targets BTK.</div><div class="NLM_p">To understand the translatability from <i>in vitro</i> biological potency to <i>in vivo</i> efficacy, BIIB068 was tested in a thymus-independent type 2 (TI-2) antigen mouse model which had previously been reported to be BTK dependent.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a></div><div class="NLM_p">In contrast to thymus dependent (TD) antigens, thymus independent (TI) antigens induce a productive antibody response in neonatally thymectomized mice or nude mice, which also lack a thymus. TI antigens can be further differentiated based on whether they can (TI-1) or cannot (TI-2) generate an antibody response in xid mice. These three classes of model antigens differ in how they mechanistically induce an antibody response <i>in vivo</i>, with TI-2 antigens relying heavily on BCR signaling. BTK mutation was later shown to be the genetic cause responsible for the xid phenotype.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> In retrospect, TI-2 antigens were defined as those antigens that require BTK expression to generate a productive antibody response <i>in vivo</i>, thus making it a well-suited <i>in vivo</i> efficacy model to test compounds that target BTK function.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a></div><div class="NLM_p">To directly evaluate the effects of BIIB068 on BTK-dependent B cell activation <i>in vivo</i>, the antigen-specific antibody response was measured from mice dosed orally with BIIB068 and immunized with a model TI-2 antigen (4-hydroxy-3-nitrophenyl) acetyl (NP) Ficoll. Twice daily (BID) dosing of BIIB068 continued for 10 consecutive days. Serum, plasma, and WB were collected on day 10 to evaluate the antigen-specific antibody responses, plasma concentration of BIIB068, and target engagement using the WB PD assay. NP-specific IgM antibody titers were compared to vehicle control animals.<named-content content-type="anchor" rid="fig6" type="simple"></named-content> Substantial reductions of these antibody titers were observed in mice treated BID with 10–50 mg/kg/dose of BIIB068 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Specifically, anti-NP IgM antibody titers were reduced by 93%, 90%, 63%, 22%, and −23% compared to vehicle control treated animals for BID BIIB068 doses of 50, 30, 10, 3, and 1 (mg/kg)/dose, respectively. The calculated ED<sub>50</sub> of BIIB068 for IgM antibody titer was 4.4 (mg/kg)/dose. To further interrogate the pharmacokinetics of BIIB068 and degree of target engagement achieved in the TI-2 efficacy model, plasma and WB samples from each of the dose or vehicle arms were collected to determine exposures and degree of target engagement using pBTK assay concurrent with serum collection.</div><figure id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0006.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. PK and PD analysis of BIIB068 (<b>1</b>) in the TI-2 efficacy model: (A) workflow of the TI-2 mice efficacy model; (B) pBTK % inhibition at 1 h, 4 h, and prelast dose; (C) total drug concentration at 1 h, 4 h, and prelast dose. Figure shows the mean and standard deviation of triplicate determination in one experiment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00702&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0007.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Dose–response trial of BIIB068 (<b>1</b>)-mediated inhibition of the antigen-specific antibody response to a TI-2 antigen. Figure shows the mean and standard deviation of triplicate determination in one experiment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00702&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The prelast dose group was used to determine the steady-state trough concentration of BIIB068 and the corresponding degree of target engagement in each dose arm. The samples taken at 1 and 4 h after the final dose were used to determine the concentration and target engagement of BIIB068 at or near the <i>t</i><sub>max</sub> in each dose arm. The effects on the NP-specific antibody response are negligible during the maximum of 4 h time difference between samples. <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a> shows the average inhibition of target engagement (% inhibition of pBTK <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B) or total exposure (nM, <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>C) in each dose group. BTK target engagement remains high, but dose-responsive, for at least 4 h after po dosing in all dose groups. In contrast, at steady-state trough levels of BIIB068 seen in the prelast dose group, target-engagement is low or absent in all but in the highest dose arm, 50 mg/kg/dose. The duration of target engagement was dependent on the dose. The <i>in vivo</i> pBTK IC<sub>50</sub> for BIIB068 is 0.13 μM (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00702/suppl_file/jm0c00702_si_001.pdf" class="ext-link">Supplementary Figure S-3</a>), which is similar to the <i>in vitro</i> pBTK IC<sub>50</sub> of 0.17 μM in mouse whole blood. The mice dosed with 30 (mg/kg)/dose show ∼90% efficacy, indicating that full target coverage throughout the entire dosing period is not necessary to drive high level of efficacy, at least in the TI-2 antibody response model. BIIB068 demonstrated good PK/PD correlation with <i>in vivo</i> EC<sub>50</sub> = 0.16 μM based on antibody response, similar to <i>in vivo</i> WB pBTK potency in mice.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Preclinical Safety</h3><div class="NLM_p">Toxicity profiling for BIIB068 was conducted in rodent (Sprague-Dawley rat) and non-rodent (cynomologus monkey) species for up to 13 weeks in GLP toxicity studies. The cynomologus monkey was chosen as the non-rodent species based on the similarities in metabolic profiles for BIIB068 in both human and monkey hepatocytes and microsomes. In both the rat and monkey 13 weeks studies, BIIB068 was demonstrated to be safe and well tolerated. No compound related adverse effects in clinical signs, body weight, food consumption, ECG, clinical pathology, organ weight, or gross pathology/histopathology were observed. BIIB068-related effects in rats were limited to nonadverse microscopic changes in the pancreas at ≥15 (mg/kg)/day.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> Thus, the no observed adverse effect level (NOAEL) was determined at 50 (mg/kg)/day for rat and 100 (mg/kg)/day for monkey which corresponded to a daily rat AUC<sub>inf</sub> 376 μg·h/mL and monkey AUC<sub>inf</sub> 129 μg·h/mL.</div><div class="NLM_p last">BIIB068 exhibited no adverse effects in the single dose CNS and respiratory studies in rats or in a single dose cardiovascular study in monkeys. BIIB068 demonstrates low genotoxic potential. BIIB068 was negative for clastogenic and mutagenic responses <i>in vitro</i> with and without metabolic activation (Aroclor-induced rat liver S9). BIIB068 was negative in the <i>in vivo</i> micronucleus assay in Sprague-Dawley rats, where it showed no clastogenic activity and/or disruption of the mitotic apparatus in the bone marrow, and negative for micronuclei in rats.</div></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> Clinical Study</h3><div class="NLM_p">Key human PK parameters were simulated utilizing both standard scaling IVIVE approaches extrapolated from the preclinical species’ observed PK data and Simcyp simulator (version 13) PBPK modeling. Clinical doses required to maintain a target level of EC<sub>75</sub> for pBTK inhibition (based on TI-2 efficacy study)<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> in human WB for approximately >10 h coverage in a 12 h dosing interval were in the range of 50 mg/dose BID (100 mg/day) to 125 mg/dose BID (250 mg/day) daily dose. The phase I SAD study<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> was designed with goal of establishing the safety and tolerability for BIIB068. BIIB068 was dosed orally as a tablet in healthy volunteers at a starting dose of 10 mg which was chosen to afford >10-fold margin to the NOAEL determined from the GLP preclinical toxicity studies. Dose escalation continued through the 120 mg cohort which based on the human PK had achieved exposures equivalent to the NOAEL exposures (plasma total AUC) identified from the cyno GLP toxicity studies. BIIB068 was well tolerated with peak plasma concentration (<i>C</i><sub>max</sub>) occurring at ∼0.9–2 h after dosing, and median <i>t</i><sub>1/2</sub> ranges from 6 to 9 h across all cohorts (<a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>). BIIB068 was effective at inhibiting BTK phosphorylation and B-cell activation dose-dependently. At single doses of ≥30 mg of BIIB068, BTK phosphorylation was inhibited ≥70% for up to 12 h postdosing. Inhibition of BTK phosphorylation was ≥90% from approximately 1 h through 8 h postdosing at 60 and 120 mg of BIIB068. Peak inhibition occurred at approximately the same time as peak BIIB068 plasma concentration. Peak inhibition of B-cell activation (60%) occurred at 1–2 h postdosing (same time as peak BIIB068 plasma concentration) at 120 mg of BIIB068 and then gradually decreased by 8 h postdosing. Overall, BIIB068 was well tolerated and effective at inhibiting BTK phosphorylation in healthy subjects. BIIB068 also inhibited B-cell activation, although the inhibition was not as robust as inhibition of BTK phosphorylation. The reason why inhibition of B-cell activation was less robust than inhibition of BTK phosphorylation is unknown and may be a future area of investigation.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> More details will be disclosed in due course.</div><figure id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0008.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Dose–response of (A) pBTK inhibition, (B) CD69 expression inhibition by BIIB068, and (C) exposure of BIIB068 (<b>1</b>) in healthy human cohorts (placebo, 10 mg, 30 mg, 60 mg, 120 mg).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00702&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i21">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46104" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46104" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">In summary, we have identified a selective, potent reversible BTK inhibitor BIIB068 through systematic rational drug design and optimization from a low micromolar screening hit. BIIB068 demonstrated favorable preclinical toxicology and DMPK properties across species which translated into good tolerability, PK, and target engagement in humans. The less robust inhibition of B cell activation measured by CD69 expression downstream of anti-IgD stimulation may require additional studies to determine if this molecule has clinical significance as is or must be optimized further before use in clinic. Nevertheless, the discovery of BIIB068 represents a substantial progress of this series toward the successful use of a reversible BTK inhibitor for the treatment of autoimmune diseases.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46176" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46176" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> General Procedures</h3><div class="NLM_p last">All solvents and chemicals were used as purchased from commercial sources without further purification. Reaction progress was monitored by LC–MS. Flash chromatography was performed with an Isco Combiflash Companion system using prepacked silica gel columns. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded at 400 MHz using a Bruker Avance III spectrometer with a BBFO probe. Liquid chromatography was performed using a SunFire  C18, 3.5 μm, 4.6 mm × 20 mm IS  column with mobile phase of 0.1% TFA in H<sub>2</sub>O (A) and 0.1% TFA in MeCN (B) and a gradient of 10–90% B with flow rate at 3.0 mL/min. Detector was set at dual wavelength 214 and 254 nm. The purity of all compounds listed was >95% at 254 nm.</div></div><div id="sec4_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> (4-Bromo-2-methylphenyl)methanamine (<b>27</b>)</h3><div class="NLM_p last">To a solution of 4-bromo-2-methylbenzonitrile (<b>26</b>) (3 g, 15 mmol) in THF (20 mL), BH<sub>3</sub>·THF (45 mL, 45 mmol) was added. The solution was stirred at 0 °C for 1 h and heated to 80 °C for 16 h. Then the mixture was quenched with MeOH. After concentration, the residue was stirred with saturated HCl/EtOAc solution and filtered. The filter cake was rinsed with ether (20 mL × 3) and dried under vacuum to afford titled product (3.2 g, yield 90%) as a white solid. ESI-MS (M + H)<sup>+</sup>: <i>m</i>/<i>z</i> 200.1. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ: 7.25–7.51 (m, 3H), 4.15 (s, 2H), 2.41–2.44 (s, 3H).</div></div><div id="sec4_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> <i>tert</i>-Butyl 4-Bromo-2-methylbenzylcarbamate (<b>28</b>)</h3><div class="NLM_p last">To a solution of (4-bromo-2-methylphenyl)methanamine (<b>27</b>) (1.2 g, 6 mmol) in DCM (30 mL), TEA (1.82 g, 18 mmol) and Boc<sub>2</sub>O (1.43 g, 6.6 mmol) were added. The mixture was stirred at room temperature for 1 h. After dilution with water (50 mL), the mixture was extracted with DCM (50 mL × 2). The combined organics were washed with brine (50 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated to give crude titled product (1.7 g, yield 95%) as a white solid, which was used directly in the next step without further purification. ESI-MS (M + H)<sup>+</sup>: <i>m</i>/<i>z</i> 300.1. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.28–7.33 (m, 2H), 7.11 (d, <i>J</i> = 8.03 Hz, 1H), 4.65–4.74 (m, 1H), 4.26 (br d, <i>J</i> = 5.77 Hz, 2H), 2.30 (s, 3H), 1.46 (s, 9H).</div></div><div id="sec4_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>tert</i>-Butyl 2-Methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzylcarbamate (<b>29</b>)</h3><div class="NLM_p last">To a solution of <i>tert</i>-butyl 4-bromo-2-methylbenzylcarbamate (<b>28</b>) (1.5 g, 5.0 mmol) in 1,4-dioxane (15 mL), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane) (1.52 g, 6.0 mmol), KOAc (1.75 g, 18 mmol) and Pd(dppf)Cl<sub>2</sub>·DCM (407 mg, 0.5 mmol) were added under N<sub>2</sub>. The mixture was stirred at 100 °C for 2 h. After cooling down to room temperature, the mixture was diluted with water (50 mL) and extracted with EtOAc (100 mL × 3). The combined organic layer was washed with brine, dried, concentrated, and purified by silica gel column (petroleum ether/EtOAc = 10:1) to give the title product (1.2 g, yield 69%) as a white solid. ESI-MS (M + H)<sup>+</sup>: <i>m</i>/<i>z</i> 348.2. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 7.61–7.59 (m, 2H), 7.26 (s, 1H), 4.68 (br, 1H), 4.33 (d, <i>J</i> = 5.6 Hz, 2H), 2.32 (s, 3H), 1.45 (s, 9H), 1.34 (s, 12H).</div></div><div id="sec4_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> <i>tert</i>-Butyl 4-(2-Chloropyrimidin-4-yl)-2-methylbenzylcarbamate (<b>30</b>)</h3><div class="NLM_p last">To a solution of <i>tert</i>-butyl 2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzylcarbamate (<b>29</b>) (3.47 g, 10 mmol) and 2,4-dichloropyrimidine (1.79 g, 12 mmol) in 1,4-dioxane (28 mL) and H<sub>2</sub>O (7 mL), Pd(dppf)Cl<sub>2</sub>.DCM (815 mg, 1.0 mmol) and K<sub>2</sub>CO<sub>3</sub> (2.76 g, 20 mmol) were added under N<sub>2</sub>. The mixture was stirred at 90 °C for 2 h. After cooling to room temperature, the mixture was diluted with H<sub>2</sub>O (80 mL) and extracted with EtOAc (80 mL × 2). The organic layers were dried and concentrated. The residue was purified by column chromatography (silica, petroleum ether/EtOAc = 5:1 to 2:1) to give the title product (2.67 g, yield 80%) as a white solid. ESI-MS (M + H) <sup>+</sup>: <i>m</i>/<i>z</i> 334.1. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ: 8.12 (d, <i>J</i> = 5.2 Hz, 1H), 7.92 (s, 1H), 7.87 (d, <i>J</i> = 8.0 Hz, 1H), 7.63 (d, <i>J</i> = 5.6 Hz, 1H), 7.40 (d, <i>J</i> = 7.6 Hz, 1H), 4.84 (br, 1H), 4.38(d, <i>J</i> = 5.2 Hz, 1H), 2.41 (s, 3H), 1.47 (s, 9H). <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ: 166.9, 161.8, 159.7, 155.7, 141.0, 136.9, 133.9, 129.2, 128.0, 125.1, 115.0, 79.8, 42.4, 28.3(3C), 19.0.</div></div><div id="sec4_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> <i>tert</i>-Butyl 2-Methyl-4-(2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrimidin-4-yl)benzylcarbamate (<b>31</b>)</h3><div class="NLM_p last">To a solution of <i>tert</i>-butyl 4-(2-chloropyrimidin-4-yl)-2-methylbenzylcarbamate (<b>30</b>) (333 mg, 1.0 mmol) and 1-methylpyrazol-4-amine (126 mg, 1.3 mmol) in 1,4-dioxane (5 mL), Pd<sub>2</sub>(dba)<sub>3</sub> (92 mg, 0.1 mmol), S-Phos (82 mg, 0.2 mmol), and Cs<sub>2</sub>CO<sub>3</sub> (650 mg, 2.0 mmol) were added under N<sub>2</sub>. The mixture was stirred at 120 °C for 2 h. After cooling to room temperature, the mixture was diluted with H<sub>2</sub>O (40 mL) and extracted with EtOAc (60 mL × 2). The organic layers were dried and concentrated. The residue was purified by column chromatography (silica, petroleum ether/EtOAc = 3:1 to 1:1) to give the title product (248 mg, yield 63%) as a white solid. ESI-MS (M + H) <sup>+</sup>: <i>m</i>/<i>z</i> 395.1. <sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD) δ: 8.38 (d, <i>J</i> = 5.2 Hz, 1H), 7.97–7.93 (m, 3H), 7.65 (s, 1H), 7.38 (d, <i>J</i> = 8.0 Hz, 1H), 7.20 (d, <i>J</i> = 9.2 Hz, 1H), 4.30 (s, 2H), 3.85 (s, 3H), 2.42 (s, 3H), 1.48 (s, 9H).</div></div><div id="sec4_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> 4-(4-(Aminomethyl)-3-methylphenyl)-<i>N</i>-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-amine (<b>32</b>)</h3><div class="NLM_p last">A mixture of <i>tert</i>-butyl 2-methyl-4-(2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrimidin-4-yl)benzylcarbamate (<b>31</b>) (3.94 g, 10.0 mmol) in a solution of HCl in methanol (30 mL, prepared from gas HCl) was stirred at room temperature for 6 h. The solvent was removed, and the solid was rinsed with cold diethyl ether (100 mL). The solid was dried under vacuum to give the title product (2.97 g, yield 90%) as a yellow solid. ESI-MS (M + H) <sup>+</sup>: <i>m</i>/<i>z</i> 295.1. <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O) δ: 7.98–7.96 (m, 1H), 7.66–7.22 (m, 6H), 4.10 (s, 2H), 3.68 (s, 3H), 2.20 (s, 3H).</div></div><div id="sec4_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> 2-(<i>tert</i>-Butyl)-<i>N</i>-(2-methyl-4-(2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrimidin-4-yl)benzyl)thiazole-5-carboxamide (<b>21</b>)</h3><div class="NLM_p last">To a mixture of 4-(4-(aminomethyl)-3-methylphenyl)-<i>N</i>-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-amine (<b>32</b>) (200 mg, 0.7 mmol), 2-(<i>tert</i>-butyl)thiazole-5-carboxylic acid (139 mg, 0.752 mmol), and <i>N</i>,<i>N</i>,<i>N</i>′,<i>N</i>′-tetramethyl-<i>O</i>-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (0.32 g, 0.84 mmol) in DMF (1.58 mL, 20.4 mmol), <i>N</i>,<i>N</i>-diisopropylethylamine (0.355 mL, 2.04 mmol) was added slowly and stirred at room temperature overnight. The mixture was filtered through Celite and washed with DMF and purified by prep HPLC to give the title product as a solid (217.5 mg, yield 70%). ESI-MS (M + H)<sup>+</sup>: <i>m</i>/<i>z</i> 462.20. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 9.57 (s, 1H), 9.10 (t, <i>J</i> = 5.48 Hz, 1H), 8.46 (d, <i>J</i> = 5.29 Hz, 1H), 8.33 (s, 1H), 7.95 (m, 3H), 7.56 (s, 1H), 7.40 (d, <i>J</i> = 7.93 Hz, 1H), 7.28 (d, <i>J</i> = 5.29 Hz, 1H), 4.50 (d, <i>J</i> = 5.29 Hz, 2H), 3.65 (s, 3H), 2.42 (s, 3H), 1.39 (s, 9H). HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>24</sub>H<sub>27</sub>N<sub>7</sub>OS [M + H]<sup>+</sup>, 462.2071; found, 462.2073.</div></div><div id="sec4_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> 3-Isopropoxy-<i>N</i>-(2-methyl-4-(2-((1-methyl-1<i>H</i>-pyrazol-4-yl)amino)pyrimidin-4-yl)benzyl)azetidine-1-carboxamide (<b>1</b>)</h3><div class="NLM_p last">To a mixture of 4-(4-(aminomethyl)-3-methylphenyl)-<i>N</i>-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyrimidin-2-amine hydrochloride (<b>32</b>) (200 mg, 0.7 mmol), 3-isopropoxyazetidine (113 mg, 0.747 mmol), and <i>N</i>,<i>N</i>-carbonyldiimidazole (0.110 g, 0.679 mmol) in DMF (1.58 mL, 20.4 mmol), <i>N</i>,<i>N</i>-diisopropylethylamine (0.473 mL, 2.72 mmol) was added slowly and stirred at room temperature overnight. The mixture was filtered through Celite and washed with DMF and purified by prep HPLC to give the title product as a solid (82 mg, yield 30%). Mp 179–181 °C. ESI-MS (M + H)<sup>+</sup>: <i>m</i>/<i>z</i> 436.3. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 9.48 (s, 1H), 8.45 (d, <i>J</i> = 5.02 Hz, 1H), 7.91–7.95 (m, 3H), 7.55 (br. s., 1H), 7.35 (d, <i>J</i> = 8.53 Hz, 1H), 7.25 (d, <i>J</i> = 5.27 Hz, 1H), 6.84 (s, 1H), 4.15–4.48 (m, 3H), 3.90–4.13 (m, 2H), 3.83 (s, 3H), 3.46–3.69 (m, 3H), 2.36 (s, 3H), 1.08 (d, <i>J</i> = 6.27 Hz, 6H). <sup>13</sup>C NMR (101 MHz, DMSO-<i>d</i><sub>6</sub>) δ: 164.3, 160.2, 160.1, 159.3, 141.8, 136.2, 135.6, 130.3, 128.7, 127.9, 124.7, 123.9, 120.8, 107.0, 70.7, 65.6, 57.9 (2C), 41.3, 39.2, 22.8 (2C), 19.3. HRMS (ESI+): <i>m</i>/<i>z</i> calcd for C<sub>23</sub>H<sub>29</sub>N<sub>7</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 436.2456; found, 436.2446.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> Protein Crystallography</h3><div class="NLM_p last">Protein expression, purification, crystallography, and structure solution were performed as previously published<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> with additional refinement in Phenix.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> In summary, a construct encoding the kinase domain of human BTK (residues 382–659) with a cleavable GST affinity tag was expressed via baculovirus infection in Sf9 insect cells. Crystallography-grade BTK was isolated from lysed cells by affinity purification on glutathione resin, removal of the GST tag, and size exclusion chromatography. Concentrated protein (5–6 mg/mL) was incubated with 0.5–1.0 mM compound and 0.1 M guanidine HCl before assembling sitting drop vapor diffusion trays in crystallization solution at pH 6.5 including ammonium sulfate or ammonium acetate and PEG5000 monomethyl ether (MME), PEG3350, or PEG2000 MME as precipitants. Crystals formed with or without seeding within 3–5 days at 4 °C were cryoprotected in mother liquor containing additional PEG5000 MME and ethylene glycol or PEG200 and were flash frozen before data collection at the LRL-CAT beamline within the Advanced Photon Source (APS) or the PXI beamline at the Swiss Light Source (SLS). The structure was solved from processed data using molecular replacement and refined. Data collection and refinement statistics are listed in <a href="/doi/suppl/10.1021/acs.jmedchem.0c00702/suppl_file/jm0c00702_si_001.pdf" class="ext-link">Supplementary Table S-1</a>, and maps, models, and additional experimental details have been deposited to the RCSB Protein Data Bank (see <a class="ref internalNav" href="#notes-2" aria-label="Accession Codes">Accession Codes</a> below).</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> BTK Biochemical Activity Assay</h3><div class="NLM_p last">BTK activity and inhibitor efficacy were evaluated by monitoring the amount of phosphorylation of a fluorescein-labeled polyGAT peptide substrate (Invitrogen PV3611) in the presence of active BTK enzyme (Upstate 14-552), ATP, and compound. For a typical assay, 24 μL of a ATP/peptide master mix (final concentration; ATP 10 μM, polyGAT 100 nM) in kinase buffer (10 mM Tris-HCl, pH 7.5, 10 mM MgCl<sub>2</sub>, 200 μM Na<sub>3</sub>PO<sub>4</sub>, 5 mM DTT, 0.01% Triton X-100, and 0.2 mg/mL casein) was aliquoted into each well of a black 96-well plate (costar 3694) followed by 1 μL of a 4-fold, 40× compound titration in 100% DMSO and 15 μL of BTK enzyme mix in 1× kinase buffer (with a final concentration of 0.25 nM). After 30 min, the reaction was quenched with 28 μL of 50 mM EDTA. 5 μL aliquots of the reaction mixture were transferred to a low volume, white 384-well plate (Corning 3674), and 5 μL of a 2× detection buffer (Invitrogen PV3574, with 4 nM Tb-PY20 antibody, Invitrogen PV3552) was added before a 45 min incubation at room temperature in the dark and time-resolved fluorescence (TRF) measurement on a Molecular Devices M5 (332 nm excitation; 488 nm emission; 518 nm fluorescein emission) instrument. IC<sub>50</sub> values were calculated using a four-parameter fit with 100% enzyme activity determined from the DMSO control and 0% activity from the EDTA control.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> pBTK WB Assay</h3><div class="NLM_p last">Heparinized venous WB was aliquoted into 96-well plate and “spiked” with serial dilutions of test compound in DMSO or with DMSO without drug. The final concentration of DMSO in all wells was 0.1%. The plate was incubated at 37 °C for 30 min. Lysis buffer containing protease and phosphatase inhibitors was added to the drug-containing samples and one of the DMSO-only samples (+PPi, high control), while lysis buffer containing protease inhibitors was added to the other DMSO-only samples (−PPi, low control). All the lysed WB samples were subjected to the total BTK capture and phosphotyrosine detection method. ECL values were graphed in Prism, and a best-fit curve with restrictions on the maximum and minimum defined by the +PPi high and −PPi low controls was used to estimate the test compound concentration that results in 50% inhibition of ECL signal by interpolation.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Clinical pBTK Assay</h3><div class="NLM_p last">Heparinized venous WB was collected from patients enrolled in the study. Within 2 h of collection, blood was aliquoted (200 μL) into appropriately labeled 1.2 mL cluster tubes. Samples were mixed with 200 μL of MSD Tris lysis buffer supplemented with protease and phosphatase inhibitors, followed by a 60 min incubation at 4 °C on a shaker set at a moderate speed. The lysed blood samples were stored at −70 °C until analyzed for phosphorylated and total BTK levels. MSD plates (anti-rabbit coated) were incubated overnight at 4 °C with rabbit anti-BTK antibody followed by treatment with blocking buffer. Frozen samples, standards, and appropriate QCs were thawed by soaking tubes in room temperature water for 5 min and added to the MSD plates. BTK present in samples was captured on the plates during an overnight incubation at 4 °C. Subsequently, plates were incubated either with mouse anti-BTK antibody to detect total levels of the protein or with antiphosphorylated Tyrosine antibody to detect phosphorylated BTK. Phosphorylated BTK levels were normalized to total levels of BTK, and the extent of inhibition was calculated based on predose samples.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Clinical CD69 Assay</h3><div class="NLM_p last">Heparinized venous WB samples from patients enrolled in the clinical study were aliquoted (100 μL) into appropriately labeled 15 mL conical tubes. One set of aliquots received 0.1 μg/mL of anti-human IgD (clone IA6-2) conjugated to dextran. All samples were incubated at 37 °C/5% CO<sub>2</sub> for 18–24 h. Upon incubation, samples were transferred to 12 × 75 mm FACS tubes and stained for 30 min at room temperature with a cocktail of antibodies containing anti-human CD19 (clone HIB19) conjugated to allophycocyanin (APC) and anti-human CD69 (clone L78) conjugated to phycoerythrin (PE). Red blood cells were lysed by incubating samples for 10 min at room temperature with 2 mL of 1× FACSLyse solution. Upon lysis, remaining cells were washed with 2 mL of PBS supplemented with 1% bovine serum albumin followed by fixation with 500 μL of 1% paraformaldehyde solution. Samples were acquired on a properly calibrated BD flow cytometer and analyzed for CD69 expression on CD19+ gated B cells. Quantum R-PE MESF beads were utilized to standardize the fluorescence intensity of CD69. The extent of inhibition was calculated based on predose samples.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> TI-2 Efficacy Methods</h3><div class="NLM_p last">Nine female DBA/1 mice (sourced from Charles River Discovery Research) per dose or vehicle arm were injected intraperitoneally with 30 μg of NP-Ficoll on day 0. BIIB068 was formulated in an aqueous vehicle of 0.5% carboxymethylcellulose and 0.1% Tween-80 in water and dosed po with BIIB068 twice a day for 10 days. The numbers on the <i>x</i>-axis in <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B indicate the amount/dose administration that was given twice a day. Serum, WB, and plasma samples were collected on day 10 and stored at −80 °C prior to assay. Serum was analyzed by ELISA for NP specific IgM. 96-well plates were precoated with NP-BSA, blocked, and washed prior to adding serial diluted serum samples. Biotinylated anti-mouse IgM and streptavidin-HRP were sequentially used to detect NP-specific IgM antibodies. ABTS substrate was used in a colorimetric assay to visualize the reaction, which was quantified by spectrophotometry at 405 nm. Softmax Pro version 5.2 software was used to determine the levels of NP specific IgM antibodies present in the experimentally treated animals, relative to a standard curve of pooled NP-Ig positive serum. OD values from an eight-point dilution of each sample were used to interpolate relative antibody titer. Mean values for treatment groups were calculated, and statistical significance was determined by one-way ANOVA followed by Dunnet’s multiple comparison test. <i>n</i> = <i>X</i>/normal controls, <i>n</i> = 10/treatment group, *<i>p</i> < 0.05 ANOVA to vehicle control.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i38"><a href="/doi/suppl/10.1021/acs.jmedchem.0c00702" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_54763" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_54763" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.0c00702?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00702</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthetic methods, characterization of key compounds, assay conditions, kinase selectivity data, receptor panel data, BioSeek data, and table of protein crystal data collection and refinement statistics (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00702/suppl_file/jm0c00702_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a href="/doi/suppl/10.1021/acs.jmedchem.0c00702/suppl_file/jm0c00702_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00702/suppl_file/jm0c00702_si_001.pdf">jm0c00702_si_001.pdf (1.21 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00702/suppl_file/jm0c00702_si_002.csv">jm0c00702_si_002.csv (1.94 kb)</a></li></ul></div></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Structure data associated with this study have been deposited to the RCSB Protein Data Bank (<a href="http://www.rcsb.org" class="extLink">http://www.rcsb.org</a>) and can be accessed with the following codes: BTK bound to <b>1</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6W07">6W07</a>, to <b>5</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VXQ">6VXQ</a>, and to <b>6</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6W06">6W06</a>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div class="testing" data-doi="10.1021/acs.jmedchem.0c00702" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_45846" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_45846" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bin Ma</span> - <span class="hlFld-Affiliation affiliation">Research &
Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-3913-0545" title="Orcid link">http://orcid.org/0000-0002-3913-0545</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#36545f58185b5776545f595153581855595b"><span class="__cf_email__" data-cfemail="90f2f9febefdf1d0f2f9fff7f5febef3fffd">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brian T. Hopkins</span> - <span class="hlFld-Affiliation affiliation">Research &
Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#1270607b737c3c7a7d62797b7c6152707b7d75777c3c717d7f"><span class="__cf_email__" data-cfemail="40223229212e6e282f302b292e330022292f27252e6e232f2d">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tonika Bohnert</span> - <span class="hlFld-Affiliation affiliation">Research &
Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kevin L. Otipoby</span> - <span class="hlFld-Affiliation affiliation">Research &
Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span>; 
    <span>Present Address:
                        K.L.O.: Pandion Therapeutics, Cambridge, MA 02142</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eric Tien</span> - <span class="hlFld-Affiliation affiliation">Research &
Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Million Arefayene</span> - <span class="hlFld-Affiliation affiliation">Research &
Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Judy Bai</span> - <span class="hlFld-Affiliation affiliation">Research &
Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bekim Bajrami</span> - <span class="hlFld-Affiliation affiliation">Research &
Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eris Bame</span> - <span class="hlFld-Affiliation affiliation">Research &
Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Timothy R. Chan</span> - <span class="hlFld-Affiliation affiliation">Research &
Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span>; 
    <span>Present Address:
                        T.R.C.: Facebook, Redmond, WA 98052</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Humora</span> - <span class="hlFld-Affiliation affiliation">Research &
Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span>; 
    <span>Present Address:
                        M.H.: J-Star Research, South Plainfield, NJ 07080</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">J. Michael MacPhee</span> - <span class="hlFld-Affiliation affiliation">Research &
Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span>; 
    <span>Present Address:
                        J.M.M.: Alkermes Inc., Waltham, MA 02451</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Douglas Marcotte</span> - <span class="hlFld-Affiliation affiliation">Research &
Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span>; 
    <span>Present Address:
                        D.Ma. and P.S.: Forma Therapeutics, Watertown, MA 02472</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Devangi Mehta</span> - <span class="hlFld-Affiliation affiliation">Research &
Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span>; 
    <span>Present Address:
                        D.Me.: Immunologix Laboratories, Tampa, FL 33634</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Claire M. Metrick</span> - <span class="hlFld-Affiliation affiliation">Research &
Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">George Moniz</span> - <span class="hlFld-Affiliation affiliation">Research &
Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Evelyne Polack</span> - <span class="hlFld-Affiliation affiliation">Research &
Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Urjana Poreci</span> - <span class="hlFld-Affiliation affiliation">Research &
Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Annick Prefontaine</span> - <span class="hlFld-Affiliation affiliation">Research &
Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarah Sheikh</span> - <span class="hlFld-Affiliation affiliation">Research &
Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span>; 
    <span>Present Address:
                        S.S: Takeda, Cambridge, MA 02142</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Patricia Schroeder</span> - <span class="hlFld-Affiliation affiliation">Research &
Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span>; 
    <span>Present Address:
                        D.Ma. and P.S.: Forma Therapeutics, Watertown, MA 02472</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Karen Smirnakis</span> - <span class="hlFld-Affiliation affiliation">Research &
Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Lei Zhang</span> - <span class="hlFld-Affiliation affiliation">Research &
Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fengmei Zheng</span> - <span class="hlFld-Affiliation affiliation">Research &
Development, Biogen, 225 Binney Street, Cambridge, Massachusetts 02142, United States</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>All authors have given approval to the final version of the manuscript.</p></li><li><span class="author-information-subsection-header">Funding</span><p>Funding was provided by Biogen, who employed all authors at the time this research was conducted.</p></li><li><span class="author-information-subsection-header">Notes</span><p>The authors declare no competing financial interest.<br /></br></p></li></ul></div><div class="ack" id="ACK-d7e2899-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i48">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_01830" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_01830" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors acknowledge Jiansheng Huang for collecting the HRMS data and the DMPK group for collecting all ADME data. Dr. Chuck Gu was greatly appreciated for helpful discussions on ADME properties. The authors thank Dr. Chris Helal for critical reviews. Adam Meyers was greatly appreciated for providing project management in multiple phases.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">CDI</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-carbonyldiimidazole</p></td></tr><tr><td class="NLM_term">ECG</td><td class="NLM_def"><p class="first last">electrocardiogram</p></td></tr><tr><td class="NLM_term">GLP</td><td class="NLM_def"><p class="first last">good laboratory practice</p></td></tr><tr><td class="NLM_term">iv</td><td class="NLM_def"><p class="first last">intravenous</p></td></tr><tr><td class="NLM_term">IVIVC</td><td class="NLM_def"><p class="first last"><i>in vivo</i>–<i>in vitro</i> correlation</p></td></tr><tr><td class="NLM_term">IVIVE</td><td class="NLM_def"><p class="first last"><i>in vivo</i>–<i>in vitro</i> extrapolation</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsome</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">multiple sclerosis</p></td></tr><tr><td class="NLM_term">PBMC</td><td class="NLM_def"><p class="first last">peripheral blood mononuclear cell</p></td></tr><tr><td class="NLM_term">PBPK</td><td class="NLM_def"><p class="first last">Physiologically based pharmacokinetic</p></td></tr><tr><td class="NLM_term">RA</td><td class="NLM_def"><p class="first last">rheumatoid arthritis</p></td></tr><tr><td class="NLM_term">RLM</td><td class="NLM_def"><p class="first last">rat liver microsome</p></td></tr><tr><td class="NLM_term">SAD</td><td class="NLM_def"><p class="first last">single ascending dosing</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i50">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_63318" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_63318" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 47 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">Targeting pathological B cell receptor signaling in lymphoid malignancies</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1038/nrd3937</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1038%2Fnrd3937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=23449308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtlamt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=229-243&author=R.+M.+Youngauthor=L.+M.+Staudt&title=Targeting+pathological+B+cell+receptor+signaling+in+lymphoid+malignancies&doi=10.1038%2Fnrd3937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting pathological B cell receptor signalling in lymphoid malignancies</span></div><div class="casAuthors">Young, Ryan M.; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">229-243</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Signalling through the B cell receptor (BCR) is central to the development and maintenance of B cells.  In light of the numerous proliferative and survival pathways activated downstream of the BCR, it comes as no surprise that malignant B cells would co-opt this receptor to promote their own growth and survival.  However, direct evidence for BCR signalling in human lymphoma has only come to light recently.  Roles for antigen-dependent and antigen-independent, or tonic, BCR signalling have now been described for several different lymphoma subtypes.  Furthermore, correlative data implicate antigen-dependent BCR signalling in many other forms of lymphoma.  A host of therapeutic agents targeting effectors of the BCR signalling pathway are now in clin. trials and have shown initial success against multiple forms of lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVUax9riiUObVg90H21EOLACvtfcHk0ljI-7FYIWAG9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtlamt78%253D&md5=3969aa6232508b72e03da0177ba8280e</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1038%2Fnrd3937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3937%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DTargeting%2520pathological%2520B%2520cell%2520receptor%2520signaling%2520in%2520lymphoid%2520malignancies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D229%26epage%3D243%26doi%3D10.1038%2Fnrd3937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bittner, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radsak, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, C.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase: An emerging key player in innate immunity</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1454</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2017.01454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.3389%2Ffimmu.2017.01454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=29167667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFemsLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1454&author=A.+N.+Weberauthor=Z.+Bittnerauthor=X.+Liuauthor=T.+Dangauthor=M.+P.+Radsakauthor=C.+Brunner&title=Bruton%E2%80%99s+tyrosine+kinase%3A+An+emerging+key+player+in+innate+immunity&doi=10.3389%2Ffimmu.2017.01454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase: an emerging key player in innate immunity</span></div><div class="casAuthors">Weber, Alexander N. R.; Bittner, Zsofia; Liu, Xiao; Dang, Truong-Minh; Radsak, Markus Philipp; Brunner, Cornelia</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1454/1-1454/6</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (BTK) was initially discovered as a crit. mediator of B cell receptor signaling in the development and functioning of adaptive immunity.  Growing evidence also suggests multiple roles for BTK in mononuclear cells of the innate immune system, esp. in dendritic cells and macrophages.  For example, BTK has been shown to function in Toll-like receptor-mediated recognition of infectious agents, cellular maturation and recruitment processes, and Fc receptor signaling.  Most recently, BTK was addnl. identified as a direct regulator of a key innate inflammatory machinery, the NLRP3 inflammasome.  BTK has thus attracted interest not only for gaining a more thorough basic understanding of the human innate immune system but also as a target to therapeutically modulate innate immunity.  We here review the latest developments on the role of BTK in mononuclear innate immune cells in mouse vs. man, with specific emphasis on the sensing of infectious agents and the induction of inflammation.  Therapeutic implications for modulating innate immunity and crit. open questions are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbuyJkEPCUhrVg90H21EOLACvtfcHk0ljI-7FYIWAG9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFemsLrK&md5=05b5e2fa9012104f7177572f8c4a72bc</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2017.01454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2017.01454%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DA.%2BN.%26aulast%3DBittner%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DDang%26aufirst%3DT.%26aulast%3DRadsak%26aufirst%3DM.%2BP.%26aulast%3DBrunner%26aufirst%3DC.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%253A%2520An%2520emerging%2520key%2520player%2520in%2520innate%2520immunity%26jtitle%3DFront.%2520Immunol.%26date%3D2017%26volume%3D8%26spage%3D1454%26doi%3D10.3389%2Ffimmu.2017.01454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Weers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verschuren, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraakman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mensink, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuurman, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Dongen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span> <span> </span><span class="NLM_article-title">The Bruton’s tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages</span>. <i>Eur. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3109</span>– <span class="NLM_lpage">3114</span>, <span class="refDoi"> DOI: 10.1002/eji.1830231210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1002%2Feji.1830231210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=8258324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADyaK2cXhtVCksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1993&pages=3109-3114&issue=12&author=M.+de%0AWeersauthor=M.+C.+Verschurenauthor=M.+E.+Kraakmanauthor=R.+G.+Mensinkauthor=R.+K.+Schuurmanauthor=J.+J.+van+Dongenauthor=R.+W.+Hendriks&title=The+Bruton%E2%80%99s+tyrosine+kinase+gene+is+expressed+throughout+B+cell+differentiation%2C+from+early+precursor+B+cell+stages+preceding+immunoglobulin+gene+rearrangement+up+to+mature+B+cell+stages&doi=10.1002%2Feji.1830231210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages</span></div><div class="casAuthors">de Weers, Michel; Verschuren, Martie C. M.; Kraakman, Margriet E. M.; Mensink, Rob G. J.; Schuurman, Ruud K. B.; van Dongen, Jacques J. M.; Hendriks, Rudolf W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Immunology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3109-14</span>CODEN:
                <span class="NLM_cas:coden">EJIMAF</span>;
        ISSN:<span class="NLM_cas:issn">0014-2980</span>.
    </div><div class="casAbstract">X-linked agammaglobulinemia (XLA) is an immunodeficiency disease in man, resulting from an arrest in early B cell differentiation.  The gene defective in XLA has recently been identified and encodes a cytoplasmic protein tyrosine kinase, named Bruton's tyrosine kinase (btk), essential for cell differentiation and proliferation at the transition from pre-B to later B cell stages.  In this study the authors investigated btk expression by Northern blotting expts. in a series of human (precursor) B cell lines, acute lymphoblastic leukemias, and plasmacytomas.  Btk was already expressed in very early stages of B cell differentiation, even prior to Ig heavy (H) or light (L) chain gene rearrangements.  Transcripts were also detected at the pre-B cell stage and in mature B cells, irresp. of the Ig H chain class expressed.  Approx. at the transition from mature B cells to plasma cells, expression of the btk gene is down-regulated.  In addn., the btk gene was expressed in myeloid cell lines and acute myeloid leukemias.  Btk expression in myeloid cells is probably not a prerequisite for myeloid differentiation, since myeloid cells in XLA patients seem not to be affected.  No btk expression was found in T-lineage cells.  The btk expression profile, i.e. from early precursor-B cell stages preceding Ig rearrangement up to mature B cells, supports the hypothesis that the XLA defect resides in a crit. step of B cell development which is independent of the Ig gene recombination machinery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPh3BF8ebN9LVg90H21EOLACvtfcHk0lgY7__hTf0Tsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtVCksL8%253D&md5=556362bf5f73ac7c7962de1d0c7ff167</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Feji.1830231210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Feji.1830231210%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BWeers%26aufirst%3DM.%26aulast%3DVerschuren%26aufirst%3DM.%2BC.%26aulast%3DKraakman%26aufirst%3DM.%2BE.%26aulast%3DMensink%26aufirst%3DR.%2BG.%26aulast%3DSchuurman%26aufirst%3DR.%2BK.%26aulast%3Dvan%2BDongen%26aufirst%3DJ.%2BJ.%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26atitle%3DThe%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520gene%2520is%2520expressed%2520throughout%2520B%2520cell%2520differentiation%252C%2520from%2520early%2520precursor%2520B%2520cell%2520stages%2520preceding%2520immunoglobulin%2520gene%2520rearrangement%2520up%2520to%2520mature%2520B%2520cell%2520stages%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D1993%26volume%3D23%26issue%3D12%26spage%3D3109%26epage%3D3114%26doi%3D10.1002%2Feji.1830231210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruton, O. C.</span></span> <span> </span><span class="NLM_article-title">Agammaglobulinemia</span>. <i>Pediatrics.</i> <span class="NLM_year" style="font-weight: bold;">1952</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">728</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=14929630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A280%3ADyaG38%252FlvFOnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1952&pages=722-728&author=O.+C.+Bruton&title=Agammaglobulinemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Agammaglobulinemia</span></div><div class="casAuthors">BRUTON O C</div><div class="citationInfo"><span class="NLM_cas:title">Pediatrics</span>
        (<span class="NLM_cas:date">1952</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">722-8</span>
        ISSN:<span class="NLM_cas:issn">0031-4005</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ99IDXIc3tbqqcneEtCi92fW6udTcc2ebsOTj1vn3IBrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaG38%252FlvFOnsg%253D%253D&md5=737a40c8a7c8f591efca619f2ba894aa</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBruton%26aufirst%3DO.%2BC.%26atitle%3DAgammaglobulinemia%26jtitle%3DPediatrics.%26date%3D1952%26volume%3D9%26spage%3D722%26epage%3D728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vorechovsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olerup, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabbani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baskin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammarstrom, L.</span></span> <span> </span><span class="NLM_article-title">X-linked agammaglobulinemia and other immunoglobulin deficiencies</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1111/j.1600-065X.1994.tb00851.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1111%2Fj.1600-065X.1994.tb00851.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=8070814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADyaK2cXkvVSnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=1994&pages=159-183&author=C.+I.+E.+Smithauthor=K.+B.+Islamauthor=I.+Vorechovskyauthor=O.+Olerupauthor=E.+Wallinauthor=H.+Rabbaniauthor=B.+Baskinauthor=L.+Hammarstrom&title=X-linked+agammaglobulinemia+and+other+immunoglobulin+deficiencies&doi=10.1111%2Fj.1600-065X.1994.tb00851.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">X-linked agammaglobulinemia and other immunoglobulin deficiencies</span></div><div class="casAuthors">Smith, C. I. Edvard; Islam, Khalid B.; Vorechovsky, Igor; Olerup, Olle; Wallin, Erik; Rabbani, Hodjattallah; Baskin, Berivan; Hammarstroem, Lennart</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">159-83</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    </div><div class="casAbstract">A review with 123 refs. discussing Ig deficiencies, isolation of the XLA gene, structure and expression of Btk, mutation anal. in patients with XLA, the naturally occurring mouse mutant CBA/N, deletions in the IgH locus, IgA deficiency and common variable immunodeficiency, genetics of IgAD and CVID, the B-lymphocyte abnormality in IgAD, and IgG3 deficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqcdUsf_XJ8LVg90H21EOLACvtfcHk0lgY7__hTf0Tsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXkvVSnsbk%253D&md5=90f59e592743c3baeb1531c8c0689946</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.1994.tb00851.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.1994.tb00851.x%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26aulast%3DIslam%26aufirst%3DK.%2BB.%26aulast%3DVorechovsky%26aufirst%3DI.%26aulast%3DOlerup%26aufirst%3DO.%26aulast%3DWallin%26aufirst%3DE.%26aulast%3DRabbani%26aufirst%3DH.%26aulast%3DBaskin%26aufirst%3DB.%26aulast%3DHammarstrom%26aufirst%3DL.%26atitle%3DX-linked%2520agammaglobulinemia%2520and%2520other%2520immunoglobulin%2520deficiencies%26jtitle%3DImmunol.%2520Rev.%26date%3D1994%26volume%3D138%26spage%3D159%26epage%3D183%26doi%3D10.1111%2Fj.1600-065X.1994.tb00851.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linton, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. S.</span></span> <span> </span><span class="NLM_article-title">Analysis of clinical presentations of Bruton disease: A review of 20 years of accumulated data from pediatric patients at severance hospital</span>. <i>Yonsei Med. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.3349/ymj.2008.49.1.28</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.3349%2Fymj.2008.49.1.28" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=18306466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktlOgsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2008&pages=28-36&issue=1&author=J.+Chunauthor=T.+J.+Leeauthor=J.+W.+Songauthor=J.+A.+Lintonauthor=D.+S.+Kim&title=Analysis+of+clinical+presentations+of+Bruton+disease%3A+A+review+of+20+years+of+accumulated+data+from+pediatric+patients+at+severance+hospital&doi=10.3349%2Fymj.2008.49.1.28"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of clinical presentations of Bruton disease: a review of 20 years of accumulated data from pediatric patients at severance hospital</span></div><div class="casAuthors">Chun, Jin-Kyong; Lee, Taek Jin; Song, Jae Woo; Linton, John A.; Kim, Dong Soo</div><div class="citationInfo"><span class="NLM_cas:title">Yonsei Medical Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-36</span>CODEN:
                <span class="NLM_cas:coden">YOMJA9</span>;
        ISSN:<span class="NLM_cas:issn">0513-5796</span>.
    
            (<span class="NLM_cas:orgname">Yonsei University College of Medicine</span>)
        </div><div class="casAbstract">X-linked agammaglobulinemia (XLA) is a humoral immunodeficiency disease caused by a mutation in the Bruton tyrosine kinase (BTK) gene resulting in defective B cell differentiation.  Because it is a relatively rare disorder, it is difficult for clinicians to have a comprehensive understanding of XLA due to a lack of exposure to the disease.  Clin. presentations of patients with XLA were analyzed and discussed to improve care plans.  During a 20-yr period, from Jan. 1987 to June 2006, a total of 19 patients were diagnosed as XLA in the Department of Pediatrics at Severance Hospital, Seoul, Korea.  A retrospective anal. of the clin. presentations of those patients was performed.  The mean age of the XLA patients included in the study was 4.89 years, with a range of 6 mo to 13 years.  Twelve patients were diagnosed before age 5, while the other 7 patients were diagnosed after age 5.  Recurrent infections obsd. in the patients included pneumonia, acute otitis media, septic arthritis, skin infection, sepsis, sinusitis, acute gastroenteritis, cervical lymphadenitis, epididymitis, meningitis, osteomyelitis, urinary tract infection and encephalitis.  Frequency of admissions was variable from 0 to 12 times, depending on the time at which Ig therapy was started.  Six cases had family histories pos. for XLA.  BTK gene mutations were found in 8 cases.  The overall prognosis of XLA is good as long as patients are diagnosed and treated early with regular intra venous gamma globulin therapy before the sequelae of recurrent infections appear.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1Fy7lQ2xLdbVg90H21EOLACvtfcHk0limLVomw2h1gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktlOgsbs%253D&md5=65dc163066c45e56dc52d0a5af572707</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.3349%2Fymj.2008.49.1.28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3349%252Fymj.2008.49.1.28%26sid%3Dliteratum%253Aachs%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DT.%2BJ.%26aulast%3DSong%26aufirst%3DJ.%2BW.%26aulast%3DLinton%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DD.%2BS.%26atitle%3DAnalysis%2520of%2520clinical%2520presentations%2520of%2520Bruton%2520disease%253A%2520A%2520review%2520of%252020%2520years%2520of%2520accumulated%2520data%2520from%2520pediatric%2520patients%2520at%2520severance%2520hospital%26jtitle%3DYonsei%2520Med.%2520J.%26date%3D2008%26volume%3D49%26issue%3D1%26spage%3D28%26epage%3D36%26doi%3D10.3349%2Fymj.2008.49.1.28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saffran, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlings, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parolini, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klisak, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparkes, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubagawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohandas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conley, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">290</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(93)90667-F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1016%2F0092-8674%2893%2990667-F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=8425221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADyaK3sXkvFensro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1993&pages=279-290&author=S.+Tsukadaauthor=D.+C.+Saffranauthor=D.+J.+Rawlingsauthor=O.+Paroliniauthor=R.+C.+Allenauthor=I.+Klisakauthor=R.+S.+Sparkesauthor=H.+Kubagawaauthor=T.+Mohandasauthor=S.+Quanauthor=J.+W.+Belmontauthor=M.+D.+Cooperauthor=M.+E.+Conleyauthor=O.+N.+Witte&title=Deficient+expression+of+a+B+cell+cytoplasmic+tyrosine+kinase+in+human+X-linked+agammaglobulinemia&doi=10.1016%2F0092-8674%2893%2990667-F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia</span></div><div class="casAuthors">Tsukada, Satoshi; Saffran, Douglas C.; Rawlings, David J.; Parolini, Ornella; Allen, R. Cutler; Klisak, Ivana; Sparkes, Robert S.; Kubagawa, Hiromi; Mohandas, Thuluvancheri; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">279-90</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">We describe a novel cytoplasmic tyrosine kinase, termed BPK (B cell progenitor kinase), which is expressed in all stages of the B lineage and in myeloid cells.  BPK has classic SH1, SH2, and SH3 domains, but lacks myristylation signals and a regulatory phosphorylation site corresponding to tyrosine 527 of c-src.  BPK has a long, basic amino-terminal region upstream of the SH3 domain.  BPK was evaluated as a candidate for human X-linked agammaglobulinemia (XLA), an inherited immunodeficiency characterized by a severe deficit of B and plasma cells and profound hypogammaglobulinemia.  BPK mapped to within 100 kb of a probe defining the polymorphism most closely linked to XLA at DXS178.  Redn. in or the absence of BPK mRNA, protein expression, and kinase activity was obsd. in XLA pre-B and B cell lines.  BPK is likely the XLA gene and functions in pathways crit. to B cell expansion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ_KGg5ilchbVg90H21EOLACvtfcHk0limLVomw2h1gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXkvFensro%253D&md5=fbc5a572b91397b1e86a8640e7759c10</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2893%2990667-F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252893%252990667-F%26sid%3Dliteratum%253Aachs%26aulast%3DTsukada%26aufirst%3DS.%26aulast%3DSaffran%26aufirst%3DD.%2BC.%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26aulast%3DParolini%26aufirst%3DO.%26aulast%3DAllen%26aufirst%3DR.%2BC.%26aulast%3DKlisak%26aufirst%3DI.%26aulast%3DSparkes%26aufirst%3DR.%2BS.%26aulast%3DKubagawa%26aufirst%3DH.%26aulast%3DMohandas%26aufirst%3DT.%26aulast%3DQuan%26aufirst%3DS.%26aulast%3DBelmont%26aufirst%3DJ.%2BW.%26aulast%3DCooper%26aufirst%3DM.%2BD.%26aulast%3DConley%26aufirst%3DM.%2BE.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DDeficient%2520expression%2520of%2520a%2520B%2520cell%2520cytoplasmic%2520tyrosine%2520kinase%2520in%2520human%2520X-linked%2520agammaglobulinemia%26jtitle%3DCell%26date%3D1993%26volume%3D72%26spage%3D279%26epage%3D290%26doi%3D10.1016%2F0092-8674%2893%2990667-F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vetrie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vorechovsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideras, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinter, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammarstrom, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinnon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levinsky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bobrow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, D. R.</span></span> <span> </span><span class="NLM_article-title">The gene involved in X-linked agammaglobulinemia is a member of the src family of protein tyrosine kinases</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1038/361226a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1038%2F361226a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=8380905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADyaK3sXitlajt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=1993&pages=226-233&author=D.+Vetrieauthor=I.+Vorechovskyauthor=P.+Siderasauthor=J.+Hollandauthor=A.+Daviesauthor=F.+Flinterauthor=L.+Hammarstromauthor=C.+Kinnonauthor=R.+Levinskyauthor=M.+Bobrowauthor=C.+I.+Smithauthor=D.+R.+Bentley&title=The+gene+involved+in+X-linked+agammaglobulinemia+is+a+member+of+the+src+family+of+protein+tyrosine+kinases&doi=10.1038%2F361226a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">The gene involved in X-linked agammaglobulinemia is a member of the src family of protein-tyrosine kinases</span></div><div class="casAuthors">Vetrie, David; Vorechovsky, Igor; Sideras, Paschalis; Holland, Jill; Davies, Angela; Flinter, Frances; Hammarstroem, Lennart; Kinnon, Christine; Levinsky, Roland; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">6409</span>),
    <span class="NLM_cas:pages">226-33</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">X-linked agammaglobulinemia (XLA) is a human immunodeficiency caused by failure of pre-B cells in the bone marrow to develop into circulating mature B cells.  A novel gene (atk) has been isolated which maps to the XLA locus, is expressed in B cells, and shows mutations in families with the disorder.  The gene is a member of the src family of protooncogenes which encode protein-tyrosine kinases.  This is, to the authors knowledge, the first evidence that mutations in a src-related gene are involved in human genetic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLGa0C4aUVMrVg90H21EOLACvtfcHk0limLVomw2h1gA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXitlajt7c%253D&md5=de1b23e0c0328d916633d0f92ddc1d68</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1038%2F361226a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F361226a0%26sid%3Dliteratum%253Aachs%26aulast%3DVetrie%26aufirst%3DD.%26aulast%3DVorechovsky%26aufirst%3DI.%26aulast%3DSideras%26aufirst%3DP.%26aulast%3DHolland%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DA.%26aulast%3DFlinter%26aufirst%3DF.%26aulast%3DHammarstrom%26aufirst%3DL.%26aulast%3DKinnon%26aufirst%3DC.%26aulast%3DLevinsky%26aufirst%3DR.%26aulast%3DBobrow%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DC.%2BI.%26aulast%3DBentley%26aufirst%3DD.%2BR.%26atitle%3DThe%2520gene%2520involved%2520in%2520X-linked%2520agammaglobulinemia%2520is%2520a%2520member%2520of%2520the%2520src%2520family%2520of%2520protein%2520tyrosine%2520kinases%26jtitle%3DNature%26date%3D1993%26volume%3D361%26spage%3D226%26epage%3D233%26doi%3D10.1038%2F361226a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlings, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">Role of Bruton’s tyrosine kinase in immunodeficiency</span>. <i>Curr. Opin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">623</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1016/0952-7915(94)90151-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1016%2F0952-7915%2894%2990151-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=7946052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADyaK2cXlsFCqur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1994&pages=623-630&author=S.+Tsukadaauthor=D.+J.+Rawlingsauthor=O.+N.+Witte&title=Role+of+Bruton%E2%80%99s+tyrosine+kinase+in+immunodeficiency&doi=10.1016%2F0952-7915%2894%2990151-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Bruton's tyrosine kinase in immunodeficiency</span></div><div class="casAuthors">Tsukada, Satoshi; Rawlings, David J.; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">623-30</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    </div><div class="casAbstract">A review, with 71 refs.  The genetic defect assocd. with human X-linked agammaglobulinemia and murine X-linked immunodeficiency was recently shown to result from lack of function of a new cytoplasmic tyrosine kinase, called Bruton's tyrosine kinase (Btk).  The phenotypes assocd. with these immunodeficiencies indicate that Btk plays a crit. role in B lymphocyte development.  The distinctive protein structure of Btk and preliminary functional studies suggest that Btk may act in a novel manner in a variety of signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAyW0bZjSS3rVg90H21EOLACvtfcHk0liHszcmnphntQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlsFCqur8%253D&md5=d9932cf5d56f7a77723a46cae519cbeb</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1016%2F0952-7915%2894%2990151-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0952-7915%252894%252990151-1%26sid%3Dliteratum%253Aachs%26aulast%3DTsukada%26aufirst%3DS.%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DRole%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520immunodeficiency%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D1994%26volume%3D6%26spage%3D623%26epage%3D630%26doi%3D10.1016%2F0952-7915%2894%2990151-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behney, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akaogi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacionales, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirakata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, W. H.</span></span> <span> </span><span class="NLM_article-title">X-linked immunodeficient mice spontaneously produce lupus-related anti-RNA helicase A autoantibodies but are resistant to pristane-induced lupus</span>. <i>Int. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1124</span>, <span class="refDoi"> DOI: 10.1093/intimm/dxg110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1093%2Fintimm%2Fdxg110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=12917264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsVGgt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2003&pages=1117-1124&issue=9&author=M.+Satohauthor=A.+Mizutaniauthor=K.+M.+Behneyauthor=Y.+Kurodaauthor=J.+Akaogiauthor=H.+Yoshidaauthor=D.+C.+Nacionalesauthor=M.+Hirakataauthor=N.+Onoauthor=W.+H.+Reeves&title=X-linked+immunodeficient+mice+spontaneously+produce+lupus-related+anti-RNA+helicase+A+autoantibodies+but+are+resistant+to+pristane-induced+lupus&doi=10.1093%2Fintimm%2Fdxg110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">X-linked immunodeficient mice spontaneously produce lupus-related anti-RNA helicase A autoantibodies, but are resistant to pristane-induced lupus</span></div><div class="casAuthors">Satoh, Minoru; Mizutani, Akiei; Behney, Krista M.; Kuroda, Yoshiki; Akaogi, Jun; Yoshida, Hideo; Nacionales, Dina C.; Hirakata, Michito; Ono, Nobutaka; Reeves, Westley H.</div><div class="citationInfo"><span class="NLM_cas:title">International Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1117-1124</span>CODEN:
                <span class="NLM_cas:coden">INIMEN</span>;
        ISSN:<span class="NLM_cas:issn">0953-8178</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Murine lupus can occur spontaneously or be induced by hydrocarbons, such as pristane.  Spontaneous disease in MRL and NZB/W F1 mice is suppressed by the xid (X-linked immunodeficiency) mutation, which greatly diminishes T cell-independent type 2 responses as well as the no. of peritoneal B1 cells.  The present study asked whether lupus induced by i.p. injection of pristane likewise is inhibited by the xid defect.  Male CBA/N (xid) mice were refractory to the induction of autoantibodies by pristane, whereas 23% of pristane-treated male CBA/CaJ controls produced anti-nRNP/Sm, -Su and/or -OJ (isoleucyl tRNA synthetase) antibodies.  Unexpectedly, 43% (12 of 28) of the xid mice spontaneously produced anti-nuclear antibodies that proved highly specific for the lupus antigen RNA helicase A (RHA).  Strikingly, this specificity was absent in CBA/CaJ mice (none of 51).  Moreover, pristane treatment suppressed the prodn. of anti-RHA antibodies when administered prior to the onset of autoantibody prodn., but enhanced anti-RHA levels when given after the onset of autoantibody prodn., suggesting that pristane interferes with anti-RHA prodn. at an early stage.  Large amts. of IgG1 anti-RHA autoantibodies were detected in the sera of xid mice, whereas pristane-induced anti-nRNP/Sm and -Su autoantibodies were almost exclusively IgG2a.  Cytokine prodn. within the peritoneal cavity reflected the predominant isotypes: IL-12 and IFN-γ predominated in pristane-treated mice, whereas IL-4 and IL-6 were more predominant in untreated xid mice.  The spontaneous prodn. of anti-RHA by xid mice and its suppression by pristane treatment at the level of autoantibody induction supports the idea that lupus autoantibodies may be generated through a variety of mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu9fB2XibBVbVg90H21EOLACvtfcHk0liHszcmnphntQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsVGgt74%253D&md5=e18338e223bd71f1ee0cfb65f7fd8c5c</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1093%2Fintimm%2Fdxg110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fintimm%252Fdxg110%26sid%3Dliteratum%253Aachs%26aulast%3DSatoh%26aufirst%3DM.%26aulast%3DMizutani%26aufirst%3DA.%26aulast%3DBehney%26aufirst%3DK.%2BM.%26aulast%3DKuroda%26aufirst%3DY.%26aulast%3DAkaogi%26aufirst%3DJ.%26aulast%3DYoshida%26aufirst%3DH.%26aulast%3DNacionales%26aufirst%3DD.%2BC.%26aulast%3DHirakata%26aufirst%3DM.%26aulast%3DOno%26aufirst%3DN.%26aulast%3DReeves%26aufirst%3DW.%2BH.%26atitle%3DX-linked%2520immunodeficient%2520mice%2520spontaneously%2520produce%2520lupus-related%2520anti-RNA%2520helicase%2520A%2520autoantibodies%2520but%2520are%2520resistant%2520to%2520pristane-induced%2520lupus%26jtitle%3DInt.%2520Immunol.%26date%3D2003%26volume%3D15%26issue%3D9%26spage%3D1117%26epage%3D1124%26doi%3D10.1093%2Fintimm%2Fdxg110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirisawad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loury, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thamm, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span> <span> </span><span class="NLM_article-title">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B cell activation and is efficacious in models of autoimmune disease and B cell malignancy</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">13075</span>– <span class="NLM_lpage">13080</span>, <span class="refDoi"> DOI: 10.1073/pnas.1004594107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1073%2Fpnas.1004594107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=20615965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=13075-13080&author=L.+A.+Honigbergauthor=A.+M.+Smithauthor=M.+Sirisawadauthor=E.+Vernerauthor=D.+Louryauthor=B.+Changauthor=S.+Liauthor=Z.+Panauthor=D.+H.+Thammauthor=R.+A.+Millerauthor=J.+J.+Buggy&title=The+Bruton+tyrosine+kinase+inhibitor+PCI-32765+blocks+B+cell+activation+and+is+efficacious+in+models+of+autoimmune+disease+and+B+cell+malignancy&doi=10.1073%2Fpnas.1004594107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span></div><div class="casAuthors">Honigberg, Lee A.; Smith, Ashley M.; Sirisawad, Mint; Verner, Erik; Loury, David; Chang, Betty; Li, Shyr; Pan, Zhengying; Thamm, Douglas H.; Miller, Richard A.; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">13075-13080, S13075/1-S13075/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases.  The Bruton tyrosine kinase (Btk) is specifically required for BCR signaling as demonstrated by human and mouse mutations that disrupt Btk function and prevent B-cell maturation at steps that require a functional BCR pathway.  Herein we describe a selective and irreversible Btk inhibitor, PCI-32765, that is currently under clin. development in patients with B-cell non-Hodgkin lymphoma.  We have used this inhibitor to investigate the biol. effects of Btk inhibition on mature B-cell function and the progression of B cell-assocd. diseases in vivo.  PCI-32765 blocked BCR signaling in human peripheral B cells at concns. that did not affect T cell receptor signaling.  In mice with collagen-induced arthritis, orally administered PCI-32765 reduced the level of circulating autoantibodies and completely suppressed disease.  PCI-32765 also inhibited autoantibody prodn. and the development of kidney disease in the MRL-Fas(lpr) lupus model.  Occupancy of the Btk active site by PCI-32765 was monitored in vitro and in vivo using a fluorescent affinity probe for Btk.  Active site occupancy of Btk was tightly correlated with the blockade of BCR signaling and in vivo efficacy.  Finally, PCI-32765 induced objective clin. responses in dogs with spontaneous B-cell non-Hodgkin lymphoma.  These findings support Btk inhibition as a therapeutic approach for the treatment of human diseases assocd. with activation of the BCR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT4OQHme7oHLVg90H21EOLACvtfcHk0liHszcmnphntQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D&md5=196ce4a05bb9c622c49cb7e908682e63</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004594107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004594107%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLoury%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520inhibitor%2520PCI-32765%2520blocks%2520B%2520cell%2520activation%2520and%2520is%2520efficacious%2520in%2520models%2520of%2520autoimmune%2520disease%2520and%2520B%2520cell%2520malignancy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D13075%26epage%3D13080%26doi%3D10.1073%2Fpnas.1004594107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamoorthi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomgren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPaolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span> <span> </span><span class="NLM_article-title">Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis</span>. <i>JCI Insight.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">e90111</span>, <span class="refDoi"> DOI: 10.1172/jci.insight.90111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1172%2Fjci.insight.90111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=28405610" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=e90111&author=A.+Katewaauthor=Y.+Wangauthor=J.+A.+Hackneyauthor=T.+Huangauthor=E.+Sutoauthor=N.+Ramamoorthiauthor=C.+D.+Austinauthor=M.+Bremerauthor=J.+Z.+Chenauthor=J.+J.+Crawfordauthor=K.+S.+Currieauthor=P.+Blomgrenauthor=J.+DeVossauthor=J.+A.+DiPaoloauthor=J.+Hauauthor=A.+Johnsonauthor=J.+Leschauthor=L.+E.+DeForgeauthor=Z.+Linauthor=M.+Liimattaauthor=J.+W.+Lubachauthor=S.+McVayauthor=Z.+Modrusanauthor=A.+Nguyenauthor=C.+Poonauthor=J.+Wangauthor=L.+Liuauthor=W.+P.+Leeauthor=H.+Wongauthor=W.+B.+Youngauthor=M.+J.+Townsendauthor=K.+Reif&title=Btk-specific+inhibition+blocks+pathogenic+plasma+cell+signatures+and+myeloid+cell-associated+damage+in+IFN%CE%B1-driven+lupus+nephritis&doi=10.1172%2Fjci.insight.90111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.90111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.90111%26sid%3Dliteratum%253Aachs%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHackney%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DSuto%26aufirst%3DE.%26aulast%3DRamamoorthi%26aufirst%3DN.%26aulast%3DAustin%26aufirst%3DC.%2BD.%26aulast%3DBremer%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DJ.%2BZ.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDiPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHau%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DLesch%26aufirst%3DJ.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMcVay%26aufirst%3DS.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DNguyen%26aufirst%3DA.%26aulast%3DPoon%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DTownsend%26aufirst%3DM.%2BJ.%26aulast%3DReif%26aufirst%3DK.%26atitle%3DBtk-specific%2520inhibition%2520blocks%2520pathogenic%2520plasma%2520cell%2520signatures%2520and%2520myeloid%2520cell-associated%2520damage%2520in%2520IFN%25CE%25B1-driven%2520lupus%2520nephritis%26jtitle%3DJCI%2520Insight.%26date%3D2017%26volume%3D2%26spage%3De90111%26doi%3D10.1172%2Fjci.insight.90111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucheron, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellmeier, W.</span></span> <span> </span><span class="NLM_article-title">The role of Tec family kinases in myeloid cells</span>. <i>Int. Arch. Allergy Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>134</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1159/000078339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1159%2F000078339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=15133303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktFKlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2004&pages=65-78&issue=1&author=U.+Schmidtauthor=N.+Boucheronauthor=B.+Ungerauthor=W.+Ellmeier&title=The+role+of+Tec+family+kinases+in+myeloid+cells&doi=10.1159%2F000078339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Tec Family Kinases in Myeloid Cells</span></div><div class="casAuthors">Schmidt, Uwe; Boucheron, Nicole; Unger, Bernd; Ellmeier, Wilfried</div><div class="citationInfo"><span class="NLM_cas:title">International Archives of Allergy and Immunology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-78</span>CODEN:
                <span class="NLM_cas:coden">IAAIEG</span>;
        ISSN:<span class="NLM_cas:issn">1018-2438</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review.  Members of the Tec kinase family (Bmx, Btk, Itk, Rlk and Tec) are primarily expressed in the hematopoietic system and form, after the Src kinase family, the second largest class of non-receptor protein tyrosine kinases.  During lymphocyte development and activation Tec kinases have important functions in signaling pathways downstream of the antigen receptors.  Tec family kinases are also expressed in cells of the myeloid lineage.  However, with the exception of mast cells and platelets, their biol. role in the myeloid system is only poorly understood.  This review summarizes the current knowledge about the function of Tec family kinases in hematopoietic cells of the myeloid lineage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpewxKP7kBxe7Vg90H21EOLACvtfcHk0lhM9BrffcNUoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktFKlsr8%253D&md5=e6e88b9b59049d9e55e95b6621a27453</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1159%2F000078339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000078339%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DU.%26aulast%3DBoucheron%26aufirst%3DN.%26aulast%3DUnger%26aufirst%3DB.%26aulast%3DEllmeier%26aufirst%3DW.%26atitle%3DThe%2520role%2520of%2520Tec%2520family%2520kinases%2520in%2520myeloid%2520cells%26jtitle%3DInt.%2520Arch.%2520Allergy%2520Immunol.%26date%3D2004%26volume%3D134%26issue%3D1%26spage%3D65%26epage%3D78%26doi%3D10.1159%2F000078339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Florence, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krupa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booshehri, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthay, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurdowska, A. K.</span></span> <span> </span><span class="NLM_article-title">Inhibiting Bruton’s tyrosine kinase rescues mice from lethal influenza-induced acute lung injury</span>. <i>Am. J. Physiol. Lung Cell Mol. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>315</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">L52</span>– <span class="NLM_lpage">L58</span>, <span class="refDoi"> DOI: 10.1152/ajplung.00047.2018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1152%2Fajplung.00047.2018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=29516781" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2018&pages=L52-L58&issue=1&author=J.+M.+Florenceauthor=A.+Krupaauthor=L.+M.+Booshehriauthor=S.+A.+Davisauthor=M.+A.+Matthayauthor=A.+K.+Kurdowska&title=Inhibiting+Bruton%E2%80%99s+tyrosine+kinase+rescues+mice+from+lethal+influenza-induced+acute+lung+injury&doi=10.1152%2Fajplung.00047.2018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1152%2Fajplung.00047.2018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajplung.00047.2018%26sid%3Dliteratum%253Aachs%26aulast%3DFlorence%26aufirst%3DJ.%2BM.%26aulast%3DKrupa%26aufirst%3DA.%26aulast%3DBooshehri%26aufirst%3DL.%2BM.%26aulast%3DDavis%26aufirst%3DS.%2BA.%26aulast%3DMatthay%26aufirst%3DM.%2BA.%26aulast%3DKurdowska%26aufirst%3DA.%2BK.%26atitle%3DInhibiting%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520rescues%2520mice%2520from%2520lethal%2520influenza-induced%2520acute%2520lung%2520injury%26jtitle%3DAm.%2520J.%2520Physiol.%2520Lung%2520Cell%2520Mol.%2520Physiol.%26date%3D2018%26volume%3D315%26issue%3D1%26spage%3DL52%26epage%3DL58%26doi%3D10.1152%2Fajplung.00047.2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smiljkovic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanzl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorofeeva, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skrabs, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Focke-Tejkl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperr, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaeger, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valent, P.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase inhibition is a potent approach to block IgE-mediated histamine release in human basophils</span>. <i>Allergy</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">1666</span>– <span class="NLM_lpage">1676</span>, <span class="refDoi"> DOI: 10.1111/all.13166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1111%2Fall.13166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=28328081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1ylsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2017&pages=1666-1676&author=D.+Smiljkovicauthor=K.+Blattauthor=G.+Stefanzlauthor=Y.+Dorofeevaauthor=C.+Skrabsauthor=M.+Focke-Tejklauthor=M.+R.+Sperrauthor=U.+Jaegerauthor=R.+Valentaauthor=P.+Valent&title=Bruton%E2%80%99s+tyrosine+kinase+inhibition+is+a+potent+approach+to+block+IgE-mediated+histamine+release+in+human+basophils&doi=10.1111%2Fall.13166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils</span></div><div class="casAuthors">Smiljkovic, D.; Blatt, K.; Stefanzl, G.; Dorofeeva, Y.; Skrabs, C.; Focke-Tejkl, M.; Sperr, W. R.; Jaeger, U.; Valenta, R.; Valent, P.</div><div class="citationInfo"><span class="NLM_cas:title">Allergy (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1666-1676</span>CODEN:
                <span class="NLM_cas:coden">LLRGDY</span>;
        ISSN:<span class="NLM_cas:issn">0105-4538</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : Recent data suggest that Bruton's tyrosine kinase (BTK) is an emerging therapeutic target in IgE receptor (IgER)-cross-linked basophils.  Methods : We examd. the effects of four BTK inhibitors (ibrutinib, dasatinib, AVL-292, and CNX-774) on IgE-dependent activation and histamine release in blood basophils obtained from allergic patients (n=11) and nonallergic donors (n=5).  In addn., we examd. the effects of these drugs on the growth of the human basophil cell line KU812 and the human mast cell line HMC-1.  Results : All four BTK blockers were found to inhibit anti-IgE-induced histamine release from basophils in nonallergic subjects and allergen-induced histamine liberation from basophils in allergic donors.  Drug effects on allergen-induced histamine release were dose dependent, with IC50 values ranging between 0.001 and 0.5 μmol/L, and the following rank order of potency: ibrutinib>AVL-292>dasatinib>CNX-774.  The basophil-targeting effect of ibrutinib was confirmed by demonstrating that IgE-dependent histamine release in ex vivo blood basophils is largely suppressed in a leukemia patient treated with ibrutinib.  Dasatinib and ibrutinib were also found to counteract anti-IgE-induced and allergen-induced upregulation of CD13, CD63, CD164, and CD203c on basophils, whereas AVL-292 and CNX-774 showed no significant effects.  Whereas dasatinib and CNX-774 were found to inhibit the growth of HMC-1 cells and KU812 cells, no substantial effects were seen with ibrutinib or AVL-292.  Conclusions : BTK-targeting drugs are potent inhibitors of IgE-dependent histamine release in human basophils.  The clin. value of BTK inhibition in the context of allergic diseases remains to be detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5v6kgqYZUS7Vg90H21EOLACvtfcHk0lhM9BrffcNUoQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1ylsL3L&md5=b912584594a8516718d443465ba2b01f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1111%2Fall.13166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fall.13166%26sid%3Dliteratum%253Aachs%26aulast%3DSmiljkovic%26aufirst%3DD.%26aulast%3DBlatt%26aufirst%3DK.%26aulast%3DStefanzl%26aufirst%3DG.%26aulast%3DDorofeeva%26aufirst%3DY.%26aulast%3DSkrabs%26aufirst%3DC.%26aulast%3DFocke-Tejkl%26aufirst%3DM.%26aulast%3DSperr%26aufirst%3DM.%2BR.%26aulast%3DJaeger%26aufirst%3DU.%26aulast%3DValenta%26aufirst%3DR.%26aulast%3DValent%26aufirst%3DP.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibition%2520is%2520a%2520potent%2520approach%2520to%2520block%2520IgE-mediated%2520histamine%2520release%2520in%2520human%2520basophils%26jtitle%3DAllergy%26date%3D2017%26volume%3D72%26spage%3D1666%26epage%3D1676%26doi%3D10.1111%2Fall.13166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elavazhagan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fatehchand, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reader, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, W. E.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butchar, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tridandapani, S.</span></span> <span> </span><span class="NLM_article-title">Analysis of the effects of the Bruton’s tyrosine kinase (Btk) inhibitor Ibrutinib on monocyte Fcγ receptor (FcγR) function</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">3043</span>– <span class="NLM_lpage">3052</span>, <span class="refDoi"> DOI: 10.1074/jbc.M115.687251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1074%2Fjbc.M115.687251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=26627823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVOqurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=3043-3052&issue=6&author=L.+Renauthor=A.+Campbellauthor=H.+Fangauthor=S.+Gautamauthor=S.+Elavazhaganauthor=K.+Fatehchandauthor=P.+Mehtaauthor=A.+Stiffauthor=B.+F.+Readerauthor=X.+Moauthor=J.+C.+Byrdauthor=W.+E.+Carsonauthor=J.+P.+Butcharauthor=S.+Tridandapani&title=Analysis+of+the+effects+of+the+Bruton%E2%80%99s+tyrosine+kinase+%28Btk%29+inhibitor+Ibrutinib+on+monocyte+Fc%CE%B3+receptor+%28Fc%CE%B3R%29+function&doi=10.1074%2Fjbc.M115.687251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function</span></div><div class="casAuthors">Ren, Li; Campbell, Amanda; Fang, Huiqing; Gautam, Shalini; Elavazhagan, Saranya; Fatehchand, Kavin; Mehta, Payal; Stiff, Andrew; Reader, Brenda F.; Mo, Xiaokui; Byrd, John C.; Carson, William E., III; Butchar, Jonathan P.; Tridandapani, Susheela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3043-3052</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The irreversible Bruton's tyrosine kinase (Btk) inhibitor ibrutinib has shown efficacy against B-cell tumors such as chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma.  Fcγ receptors (FcγR) on immune cells such as macrophages play an important role in tumor-specific antibody-mediated immune responses, but many such responses involve Btk.  Here we tested the effects of ibrutinib on FcγR-mediated activities in monocytes.  We found that ibrutinib did not affect monocyte FcγR-mediated phagocytosis, even at concns. higher than those achieved physiol., but suppressed FcγR-mediated cytokine prodn.  We confirmed these findings in macrophages from Xid mice in which Btk signaling is defective.  Because calcium flux is a major event downstream of Btk, we tested whether it was involved in phagocytosis.  The results showed that blocking intracellular calcium flux decreased FcγR-mediated cytokine prodn. but not phagocytosis.  To verify this, we measured activation of the GTPase Rac, which is responsible for actin polymn.  Results showed that ibrutinib did not inhibit Rac activation, nor did the calcium chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetrakis(acetoxymethyl ester).  We next asked whether the effect of ibrutinib on monocyte FcγR-mediated cytokine prodn. could be rescued by IFNγ priming because NK cells produce IFNγ in response to antibody therapy.  Pretreatment of monocytes with IFNγ abrogated the effects of ibrutinib on FcγR-mediated cytokine prodn., suggesting that IFNγ priming could overcome this Btk inhibition.  Furthermore, in monocyte-natural killer cell co-cultures, ibrutinib did not inhibit FcγR-mediated cytokine prodn. despite doing so in single cultures.  These results suggest that combining ibrutinib with monoclonal antibody therapy could enhance chronic lymphocytic leukemia cell killing without affecting macrophage effector function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-NSO3o-f2tbVg90H21EOLACvtfcHk0li8tmIdyn7i1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVOqurk%253D&md5=e40fc279a85f9903f06d902cf8ef8b2c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.687251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.687251%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DGautam%26aufirst%3DS.%26aulast%3DElavazhagan%26aufirst%3DS.%26aulast%3DFatehchand%26aufirst%3DK.%26aulast%3DMehta%26aufirst%3DP.%26aulast%3DStiff%26aufirst%3DA.%26aulast%3DReader%26aufirst%3DB.%2BF.%26aulast%3DMo%26aufirst%3DX.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DCarson%26aufirst%3DW.%2BE.%26aulast%3DButchar%26aufirst%3DJ.%2BP.%26aulast%3DTridandapani%26aufirst%3DS.%26atitle%3DAnalysis%2520of%2520the%2520effects%2520of%2520the%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528Btk%2529%2520inhibitor%2520Ibrutinib%2520on%2520monocyte%2520Fc%25CE%25B3%2520receptor%2520%2528Fc%25CE%25B3R%2529%2520function%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26issue%3D6%26spage%3D3043%26epage%3D3052%26doi%3D10.1074%2Fjbc.M115.687251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Akinleye, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib and novel BTK inhibitors in clinical development</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">59</span>, <span class="refDoi"> DOI: 10.1186/1756-8722-6-59</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1186%2F1756-8722-6-59" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=23958373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVagtrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=59&author=A.+Akinleyeauthor=Y.+I.+Chenauthor=N.+Mukhiauthor=Y.+Songauthor=D.+Liu&title=Ibrutinib+and+novel+BTK+inhibitors+in+clinical+development&doi=10.1186%2F1756-8722-6-59"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib and novel BTK inhibitors in clinical development</span></div><div class="casAuthors">Akinleye, Akintunde; Chen, Yamei; Mukhi, Nikhil; Song, Yongping; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Small mol. inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have significantly improved clin. outcomes in cancer patients.  Recently Bruton's tyrosine kinase (BTK), a crucial terminal kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has emerged as an attractive target for therapeutic intervention in human malignancies and autoimmune disorders.  Ibrutinib, a novel first-in-human BTK inhibitor, has demonstrated clin. effectiveness and tolerability in early clin. trials and has progressed into phase III trials.  However, addnl. research is necessary to identify the optimal dosing schedule, as well as patients most likely to benefit from BTK inhibition.  This review summarizes preclin. and clin. development of ibrutinib and other novel BTK inhibitors (GDC-0834, CGI-560, CGI-1746, HM-71224, CC-292 and ONO-4059, CNX-774, LFM-A13) in the treatment of B-cell malignancies and autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-fz7_rhCHvbVg90H21EOLACvtfcHk0li8tmIdyn7i1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVagtrjI&md5=e5067b998c61818e2efbb62da935b490</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-6-59&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-6-59%26sid%3Dliteratum%253Aachs%26aulast%3DAkinleye%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.%2BI.%26aulast%3DMukhi%26aufirst%3DN.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DIbrutinib%2520and%2520novel%2520BTK%2520inhibitors%2520in%2520clinical%2520development%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2013%26volume%3D6%26spage%3D59%26doi%3D10.1186%2F1756-8722-6-59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thareja, S.</span></span> <span> </span><span class="NLM_article-title">The development of Bruton’s tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1016%2Fj.ejmech.2018.03.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=29631132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1ehtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=315-326&author=C.+Liangauthor=D.+Tianauthor=X.+Renauthor=S.+Dingauthor=M.+Jiaauthor=M.+Xinauthor=S.+Thareja&title=The+development+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitors+from+2012+to+2017%3A+A+mini-review&doi=10.1016%2Fj.ejmech.2018.03.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review</span></div><div class="casAuthors">Liang, Chengyuan; Tian, Danni; Ren, Xiaodong; Ding, Shunjun; Jia, Minyi; Xin, Minhang; Thareja, Suresh</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">315-326</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (BTK) has emerged as a promising drug target for multiple diseases, particularly hematopoietic malignancies and autoimmune diseases related to B lymphocytes.  This review focuses on the diverse, small-mol. inhibitors of BTK kinase that have shown good prospects for clin. application.  Individual examples of these inhibitors, including both reversible and irreversible inhibitors and a recently developed reversible covalent inhibitor of BTK, are discussed.  Considerable progress has been made in the development of irreversible inhibitors, most of which target the SH3 pocket and the cysteine 481 residue of BTK.  The present review also surveys the pharmacol. advantages and deficiencies of both reversible and irreversible BTK drugs, with a focus on the structure-activity relationship (SARs) and binding modes of representative drugs, which could inspire crit. thinking and new ideas for developing potent BTK inhibitors with less unwanted off-target effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptNAsX0qwSHLVg90H21EOLACvtfcHk0li8tmIdyn7i1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1ehtL0%253D&md5=1ea0bf36d8ebadbfba624f858911b182</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.062%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DTian%26aufirst%3DD.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DM.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DThareja%26aufirst%3DS.%26atitle%3DThe%2520development%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitors%2520from%25202012%2520to%25202017%253A%2520A%2520mini-review%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D315%26epage%3D326%26doi%3D10.1016%2Fj.ejmech.2018.03.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isenberg, D. A.</span></span> <span> </span><span class="NLM_article-title">New therapies for systemic lupus erythematosus - past imperfect, future tense</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">403</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1038/s41584-019-0235-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1038%2Fs41584-019-0235-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=31165780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A280%3ADC%252BB3M3jsVCjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=403-412&author=G.+Murphyauthor=D.+A.+Isenberg&title=New+therapies+for+systemic+lupus+erythematosus+-+past+imperfect%2C+future+tense&doi=10.1038%2Fs41584-019-0235-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14cR"><div class="casContent"><span class="casTitleNuber">14c</span><div class="casTitle"><span class="NLM_cas:atitle">New therapies for systemic lupus erythematosus - past imperfect, future tense</span></div><div class="casAuthors">Murphy Grainne; Isenberg David A</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Rheumatology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">403-412</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The failure of many new, mostly biologic, drugs to meet their primary end points in double-blind clinical trials in patients with systemic lupus erythematosus (SLE) has caused a profound sense of disappointment among both physicians and patients.  Arguably, the success of B cell depletion with rituximab in open-label clinical trials, the approval of belimumab (which blocks B cell-activating factor (BAFF)) for use in patients with lupus nephritis in the USA and in difficult-to-treat patients with SLE in the UK and the recognition that clinical trial design can be improved have given some cause for hope.  However, changes to therapies in current use and the development of new approaches are urgently needed.  The results of the latest studies investigating the use of several new approaches to treating SLE are discussed in this Review, including: fully humanized anti-CD20 and anti-CD19 monoclonal antibodies; inhibition of tyrosine-protein kinase BTK; CD40 ligand blockade; interfering with the presentation of antigen to autoreactive T cells using a peptide approach; a receptor decoy approach using an analogue of Fcγ receptor IIB; dual blockade of IL-12 and IL-23; and inhibition of Janus kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSCLtu0y2YGaOxsqfvU0ziafW6udTcc2eZwv2kdlDmNk7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3jsVCjtQ%253D%253D&md5=f978e2a3b6c87b6acafcc7195e8a5857</span></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1038%2Fs41584-019-0235-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41584-019-0235-5%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DG.%26aulast%3DIsenberg%26aufirst%3DD.%2BA.%26atitle%3DNew%2520therapies%2520for%2520systemic%2520lupus%2520erythematosus%2520-%2520past%2520imperfect%252C%2520future%2520tense%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2019%26volume%3D15%26spage%3D403%26epage%3D412%26doi%3D10.1038%2Fs41584-019-0235-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit14d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pal Singh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dammeijer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span> <span> </span><span class="NLM_article-title">Role of Bruton’s tyrosine kinase in B cells and malignancies</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">57</span>, <span class="refDoi"> DOI: 10.1186/s12943-018-0779-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1186%2Fs12943-018-0779-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=29455639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A280%3ADC%252BC1MrivVektQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=57&issue=1&author=S.+Pal+Singhauthor=F.+Dammeijerauthor=R.+W.+Hendriks&title=Role+of+Bruton%E2%80%99s+tyrosine+kinase+in+B+cells+and+malignancies&doi=10.1186%2Fs12943-018-0779-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14dR"><div class="casContent"><span class="casTitleNuber">14d</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Bruton's tyrosine kinase in B cells and malignancies</span></div><div class="casAuthors">Pal Singh Simar; Dammeijer Floris; Hendriks Rudi W; Pal Singh Simar; Pal Singh Simar; Dammeijer Floris; Dammeijer Floris</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies.  BTK was initially shown to be defective in the primary immunodeficiency X-linked agammaglobulinemia (XLA) and is essential both for B cell development and function of mature B cells.  Shortly after its discovery, BTK was placed in the signal transduction pathway downstream of the B cell antigen receptor (BCR).  More recently, small-molecule inhibitors of this kinase have shown excellent anti-tumor activity, first in animal models and subsequently in clinical studies.  In particular, the orally administered irreversible BTK inhibitor ibrutinib is associated with high response rates in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and mantle-cell lymphoma (MCL), including patients with high-risk genetic lesions.  Because ibrutinib is generally well tolerated and shows durable single-agent efficacy, it was rapidly approved for first-line treatment of patients with CLL in 2016.  To date, evidence is accumulating for efficacy of ibrutinib in various other B cell malignancies.  BTK inhibition has molecular effects beyond its classic role in BCR signaling.  These involve B cell-intrinsic signaling pathways central to cellular survival, proliferation or retention in supportive lymphoid niches.  Moreover, BTK functions in several myeloid cell populations representing important components of the tumor microenvironment.  As a result, there is currently a considerable interest in BTK inhibition as an anti-cancer therapy, not only in B cell malignancies but also in solid tumors.  Efficacy of BTK inhibition as a single agent therapy is strong, but resistance may develop, fueling the development of combination therapies that improve clinical responses.  In this review, we discuss the role of BTK in B cell differentiation and B cell malignancies and highlight the importance of BTK inhibition in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTp0F3T0LEJd4vKgEt20y1XfW6udTcc2eZwv2kdlDmNk7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrivVektQ%253D%253D&md5=de1ba14dc19e6a123c21b89f1f4133f4</span></div><a href="/servlet/linkout?suffix=cit14d&amp;dbid=16384&amp;doi=10.1186%2Fs12943-018-0779-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-018-0779-z%26sid%3Dliteratum%253Aachs%26aulast%3DPal%2BSingh%26aufirst%3DS.%26aulast%3DDammeijer%26aufirst%3DF.%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26atitle%3DRole%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520B%2520cells%2520and%2520malignancies%26jtitle%3DMol.%2520Cancer%26date%3D2018%26volume%3D17%26issue%3D1%26spage%3D57%26doi%3D10.1186%2Fs12943-018-0779-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span>US Food
and Drug Administration. Approved Drugs: Ibrutinib. Available at <a href="https://wayback.archive-it.org/7993/20170111231706/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm374857.htm" class="extLink">https://wayback.archive-it.org/7993/20170111231706/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm374857.htm</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=US+Food%0Aand+Drug+Administration.+Approved+Drugs%3A+Ibrutinib.+Available+at+https%3A%2F%2Fwayback.archive-it.org%2F7993%2F20170111231706%2Fhttp%3A%2F%2Fwww.fda.gov%2FDrugs%2FInformationOnDrugs%2FApprovedDrugs%2Fucm374857.htm."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">21</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0250-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1186%2Fs13045-016-0250-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=26957112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1eisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=21&author=J.+Wuauthor=M.+Zhangauthor=D.+Liu&title=Acalabrutinib+%28ACP-196%29%3A+a+selective+second-generation+BTK+inhibitor&doi=10.1186%2Fs13045-016-0250-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor</span></div><div class="casAuthors">Wu, Jingjing; Zhang, Mingzhi; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21/1-21/4</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">More and more targeted agents become available for B cell malignancies with increasing precision and potency.  The first-in-class Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clin. use for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia.  More selective BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being explored.  Acalabrutinib (ACP-196) is a novel irreversible second-generation BTK inhibitor that was shown to be more potent and selective than ibrutinib.  This review summarized the preclin. research and clin. data of acalabrutinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAU072sMxzmLVg90H21EOLACvtfcHk0lgbAv_rWtTTiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1eisrw%253D&md5=a6a8f9b9236abe7ef1054a41e1c71e5a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0250-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0250-9%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DAcalabrutinib%2520%2528ACP-196%2529%253A%2520a%2520selective%2520second-generation%2520BTK%2520inhibitor%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D21%26doi%3D10.1186%2Fs13045-016-0250-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of Zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton’s tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7923</span>– <span class="NLM_lpage">7940</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00687</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00687" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFSku7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7923-7940&issue=17&author=Y.+Guoauthor=Y.+Liuauthor=N.+Huauthor=D.+Yuauthor=C.+Zhouauthor=G.+Shiauthor=B.+Zhangauthor=M.+Weiauthor=J.+Liuauthor=L.+Luoauthor=Z.+Tangauthor=H.+Songauthor=Y.+Guoauthor=X.+Liuauthor=D.+Suauthor=S.+Zhangauthor=X.+Songauthor=X.+Zhouauthor=Y.+Hongauthor=S.+Chenauthor=Z.+Chengauthor=S.+Youngauthor=Q.+Weiauthor=H.+Wangauthor=Q.+Wangauthor=L.+Lvauthor=F.+Wangauthor=H.+Xuauthor=H.+Sunauthor=H.+Xingauthor=N.+Liauthor=W.+Zhangauthor=Z.+Wangauthor=G.+Liuauthor=Z.+Sunauthor=D.+Zhouauthor=W.+Liauthor=L.+Liuauthor=L.+Wangauthor=Z.+Wang&title=Discovery+of+Zanubrutinib+%28BGB-3111%29%2C+a+novel%2C+potent%2C+and+selective+covalent+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1021%2Facs.jmedchem.9b00687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase</span></div><div class="casAuthors">Guo, Yunhang; Liu, Ye; Hu, Nan; Yu, Desheng; Zhou, Changyou; Shi, Gongyin; Zhang, Bo; Wei, Min; Liu, Junhua; Luo, Lusong; Tang, Zhiyu; Song, Huipeng; Guo, Yin; Liu, Xuesong; Su, Dan; Zhang, Shuo; Song, Xiaomin; Zhou, Xing; Hong, Yuan; Chen, Shuaishuai; Cheng, Zhenzhen; Young, Steve; Wei, Qiang; Wang, Haisheng; Wang, Qiuwen; Lv, Lei; Wang, Fan; Xu, Haipeng; Sun, Hanzi; Xing, Haimei; Li, Na; Zhang, Wei; Wang, Zhongbo; Liu, Guodong; Sun, Zhijian; Zhou, Dongping; Li, Wei; Liu, Libin; Wang, Lai; Wang, Zhiwei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7923-7940</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aberrant activation of Bruton's tyrosine kinase (BTK) plays an important role in pathogenesis of B-cell lymphomas, suggesting that inhibition of BTK is useful in the treatment of hematol. malignancies.  The discovery of a more selective on-target covalent BTK inhibitor is of high value.  Herein, we disclose the discovery and preclin. characterization of a potent, selective, and irreversible BTK inhibitor as our clin. candidate by using in vitro potency, selectivity, pharmacokinetics (PK), and in vivo pharmacodynamic for prioritizing compds.  Compd. BGB-3111 (31a, Zanubrutinib) demonstrates (i) potent activity against BTK and excellent selectivity over other TEC, EGFR and Src family kinases, (ii) desirable ADME, excellent in vivo pharmacodynamic in mice and efficacy in OCI-LY10 xenograft models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgRMQ-gBKtdbVg90H21EOLACvtfcHk0ljQooKglPtEyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFSku7bP&md5=5cdb551d296e60eb1e82b03b7a0384ee</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00687%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DWei%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSu%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DHong%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DZ.%26aulast%3DYoung%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLv%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DXing%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DSun%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520Zanubrutinib%2520%2528BGB-3111%2529%252C%2520a%2520novel%252C%2520potent%252C%2520and%2520selective%2520covalent%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D17%26spage%3D7923%26epage%3D7940%26doi%3D10.1021%2Facs.jmedchem.9b00687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Second-generation inhibitors of Bruton tyrosine kinase</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">80</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0313-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1186%2Fs13045-016-0313-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=27590878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVajtr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=80&author=J.+Wuauthor=C.+Liuauthor=S.+T.+Tsuiauthor=D.+Liu&title=Second-generation+inhibitors+of+Bruton+tyrosine+kinase&doi=10.1186%2Fs13045-016-0313-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Second-generation inhibitors of Bruton tyrosine kinase</span></div><div class="casAuthors">Wu, Jingjing; Liu, Christina; Tsui, Stella T.; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">80/1-80/7</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Bruton tyrosine kinase (BTK) is a crit. effector mol. for B cell development and plays a major role in lymphoma genesis.  Ibrutinib is the first-generation BTK inhibitor.  Ibrutinib has off-target effects on EGFR, ITK, and Tec family kinases, which explains the untoward effects of ibrutinib.  Resistance to ibrutinib was also reported.  The C481S mutation in the BTK kinase domain was reported to be a major mechanism of resistance to ibrutinib.  This review summarizes the clin. development of novel BTK inhibitors, ACP-196 (acalabrutinib), ONO/GS-4059, and BGB-3111.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb086cwyJYLrVg90H21EOLACvtfcHk0ljQooKglPtEyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVajtr7L&md5=b6140d9f7a24665131f5e772d55f29eb</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0313-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0313-y%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DTsui%26aufirst%3DS.%2BT.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DSecond-generation%2520inhibitors%2520of%2520Bruton%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D80%26doi%3D10.1186%2Fs13045-016-0313-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montalban, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staikov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piasecka-Stryczynska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willmer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dangond, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolinsky, J. S.</span></span> <span> </span><span class="NLM_article-title">Placebo-controlled trial of an oral BTK inhibitor in Multiple Sclerosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">2406</span>– <span class="NLM_lpage">2417</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1901981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1056%2FNEJMoa1901981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=31075187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsFGqurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=2406-2417&issue=25&author=X.+Montalbanauthor=D.+L.+Arnoldauthor=M.+S.+Weberauthor=I.+Staikovauthor=K.+Piasecka-Stryczynskaauthor=J.+Willmerauthor=E.+C.+Martinauthor=F.+Dangondauthor=S.+Syedauthor=J.+S.+Wolinsky&title=Placebo-controlled+trial+of+an+oral+BTK+inhibitor+in+Multiple+Sclerosis&doi=10.1056%2FNEJMoa1901981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis</span></div><div class="casAuthors">Montalban, Xavier; Arnold, Douglas L.; Weber, Martin S.; Staikov, Ivan; Piasecka-Stryczynska, Karolina; Willmer, Jonathan; Martin, Emily C.; Dangond, Fernando; Syed, Sana; Wolinsky, Jerry S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2406-2417</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Bruton's tyrosine kinase (BTK) regulates the functions of B cells and myeloid cells that are implicated in the pathogenesis of multiple sclerosis.  Evobrutinib is a selective oral BTK inhibitor that has been shown to inhibit B-cell activation both in vitro and in vivo. methods In this double-blind, randomized, phase 2 trial, we assigned patients with relapsing multiple sclerosis to one of five groups: placebo, evobrutinib (at a dose of 25 mg once daily, 75 mg once daily, or 75 mg twice daily), or open-label di-Me fumarate (DMF) as a ref.  The primary end point was the total (cumulative) no. of gadolinium-enhancing lesions identified on T1-weighted magnetic resonance imaging at weeks 12, 16, 20, and 24.  Key secondary end points included the annualized relapse rate and change from baseline in the score on the Expanded Disability Status Scale (EDSS). results A total of 267 patients were randomly assigned to a trial group.  The mean (±SD) total no. of gadolinium-enhancing lesions during weeks 12 through 24 was 3.85 ± 5.44 in the placebo group, 4.06 ± 8.02 in the evobrutinib 25-mg group, 1.69 ± 4.69 in the evobrutinib 75-mg once-daily group, 1.15 ± 3.70 in the evobrutinib 75-mg twice-daily group, and 4.78 ± 22.05 in the DMF group.  The baseline adjusted rate ratios for the total no. of lesions over time as compared with placebo were 1.45 in the evobrutinib 25-mg group (P = 0.32), 0.30 in the evobrutinib 75-mg once-daily group (P = 0.005), and 0.44 in the evobrutinib 75-mg twice-daily group (P = 0.06).  The unadjusted annualized relapse rate at week 24 was 0.37 in the placebo group, 0.57 in the evobrutinib 25-mg group, 0.13 in the evobrutinib 75-mg once-daily group, 0.08 in the evobrutinib 75-mg twice-daily group, and 0.20 in the DMF group.  There was no significant effect of trial group on the change from baseline in the EDSS score.  Elevations in liver aminotransferase values were obsd. with evobrutinib. conclusions Patients with relapsing multiple sclerosis who received 75 mg of evobrutinib once daily had significantly fewer enhancing lesions during weeks 12 through 24 than those who received placebo.  There was no significant difference with placebo for either the 25-mg once-daily or 75-mg twice-daily dose of evobrutinib, nor in the annualized relapse rate or disability progression at any dose.  Longer and larger trials are required to det. the effect and risks of evobrutinib in patients with multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBCts7AZpkC7Vg90H21EOLACvtfcHk0ljQooKglPtEyQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsFGqurs%253D&md5=86489e8fe1c2130c8ab46986f0b52881</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1901981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1901981%26sid%3Dliteratum%253Aachs%26aulast%3DMontalban%26aufirst%3DX.%26aulast%3DArnold%26aufirst%3DD.%2BL.%26aulast%3DWeber%26aufirst%3DM.%2BS.%26aulast%3DStaikov%26aufirst%3DI.%26aulast%3DPiasecka-Stryczynska%26aufirst%3DK.%26aulast%3DWillmer%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DE.%2BC.%26aulast%3DDangond%26aufirst%3DF.%26aulast%3DSyed%26aufirst%3DS.%26aulast%3DWolinsky%26aufirst%3DJ.%2BS.%26atitle%3DPlacebo-controlled%2520trial%2520of%2520an%2520oral%2520BTK%2520inhibitor%2520in%2520Multiple%2520Sclerosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26issue%3D25%26spage%3D2406%26epage%3D2417%26doi%3D10.1056%2FNEJMoa1901981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swami, A.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib</span>. <i>Ann. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>96</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1175</span>– <span class="NLM_lpage">1184</span>, <span class="refDoi"> DOI: 10.1007/s00277-017-2973-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1007%2Fs00277-017-2973-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=28342031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltl2ht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2017&pages=1175-1184&issue=7&author=V.+Kaurauthor=A.+Swami&title=Ibrutinib+in+CLL%3A+a+focus+on+adverse+events%2C+resistance%2C+and+novel+approaches+beyond+ibrutinib&doi=10.1007%2Fs00277-017-2973-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib</span></div><div class="casAuthors">Kaur, Varinder; Swami, Arjun</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Hematology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1175-1184</span>CODEN:
                <span class="NLM_cas:coden">ANHEE8</span>;
        ISSN:<span class="NLM_cas:issn">0939-5555</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a mediator in B cell receptor signaling has been successfully exploited as a therapeutic target in treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).  Ibrutinib is a BTK inhibitor that has shown excellent efficacy in treatment-naive, heavily pre-treated, and high-risk CLL/SLL.  With remarkable efficacy, good oral bioavailability, and modest adverse events profile, ibrutinib use is likely to continue to increase.  As data with ibrutinib use in CLL matures, concerns regarding adverse events and drug resistance have emerged.  New insights into mechanisms of ibrutinib resistance in CLL have uncovered potential therapeutic targets.  Several promising novel agents are currently in early phases of development for overcoming ibrutinib resistance in CLL/SLL.  We provide a comprehensive anal. of emerging adverse events profile of ibrutinib, summarize our current understanding of ibrutinib resistance in CLL, and review promising novel therapeutic tools to overcome this challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRsUgeFPl8N7Vg90H21EOLACvtfcHk0lgpr-fgpI4p0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltl2ht70%253D&md5=833537673bfe80fd7931dcc132c9b5aa</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs00277-017-2973-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00277-017-2973-2%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DV.%26aulast%3DSwami%26aufirst%3DA.%26atitle%3DIbrutinib%2520in%2520CLL%253A%2520a%2520focus%2520on%2520adverse%2520events%252C%2520resistance%252C%2520and%2520novel%2520approaches%2520beyond%2520ibrutinib%26jtitle%3DAnn.%2520Hematol.%26date%3D2017%26volume%3D96%26issue%3D7%26spage%3D1175%26epage%3D1184%26doi%3D10.1007%2Fs00277-017-2973-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, R. G.</span></span> <span> </span><span class="NLM_article-title">Idiosyncratic toxicity: A convergence of risk factors</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1146/annurev.med.58.072905.160823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1146%2Fannurev.med.58.072905.160823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=16958561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisV2jsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2007&pages=17-34&author=R.+G.+Ulrich&title=Idiosyncratic+toxicity%3A+A+convergence+of+risk+factors&doi=10.1146%2Fannurev.med.58.072905.160823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Idiosyncratic toxicity: a convergence of risk factors</span></div><div class="casAuthors">Ulrich, Roger G.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17-34</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The therapeutic margin for any drug is based on both toxicity and efficacy.  Generally, toxicity is dose-dependent and is driven either by the therapeutic target or by an untoward target.  However, idiosyncratic toxicities are usually not obsd. until a drug has been on the market and has gained broad exposure.  Except in the case of pharmacokinetic interactions, these toxicities are not driven solely by drug exposure but rather depend on several drug- and patient-related risk factors.  Drug-related risk factors include metab., bioactivation and covalent binding, and the inhibition of key cell functions.  Patient-related risk factors include underlying disease, age, gender, comedications, nutritional status, activation of the innate immune system, phys. activity, and genetic predispositions.  Idiosyncratic toxicity can occur when a convergence of risk factors, including drug exposure, tips the risk-benefit balance away from benefit and toward risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4gp_C2QKITbVg90H21EOLACvtfcHk0lgpr-fgpI4p0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisV2jsLs%253D&md5=8f2b7ffb21a38b648a83bc1a8430a17c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1146%2Fannurev.med.58.072905.160823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.med.58.072905.160823%26sid%3Dliteratum%253Aachs%26aulast%3DUlrich%26aufirst%3DR.%2BG.%26atitle%3DIdiosyncratic%2520toxicity%253A%2520A%2520convergence%2520of%2520risk%2520factors%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2007%26volume%3D58%26spage%3D17%26epage%3D34%26doi%3D10.1146%2Fannurev.med.58.072905.160823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tester, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witowski, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounsbury, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazdiyasni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W. F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>346</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.203489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1124%2Fjpet.113.203489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=23709115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=219-228&author=E.+K.+Evansauthor=R.+Testerauthor=S.+Aslanianauthor=R.+Karpauthor=M.+Sheetsauthor=M.+T.+Labenskiauthor=S.+R.+Witowskiauthor=H.+Lounsburyauthor=P.+Chaturvediauthor=H.+Mazdiyasniauthor=Z.+Zhuauthor=M.+Nachtauthor=M.+I.+Freedauthor=R.+C.+Petterauthor=A.+Dubrovskiyauthor=J.+Singhauthor=W.+F.+Westlin&title=Inhibition+of+Btk+with+CC-292+provides+early+pharmacodynamic+assessment+of+activity+in+mice+and+humans&doi=10.1124%2Fjpet.113.203489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span></div><div class="casAuthors">Evans, Erica K.; Tester, Richland; Aslanian, Sharon; Karp, Russell; Sheets, Michael; Labenski, Matthew T.; Witowski, Steven R.; Lounsbury, Heather; Chaturvedi, Prasoon; Mazdiyasni, Hormoz; Zhu, Zhendong; Nacht, Mariana; Freed, Martin I.; Petter, Russell C.; Dubrovskiy, Alex; Singh, Juswinder; Westlin, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-228</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as promising agents in autoimmune disease and B cell malignancies.  Bruton's tyrosine kinase (Btk) plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity.  N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide (CC-292) is a highly selective, covalent Btk inhibitor and a sensitive and quant. assay that measures CC-292-Btk engagement has been developed.  This translational pharmacodynamic assay has accompanied CC-292 through each step of drug discovery and development.  These studies demonstrate the quantity of Btk bound by CC-292 correlates with the efficacy of CC-292 in vitro and in the collagen-induced arthritis model of autoimmune disease.  Recently, CC-292 has entered human clin. trials with a trial design that has provided rapid insight into safety, pharmacokinetics, and pharmacodynamics.  This first-in-human healthy volunteer trial has demonstrated that a single oral dose of 2 mg/kg CC-292 consistently engaged all circulating Btk protein and provides the basis for rational dose selection in future clin. trials.  This targeted covalent drug design approach has enabled the discovery and early clin. development of CC-292 and has provided support for Btk as a valuable drug target for B-cell mediated disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN2l8ZCVqCFLVg90H21EOLACvtfcHk0lgpr-fgpI4p0A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM&md5=95fac997a246e59d943dd554af358a65</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.203489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.203489%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DE.%2BK.%26aulast%3DTester%26aufirst%3DR.%26aulast%3DAslanian%26aufirst%3DS.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DLabenski%26aufirst%3DM.%2BT.%26aulast%3DWitowski%26aufirst%3DS.%2BR.%26aulast%3DLounsbury%26aufirst%3DH.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DMazdiyasni%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DFreed%26aufirst%3DM.%2BI.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26atitle%3DInhibition%2520of%2520Btk%2520with%2520CC-292%2520provides%2520early%2520pharmacodynamic%2520assessment%2520of%2520activity%2520in%2520mice%2520and%2520humans%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26spage%3D219%26epage%3D228%26doi%3D10.1124%2Fjpet.113.203489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span>A Study
of LY3337641 in Rheumatoid Arthritis (RAjuvenate). ClinicalTrials.gov
Identifier: NCT02628028. <a href="https://clinicaltrials.gov/ct2/show/NCT02628028" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02628028</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study%0Aof+LY3337641+in+Rheumatoid+Arthritis+%28RAjuvenate%29.+ClinicalTrials.gov%0AIdentifier%3A+NCT02628028.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02628028."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin
Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elzinga, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westhouse, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catlett, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pokross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allentoff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of Branebrutinib (BMS-986195): a strategy for identifying a highly potent and selective covalent inhibitor providing rapid in vivo inactivation of Bruton’s tyrosine kinase (BTK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3228</span>– <span class="NLM_lpage">3250</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00167</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00167" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1MXls1aks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3228-3250&issue=7&author=S.+H.+Wattersonauthor=Q.+Liuauthor=M.+Beaudoin%0ABertrandauthor=D.+G.+Battauthor=L.+Liauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+Chengauthor=M.+T.+Obermeierauthor=R.+Mooreauthor=Z.+Yangauthor=R.+Vickeryauthor=P.+A.+Elzingaauthor=L.+Discenzaauthor=C.+D%E2%80%99Arienzoauthor=K.+M.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicicchioauthor=Y.+Zhangauthor=E.+Heimrichauthor=K.+W.+McIntyreauthor=Q.+Ruanauthor=R.+A.+Westhouseauthor=I.+M.+Catlettauthor=N.+Zhengauthor=C.+Chaudhryauthor=J.+Daiauthor=M.+A.+Galellaauthor=A.+J.+Tebbenauthor=M.+Pokrossauthor=J.+Liauthor=R.+Zhaoauthor=D.+Smithauthor=R.+Rampullaauthor=A.+Allentoffauthor=M.+A.+Wallaceauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+E.+Macorauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+Tino&title=Discovery+of+Branebrutinib+%28BMS-986195%29%3A+a+strategy+for+identifying+a+highly+potent+and+selective+covalent+inhibitor+providing+rapid+in+vivo+inactivation+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29&doi=10.1021%2Facs.jmedchem.9b00167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK)</span></div><div class="casAuthors">Watterson, Scott H.; Liu, Qingjie; Beaudoin Bertrand, Myra; Batt, Douglas G.; Li, Ling; Pattoli, Mark A.; Skala, Stacey; Cheng, Lihong; Obermeier, Mary T.; Moore, Robin; Yang, Zheng; Vickery, Rodney; Elzinga, Paul A.; Discenza, Lorell; D'Arienzo, Celia; Gillooly, Kathleen M.; Taylor, Tracy L.; Pulicicchio, Claudine; Zhang, Yifan; Heimrich, Elizabeth; McIntyre, Kim W.; Ruan, Qian; Westhouse, Richard A.; Catlett, Ian M.; Zheng, Naiyu; Chaudhry, Charu; Dai, Jun; Galella, Michael A.; Tebben, Andrew J.; Pokross, Matt; Li, Jianqing; Zhao, Rulin; Smith, Daniel; Rampulla, Richard; Allentoff, Alban; Wallace, Michael A.; Mathur, Arvind; Salter-Cid, Luisa; Macor, John E.; Carter, Percy H.; Fura, Aberra; Burke, James R.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3228-3250</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a non-receptor tyrosine kinase, is a member of the Tec family of kinases and is essential for B cell receptor (BCR) mediated signaling.  BTK also plays a crit. role in the downstream signaling pathways for the Fcγ receptor in monocytes, the Fcε receptor in granulocytes, and the RANK receptor in osteoclasts.  As a result, pharmacol. inhibition of BTK is anticipated to provide an effective strategy for the clin. treatment of autoimmune diseases such as rheumatoid arthritis and lupus.  This article will outline the evolution of our strategy to identify a covalent, irreversible inhibitor of BTK that has the intrinsic potency, selectivity, and pharmacokinetic properties necessary to provide a rapid rate of inactivation systemically following a very low dose.  With excellent in vivo efficacy and a very desirable tolerability profile, 5a (branebrutinib, BMS-986195) has advanced into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGr5oQEoebirVg90H21EOLACvtfcHk0ljwc3eynPXAkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXls1aks7w%253D&md5=2d521ec7c06d503f940cb44d381af58d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00167%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DElzinga%26aufirst%3DP.%2BA.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DWesthouse%26aufirst%3DR.%2BA.%26aulast%3DCatlett%26aufirst%3DI.%2BM.%26aulast%3DZheng%26aufirst%3DN.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DAllentoff%26aufirst%3DA.%26aulast%3DWallace%26aufirst%3DM.%2BA.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520Branebrutinib%2520%2528BMS-986195%2529%253A%2520a%2520strategy%2520for%2520identifying%2520a%2520highly%2520potent%2520and%2520selective%2520covalent%2520inhibitor%2520providing%2520rapid%2520in%2520vivo%2520inactivation%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D7%26spage%3D3228%26epage%3D3250%26doi%3D10.1021%2Facs.jmedchem.9b00167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Askew, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camps, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanabal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardberg, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goutopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenningloh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healey, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodous, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huck, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mochalkin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyring, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potnick, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shutes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbahns, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Follis, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegener, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerli, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Bujalski, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of Evobrutinib: an oral, potent, and highly selective, covalent Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of immunological diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7643</span>– <span class="NLM_lpage">7655</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00794</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00794" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsV2jtr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7643-7655&issue=17&author=R.+D.+Caldwellauthor=H.+Qiuauthor=B.+C.+Askewauthor=A.+T.+Benderauthor=N.+Bruggerauthor=M.+Campsauthor=M.+Dhanabalauthor=V.+Duttauthor=T.+Eichhornauthor=A.+S.+Gardbergauthor=A.+Goutopoulosauthor=R.+Grenninglohauthor=J.+Headauthor=B.+Healeyauthor=B.+L.+Hodousauthor=B.+R.+Huckauthor=T.+L.+Johnsonauthor=C.+Jonesauthor=R.+C.+Jonesauthor=I.+Mochalkinauthor=F.+Morandiauthor=N.+Nguyenauthor=M.+Meyringauthor=J.+R.+Potnickauthor=D.+C.+Santosauthor=R.+Schmidtauthor=B.+Shererauthor=A.+Shutesauthor=K.+Urbahnsauthor=A.+V.+Follisauthor=A.+A.+Wegenerauthor=S.+C.+Zimmerliauthor=L.+Liu-Bujalski&title=Discovery+of+Evobrutinib%3A+an+oral%2C+potent%2C+and+highly+selective%2C+covalent+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitor+for+the+treatment+of+immunological+diseases&doi=10.1021%2Facs.jmedchem.9b00794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases</span></div><div class="casAuthors">Caldwell, Richard D.; Qiu, Hui; Askew, Ben C.; Bender, Andrew T.; Brugger, Nadia; Camps, Montserrat; Dhanabal, Mohanraj; Dutt, Vikram; Eichhorn, Thomas; Gardberg, Anna S.; Goutopoulos, Andreas; Grenningloh, Roland; Head, Jared; Healey, Brian; Hodous, Brian L.; Huck, Bayard R.; Johnson, Theresa L.; Jones, Christopher; Jones, Reinaldo C.; Mochalkin, Igor; Morandi, Federica; Nguyen, Ngan; Meyring, Michael; Potnick, Justin R.; Santos, Dusica Cvetinovic; Schmidt, Ralf; Sherer, Brian; Shutes, Adam; Urbahns, Klaus; Follis, Ariele Viacava; Wegener, Ansgar A.; Zimmerli, Simone C.; Liu-Bujalski, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7643-7655</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) inhibitors such as ibrutinib hold a prominent role in the treatment of B cell malignancies.  However, further refinement is needed to this class of agents, particularly in terms of adverse events (potentially driven by kinase promiscuity), which preclude their evaluation in nononcol. indications.  Here, we report the discovery and preclin. characterization of evobrutinib, a potent, obligate covalent inhibitor with high kinase selectivity.  Evobrutinib displayed sufficient preclin. pharmacokinetic and pharmacodynamic characteristics which allowed for in vivo evaluation in efficacy models.  Moreover, the high selectivity of evobrutinib for BTK over epidermal growth factor receptor and other Tec family kinases suggested a low potential for off-target related adverse effects.  Clin. investigation of evobrutinib is ongoing in several autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFmL8DnlfGl7Vg90H21EOLACvtfcHk0ljxFxN6VrjR5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsV2jtr7P&md5=f9711d8a18803afc356dbac848067acf</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00794%26sid%3Dliteratum%253Aachs%26aulast%3DCaldwell%26aufirst%3DR.%2BD.%26aulast%3DQiu%26aufirst%3DH.%26aulast%3DAskew%26aufirst%3DB.%2BC.%26aulast%3DBender%26aufirst%3DA.%2BT.%26aulast%3DBrugger%26aufirst%3DN.%26aulast%3DCamps%26aufirst%3DM.%26aulast%3DDhanabal%26aufirst%3DM.%26aulast%3DDutt%26aufirst%3DV.%26aulast%3DEichhorn%26aufirst%3DT.%26aulast%3DGardberg%26aufirst%3DA.%2BS.%26aulast%3DGoutopoulos%26aufirst%3DA.%26aulast%3DGrenningloh%26aufirst%3DR.%26aulast%3DHead%26aufirst%3DJ.%26aulast%3DHealey%26aufirst%3DB.%26aulast%3DHodous%26aufirst%3DB.%2BL.%26aulast%3DHuck%26aufirst%3DB.%2BR.%26aulast%3DJohnson%26aufirst%3DT.%2BL.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DR.%2BC.%26aulast%3DMochalkin%26aufirst%3DI.%26aulast%3DMorandi%26aufirst%3DF.%26aulast%3DNguyen%26aufirst%3DN.%26aulast%3DMeyring%26aufirst%3DM.%26aulast%3DPotnick%26aufirst%3DJ.%2BR.%26aulast%3DSantos%26aufirst%3DD.%2BC.%26aulast%3DSchmidt%26aufirst%3DR.%26aulast%3DSherer%26aufirst%3DB.%26aulast%3DShutes%26aufirst%3DA.%26aulast%3DUrbahns%26aufirst%3DK.%26aulast%3DFollis%26aufirst%3DA.%2BV.%26aulast%3DWegener%26aufirst%3DA.%2BA.%26aulast%3DZimmerli%26aufirst%3DS.%2BC.%26aulast%3DLiu-Bujalski%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520Evobrutinib%253A%2520an%2520oral%252C%2520potent%252C%2520and%2520highly%2520selective%252C%2520covalent%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520immunological%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D17%26spage%3D7643%26epage%3D7655%26doi%3D10.1021%2Facs.jmedchem.9b00794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnarajah, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunn, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masjedizadeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gourlay, S. G.</span></span> <span> </span><span class="NLM_article-title">A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton’s tyrosine kinase, in healthy volunteers</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>83</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2367</span>– <span class="NLM_lpage">2376</span>, <span class="refDoi"> DOI: 10.1111/bcp.13351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1111%2Fbcp.13351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=28636208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslWrsLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2017&pages=2367-2376&issue=11&author=P.+F.+Smithauthor=J.+Krishnarajahauthor=P.+A.+Nunnauthor=R.+J.+Hillauthor=D.+Karrauthor=D.+Tamauthor=M.+Masjedizadehauthor=J.+O.+Funkauthor=S.+G.+Gourlay&title=A+phase+I+trial+of+PRN1008%2C+a+novel+reversible+covalent+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase%2C+in+healthy+volunteers&doi=10.1111%2Fbcp.13351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers</span></div><div class="casAuthors">Smith, Patrick F.; Krishnarajah, Janakan; Nunn, Philip A.; Hill, Ron J.; Karr, Dane; Tam, D.; Masjedizadeh, Mohammad; Funk, Jens O.; Gourlay, Steve G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2367-2376</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">To evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of PRN1008, a novel Bruton's tyrosine kinase (BTK) inhibitor, in healthy volunteers, and thus det. the dose range for future clin. studies.  This was a two-part randomized, placebo controlled study in healthy volunteers using a liq. formulation.  Part I was a single ascending dose design with dose levels of 50-1200 mg (n = 6 active, two placebos per cohort); Part II was a multiple ascending dose design, with dose regimens ranging from 300 to 900 mg daily, either four times or twice daily for 10 days.  Plasma pharmacokinetics, adverse events, vital signs, electrocardiograms and lab. parameters were assessed.  BTK occupancy in peripheral blood mononuclear cells was evaluated as a marker of target engagement.  PRN1008 was rapidly absorbed following oral administration, and was safe and well tolerated in all dose regimens evaluated in both single and multiple doses.  PRN1008 demonstrated a large vol. of distribution, and a half-life of approx. 3-4 h.  BTK occupancy of >90% was obsd. within 4 h after dosing in both single and multiple dose regimens, and was closely linked to max. plasma concn.  BTK occupancy decay was slow (-1.6% h-1), and occupancy was sustained despite drug concns. being undetectable.  No severe or serious adverse events occurred, and the most common adverse events were gastrointestinal in nature.  PRN1008 was safe and well-tolerated following oral administration, and achieved high, sustained levels of BTK occupancy in peripheral blood mononuclear cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDCmAr26_VXLVg90H21EOLACvtfcHk0ljxFxN6VrjR5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslWrsLnE&md5=8da03545b8beec4c50cdd95854bcad8f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13351%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DP.%2BF.%26aulast%3DKrishnarajah%26aufirst%3DJ.%26aulast%3DNunn%26aufirst%3DP.%2BA.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DKarr%26aufirst%3DD.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DMasjedizadeh%26aufirst%3DM.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26aulast%3DGourlay%26aufirst%3DS.%2BG.%26atitle%3DA%2520phase%2520I%2520trial%2520of%2520PRN1008%252C%2520a%2520novel%2520reversible%2520covalent%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%252C%2520in%2520healthy%2520volunteers%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2017%26volume%3D83%26issue%3D11%26spage%3D2367%26epage%3D2376%26doi%3D10.1111%2Fbcp.13351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.1080/13543776.2019.1594777</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1080%2F13543776.2019.1594777" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=30888232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnt1Wrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=217-241&issue=4&author=Y.+Fengauthor=W.+Duanauthor=X.+Cuauthor=C.+Liangauthor=M.+Xin&title=Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitors+in+treating+cancer%3A+a+patent+review+%282010-2018%29&doi=10.1080%2F13543776.2019.1594777"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018)</span></div><div class="casAuthors">Feng, Yifan; Duan, Weiming; Cu, Xiaochuan; Liang, Chengyuan; Xin, Minhang</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">217-241</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (BTK) plays a crit. role in the regulation of survival, proliferation, activation and differentiation of B-lineage cells.  It participates by regulating multiple cellular signaling pathways, including B cell receptor and FcR signaling cascades.  BTK is abundantly expressed and constitutively active in the pathogenesis of B cell hematol. malignancies, as well as several autoimmune diseases.  Therefore, BTK is considered as an attractive target for treatment of B-lineage lymphomas, leukemias, and some autoimmune diseases.  Many industry and academia efforts have been made to explore small mol. BTK inhibitors.  This review aims to provide an overview of the patented BTK inhibitors for the treatment of cancer from 2010 to 2018.  BTK inhibitors attract much interest for their therapeutic potential in the treatment of cancers and autoimmune diseases, esp. for B cell hematol. malignancies.  In 2013, ibrutinib was approved by the FDA as the first-in-class BTK inhibitors for the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), and now it is also undergoing clin. evaluation for other indications in either single or combined therapy.  It is clear that BTK inhibitors can provide a promising clin. benefit in treating B-lineage lymphomas and leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJGOIlTJf7g7Vg90H21EOLACvtfcHk0ljxFxN6VrjR5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnt1Wrsbo%253D&md5=2f31c214c46945f7818532a39430ec00</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1080%2F13543776.2019.1594777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2019.1594777%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DDuan%26aufirst%3DW.%26aulast%3DCu%26aufirst%3DX.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DXin%26aufirst%3DM.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitors%2520in%2520treating%2520cancer%253A%2520a%2520patent%2520review%2520%25282010-2018%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2019%26volume%3D29%26issue%3D4%26spage%3D217%26epage%3D241%26doi%3D10.1080%2F13543776.2019.1594777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Angst, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gessier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janser, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wälchli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beerli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littlewood-Evans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuesslein-Hildesheim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieczorek, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheufler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinniger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funhoff, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cenni, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of LOU064 (remibrutinib), a potent and highly selective covalent inhibitor of Bruton’s tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">5102</span>– <span class="NLM_lpage">5118</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01916</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01916" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjs1KiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=5102-5118&author=D.+Angstauthor=F.+Gessierauthor=P.+Janserauthor=A.+Vulpettiauthor=R.+W%C3%A4lchliauthor=C.+Beerliauthor=A.+Littlewood-Evansauthor=J.+Dawsonauthor=B.+Nuesslein-Hildesheimauthor=G.+Wieczorekauthor=S.+Gutmannauthor=C.+Scheuflerauthor=A.+Hinnigerauthor=A.+Zimmerlinauthor=E.+G.+Funhoffauthor=R.+Pulzauthor=B.+Cenni&title=Discovery+of+LOU064+%28remibrutinib%29%2C+a+potent+and+highly+selective+covalent+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1021%2Facs.jmedchem.9b01916"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase</span></div><div class="casAuthors">Angst, Daniela; Gessier, Francois; Janser, Philipp; Vulpetti, Anna; Walchli, Rudolf; Beerli, Christian; Littlewood-Evans, Amanda; Dawson, Janet; Nuesslein-Hildesheim, Barbara; Wieczorek, Grazyna; Gutmann, Sascha; Scheufler, Clemens; Hinniger, Alexandra; Zimmerlin, Alfred; Funhoff, Enrico G.; Pulz, Robert; Cenni, Bruno</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5102-5118</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases.  The use of currently marketed covalent BTK inhibitors is limited to oncol. indications based on their suboptimal kinase selectivity.  We describe the discovery and preclin. profile of LOU064 (remibrutinib, 25), a potent, highly selective covalent BTK inhibitor.  LOU064 exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for a best-in-class covalent BTK inhibitor for the treatment of autoimmune diseases.  It demonstrates potent in vivo target occupancy with an EC90 of 1.6 mg/kg and dose-dependent efficacy in rat collagen-induced arthritis.  LOU064 is currently being tested in phase 2 clin. studies for chronic spontaneous urticaria and Sjoegren's syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBR_esJ38IMrVg90H21EOLACvtfcHk0liyF-EBAOOSsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjs1KiurY%253D&md5=9122b310c294d6071ae7cd73cdb91b3d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01916%26sid%3Dliteratum%253Aachs%26aulast%3DAngst%26aufirst%3DD.%26aulast%3DGessier%26aufirst%3DF.%26aulast%3DJanser%26aufirst%3DP.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DW%25C3%25A4lchli%26aufirst%3DR.%26aulast%3DBeerli%26aufirst%3DC.%26aulast%3DLittlewood-Evans%26aufirst%3DA.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DNuesslein-Hildesheim%26aufirst%3DB.%26aulast%3DWieczorek%26aufirst%3DG.%26aulast%3DGutmann%26aufirst%3DS.%26aulast%3DScheufler%26aufirst%3DC.%26aulast%3DHinniger%26aufirst%3DA.%26aulast%3DZimmerlin%26aufirst%3DA.%26aulast%3DFunhoff%26aufirst%3DE.%2BG.%26aulast%3DPulz%26aufirst%3DR.%26aulast%3DCenni%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520LOU064%2520%2528remibrutinib%2529%252C%2520a%2520potent%2520and%2520highly%2520selective%2520covalent%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D5102%26epage%3D5118%26doi%3D10.1021%2Facs.jmedchem.9b01916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coraggio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of GDC-0853: a potent, selective, and noncovalent Bruton’s tyrosine kinase inhibitor in early clinical development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2227</span>– <span class="NLM_lpage">2245</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01712</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01712" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2227-2245&author=J.+J.+Crawfordauthor=A.+R.+Johnsonauthor=D.+L.+Misnerauthor=L.+D.+Belmontauthor=G.+Castanedoauthor=R.+Choyauthor=M.+Coraggioauthor=L.+Dongauthor=C.+Eigenbrotauthor=R.+Ericksonauthor=N.+Ghilardiauthor=J.+Hauauthor=A.+Katewaauthor=P.+B.+Kohliauthor=W.+Leeauthor=J.+W.+Lubachauthor=B.+S.+McKenzieauthor=D.+F.+Ortwineauthor=L.+Schuttauthor=S.+Tayauthor=B.+Weiauthor=K.+Reifauthor=L.+Liuauthor=H.+Wongauthor=W.+B.+Young&title=Discovery+of+GDC-0853%3A+a+potent%2C+selective%2C+and+noncovalent+Bruton%E2%80%99s+tyrosine+kinase+inhibitor+in+early+clinical+development&doi=10.1021%2Facs.jmedchem.7b01712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development</span></div><div class="casAuthors">Crawford, James J.; Johnson, Adam R.; Misner, Dinah L.; Belmont, Lisa D.; Castanedo, Georgette; Choy, Regina; Coraggio, Melis; Dong, Liming; Eigenbrot, Charles; Erickson, Rebecca; Ghilardi, Nico; Hau, Jonathan; Katewa, Arna; Kohli, Pawan Bir; Lee, Wendy; Lubach, Joseph W.; McKenzie, Brent S.; Ortwine, Daniel F.; Schutt, Leah; Tay, Suzanne; Wei, BinQing; Reif, Karin; Liu, Lichuan; Wong, Harvey; Young, Wendy B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2227-2245</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, resp.  Preclin. studies have indicated that inhibition of Btk activity might offer a potential therapy in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.  Here we disclose the discovery and preclin. characterization of a potent, selective, and noncovalent Btk inhibitor currently in clin. development.  GDC-0853 (29) suppresses B cell- and myeloid cell-mediated components of disease and demonstrates dose-dependent activity in an in vivo rat model of inflammatory arthritis.  It demonstrates highly favorable safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in preclin. and Phase 2 studies ongoing in patients with rheumatoid arthritis, lupus, and chronic spontaneous urticaria.  On the basis of its potency, selectivity, long target residence time, and noncovalent mode of inhibition, 29 has the potential to be a best-in-class Btk inhibitor for a wide range of immunol. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOUJgTOFJ-o7Vg90H21EOLACvtfcHk0liyF-EBAOOSsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D&md5=eddbd31f387fe86827a7469e8be45430</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01712%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChoy%26aufirst%3DR.%26aulast%3DCoraggio%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DErickson%26aufirst%3DR.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DHau%26aufirst%3DJ.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DSchutt%26aufirst%3DL.%26aulast%3DTay%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DDiscovery%2520of%2520GDC-0853%253A%2520a%2520potent%252C%2520selective%252C%2520and%2520noncovalent%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%2520in%2520early%2520clinical%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2227%26epage%3D2245%26doi%3D10.1021%2Facs.jmedchem.7b01712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit28b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lucca, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langevine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traeger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): a reversible inhibitor of Bruton’s tyrosine kinase (BTK) conformationally constrained by two locked atropisomers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9173</span>– <span class="NLM_lpage">9200</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01088</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01088" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKjsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9173-9200&author=S.+H.+Wattersonauthor=G.+V.+De+Luccaauthor=Q.+Shiauthor=C.+M.+Langevineauthor=Q.+Liuauthor=D.+G.+Battauthor=M.+B.+Bertrandauthor=H.+Gongauthor=J.+Daiauthor=S.+Yipauthor=P.+Liauthor=D.+Sunauthor=D.-R.+Wuauthor=C.+Wangauthor=Y.+Zhangauthor=S.+C.+Traegerauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+Chengauthor=M.+T.+Obermeierauthor=R.+Vickeryauthor=L.+N.+Discenzaauthor=C.+J.+D%E2%80%99Arienzoauthor=Y.+Zhangauthor=E.+Heimrichauthor=K.+M.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicicchioauthor=K.+W.+McIntyreauthor=M.+A.+Galellaauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+A.+Tino&title=Discovery+of+6-Fluoro-5-%28R%29-%283-%28S%29-%288-fluoro-1-methyl-2%2C4-dioxo-1%2C2-dihydroquinazolin-3%284H%29-yl%29-2-methylphenyl%29-2-%28S%29-%282-hydroxypropan-2-yl%29-2%2C3%2C4%2C9-tetrahydro-1H-carbazole-8-carboxamide+%28BMS-986142%29%3A+a+reversible+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+conformationally+constrained+by+two+locked+atropisomers&doi=10.1021%2Facs.jmedchem.6b01088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers</span></div><div class="casAuthors">Watterson, Scott H.; De Lucca, George V.; Shi, Qing; Langevine, Charles M.; Liu, Qingjie; Batt, Douglas G.; Beaudoin Bertrand, Myra; Gong, Hua; Dai, Jun; Yip, Shiuhang; Li, Peng; Sun, Dawn; Wu, Dauh-Rurng; Wang, Chunlei; Zhang, Yingru; Traeger, Sarah C.; Pattoli, Mark A.; Skala, Stacey; Cheng, Lihong; Obermeier, Mary T.; Vickery, Rodney; Discenza, Lorell N.; D'Arienzo, Celia J.; Zhang, Yifan; Heimrich, Elizabeth; Gillooly, Kathleen M.; Taylor, Tracy L.; Pulicicchio, Claudine; McIntyre, Kim W.; Galella, Michael A.; Tebben, Andy J.; Muckelbauer, Jodi K.; Chang, ChiehYing; Rampulla, Richard; Mathur, Arvind; Salter-Cid, Luisa; Barrish, Joel C.; Carter, Percy H.; Fura, Aberra; Burke, James R.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9173-9200</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a member of the Tec family of kinases.  BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcγ receptor signaling in monocytes and Fcε receptor signaling in mast cells and basophils, all of which have been implicated in the pathophysiol. of autoimmune disease.  As a result, inhibition of BTK is anticipated to provide an effective strategy for the clin. treatment of autoimmune diseases such as lupus and rheumatoid arthritis.  This article details the structure-activity relationships (SAR) leading to a novel series of highly potent and selective carbazole and tetrahydrocarbazole based, reversible inhibitors of BTK.  Of particular interest is that two atropisomeric centers were rotationally locked to provide a single, stable atropisomer, resulting in enhanced potency and selectivity as well as a redn. in safety liabilities.  With significantly enhanced potency and selectivity, excellent in vivo properties and efficacy, and a very desirable tolerability and safety profile, 14f (BMS-986142) was advanced into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpBAygRAsYrVg90H21EOLACvtfcHk0li_tamqEoLCnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKjsrfF&md5=91098abc802521b9ad91563d20ac5893</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01088%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLangevine%26aufirst%3DC.%2BM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBertrand%26aufirst%3DM.%2BB.%26aulast%3DGong%26aufirst%3DH.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DYip%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTraeger%26aufirst%3DS.%2BC.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DDiscenza%26aufirst%3DL.%2BN.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25206-Fluoro-5-%2528R%2529-%25283-%2528S%2529-%25288-fluoro-1-methyl-2%252C4-dioxo-1%252C2-dihydroquinazolin-3%25284H%2529-yl%2529-2-methylphenyl%2529-2-%2528S%2529-%25282-hydroxypropan-2-yl%2529-2%252C3%252C4%252C9-tetrahydro-1H-carbazole-8-carboxamide%2520%2528BMS-986142%2529%253A%2520a%2520reversible%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520conformationally%2520constrained%2520by%2520two%2520locked%2520atropisomers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9173%26epage%3D9200%26doi%3D10.1021%2Facs.jmedchem.6b01088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit28c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kawahata, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyoi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asamitsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawa, M.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of novel amino-triazine analogues as selective Bruton’s tyrosine kinase inhibitors for treatment of Rheumatoid Arthritis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8917</span>– <span class="NLM_lpage">8933</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01147</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01147" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslaitLbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8917-8933&author=W.+Kawahataauthor=T.+Asamiauthor=T.+Kiyoiauthor=T.+Irieauthor=H.+Taniguchiauthor=Y.+Asamitsuauthor=T.+Inoueauthor=T.+Miyakeauthor=M.+Sawa&title=Design+and+synthesis+of+novel+amino-triazine+analogues+as+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitors+for+treatment+of+Rheumatoid+Arthritis&doi=10.1021%2Facs.jmedchem.8b01147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28cR"><div class="casContent"><span class="casTitleNuber">28c</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis</span></div><div class="casAuthors">Kawahata, Wataru; Asami, Tokiko; Kiyoi, Takao; Irie, Takayuki; Taniguchi, Haruka; Asamitsu, Yuko; Inoue, Tomoko; Miyake, Takahiro; Sawa, Masaaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8917-8933</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) is a promising drug target for the treatment of multiple diseases, such as B-cell malignances, asthma, and rheumatoid arthritis.  A series of novel aminotriazines were identified as highly selective inhibitors of BTK by a scaffold-hopping approach.  Subsequent SAR studies of this series using two conformationally different BTK proteins, an activated form of BTK and an unactivated form of BTK, led to the discovery of a highly selective BTK inhibitor, I.  With significant efficacy in models in vivo and good ADME and safety profiles, I was advanced into preclin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_BGbFneA5HbVg90H21EOLACvtfcHk0li_tamqEoLCnw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslaitLbK&md5=56afc013f74a2912624c57c61a197845</span></div><a href="/servlet/linkout?suffix=cit28c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01147%26sid%3Dliteratum%253Aachs%26aulast%3DKawahata%26aufirst%3DW.%26aulast%3DAsami%26aufirst%3DT.%26aulast%3DKiyoi%26aufirst%3DT.%26aulast%3DIrie%26aufirst%3DT.%26aulast%3DTaniguchi%26aufirst%3DH.%26aulast%3DAsamitsu%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DMiyake%26aufirst%3DT.%26aulast%3DSawa%26aufirst%3DM.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520amino-triazine%2520analogues%2520as%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%2520for%2520treatment%2520of%2520Rheumatoid%2520Arthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8917%26epage%3D8933%26doi%3D10.1021%2Facs.jmedchem.8b01147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuckwell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsumoto, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damjanov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedkov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span> <span> </span><span class="NLM_article-title">OP0025 Fenebrutinib compared to placebo and adalimumab in patients with inadequate response to either methotrexate therapy or prior TNF therapy: Phase 2 study</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2019-eular.4469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1136%2Fannrheumdis-2019-eular.4469" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2019&pages=80-81&author=S.+Cohenauthor=K.+Tuckwellauthor=T.+R.+Katsumotoauthor=R.+Zhaoauthor=C.+Leeauthor=A.+Bermanauthor=N.+Damjanovauthor=D.+Fedkovauthor=S.+Jekaauthor=M.+C.+Genovese&title=OP0025+Fenebrutinib+compared+to+placebo+and+adalimumab+in+patients+with+inadequate+response+to+either+methotrexate+therapy+or+prior+TNF+therapy%3A+Phase+2+study&doi=10.1136%2Fannrheumdis-2019-eular.4469"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2019-eular.4469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2019-eular.4469%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DTuckwell%26aufirst%3DK.%26aulast%3DKatsumoto%26aufirst%3DT.%2BR.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DBerman%26aufirst%3DA.%26aulast%3DDamjanov%26aufirst%3DN.%26aulast%3DFedkov%26aufirst%3DD.%26aulast%3DJeka%26aufirst%3DS.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26atitle%3DOP0025%2520Fenebrutinib%2520compared%2520to%2520placebo%2520and%2520adalimumab%2520in%2520patients%2520with%2520inadequate%2520response%2520to%2520either%2520methotrexate%2520therapy%2520or%2520prior%2520TNF%2520therapy%253A%2520Phase%25202%2520study%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2019%26volume%3D78%26spage%3D80%26epage%3D81%26doi%3D10.1136%2Fannrheumdis-2019-eular.4469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prohn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huisman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matzuka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanley, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuckwell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quartino, A.</span></span> <span> </span><span class="NLM_article-title">Population pharmacokinetics, efficacy exposure-response analysis, and model-based meta-analysis of Fenebrutinib in subjects with Rheumatoid Arthritis</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">25</span>, <span class="refDoi"> DOI: 10.1007/s11095-019-2752-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1007%2Fs11095-019-2752-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=31907670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktVSmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2020&pages=25&author=P.+Chanauthor=J.+Yuauthor=L.+Chinnauthor=M.+Prohnauthor=J.+Huismanauthor=B.+Matzukaauthor=W.+Hanleyauthor=K.+Tuckwellauthor=A.+Quartino&title=Population+pharmacokinetics%2C+efficacy+exposure-response+analysis%2C+and+model-based+meta-analysis+of+Fenebrutinib+in+subjects+with+Rheumatoid+Arthritis&doi=10.1007%2Fs11095-019-2752-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30aR"><div class="casContent"><span class="casTitleNuber">30a</span><div class="casTitle"><span class="NLM_cas:atitle">Population Pharmacokinetics, Efficacy Exposure-Response Analysis</span></div><div class="casAuthors">Chan, Phyllis; Yu, Jiajie; Chinn, Leslie; Prohn, Marita; Huisman, Jan; Matzuka, Brett; Hanley, William; Tuckwell, Katie; Quartino, Angelica</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">25</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Fenebrutinib (GDC-0853), a Bruton's tyrosine kinase (BTK) inhibitor was investigated in a Phase 2 clin. trial in patients with rheumatoid arthritis (RA).  Our aim was to apply a model-informed drug development (MIDD) approach to examine the totality of available clin. efficacy data.  Methods: Population pharmacokinetics (popPK) modeling, exposure-response (E-R) anal., and model-based meta-anal. (MBMA) of fenebrutinib were performed based on the Phase 2 data.  Results: PopPK of fenebrutinib after oral administration was described using a 3-compartment model with linear elimination and a flexible absorption transit compartment model.  Healthy subjects had a 52% higher apparent clearance than patients.  E-R analyses based on longitudinal ACR20, ACR50, and ACR70 and DAS28 (CRP) data modeled fenebrutinib effect with an Emax function, and an efficacy plateau was achieved within the exposure range obtained in the Phase 2 clin. trial.  Based on literature data, a summary-level clin. efficacy database was constructed, and MBMA detd. ACR20, ACR50, and ACR70 responder rates in the placebo and adalimumab arms of the Phase 2 clin. trial were found to be consistent with historical data for these treatments.  Conclusions: Our multi-pronged approach applied MIDD to maximize knowledge extn. of efficacy data and enabled robust interpretation from a Phase 2 clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4w0ut42EyLbVg90H21EOLACvtfcHk0lgH-h6eSQbIxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktVSmuw%253D%253D&md5=9595cdee744a104468d889a049a6dd4a</span></div><a href="/servlet/linkout?suffix=cit30a&amp;dbid=16384&amp;doi=10.1007%2Fs11095-019-2752-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-019-2752-y%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DP.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DChinn%26aufirst%3DL.%26aulast%3DProhn%26aufirst%3DM.%26aulast%3DHuisman%26aufirst%3DJ.%26aulast%3DMatzuka%26aufirst%3DB.%26aulast%3DHanley%26aufirst%3DW.%26aulast%3DTuckwell%26aufirst%3DK.%26aulast%3DQuartino%26aufirst%3DA.%26atitle%3DPopulation%2520pharmacokinetics%252C%2520efficacy%2520exposure-response%2520analysis%252C%2520and%2520model-based%2520meta-analysis%2520of%2520Fenebrutinib%2520in%2520subjects%2520with%2520Rheumatoid%2520Arthritis%26jtitle%3DPharm.%2520Res.%26date%3D2020%26volume%3D37%26spage%3D25%26doi%3D10.1007%2Fs11095-019-2752-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit30b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kivitz, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korish, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azaryan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hough, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringheim, G. E.</span></span> <span> </span><span class="NLM_article-title">Spebrutinib (CC-292) affects markers of B cell activation, chemotaxis, and osteoclasts in patients with Rheumatoid Arthritis: Results from a mechanistic study</span>. <i>Rheumatol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1007/s40744-019-00182-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1007%2Fs40744-019-00182-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=31721017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A280%3ADC%252BB3MjosFOmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2020&pages=101-119&author=P.+H.+Schaferauthor=A.+J.+Kivitzauthor=J.+Maauthor=S.+Korishauthor=D.+Sutherlandauthor=L.+Liauthor=A.+Azaryanauthor=J.+Kosekauthor=M.+Adamsauthor=L.+Caponeauthor=E.+M.+Hurauthor=D.+R.+Houghauthor=G.+E.+Ringheim&title=Spebrutinib+%28CC-292%29+affects+markers+of+B+cell+activation%2C+chemotaxis%2C+and+osteoclasts+in+patients+with+Rheumatoid+Arthritis%3A+Results+from+a+mechanistic+study&doi=10.1007%2Fs40744-019-00182-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30bR"><div class="casContent"><span class="casTitleNuber">30b</span><div class="casTitle"><span class="NLM_cas:atitle">Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study</span></div><div class="casAuthors">Schafer Peter H; Kivitz Alan J; Ma Jianglin; Korish Shimon; Sutherland Donna; Li Li; Azaryan Ada; Kosek Jolanta; Adams Mary; Capone Lori; Hur Eun Mi; Hough Douglas R; Ringheim Garth E</div><div class="citationInfo"><span class="NLM_cas:title">Rheumatology and therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">101-119</span>
        ISSN:<span class="NLM_cas:issn">2198-6576</span>.
    </div><div class="casAbstract">INTRODUCTION:  Spebrutinib (CC-292) is an orally administered, covalent, small-molecule inhibitor of Bruton's tyrosine kinase (BTK), part of the B-cell and Fc receptor signaling pathways.  This study evaluated spebrutinib pharmacology and mechanism of action over a 4-week treatment period in patients with active rheumatoid arthritis (RA).  METHODS:  Primary human B cells, T cells, natural killer cells, macrophages, dendritic cells, basophils, and osteoclasts were treated with spebrutinib in vitro.  Clinical pharmacodynamics were studied in 47 patients with active RA on background methotrexate therapy randomized to oral spebrutinib 375 mg/day or placebo.  RESULTS:  In vitro, spebrutinib inhibited B-cell proliferation more potently than T-cell proliferation and reduced both lymphoid and myeloid cytokine production and degranulation, as well as osteoclastogenesis.  Clinical efficacy trended higher in spebrutinib-treated RA patients, with 41.7% (10/24) achieving ≥ 20% improvement in ACR response criteria (ACR20) versus 21.7% (5/23) of placebo patients at week 4 (P = 0.25).  Treatment-emergent adverse events were comparable between treatment groups.  In spebrutinib-treated patients, median BTK occupancy in peripheral blood was 83%, and significant increases in total CD19(+) and mature-naive CD27(-)CD38(-)IgD(+) B cells and decreases in transitional CD27(-)CD38(+) B cells were observed.  Spebrutinib significantly reduced serum chemokines chemokine ligand 13 (CXCL13), macrophage inflammatory protein-1β (MIP-1β), and the bone resorption biomarker carboxy-terminal collagen cross-linking telopeptide (CTX-I) (P < 0.05).  Clinical response to spebrutinib was associated with lower increases in CD19(+) B cells and greater decreases in CXCL13 and MIP-1β from baseline to week 4.  High CD19(+) B cells and low CTX-I at baseline were associated with better spebrutinib clinical response.  CONCLUSIONS:  Spebrutinib inhibited various leukocyte responses in vitro, including those of B cells and osteoclasts.  In this small study in RA patients, spebrutinib was well tolerated, showed a downward trend for symptoms, significantly modulated B-cell populations, and reduced markers of chemotaxis and osteoclast activity.  TRIAL REGISTRATION:  NCT01975610.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR6nFX1j3hnRlVwdslNBF-tfW6udTcc2eYV7_BTzGrpirntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjosFOmtg%253D%253D&md5=25075a1cf6ebb264232fb345ccf77670</span></div><a href="/servlet/linkout?suffix=cit30b&amp;dbid=16384&amp;doi=10.1007%2Fs40744-019-00182-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40744-019-00182-7%26sid%3Dliteratum%253Aachs%26aulast%3DSchafer%26aufirst%3DP.%2BH.%26aulast%3DKivitz%26aufirst%3DA.%2BJ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DKorish%26aufirst%3DS.%26aulast%3DSutherland%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DAzaryan%26aufirst%3DA.%26aulast%3DKosek%26aufirst%3DJ.%26aulast%3DAdams%26aufirst%3DM.%26aulast%3DCapone%26aufirst%3DL.%26aulast%3DHur%26aufirst%3DE.%2BM.%26aulast%3DHough%26aufirst%3DD.%2BR.%26aulast%3DRingheim%26aufirst%3DG.%2BE.%26atitle%3DSpebrutinib%2520%2528CC-292%2529%2520affects%2520markers%2520of%2520B%2520cell%2520activation%252C%2520chemotaxis%252C%2520and%2520osteoclasts%2520in%2520patients%2520with%2520Rheumatoid%2520Arthritis%253A%2520Results%2520from%2520a%2520mechanistic%2520study%26jtitle%3DRheumatol.%2520Ther.%26date%3D2020%26volume%3D7%26spage%3D101%26epage%3D119%26doi%3D10.1007%2Fs40744-019-00182-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit30c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spindler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sagawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kivitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barchuk, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nirula, A.</span></span> <span> </span><span class="NLM_article-title">SAT0089 Safety and efficacy of LY3337641, a Bruton’s tyrosine kinase inhibitor in patients with Rheumatoid Arthritis: A randomized, double-blinded, placebo-controlled, 2-part phase 2 study</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1109</span>– <span class="NLM_lpage">1110</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2019-eular.2672</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1136%2Fannrheumdis-2019-eular.2672" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2019&pages=1109-1110&author=M.+C.+Genoveseauthor=A.+Spindlerauthor=A.+Sagawaauthor=W.+Parkauthor=A.+Dudekauthor=A.+Kivitzauthor=J.+Chaoauthor=L.+Chanauthor=W.+Barchukauthor=A.+Nirula&title=SAT0089+Safety+and+efficacy+of+LY3337641%2C+a+Bruton%E2%80%99s+tyrosine+kinase+inhibitor+in+patients+with+Rheumatoid+Arthritis%3A+A+randomized%2C+double-blinded%2C+placebo-controlled%2C+2-part+phase+2+study&doi=10.1136%2Fannrheumdis-2019-eular.2672"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30c&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2019-eular.2672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2019-eular.2672%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DSpindler%26aufirst%3DA.%26aulast%3DSagawa%26aufirst%3DA.%26aulast%3DPark%26aufirst%3DW.%26aulast%3DDudek%26aufirst%3DA.%26aulast%3DKivitz%26aufirst%3DA.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DL.%26aulast%3DBarchuk%26aufirst%3DW.%26aulast%3DNirula%26aufirst%3DA.%26atitle%3DSAT0089%2520Safety%2520and%2520efficacy%2520of%2520LY3337641%252C%2520a%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%2520in%2520patients%2520with%2520Rheumatoid%2520Arthritis%253A%2520A%2520randomized%252C%2520double-blinded%252C%2520placebo-controlled%252C%25202-part%2520phase%25202%2520study%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2019%26volume%3D78%26spage%3D1109%26epage%3D1110%26doi%3D10.1136%2Fannrheumdis-2019-eular.2672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bame, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowden-Verhoek, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cancilla, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conlon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlanson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs-Knotts, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heumann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcotte, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertsching, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negrou, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otipoby, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poreci, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanowski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, M.</span></span> <span> </span><span class="NLM_article-title">Optimization of novel reversible Bruton’s tyrosine kinase inhibitors identified using tethering-fragment-based screens</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2905</span>– <span class="NLM_lpage">2913</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.05.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1016%2Fj.bmc.2019.05.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=31138459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVersb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=2905-2913&author=B.+T.+Hopkinsauthor=E.+Bameauthor=N.+Bellauthor=T.+Bohnertauthor=J.+K.+Bowden-Verhoekauthor=M.+Buiauthor=M.+T.+Cancillaauthor=P.+Conlonauthor=P.+Cullenauthor=D.+A.+Erlansonauthor=J.+Fanauthor=T.+Fuchs-Knottsauthor=S.+Hansenauthor=S.+Heumannauthor=T.+J.+Jenkinsauthor=D.+Marcotteauthor=B.+McDowellauthor=E.+Mertschingauthor=E.+Negrouauthor=K.+L.+Otipobyauthor=U.+Poreciauthor=M.+J.+Romanowskiauthor=D.+Scottauthor=L.+Silvianauthor=W.+Yangauthor=M.+Zhong&title=Optimization+of+novel+reversible+Bruton%E2%80%99s+tyrosine+kinase+inhibitors+identified+using+tethering-fragment-based+screens&doi=10.1016%2Fj.bmc.2019.05.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screens</span></div><div class="casAuthors">Hopkins, Brian T.; Bame, Eris; Bell, Noah; Bohnert, Tonika; Bowden-Verhoek, Jon K.; Bui, Minna; Cancilla, Mark T.; Conlon, Patrick; Cullen, Patrick; Erlanson, Daniel A.; Fan, Junfa; Fuchs-Knotts, Tarra; Hansen, Stig; Heumann, Stacey; Jenkins, Tracy J.; Marcotte, Douglas; McDowell, Bob; Mertsching, Elisabeth; Negrou, Ella; Otipoby, Kevin L.; Poreci, Urjana; Romanowski, Michael J.; Scott, Daniel; Silvian, Laura; Yang, Wenjin; Zhong, Min</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2905-2913</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Since the approval of ibrutinib for the treatment of B-cell malignancies in 2012, numerous clin. trials have been reported using covalent inhibitors to target Bruton's tyrosine kinase (BTK) for oncol. indications.  However, a formidable challenge for the pharmaceutical industry has been the identification of reversible, selective, potent mols. for inhibition of BTK.  Herein, we report application of Tethering-fragment-based screens to identify low mol. wt. fragments which were further optimized to improve on-target potency and ADME properties leading to the discovery of reversible, selective, potent BTK inhibitors suitable for pre-clin. proof-of-concept studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVW3LeOScif7Vg90H21EOLACvtfcHk0lgxV9KAGqxnyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVersb7P&md5=3c5471a75a4b950e417d410f9a542a95</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.05.021%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DB.%2BT.%26aulast%3DBame%26aufirst%3DE.%26aulast%3DBell%26aufirst%3DN.%26aulast%3DBohnert%26aufirst%3DT.%26aulast%3DBowden-Verhoek%26aufirst%3DJ.%2BK.%26aulast%3DBui%26aufirst%3DM.%26aulast%3DCancilla%26aufirst%3DM.%2BT.%26aulast%3DConlon%26aufirst%3DP.%26aulast%3DCullen%26aufirst%3DP.%26aulast%3DErlanson%26aufirst%3DD.%2BA.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DFuchs-Knotts%26aufirst%3DT.%26aulast%3DHansen%26aufirst%3DS.%26aulast%3DHeumann%26aufirst%3DS.%26aulast%3DJenkins%26aufirst%3DT.%2BJ.%26aulast%3DMarcotte%26aufirst%3DD.%26aulast%3DMcDowell%26aufirst%3DB.%26aulast%3DMertsching%26aufirst%3DE.%26aulast%3DNegrou%26aufirst%3DE.%26aulast%3DOtipoby%26aufirst%3DK.%2BL.%26aulast%3DPoreci%26aufirst%3DU.%26aulast%3DRomanowski%26aufirst%3DM.%2BJ.%26aulast%3DScott%26aufirst%3DD.%26aulast%3DSilvian%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DZhong%26aufirst%3DM.%26atitle%3DOptimization%2520of%2520novel%2520reversible%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%2520identified%2520using%2520tethering-fragment-based%2520screens%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D2905%26epage%3D2913%26doi%3D10.1016%2Fj.bmc.2019.05.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenningloh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haselmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Bujalski, L.</span></span> <span> </span><span class="NLM_article-title">Ability of Bruton’s tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc receptor but not B-cell receptor signaling</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">208</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1124/mol.116.107037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1124%2Fmol.116.107037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=28062735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpsFajtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2017&pages=208-219&issue=3&author=A.+T.+Benderauthor=A.+Gardbergauthor=A.+Pereiraauthor=T.+Johnsonauthor=Y.+Wuauthor=R.+Grenninglohauthor=J.+Headauthor=F.+Morandiauthor=P.+Haselmayerauthor=L.+Liu-Bujalski&title=Ability+of+Bruton%E2%80%99s+tyrosine+kinase+inhibitors+to+sequester+Y551+and+prevent+phosphorylation+determines+potency+for+inhibition+of+Fc+receptor+but+not+B-cell+receptor+signaling&doi=10.1124%2Fmol.116.107037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Ability of Bruton's tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc receptor but not B-cell receptor signaling</span></div><div class="casAuthors">Bender, Andrew T.; Gardberg, Anna; Pereira, Albertina; Johnson, Theresa; Wu, Yin; Grenningloh, Roland; Head, Jared; Morandi, Federica; Haselmayer, Philipp; Liu-Bujalski, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">208-219</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is expressed in a variety of hematopoietic cells.  Btk has been demonstrated to regulate signaling downstream of the B-cell receptor (BCR), Fc receptors (FcRs), and toll-like receptors.  It has become an attractive drug target because its inhibition may provide significant efficacy by simultaneously blocking multiple disease mechanisms.  Consequently, a large no. of Btk inhibitors have been developed.  These compds. have diverse binding modes, and both reversible and irreversible inhibitors have been developed.  Reported herein, we have tested nine Btk inhibitors and characterized on a mol. level how their interactions with Btk define their ability to block different signaling pathways.  By solving the crystal structures of Btk inhibitors bound to the enzyme, we discovered that the compds. can be classified by their ability to trigger sequestration of Btk residue Y551.  In cells, we found that sequestration of Y551 renders it inaccessible for phosphorylation.  The ability to sequester Y551 was an important determinant of potency against FcγR signaling as Y551 sequestering compds. were more potent for inhibiting basophils and mast cells.  This result was true for the inhibition of FcγR signaling as well.  In contrast, Y551 sequestration was less a factor in detg. potency against BCR signaling.  We also found that Btk activity is regulated differentially in basophils and B cells.  These results elucidate important determinants for Btk inhibitor potency against different signaling pathways and provide insight for designing new compds. with a broader inhibitory profile that will likely result in greater efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrN8F--ON3M7Vg90H21EOLACvtfcHk0lgxV9KAGqxnyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpsFajtr8%253D&md5=f869d52d6bc1aabf352988787ff1cbcf</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1124%2Fmol.116.107037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.116.107037%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%2BT.%26aulast%3DGardberg%26aufirst%3DA.%26aulast%3DPereira%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DGrenningloh%26aufirst%3DR.%26aulast%3DHead%26aufirst%3DJ.%26aulast%3DMorandi%26aufirst%3DF.%26aulast%3DHaselmayer%26aufirst%3DP.%26aulast%3DLiu-Bujalski%26aufirst%3DL.%26atitle%3DAbility%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%2520to%2520sequester%2520Y551%2520and%2520prevent%2520phosphorylation%2520determines%2520potency%2520for%2520inhibition%2520of%2520Fc%2520receptor%2520but%2520not%2520B-cell%2520receptor%2520signaling%26jtitle%3DMol.%2520Pharmacol.%26date%3D2017%26volume%3D91%26issue%3D3%26spage%3D208%26epage%3D219%26doi%3D10.1124%2Fmol.116.107037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barck, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/nchembio.481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di%0APaoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+Btk+inhibition+suppresses+B+cell-+and+myeloid+cell-mediated+arthritis&doi=10.1038%2Fnchembio.481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0lgxV9KAGqxnyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520Btk%2520inhibition%2520suppresses%2520B%2520cell-%2520and%2520myeloid%2520cell-mediated%2520arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50%26doi%3D10.1038%2Fnchembio.481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span> <span> </span><span class="NLM_article-title">Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1359</span>– <span class="NLM_lpage">1369</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=9394025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADyaK2sXotVymt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1997&pages=1359-1369&issue=12&author=R.+S.+Obach&title=Nonspecific+binding+to+microsomes%3A+impact+on+scale-up+of+in+vitro+intrinsic+clearance+to+hepatic+clearance+as+assessed+through+examination+of+warfarin%2C+imipramine%2C+and+propranolol"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34aR"><div class="casContent"><span class="casTitleNuber">34a</span><div class="casTitle"><span class="NLM_cas:atitle">Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1359-1369</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The nonspecific, noncovalent binding of three drugs, imipramine, warfarin, and propranolol, to pooled human and animal liver microsomes has been detd. using equil. dialysis in conditions where no cofactor (NADPH) was included in the incubation.  The binding of warfarin was dependent upon both protein and drug concn., whereas the binding of propranolol and imipramine was also dependent upon protein concn. but generally independent of drug concn.  At a microsomal protein concn. of 1.0 mg/mL and a warfarin concn. of 10 μM, the free fraction (fu(mic)) was 0.85.  The corresponding values for propranolol and imipramine were 0.41 and 0.16, resp.  Thus, although all three drugs exhibit high binding in plasma (fu <0.1) the acidic drug warfarin differs from the basic drugs propranolol and imipramine in the extent to which each binds to microsomal protein.  The binding of all three drugs to liver microsomes obtained from commonly studied animal species (rat, dog, and monkey) was almost identical to that obsd. in human.  Addnl., the binding of warfarin and propranolol to microsomes obtained from insect cells used in baculovirus cytochrome P 450 expression systems was similar to that exhibited in liver microsomes, when equal protein concns. were compared.  The enzyme kinetics of propranolol, imipramine; and warfarin oxidative metab. were detd. in pooled human liver microsomes, and the intrinsic clearance values obtained were used in scaling up to project human in vivo clearance.  The values obtained by incorporating microsomal binding were compared with those in which this factor is ignored.  The findings suggest that the parameter fu(mic) is important to obtain when attempting to relate in vitro intrinsic clearance to in vivo clearance.  Also, this value is important to consider when comparing substrates with respect to enzyme specificity, since measured apparent KM values should be converted to true "free KM" values by correcting for the free fraction in the in vitro incubation.  Furthermore, the extent of nonspecific binding to microsomes is likely an important parameter to consider when attempting to relate Ki values measured in vitro to observations of drug-drug interactions (or the lack thereof) in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTI5meSXnqbrVg90H21EOLACvtfcHk0lghga3-ClcW0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXotVymt74%253D&md5=b8c792b5c477d7eb653c2d0f9ef77e49</span></div><a href="/servlet/linkout?suffix=cit34a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DNonspecific%2520binding%2520to%2520microsomes%253A%2520impact%2520on%2520scale-up%2520of%2520in%2520vitro%2520intrinsic%2520clearance%2520to%2520hepatic%2520clearance%2520as%2520assessed%2520through%2520examination%2520of%2520warfarin%252C%2520imipramine%252C%2520and%2520propranolol%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1997%26volume%3D25%26issue%3D12%26spage%3D1359%26epage%3D1369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit34b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span> <span> </span><span class="NLM_article-title">Interpretation of non-clinical data for prediction of human pharmacokinetic parameters: in vitro-in vivo extrapolation and allometric scaling</span>. <i>Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">168</span>, <span class="refDoi"> DOI: 10.3390/pharmaceutics11040168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.3390%2Fpharmaceutics11040168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVSrtbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=168&author=G.+Choiauthor=Y.+Leeauthor=H.+Cho&title=Interpretation+of+non-clinical+data+for+prediction+of+human+pharmacokinetic+parameters%3A+in+vitro-in+vivo+extrapolation+and+allometric+scaling&doi=10.3390%2Fpharmaceutics11040168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34bR"><div class="casContent"><span class="casTitleNuber">34b</span><div class="casTitle"><span class="NLM_cas:atitle">Interpretation of non-clinical data for prediction of human pharmacokinetic parameters: in vitro-in vivo extrapolation and allometric scaling</span></div><div class="casAuthors">Choi, Go-Wun; Lee, Yong-Bok; Cho, Hea-Young</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">168</span>CODEN:
                <span class="NLM_cas:coden">PHARK5</span>;
        ISSN:<span class="NLM_cas:issn">1999-4923</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Extrapolation of pharmacokinetic (PK) parameters from in vitro or in vivo animal to human is one of the main tasks in the drug development process.  Translational approaches provide evidence for go or no-go decision-making during drug discovery and the development process, and the prediction of human PKs prior to the first-in-human clin. trials.  In vitro-in vivo extrapolation and allometric scaling are the choice of method for projection to human situations.  Although these methods are useful tools for the estn. of PK parameters, it is a challenge to apply these methods since underlying biochem., math., physiol., and background knowledge of PKs are required.  In addn., it is difficult to select an appropriate methodol. depending on the data available.  Therefore, this review covers the principles of PK parameters pertaining to the clearance, vol. of distribution, elimination half-life, absorption rate const., and prediction method from the original idea to recently developed models in order to introduce optimal models for the prediction of PK parameters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7QdeHYCk3oLVg90H21EOLACvtfcHk0lghga3-ClcW0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVSrtbzK&md5=9757266a6e6cda7cdcb4a2add87f2007</span></div><a href="/servlet/linkout?suffix=cit34b&amp;dbid=16384&amp;doi=10.3390%2Fpharmaceutics11040168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fpharmaceutics11040168%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DH.%26atitle%3DInterpretation%2520of%2520non-clinical%2520data%2520for%2520prediction%2520of%2520human%2520pharmacokinetic%2520parameters%253A%2520in%2520vitro-in%2520vivo%2520extrapolation%2520and%2520allometric%2520scaling%26jtitle%3DPharmaceutics%26date%3D2019%26volume%3D11%26spage%3D168%26doi%3D10.3390%2Fpharmaceutics11040168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span> <i>Evaluation of Enzyme Inhibitors in Drug Discovery</i>; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">2005</span>; pp  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">177</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=141-177&author=R.+A.+Copeland&title=Evaluation+of+Enzyme+Inhibitors+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26btitle%3DEvaluation%2520of%2520Enzyme%2520Inhibitors%2520in%2520Drug%2520Discovery%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2005%26spage%3D141%26epage%3D177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berg, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polokoff, M. A.</span></span> <span> </span><span class="NLM_article-title">Building predictive models for mechanism-of-action classification from phenotypic assay data sets</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1260</span>– <span class="NLM_lpage">1269</span>, <span class="refDoi"> DOI: 10.1177/1087057113505324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1177%2F1087057113505324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=24088371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslWjsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=1260-1269&author=E.+L.+Bergauthor=J.+Yangauthor=M.+A.+Polokoff&title=Building+predictive+models+for+mechanism-of-action+classification+from+phenotypic+assay+data+sets&doi=10.1177%2F1087057113505324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Building predictive models for mechanism-of-action classification from phenotypic assay data sets</span></div><div class="casAuthors">Berg, Ellen L.; Yang, Jian; Polokoff, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1260-1269, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Compd. mechanism-of-action information can be crit. for drug development decisions but is often challenging for phenotypic drug discovery programs.  One concern is that compds. selected by phenotypic screening will have a previously known but undesirable target mechanism.  Here we describe a useful method for assigning mechanism class to compds. and bioactive agents using an 84-feature signature from a panel of primary human cell systems (BioMAP systems).  For this approach, a ref. data set of well-characterized compds. was used to develop predictive models for 28 mechanism classes using support vector machines.  These mechanism classes encompass safety and efficacy-related mechanisms, include both target-specific and pathway-based classes, and cover the most common mechanisms identified in phenotypic screens, such as inhibitors of mitochondrial and microtubule function, histone deacetylase, and cAMP elevators.  Here we describe the performance and the application of these predictive models in a decision scheme for triaging phenotypic screening hits using a previously published data set of 309 environmental chems. tested as part of the Environmental Protection Agency's ToxCast program.  By providing quantified membership in specific mechanism classes, this approach is suitable for identification of off-target toxicity mechanisms as well as enabling target deconvolution of phenotypic drug discovery hits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSbGfCpuChA7Vg90H21EOLACvtfcHk0lghga3-ClcW0Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslWjsLvP&md5=1177a3a1dbae60621bbc2249f0e8e0ac</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1177%2F1087057113505324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057113505324%26sid%3Dliteratum%253Aachs%26aulast%3DBerg%26aufirst%3DE.%2BL.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DPolokoff%26aufirst%3DM.%2BA.%26atitle%3DBuilding%2520predictive%2520models%2520for%2520mechanism-of-action%2520classification%2520from%2520phenotypic%2520assay%2520data%2520sets%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2013%26volume%3D18%26spage%3D1260%26epage%3D1269%26doi%3D10.1177%2F1087057113505324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haselmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camps, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Bujalski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mahony, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerli, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruns, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenningloh, R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and pharmacodynamic modeling of the BTK inhibitor Evobrutinib in autoimmune disease models</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>202</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2888</span>– <span class="NLM_lpage">2906</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1800583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.4049%2Fjimmunol.1800583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=30988116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvF2ntLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=2019&pages=2888-2906&issue=10&author=P.+Haselmayerauthor=M.+Campsauthor=L.+Liu-Bujalskiauthor=N.+Nguyenauthor=F.+Morandiauthor=J.+Headauthor=A.+O%E2%80%99Mahonyauthor=S.+C.+Zimmerliauthor=L.+Brunsauthor=A.+T.+Benderauthor=P.+Schroederauthor=R.+Grenningloh&title=Efficacy+and+pharmacodynamic+modeling+of+the+BTK+inhibitor+Evobrutinib+in+autoimmune+disease+models&doi=10.4049%2Fjimmunol.1800583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and pharmacodynamic modeling of the BTK inhibitor evobrutinib in autoimmune disease models</span></div><div class="casAuthors">Haselmayer, Philipp; Camps, Montserrat; Liu-Bujalski, Lesley; Nguyen, Ngan; Morandi, Federica; Head, Jared; O'Mahony, Alison; Zimmerli, Simone C.; Bruns, Lisa; Bender, Andrew T.; Schroeder, Patricia; Grenningloh, Roland</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">202</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2888-2906</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Because of its role in mediating both B cell and Fc receptor signaling, Bruton's tyrosine kinase (BTK) is a promising target for the treatment of autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).  Evobrutinib is a novel, highly selective, irreversible BTK inhibitor that potently inhibits BCR- and Fc receptor-mediated signaling and, thus, subsequent activation and function of human B cells and innate immune cells such as monocytes and basophils.  We evaluated evobrutinib in preclin. models of RA and SLE and characterized the relationship between BTK occupancy and inhibition of disease activity.  In mouse models of RA and SLE, orally administered evobrutinib displayed robust efficacy, as demonstrated by redn. of disease severity and histol. damage.  In the SLE model, evobrutinib inhibited B cell activation, reduced autoantibody prodn. and plasma cell nos., and normalized B and T cell subsets.  In the RA model, efficacy was achieved despite failure to reduce autoantibodies.  Pharmacokinetic/pharmacodynamic modeling showed that mean BTK occupancy in blood cells of 80% was linked to near-complete disease inhibition in both RA and SLE mouse models.  In addn., evobrutinib inhibited mast cell activation in a passive cutaneous anaphylaxis model.  Thus, evobrutinib achieves efficacy by acting both on B cells and innate immune cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLVxS4palhvbVg90H21EOLACvtfcHk0lhwVdCV1Fq-7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvF2ntLg%253D&md5=9a339003f40e52527127ac12a2593ae9</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1800583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1800583%26sid%3Dliteratum%253Aachs%26aulast%3DHaselmayer%26aufirst%3DP.%26aulast%3DCamps%26aufirst%3DM.%26aulast%3DLiu-Bujalski%26aufirst%3DL.%26aulast%3DNguyen%26aufirst%3DN.%26aulast%3DMorandi%26aufirst%3DF.%26aulast%3DHead%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DZimmerli%26aufirst%3DS.%2BC.%26aulast%3DBruns%26aufirst%3DL.%26aulast%3DBender%26aufirst%3DA.%2BT.%26aulast%3DSchroeder%26aufirst%3DP.%26aulast%3DGrenningloh%26aufirst%3DR.%26atitle%3DEfficacy%2520and%2520pharmacodynamic%2520modeling%2520of%2520the%2520BTK%2520inhibitor%2520Evobrutinib%2520in%2520autoimmune%2520disease%2520models%26jtitle%3DJ.%2520Immunol.%26date%3D2019%26volume%3D202%26issue%3D10%26spage%3D2888%26epage%3D2906%26doi%3D10.4049%2Fjimmunol.1800583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyaura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span> <span> </span><span class="NLM_article-title">Palladium-catalyzed cross-coupling reactions of organoboron compounds</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>95</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2457</span>– <span class="NLM_lpage">2483</span>, <span class="refDoi"> DOI: 10.1021/cr00039a007</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr00039a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1995&pages=2457-2483&issue=7&author=N.+Miyauraauthor=A.+Suzuki&title=Palladium-catalyzed+cross-coupling+reactions+of+organoboron+compounds&doi=10.1021%2Fcr00039a007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds</span></div><div class="casAuthors">Miyaura, Norio; Suzuki, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2457-83</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with >250 refs. including title reactions and their mechanisms, prepn. of organoboron reagents, alkoxycarbonylation and dimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHwupBJT1UCbVg90H21EOLACvtfcHk0lhwVdCV1Fq-7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D&md5=d127b414a75161652876eebc3ed0c486</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fcr00039a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr00039a007%26sid%3Dliteratum%253Aachs%26aulast%3DMiyaura%26aufirst%3DN.%26aulast%3DSuzuki%26aufirst%3DA.%26atitle%3DPalladium-catalyzed%2520cross-coupling%2520reactions%2520of%2520organoboron%2520compounds%26jtitle%3DChem.%2520Rev.%26date%3D1995%26volume%3D95%26issue%3D7%26spage%3D2457%26epage%3D2483%26doi%3D10.1021%2Fcr00039a007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tundel, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">Monodentate phosphines provide highly active catalysts for Pd-catalyzed CN bond-forming reactions of heteroaromatic halides/amines and (H)N-heterocycles</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">39</span>),  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6527</span>, <span class="refDoi"> DOI: 10.1002/anie.200601612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1002%2Fanie.200601612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWgsrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=6523-6527&issue=39&author=K.+W.+Andersonauthor=R.+E.+Tundelauthor=T.+Ikawaauthor=R.+A.+Altmanauthor=S.+L.+Buchwald&title=Monodentate+phosphines+provide+highly+active+catalysts+for+Pd-catalyzed+CN+bond-forming+reactions+of+heteroaromatic+halides%2Famines+and+%28H%29N-heterocycles&doi=10.1002%2Fanie.200601612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Monodentate phosphines provide highly active catalysts for Pd-catalyzed C-N bond-forming reactions of heteroaromatic halides/amines and (H)N-heterocycles</span></div><div class="casAuthors">Anderson, Kevin W.; Tundel, Rachel E.; Ikawa, Takashi; Altman, Ryan A.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">6523-6527</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Highly reactive catalysts based on palladium and dialkylbiarylphosphino ligands provide unprecedented reactivity and selectivity in C-N bond-forming processes.  The bulky monophosphine catalyst system Pd2(dba)3/I is effective for the reaction of aryl/heteroaryl halides bearing primary amides and 2-aminoheterocycles, thus showing that monodentate phosphines are viable alternatives to, and sometimes superior to, chelating ligands.  E.g., amination of 3-chlorobenzamide by morpholine gave 81% II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwitHXua7pPbVg90H21EOLACvtfcHk0lhwVdCV1Fq-7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWgsrnP&md5=5958e76b262517af3527cea57573210a</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fanie.200601612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200601612%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DK.%2BW.%26aulast%3DTundel%26aufirst%3DR.%2BE.%26aulast%3DIkawa%26aufirst%3DT.%26aulast%3DAltman%26aufirst%3DR.%2BA.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DMonodentate%2520phosphines%2520provide%2520highly%2520active%2520catalysts%2520for%2520Pd-catalyzed%2520CN%2520bond-forming%2520reactions%2520of%2520heteroaromatic%2520halides%252Famines%2520and%2520%2528H%2529N-heterocycles%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2006%26volume%3D45%26issue%3D39%26spage%3D6523%26epage%3D6527%26doi%3D10.1002%2Fanie.200601612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alt, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstein, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malynn, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathbun, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantor, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzenberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideras, P.</span></span> <span> </span><span class="NLM_article-title">Defective B cell development and function in Btk-deficient mice</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1016/1074-7613(95)90114-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1016%2F1074-7613%2895%2990114-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=7552994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADyaK2MXosVygu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1995&pages=283-299&author=W.+N.+Khanauthor=F.+W.+Altauthor=R.+M.+Gersteinauthor=B.+A.+Malynnauthor=I.+Larssonauthor=G.+Rathbunauthor=L.+Davidsonauthor=S.+Mullerauthor=A.+B.+Kantorauthor=L.+A.+Herzenbergauthor=F.+S.+Rosenauthor=P.+Sideras&title=Defective+B+cell+development+and+function+in+Btk-deficient+mice&doi=10.1016%2F1074-7613%2895%2990114-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40aR"><div class="casContent"><span class="casTitleNuber">40a</span><div class="casTitle"><span class="NLM_cas:atitle">Defective B cell development and function in Btk-deficient mice</span></div><div class="casAuthors">Khan, Wasif N.; Alt, Frederick W.; Gerstein, Rachel M.; Malynn, Barbara A.; Larsson, Irene; Rathbun, Gary; Davidson, Laurie; Mueller, Sussane; Kantor, Aaron B.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">283-99</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the Bruton's tyrosine kinase (Btk) gene have been linked to severe early B cell developmental blocks in human X-linked agammaglobulinemia (XLA), and to milder B cell activation deficiencies in murine X-linked immune deficiency (Xid).  To elucidate unequivocally potential Btk functions in mice, we generated mutations in embryonic stem cells, which eliminated the ability to encode Btk pleckstrin homol. or kinase domains, and assayed their effects by RAG2-deficient blastocyst complementation of introduction into the germline.  Both mutations block expression of Btk protein and lead to reduced nos. of mature conventional B cells, severe B1 cell deficiency, serum IgM and IgG3 deficiency, and defective responses in vitro to various B cell activators and in vivo by immunization with thymus-independent type II antigens.  These results prove that lack of Btk function results in an Xid phenotype and further suggest a differential requirement for Btκ during the early stages of murine vs. human B lymphocyte development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5A-ze-ib1c7Vg90H21EOLACvtfcHk0liMg088EqJuHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXosVygu7o%253D&md5=fdae8fd170f35068b44a0475568c3d95</span></div><a href="/servlet/linkout?suffix=cit40a&amp;dbid=16384&amp;doi=10.1016%2F1074-7613%2895%2990114-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F1074-7613%252895%252990114-0%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DW.%2BN.%26aulast%3DAlt%26aufirst%3DF.%2BW.%26aulast%3DGerstein%26aufirst%3DR.%2BM.%26aulast%3DMalynn%26aufirst%3DB.%2BA.%26aulast%3DLarsson%26aufirst%3DI.%26aulast%3DRathbun%26aufirst%3DG.%26aulast%3DDavidson%26aufirst%3DL.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DKantor%26aufirst%3DA.%2BB.%26aulast%3DHerzenberg%26aufirst%3DL.%2BA.%26aulast%3DRosen%26aufirst%3DF.%2BS.%26aulast%3DSideras%26aufirst%3DP.%26atitle%3DDefective%2520B%2520cell%2520development%2520and%2520function%2520in%2520Btk-deficient%2520mice%26jtitle%3DImmunity%26date%3D1995%26volume%3D3%26spage%3D283%26epage%3D299%26doi%3D10.1016%2F1074-7613%2895%2990114-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit40b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Goess, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murdock, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Twomey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mario, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goedken, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, A. J.</span></span> <span> </span><span class="NLM_article-title">ABBV-105, a selective and irreversible inhibitor of Bruton’s tyrosine kinase, is efficacious in multiple preclinical models of inflammation</span>. <i>Mod. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">510</span>– <span class="NLM_lpage">522</span>, <span class="refDoi"> DOI: 10.1080/14397595.2018.1484269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1080%2F14397595.2018.1484269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=29862859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSmsr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=510-522&author=C.+Goessauthor=C.+M.+Harrisauthor=S.+Murdockauthor=R.+W.+McCarthyauthor=E.+Sampsonauthor=R.+Twomeyauthor=S.+Mathieuauthor=R.+Marioauthor=M.+Perhamauthor=E.+R.+Goedkenauthor=A.+J.+Long&title=ABBV-105%2C+a+selective+and+irreversible+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase%2C+is+efficacious+in+multiple+preclinical+models+of+inflammation&doi=10.1080%2F14397595.2018.1484269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40bR"><div class="casContent"><span class="casTitleNuber">40b</span><div class="casTitle"><span class="NLM_cas:atitle">ABBV-105, a selective and irreversible inhibitor of Bruton's tyrosine kinase, is efficacious in multiple preclinical models of inflammation</span></div><div class="casAuthors">Goess, Christian; Harris, Christopher M.; Murdock, Sara; McCarthy, Richard W.; Sampson, Erik; Twomey, Rachel; Mathieu, Suzanne; Mario, Regina; Perham, Matthew; Goedken, Eric R.; Long, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Modern Rheumatology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">510-522</span>CODEN:
                <span class="NLM_cas:coden">MROHA4</span>;
        ISSN:<span class="NLM_cas:issn">1439-7595</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) is a non-receptor tyrosine kinase required for intracellular signaling downstream of multiple immunoreceptors.  We evaluated ABBV-105, a covalent BTK inhibitor, using in vitro and in vivo assays to det. potency, selectivity, and efficacy to validate the therapeutic potential of ABBV-105 in inflammatory disease.  ABBV-105 potency and selectivity were evaluated in enzymic and cellular assays.  The impact of ABBV-105 on B cell function in vivo was assessed using mechanistic models of antibody prodn.  Efficacy of ABBV-105 in chronic inflammatory disease was evaluated in animal models of arthritis and lupus.  Measurement of BTK occupancy was employed as a target engagement biomarker.  ABBV-105 irreversibly inhibits BTK, demonstrating superior kinome selectivity and is potent in B cell receptor, Fc receptor, and TLR-9-dependent cellular assays.  Oral administration resulted in rapid clearance in plasma, but maintenance of BTK splenic occupancy.  ABBV-105 inhibited antibody responses to thymus-independent and thymus-dependent antigens, paw swelling and bone destruction in rat collagen induced arthritis, and reduced disease in an IFNα-accelerated lupus nephritis model.  BTK occupancy in disease models correlated with in vivo efficacy.  ABBV-105, a selective BTK inhibitor, demonstrates compelling efficacy in pre-clin. mechanistic models of antibody prodn. and in models of rheumatoid arthritis and lupus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRiXhHbdCpgbVg90H21EOLACvtfcHk0liMg088EqJuHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSmsr%252FP&md5=27a6e678e069976360dc9f2893c39c61</span></div><a href="/servlet/linkout?suffix=cit40b&amp;dbid=16384&amp;doi=10.1080%2F14397595.2018.1484269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14397595.2018.1484269%26sid%3Dliteratum%253Aachs%26aulast%3DGoess%26aufirst%3DC.%26aulast%3DHarris%26aufirst%3DC.%2BM.%26aulast%3DMurdock%26aufirst%3DS.%26aulast%3DMcCarthy%26aufirst%3DR.%2BW.%26aulast%3DSampson%26aufirst%3DE.%26aulast%3DTwomey%26aufirst%3DR.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DMario%26aufirst%3DR.%26aulast%3DPerham%26aufirst%3DM.%26aulast%3DGoedken%26aufirst%3DE.%2BR.%26aulast%3DLong%26aufirst%3DA.%2BJ.%26atitle%3DABBV-105%252C%2520a%2520selective%2520and%2520irreversible%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%252C%2520is%2520efficacious%2520in%2520multiple%2520preclinical%2520models%2520of%2520inflammation%26jtitle%3DMod.%2520Rheumatol.%26date%3D2019%26volume%3D29%26spage%3D510%26epage%3D522%26doi%3D10.1080%2F14397595.2018.1484269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drabek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raguz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Wit, T. P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingjan, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savelkoul, H. F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosveld, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span> <span> </span><span class="NLM_article-title">Correction of the X-linked immunodeficiency phenotype by transgenic expression of human Bruton tyrosine kinase under the control of the class II major histocompatibility complex Ea locus control region</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">610</span>– <span class="NLM_lpage">615</span>, <span class="refDoi"> DOI: 10.1073/pnas.94.2.610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1073%2Fpnas.94.2.610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=9012832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADyaK2sXnslOktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=610-615&issue=2&author=D.+Drabekauthor=S.+Raguzauthor=T.+P.+M.+De+Witauthor=G.+M.+Dingjanauthor=H.+F.+J.+Savelkoulauthor=F.+Grosveldauthor=R.+W.+Hendriks&title=Correction+of+the+X-linked+immunodeficiency+phenotype+by+transgenic+expression+of+human+Bruton+tyrosine+kinase+under+the+control+of+the+class+II+major+histocompatibility+complex+Ea+locus+control+region&doi=10.1073%2Fpnas.94.2.610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Correction of the X-linked immunodeficiency phenotype by transgenic expression of human Bruton tyrosine kinase under the control of the class II major histocompatibility complex Ea locus control region</span></div><div class="casAuthors">Drabek, Dubravka; Raguz, Selina; De Wit, Ton P. M.; Dingjan, Gemma M.; Savelkoul, Huub F.; Grosveld, Frank; Hendriks, Rudolf W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">610-615</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Bruton tyrosine kinase (Btk) is essential for the development of pre-B cells to mature B cell stages.  Btk-deficient mice manifest an X-linked immunodeficiency (xid) defect characterized by a redn. of peripheral IgMlow IgDhigh B cells, a lack of peritoneal CD5+ B cells, low serum levels of IgM and IgG3, and impaired responses to T cell independent type Ii (TI-II) antigens.  We have generated transgenic mice in which expression of the human Btk genes is driven by the murine class II major histocompatibility complex Ea gene locus control region, which provides gene expression from the pre-B cell stage onwards.  When these transgenic mice were mated onto a Btk- background, correction of the xid B cell defects was obsd.: B cells differentiated to mature IgMlowIgDhigh stages, peritoneal CD5+ B cells were present, and serum Ig levels and in vivo responses to TI-II antigens were in the normal ranges.  A comparable rescue by transgenic Btk expression was also obsd. in heterozygous Btk+/- female mice in those B-lineage cells that were Btk-deficient as a result of X chromosome inactivation.  These findings indicate that the Btk- phenotype in the mouse can be cor. by expression of human Btk from the pre-B cell stage onwards.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocQdhQ4ERPwbVg90H21EOLACvtfcHk0liMg088EqJuHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnslOktQ%253D%253D&md5=2f4e1543f97a6f72198ed8eb31cbced5</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1073%2Fpnas.94.2.610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.94.2.610%26sid%3Dliteratum%253Aachs%26aulast%3DDrabek%26aufirst%3DD.%26aulast%3DRaguz%26aufirst%3DS.%26aulast%3DDe%2BWit%26aufirst%3DT.%2BP.%2BM.%26aulast%3DDingjan%26aufirst%3DG.%2BM.%26aulast%3DSavelkoul%26aufirst%3DH.%2BF.%2BJ.%26aulast%3DGrosveld%26aufirst%3DF.%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26atitle%3DCorrection%2520of%2520the%2520X-linked%2520immunodeficiency%2520phenotype%2520by%2520transgenic%2520expression%2520of%2520human%2520Bruton%2520tyrosine%2520kinase%2520under%2520the%2520control%2520of%2520the%2520class%2520II%2520major%2520histocompatibility%2520complex%2520Ea%2520locus%2520control%2520region%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1997%26volume%3D94%26issue%3D2%26spage%3D610%26epage%3D615%26doi%3D10.1073%2Fpnas.94.2.610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, K.</span></span> <i>Janeway’s Immunobiology</i>; <span class="NLM_edition">8</span>th ed.; <span class="NLM_publisher-name">Garland Science</span>: <span class="NLM_publisher-loc">London</span>, <span class="NLM_year">2012</span>; xix, 868 s.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=K.+Murphy&title=Janeway%E2%80%99s+Immunobiology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DK.%26btitle%3DJaneway%25E2%2580%2599s%2520Immunobiology%26pub%3DGarland%2520Science%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Brenneman, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaiah, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohde, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messing, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neil, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantena, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shevlin, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokolowski, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carraher, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jesson, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlinson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bobrowski, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteley, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. W.,  II</span></span> <span> </span><span class="NLM_article-title">Mechanistic investigations of test article–induced pancreatic toxicity at the endocrine–exocrine interface in the rat</span>. <i>Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1177/0192623313508851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1177%2F0192623313508851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=24226507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1OmsrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=229-242&author=K.+A.+Brennemanauthor=S.+K.+Ramaiahauthor=C.+M.+Rohdeauthor=D.+M.+Messingauthor=S.+P.+O%E2%80%99Neilauthor=L.+M.+Gauthierauthor=Z.+S.+Stewartauthor=S.+R.+Mantenaauthor=K.+M.+Shevlinauthor=C.+G.+Leonardauthor=S.+A.+Sokolowskiauthor=H.+Linauthor=D.+C.+Carraherauthor=M.+I.+Jessonauthor=L.+Tomlinsonauthor=Y.+Zhanauthor=W.+F.+Bobrowskiauthor=S.+A.+Baileyauthor=W.+M.+Vogelauthor=D.+L.+Morrisauthor=L.+O.+Whiteleyauthor=J.+W.+Davis&title=Mechanistic+investigations+of+test+article%E2%80%93induced+pancreatic+toxicity+at+the+endocrine%E2%80%93exocrine+interface+in+the+rat&doi=10.1177%2F0192623313508851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43aR"><div class="casContent"><span class="casTitleNuber">43a</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic investigations of test article-induced pancreatic toxicity at the endocrine-exocrine interface in the rat</span></div><div class="casAuthors">Brenneman, Karrie A.; Ramaiah, Shashi K.; Rohde, Cynthia M.; Messing, Dean M.; O'neil, Shawn P.; Gauthier, Lauren M.; Stewart, Zachary S.; Mantena, Srinivasa R.; Shevlin, Kimberly M.; Leonard, Christopher G.; Sokolowski, Sharon A.; Lin, Hungyun; Carraher, Deborah C.; Jesson, Michael I.; Tomlinson, Lindsay; Zhan, Yutian; Bobrowski, Walter F.; Bailey, Steven A.; Vogel, W. Mark; Morris, Dale L.; Whiteley, Laurence O.; Davis, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">229-242, 14</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Pancreatic toxicity commonly affects the endocrine or exocrine pancreas.  However, it can also occur at the endocrine-exocrine interface (EEI), where the capillary network of the islet merges with the capillaries of the surrounding acinar tissue, i.e., the insulo-acinar portal system.  The goal of this article is to describe a novel, test article-induced pancreatic toxicity that originated at the EEI and to summarize investigations into the mechanistic basis of the injury.  This injury was initially characterized by light microscopy in 7/14 day-toxicity studies in Sprague-Dawley (Crl: CD[SD]) rats with undisclosed test articles.  Microvascular injury at the interface resulted in peri-islet serum exudation, fibrin deposition, hemorrhage, inflammation, and secondary degeneration/necrosis of surrounding exocrine tissue.  More chronic injury presented as islet fibrosis and lobular atrophy.  Direct cytotoxicity affecting the capillary endothelium at the EEI was confirmed ultrastructurally on day 4.  Endothelial microparticle and blood flow studies further confirmed endothelial involvement.  Similar lesions occurred less frequently in 2 other rat strains and not in the mouse, dog, or cynomolgus macaque.  In summary, in vivo and investigative study data confirmed primary endothelial cytotoxicity in the pathogenesis of this lesion and suggested that the lesion may be rat/rat strain-specific and of uncertain relevance for human safety risk assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXHld_SeCbYrVg90H21EOLACvtfcHk0lhrQ_LjtiBuog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1OmsrrJ&md5=da42f344ccd6ae6d4d6ed0d58bc12afe</span></div><a href="/servlet/linkout?suffix=cit43a&amp;dbid=16384&amp;doi=10.1177%2F0192623313508851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623313508851%26sid%3Dliteratum%253Aachs%26aulast%3DBrenneman%26aufirst%3DK.%2BA.%26aulast%3DRamaiah%26aufirst%3DS.%2BK.%26aulast%3DRohde%26aufirst%3DC.%2BM.%26aulast%3DMessing%26aufirst%3DD.%2BM.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DS.%2BP.%26aulast%3DGauthier%26aufirst%3DL.%2BM.%26aulast%3DStewart%26aufirst%3DZ.%2BS.%26aulast%3DMantena%26aufirst%3DS.%2BR.%26aulast%3DShevlin%26aufirst%3DK.%2BM.%26aulast%3DLeonard%26aufirst%3DC.%2BG.%26aulast%3DSokolowski%26aufirst%3DS.%2BA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DCarraher%26aufirst%3DD.%2BC.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DTomlinson%26aufirst%3DL.%26aulast%3DZhan%26aufirst%3DY.%26aulast%3DBobrowski%26aufirst%3DW.%2BF.%26aulast%3DBailey%26aufirst%3DS.%2BA.%26aulast%3DVogel%26aufirst%3DW.%2BM.%26aulast%3DMorris%26aufirst%3DD.%2BL.%26aulast%3DWhiteley%26aufirst%3DL.%2BO.%26aulast%3DDavis%26aufirst%3DJ.%2BW.%26atitle%3DMechanistic%2520investigations%2520of%2520test%2520article%25E2%2580%2593induced%2520pancreatic%2520toxicity%2520at%2520the%2520endocrine%25E2%2580%2593exocrine%2520interface%2520in%2520the%2520rat%26jtitle%3DToxicol.%2520Pathol.%26date%3D2014%26volume%3D42%26spage%3D229%26epage%3D242%26doi%3D10.1177%2F0192623313508851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit43b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spolverato, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlik, T. M.</span></span> <span> </span><span class="NLM_article-title">Long-term therapy with sorafenib is associated with pancreatic atrophy</span>. <i>J. Surg. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>199</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">314</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.1016/j.jss.2015.04.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1016%2Fj.jss.2015.04.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=26115806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVKmt7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=199&publication_year=2015&pages=314-321&issue=2&author=L.+Xuauthor=D.+Zhouauthor=J.+Zhaoauthor=G.+Spolveratoauthor=Y.+Zhangauthor=S.+Liauthor=M.+Chenauthor=T.+M.+Pawlik&title=Long-term+therapy+with+sorafenib+is+associated+with+pancreatic+atrophy&doi=10.1016%2Fj.jss.2015.04.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43bR"><div class="casContent"><span class="casTitleNuber">43b</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term therapy with sorafenib is associated with pancreatic atrophy</span></div><div class="casAuthors">Xu, Li; Zhou, Dong-Sheng; Zhao, Jing; Spolverato, Gaya; Zhang, Yao-Jun; Li, Sheng-Ping; Chen, Min-Shan; Pawlik, Timothy M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Surgical Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">199</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">314-321</span>CODEN:
                <span class="NLM_cas:coden">JSGRA2</span>;
        ISSN:<span class="NLM_cas:issn">0022-4804</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Although the short-term adverse effects of sorafenib are well known, few data exist on long-term toxicity.  The objective of the present study was to investigate the prevalence of pancreatic atrophy among a cohort of patients with hepatocellular carcinoma (HCC) who were treated with sorafenib for ≥2 y.  Between March 2007 and Dec. 2013, 31 patients with HCC who were treated with sorafenib for ≥2 y were identified.  The effect of pancreatic atrophy and enhancement on incidence of adverse events, tumor response, and overall survival (OS) were assessed.  Thirty-one patients with HCC were treated with sorafenib for ≥2 y and met inclusion criteria; 11 patients (35.5%) were Barcelona-clinic liver cancer stage B, whereas 20 patients (64.5%) were Barcelona-clinic liver cancer stage C.  Median duration of treatment with sorafenib was 35.2 mo.  Pancreatic atrophy and a decrease in pancreatic enhancement occurred in 24 patients (77.4%) and 15 patients (48.4%), resp.  On the basis of the modified response evaluation criteria in solid tumors, four patients (12.9%) had a complete response, 10 patients (32.3%) had a partial response, and 17 patients (54.8%) had stable disease.  Patients treated with sorafenib with pancreatic atrophy had a median OS of 49.4 mo (95% confidence interval, 41.2-57.5 mo) compared with 31.2 mo (95% confidence interval, 25.7-36.7 mo) among patients who did not develop pancreatic atrophy (P = 0.009).  In contrast, survival was not assocd. with decreased vs. normal enhancement of the pancreas (OS, 47.7 mo vs. 41.7 mo, resp.; P = 0.739).  Pancreatic atrophy occurred in many HCC patients after 2 y of treatment with sorafenib.  Patients who experienced pancreatic atrophy had a better tumor response and OS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFi1PX3aL37LVg90H21EOLACvtfcHk0lhrQ_LjtiBuog"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVKmt7nF&md5=ab4757b6bddaa63070a268156f71421c</span></div><a href="/servlet/linkout?suffix=cit43b&amp;dbid=16384&amp;doi=10.1016%2Fj.jss.2015.04.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jss.2015.04.035%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DSpolverato%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DPawlik%26aufirst%3DT.%2BM.%26atitle%3DLong-term%2520therapy%2520with%2520sorafenib%2520is%2520associated%2520with%2520pancreatic%2520atrophy%26jtitle%3DJ.%2520Surg.%2520Res.%26date%3D2015%26volume%3D199%26issue%3D2%26spage%3D314%26epage%3D321%26doi%3D10.1016%2Fj.jss.2015.04.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit43c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutt, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarrant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin-Koh, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedehus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staflin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambach, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase small molecule inhibitors induce a distinct pancreatic toxicity in rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.236224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1124%2Fjpet.116.236224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=27821712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC2sXptVOjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2017&pages=226-238&author=R.+I.+Ericksonauthor=L.+K.+Schuttauthor=J.+M.+Tarrantauthor=M.+McDowellauthor=L.+Liuauthor=A.+R.+Johnsonauthor=S.-C.+Lewin-Kohauthor=M.+Hedehusauthor=J.+Rossauthor=R.+A.+Caranoauthor=K.+Staflinauthor=F.+Zhongauthor=J.+J.+Crawfordauthor=S.+Zhongauthor=K.+Reifauthor=A.+Katewaauthor=H.+Wongauthor=W.+B.+Youngauthor=D.+M.+Dambachauthor=D.+L.+Misner&title=Bruton%E2%80%99s+tyrosine+kinase+small+molecule+inhibitors+induce+a+distinct+pancreatic+toxicity+in+rats&doi=10.1124%2Fjpet.116.236224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43cR"><div class="casContent"><span class="casTitleNuber">43c</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase small molecule inhibitors induce a distinct pancreatic toxicity in rats</span></div><div class="casAuthors">Erickson, Rebecca I.; Schutt, Leah K.; Tarrant, Jacqueline M.; McDowell, Michelle; Liu, Lichuan; Johnson, Adam R.; Lewin-Koh, Sock-Cheng; Hedehus, Maj; Ross, Jed; Carano, Richard A. D.; Staflin, Karin; Zhong, Fiona; Crawford, James J.; Zhong, Shelly; Reif, Karin; Katewa, Arna; Wong, Harvey; Young, Wendy B.; Dambach, Donna M.; Misner, Dinah L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">226-238</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) is a member of the Tec family of cytoplasmic tyrosine kinases involved in B-cell and myeloid cell signaling.  Small mol. inhibitors of BTK are being investigated for treatment of several hematol. cancers and autoimmune diseases.  GDC-0853 ((S)-2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4'-bipyridin]-2'-yl)-7,7-dimethyl-3,4,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one) is a selective and reversible oral small-mol. BTK inhibitor in development for the treatment of rheumatoid arthritis and systemic lupus erythematosus.  In Sprague-Dawley (SD) rats, administration of GDC-0853 and other structurally diverse BTK inhibitors for 7 days or longer caused pancreatic lesions consisting of multifocal islet-centered hemorrhage, inflammation, fibrosis, and pigment-laden macrophages with adjacent lobular exocrine acinar cell atrophy, degeneration, and inflammation.  Similar findings were not obsd. in mice or dogs at much higher exposures.  Hemorrhage in the peri-islet vasculature emerged between four and seven daily doses of GDC-0853 and was histol. similar to spontaneously occurring changes in aging SD rats.  This suggests that GDC-0853 could exacerbate a background finding in younger animals.  Glucose homeostasis was dysregulated following a glucose challenge; however, this occurred only after 28 days of administration and was not directly assocd. with onset or severity of pancreatic lesions.  There were no changes in other common serum biomarkers assessing endocrine and exocrine pancreatic function.  Addnl., these lesions were not readily detectable via Doppler ultrasound, computed tomog., or magnetic resonance imaging.  Our results indicate that pancreatic lesions in rats are likely a class effect of BTK inhibitors, which may exacerbate an islet-centered pathol. that is unlikely to be relevant to humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgiBmsDhUKIbVg90H21EOLACvtfcHk0lhAHtG-yzEQmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXptVOjtLo%253D&md5=15b2ef2030ed978d81cec5be5e0a74c8</span></div><a href="/servlet/linkout?suffix=cit43c&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.236224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.236224%26sid%3Dliteratum%253Aachs%26aulast%3DErickson%26aufirst%3DR.%2BI.%26aulast%3DSchutt%26aufirst%3DL.%2BK.%26aulast%3DTarrant%26aufirst%3DJ.%2BM.%26aulast%3DMcDowell%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DLewin-Koh%26aufirst%3DS.-C.%26aulast%3DHedehus%26aufirst%3DM.%26aulast%3DRoss%26aufirst%3DJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%26aulast%3DStaflin%26aufirst%3DK.%26aulast%3DZhong%26aufirst%3DF.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DZhong%26aufirst%3DS.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DDambach%26aufirst%3DD.%2BM.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520small%2520molecule%2520inhibitors%2520induce%2520a%2520distinct%2520pancreatic%2520toxicity%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D360%26spage%3D226%26epage%3D238%26doi%3D10.1124%2Fjpet.116.236224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="cit43d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bhaskaran, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornwell, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorden, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elwell, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritt, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahle, J. L.</span></span> <span> </span><span class="NLM_article-title">Pancreatic effects of a Bruton’s tyrosine kinase small-molecule inhibitor in rats are strain-dependent</span>. <i>Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">460</span>– <span class="NLM_lpage">472</span>, <span class="refDoi"> DOI: 10.1177/0192623318770163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1177%2F0192623318770163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=29699458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1agtrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=460-472&issue=4&author=M.+Bhaskaranauthor=P.+D.+Cornwellauthor=S.+D.+Sordenauthor=M.+R.+Elwellauthor=N.+R.+Russellauthor=M.+L.+Prittauthor=J.+L.+Vahle&title=Pancreatic+effects+of+a+Bruton%E2%80%99s+tyrosine+kinase+small-molecule+inhibitor+in+rats+are+strain-dependent&doi=10.1177%2F0192623318770163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43dR"><div class="casContent"><span class="casTitleNuber">43d</span><div class="casTitle"><span class="NLM_cas:atitle">Pancreatic Effects of a Bruton's Tyrosine Kinase Small-molecule Inhibitor in Rats Are Strain-dependent</span></div><div class="casAuthors">Bhaskaran, Manoj; Cornwell, Paul D.; Sorden, Steven D.; Elwell, Michael R.; Russell, Natalie R.; Pritt, Michael L.; Vahle, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">460-472</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Inhibitors of Bruton's tyrosine kinase (BTK) are under development as potential therapies for various autoimmune diseases.  In repeat-dose toxicity studies, small-mol. BTK inhibitors (BTKi) have been reported to cause a constellation of histol. effects at the pancreatic endocrine-exocrine interface in male rats; however, similar findings were not reported in other species.  Since the BTKi-induced pancreatic effect is morphol. similar to well-documented spontaneous changes (predominantly characterized by insular/peri-insular hemorrhage, pigment deposition, chronic inflammation, and fibrosis) that are known to vary by rat strain, we investigated potential strain-dependent differences in the pancreatic effects of a small-mol. BTKi, LY3337641.  Following 13 wk of LY3337641 treatment, Crl:CD(SD) rats were most sensitive, Crl:WI(Han) rats were of intermediate sensitivity, and Hsd:SD rats were least sensitive.  These strain differences appear to be related to differences in rate of wt. gain across strains and sexes; however, a definitive mechanism was not detd.  This study demonstrated that BTKi-induced pancreatic effects were highly dependent on rat strain and correlated with differences in the incidence and severity of the spontaneous background change.  When considered with the lack of pancreas effects in nonrat species, these changes in rats are unlikely predictive of similar changes in humans administered a BTK inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqENYhd4tz4wLVg90H21EOLACvtfcHk0lhAHtG-yzEQmw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1agtrjO&md5=fd64740a984a2adacd3debce4dadc335</span></div><a href="/servlet/linkout?suffix=cit43d&amp;dbid=16384&amp;doi=10.1177%2F0192623318770163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623318770163%26sid%3Dliteratum%253Aachs%26aulast%3DBhaskaran%26aufirst%3DM.%26aulast%3DCornwell%26aufirst%3DP.%2BD.%26aulast%3DSorden%26aufirst%3DS.%2BD.%26aulast%3DElwell%26aufirst%3DM.%2BR.%26aulast%3DRussell%26aufirst%3DN.%2BR.%26aulast%3DPritt%26aufirst%3DM.%2BL.%26aulast%3DVahle%26aufirst%3DJ.%2BL.%26atitle%3DPancreatic%2520effects%2520of%2520a%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520small-molecule%2520inhibitor%2520in%2520rats%2520are%2520strain-dependent%26jtitle%3DToxicol.%2520Pathol.%26date%3D2018%26volume%3D46%26issue%3D4%26spage%3D460%26epage%3D472%26doi%3D10.1177%2F0192623318770163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span> <span> </span><span class="NLM_article-title">Antiarthritis effect of a novel Bruton’s tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>338</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.181545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1124%2Fjpet.111.181545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=21521773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFCiu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=154-163&issue=1&author=L.+Liuauthor=J.+Di+Paoloauthor=J.+Barbosaauthor=H.+Rongauthor=K.+Reifauthor=H.+Wong&title=Antiarthritis+effect+of+a+novel+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitor+in+rat+collagen-induced+arthritis+and+mechanism-based+pharmacokinetic%2Fpharmacodynamic+modeling%3A+relationships+between+inhibition+of+BTK+phosphorylation+and+efficacy&doi=10.1124%2Fjpet.111.181545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy</span></div><div class="casAuthors">Liu, Lichuan; Di Paolo, Julie; Barbosa, Jim; Rong, Hong; Reif, Karin; Wong, Harvey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">154-163</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) plays a crit. role in the development, differentiation, and proliferation of B-lineage cells, making it an attractive target for the treatment of rheumatoid arthritis.  The objective of this study was to evaluate the antiarthritis effect of GDC-0834 [R-N-(3-(6-(4-(1,4-dimethyl-3-oxopiperazin-2-yl)phenylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide], a potent and selective BTK inhibitor, and characterize the relationship between inhibition of BTK phosphorylation (pBTK) and efficacy.  GDC-0834 inhibited BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochem. and cellular assays, resp., and in vivo IC50 of 1.1 and 5.6 μM in mouse and rat, resp.  Administration of GDC-0834 (30-100 mg/kg) in a rat collagen-induced arthritis (CIA) model resulted in a dose-dependent decrease of ankle swelling and redn. of morphol. pathol.  An integrated disease progression pharmacokinetic/pharmacodynamic model where efficacy is driven by pBTK inhibition was fit to ankle-diam. time-course data.  This model incorporated a transit model to characterize nondrug-related decreases in ankle swelling occurring at later stages of disease progression in CIA rats.  The time course of ankle swelling in vehicle animals was described well by the base model.  Simultaneous fitting of data from vehicle- and GDC-0834-treated groups showed that overall 73% inhibition of pBTK was needed to decrease the rate const. describing the ankle swelling increase (kin) by half.  These findings suggest a high degree of pBTK inhibition is required for maximal activity of the pathway on inflammatory arthritis in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUtceutx0oDrVg90H21EOLACvtfcHk0ljSKnJlLs4XnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFCiu7w%253D&md5=52ec6f33d9fc743036baea87a2d6bce1</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.181545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.181545%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DWong%26aufirst%3DH.%26atitle%3DAntiarthritis%2520effect%2520of%2520a%2520novel%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitor%2520in%2520rat%2520collagen-induced%2520arthritis%2520and%2520mechanism-based%2520pharmacokinetic%252Fpharmacodynamic%2520modeling%253A%2520relationships%2520between%2520inhibition%2520of%2520BTK%2520phosphorylation%2520and%2520efficacy%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26issue%3D1%26spage%3D154%26epage%3D163%26doi%3D10.1124%2Fjpet.111.181545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span>SLE:
A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic
(PK), and Pharmacodynamic (PD) Study of BIIB068 in Healthy Participants.
ClinicalTrials.gov Identifier: NCT02829541. <a href="https://clinicaltrials.gov/ct2/show/NCT02829541" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02829541</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=SLE%3A%0AA+Phase+1%2C+Single-Ascending-Dose%2C+Safety%2C+Tolerability%2C+Pharmacokinetic%0A%28PK%29%2C+and+Pharmacodynamic+%28PD%29+Study+of+BIIB068+in+Healthy+Participants.%0AClinicalTrials.gov+Identifier%3A+NCT02829541.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02829541."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcotte, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arduini, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hession, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miatkowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildes, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullen, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertsching, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanowski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvian, L. F.</span></span> <span> </span><span class="NLM_article-title">Structures of human Bruton’s tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1002/pro.321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1002%2Fpro.321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=20052711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFOhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=429-439&issue=3&author=D.+J.+Marcotteauthor=Y.-T.+Liuauthor=R.+M.+Arduiniauthor=C.+A.+Hessionauthor=K.+Miatkowskiauthor=C.+P.+Wildesauthor=P.+F.+Cullenauthor=V.+Hongauthor=B.+T.+Hopkinsauthor=E.+Mertschingauthor=T.+J.+Jenkinsauthor=M.+J.+Romanowskiauthor=D.+P.+Bakerauthor=L.+F.+Silvian&title=Structures+of+human+Bruton%E2%80%99s+tyrosine+kinase+in+active+and+inactive+conformations+suggest+a+mechanism+of+activation+for+TEC+family+kinases&doi=10.1002%2Fpro.321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases</span></div><div class="casAuthors">Marcotte, Douglas J.; Liu, Yu-Ting; Arduini, Robert M.; Hession, Catherine A.; Miatkowski, Konrad; Wildes, Craig P.; Cullen, Patrick F.; Hong, Victor; Hopkins, Brian T.; Mertsching, Elisabeth; Jenkins, Tracy J.; Romanowski, Michael J.; Baker, Darren P.; Silvian, Laura F.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">429-439</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a member of the TEC family of kinases, plays a crucial role in B-cell maturation and mast cell activation.  Although the structures of the unphosphorylated mouse BTK kinase domain and the unphosphorylated and phosphorylated kinase domains of human ITK are known, understanding the kinase selectivity profiles of BTK inhibitors has been hampered by the lack of availability of a high resoln., ligand-bound BTK structure.  Here, we report the crystal structures of the human BTK kinase domain bound to either Dasatinib (BMS-354825) at 1.9 Å resoln. or to 4-amino-5-(4-phenoxyphenyl)-7H-pyrrolospyrimidin-7-yl-cyclopentane at 1.6 Å resoln.  This data provides information relevant to the development of small mol. inhibitors targeting BTK and the TEC family of nonreceptor tyrosine kinases.  Anal. of the structural differences between the TEC and Src families of kinases near the Trp-Glu-Ile motif in the N-terminal region of the kinase domain suggests a mechanism of regulation of the TEC family members.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBETS8unO82rVg90H21EOLACvtfcHk0ljSKnJlLs4XnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFOhtbs%253D&md5=8c2dae6949f8bdb627d68ee14edc8d4f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fpro.321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.321%26sid%3Dliteratum%253Aachs%26aulast%3DMarcotte%26aufirst%3DD.%2BJ.%26aulast%3DLiu%26aufirst%3DY.-T.%26aulast%3DArduini%26aufirst%3DR.%2BM.%26aulast%3DHession%26aufirst%3DC.%2BA.%26aulast%3DMiatkowski%26aufirst%3DK.%26aulast%3DWildes%26aufirst%3DC.%2BP.%26aulast%3DCullen%26aufirst%3DP.%2BF.%26aulast%3DHong%26aufirst%3DV.%26aulast%3DHopkins%26aufirst%3DB.%2BT.%26aulast%3DMertsching%26aufirst%3DE.%26aulast%3DJenkins%26aufirst%3DT.%2BJ.%26aulast%3DRomanowski%26aufirst%3DM.%2BJ.%26aulast%3DBaker%26aufirst%3DD.%2BP.%26aulast%3DSilvian%26aufirst%3DL.%2BF.%26atitle%3DStructures%2520of%2520human%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520active%2520and%2520inactive%2520conformations%2520suggest%2520a%2520mechanism%2520of%2520activation%2520for%2520TEC%2520family%2520kinases%26jtitle%3DProtein%2520Sci.%26date%3D2010%26volume%3D19%26issue%3D3%26spage%3D429%26epage%3D439%26doi%3D10.1002%2Fpro.321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afonine, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunkóczi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echols, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeffner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwart, P. H.</span></span> <span> </span><span class="NLM_article-title">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1107/S0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+D.+Adamsauthor=P.+V.+Afonineauthor=G.+Bunk%C3%B3cziauthor=V.+B.+Chenauthor=I.+W.+Davisauthor=N.+Echolsauthor=J.+J.+Headdauthor=L.+Hungauthor=G.+J.+Kapralauthor=R.+W.+Grosse-Kunstleveauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+Oeffnerauthor=R.+J.+Readauthor=D.+C.+Richardsonauthor=J.+S.+Richardsonauthor=T.+C.+Terwilligerauthor=P.+H.+Zwart&title=PHENIX%3A+a+comprehensive+Python-based+system+for+macromolecular+structure+solution&doi=10.1107%2FS0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0ljSKnJlLs4XnQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBunk%25C3%25B3czi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DHung%26aufirst%3DL.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26atitle%3DPHENIX%253A%2520a%2520comprehensive%2520Python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2FS0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6a','cit6b'],'ref7':['cit7a','cit7b'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14a','cit14b','cit14c','cit14d'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17a','cit17b'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28a','cit28b','cit28c'],'ref29':['cit29'],'ref30':['cit30a','cit30b','cit30c'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34a','cit34b'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40a','cit40b'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43a','cit43b','cit43c','cit43d'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 4 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor "> Bin    Ma    </span><span class="hlFld-ContribAuthor "> Chaomin    Li </span><span class="hlFld-ContribAuthor "> Brian T.    Hopkins </span><span class="hlFld-ContribAuthor "> Lloyd    Franklin </span><span class="hlFld-ContribAuthor "> Robbie    Chen    </span><span class="hlFld-ContribAuthor "> Tamera    Mack </span><span class="hlFld-ContribAuthor "> Daniel    Patience </span><span class="hlFld-ContribAuthor "> William F.    Kiesman </span><span class="hlFld-ContribAuthor "> Erin M.    O’Brien    </span>. </span><span class="cited-content_cbyCitation_article-title">Discovery and Process Development of BIIB068: A Reversible Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Autoimmune Diseases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,, 313-337. <a href="https://doi.org/10.1021/bk-2020-1369.ch010" title="DOI URL">https://doi.org/10.1021/bk-2020-1369.ch010</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/bk-2020-1369.ch010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fbk-2020-1369.ch010%26sid%3Dliteratum%253Aachs%26atitle%3DDiscovery%252Band%252BProcess%252BDevelopment%252Bof%252BBIIB068%25253A%252BA%252BReversible%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252B%252528BTK%252529%252BInhibitor%252Bfor%252Bthe%252BTreatment%252Bof%252BAutoimmune%252BDiseases%26aulast%3DMa%26aufirst%3DBin%26date%3D2020%26date%3D2020%26spage%3D313%26epage%3D337%26atitle%3DComplete%252BAccounts%252Bof%252BIntegrated%252BDrug%252BDiscovery%252Band%252BDevelopment%25253A%252BRecent%252BExamples%252Bfrom%252Bthe%252BPharmaceutical%252BIndustry%252BVolume%252B3%26aulast%3DPesti%26aufirst%3DJaan%2BA.%26date%3D2020%26date%3D2020%26volume%3D1369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hui  Qiu</span>, <span class="hlFld-ContribAuthor ">Zahid  Ali</span>, <span class="hlFld-ContribAuthor ">Andrew  Bender</span>, <span class="hlFld-ContribAuthor ">Richard  Caldwell</span>, <span class="hlFld-ContribAuthor ">Yi-Ying  Chen</span>, <span class="hlFld-ContribAuthor ">Zhizhou  Fang</span>, <span class="hlFld-ContribAuthor ">Anna  Gardberg</span>, <span class="hlFld-ContribAuthor ">Nina  Glaser</span>, <span class="hlFld-ContribAuthor ">Anja  Goettsche</span>, <span class="hlFld-ContribAuthor ">Andreas  Goutopoulos</span>, <span class="hlFld-ContribAuthor ">Roland  Grenningloh</span>, <span class="hlFld-ContribAuthor ">Bettina  Hanschke</span>, <span class="hlFld-ContribAuthor ">Jared  Head</span>, <span class="hlFld-ContribAuthor ">Theresa  Johnson</span>, <span class="hlFld-ContribAuthor ">Christopher  Jones</span>, <span class="hlFld-ContribAuthor ">Reinaldo  Jones</span>, <span class="hlFld-ContribAuthor ">Shashank  Kulkarni</span>, <span class="hlFld-ContribAuthor ">Christine  Maurer</span>, <span class="hlFld-ContribAuthor ">Federica  Morandi</span>, <span class="hlFld-ContribAuthor ">Constantin  Neagu</span>, <span class="hlFld-ContribAuthor ">Sven  Poetzsch</span>, <span class="hlFld-ContribAuthor ">Justin  Potnick</span>, <span class="hlFld-ContribAuthor ">Ralf  Schmidt</span>, <span class="hlFld-ContribAuthor ">Katherine  Roe</span>, <span class="hlFld-ContribAuthor ">Ariele  Viacava Follis</span>, <span class="hlFld-ContribAuthor ">Carolyn  Wing</span>, <span class="hlFld-ContribAuthor ">Xiaohua  Zhu</span>, <span class="hlFld-ContribAuthor ">Brian  Sherer</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of potent and selective reversible Bruton’s tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>40 </em>, 116163. <a href="https://doi.org/10.1016/j.bmc.2021.116163" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116163</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116163%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpotent%252Band%252Bselective%252Breversible%252BBruton%2525E2%252580%252599s%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DQiu%26aufirst%3DHui%26date%3D2021%26volume%3D40%26spage%3D116163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brian T.  Hopkins</span>, <span class="hlFld-ContribAuthor ">Eris  Bame</span>, <span class="hlFld-ContribAuthor ">Noah  Bell</span>, <span class="hlFld-ContribAuthor ">Tonika  Bohnert</span>, <span class="hlFld-ContribAuthor ">Jon K.  Bowden-Verhoek</span>, <span class="hlFld-ContribAuthor ">Minna  Bui</span>, <span class="hlFld-ContribAuthor ">Mark T.  Cancilla</span>, <span class="hlFld-ContribAuthor ">Patrick  Conlon</span>, <span class="hlFld-ContribAuthor ">Patrick  Cullen</span>, <span class="hlFld-ContribAuthor ">Daniel A.  Erlanson</span>, <span class="hlFld-ContribAuthor ">Junfa  Fan</span>, <span class="hlFld-ContribAuthor ">Tarra  Fuchs-Knotts</span>, <span class="hlFld-ContribAuthor ">Stig  Hansen</span>, <span class="hlFld-ContribAuthor ">Stacey  Heumann</span>, <span class="hlFld-ContribAuthor ">Tracy J.  Jenkins</span>, <span class="hlFld-ContribAuthor ">Chuck  Gua</span>, <span class="hlFld-ContribAuthor ">Ying  Yiu</span>, <span class="hlFld-ContribAuthor ">YuTing  Liu</span>, <span class="hlFld-ContribAuthor ">Mukush  Lulla</span>, <span class="hlFld-ContribAuthor ">Douglas  Marcotte</span>, <span class="hlFld-ContribAuthor ">Isaac  Marx</span>, <span class="hlFld-ContribAuthor ">Bob  McDowell</span>, <span class="hlFld-ContribAuthor ">Elisabeth  Mertsching</span>, <span class="hlFld-ContribAuthor ">Ella  Negrou</span>, <span class="hlFld-ContribAuthor ">Michael J.  Romanowski</span>, <span class="hlFld-ContribAuthor ">Daniel  Scott</span>, <span class="hlFld-ContribAuthor ">Laura  Silvian</span>, <span class="hlFld-ContribAuthor ">Wenjin  Yang</span>, <span class="hlFld-ContribAuthor ">Min  Zhong</span>. </span><span class="cited-content_cbyCitation_article-title">Utilizing Structure Based Drug Design and Metabolic Soft Spot Identification to optimize the in vitro potency and in vivo Pharmacokinetic Properties Leading to the Discovery of Novel Reversible Bruton’s Tyrosine Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>23 </em>, 116275. <a href="https://doi.org/10.1016/j.bmc.2021.116275" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116275</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116275%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DUtilizing%252BStructure%252BBased%252BDrug%252BDesign%252Band%252BMetabolic%252BSoft%252BSpot%252BIdentification%252Bto%252Boptimize%252Bthe%252Bin%252Bvitro%252Bpotency%252Band%252Bin%252Bvivo%252BPharmacokinetic%252BProperties%252BLeading%252Bto%252Bthe%252BDiscovery%252Bof%252BNovel%252BReversible%252BBruton%2525E2%252580%252599s%252BTyrosine%252BKinase%252BInhibitors%26aulast%3DHopkins%26aufirst%3DBrian%2BT.%26date%3D2021%26volume%3D23%26spage%3D116275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eris  Bame</span>, <span class="hlFld-ContribAuthor ">Hao  Tang</span>, <span class="hlFld-ContribAuthor ">Jeremy C  Burns</span>, <span class="hlFld-ContribAuthor ">Million  Arefayene</span>, <span class="hlFld-ContribAuthor ">Klaus  Michelsen</span>, <span class="hlFld-ContribAuthor ">Bin  Ma</span>, <span class="hlFld-ContribAuthor ">Isaac  Marx</span>, <span class="hlFld-ContribAuthor ">Robin  Prince</span>, <span class="hlFld-ContribAuthor ">Allie M  Roach</span>, <span class="hlFld-ContribAuthor ">Urjana  Poreci</span>, <span class="hlFld-ContribAuthor ">Douglas  Donaldson</span>, <span class="hlFld-ContribAuthor ">Patrick  Cullen</span>, <span class="hlFld-ContribAuthor ">Fergal  Casey</span>, <span class="hlFld-ContribAuthor ">Jing  Zhu</span>, <span class="hlFld-ContribAuthor ">Thomas M  Carlile</span>, <span class="hlFld-ContribAuthor ">Dipen  Sangurdekar</span>, <span class="hlFld-ContribAuthor ">Baohong  Zhang</span>, <span class="hlFld-ContribAuthor ">Patrick  Trapa</span>, <span class="hlFld-ContribAuthor ">Joseph  Santoro</span>, <span class="hlFld-ContribAuthor ">Param  Muragan</span>, <span class="hlFld-ContribAuthor ">Alex  Pellerin</span>, <span class="hlFld-ContribAuthor ">Stephen  Rubino</span>, <span class="hlFld-ContribAuthor ">Davide  Gianni</span>, <span class="hlFld-ContribAuthor ">Bekim  Bajrami</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Peng</span>, <span class="hlFld-ContribAuthor ">Alex  Coppell</span>, <span class="hlFld-ContribAuthor ">Katherine  Riester</span>, <span class="hlFld-ContribAuthor ">Shibeshih  Belachew</span>, <span class="hlFld-ContribAuthor ">Devangi  Mehta</span>, <span class="hlFld-ContribAuthor ">Mike  Palte</span>, <span class="hlFld-ContribAuthor ">Brian T  Hopkins</span>, <span class="hlFld-ContribAuthor ">Matthew  Scaramozza</span>, <span class="hlFld-ContribAuthor ">Nathalie  Franchimont</span>, <span class="hlFld-ContribAuthor ">Michael  Mingueneau</span>. </span><span class="cited-content_cbyCitation_article-title">Next‐generation Bruton's tyrosine kinase inhibitor BIIB091 selectively and potently inhibits B cell and Fc receptor signaling and downstream functions in B cells and myeloid cells. </span><span class="cited-content_cbyCitation_journal-name">Clinical & Translational Immunology</span><span> <strong>2021,</strong> <em>10 </em>
                                    (6)
                                     <a href="https://doi.org/10.1002/cti2.1295" title="DOI URL">https://doi.org/10.1002/cti2.1295</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cti2.1295&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcti2.1295%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520%2526%2520Translational%2520Immunology%26atitle%3DNext%2525E2%252580%252590generation%252BBruton%252527s%252Btyrosine%252Bkinase%252Binhibitor%252BBIIB091%252Bselectively%252Band%252Bpotently%252Binhibits%252BB%252Bcell%252Band%252BFc%252Breceptor%252Bsignaling%252Band%252Bdownstream%252Bfunctions%252Bin%252BB%252Bcells%252Band%252Bmyeloid%252Bcells%26aulast%3DBame%26aufirst%3DEris%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0017.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0017.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00702&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0001.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Chemical structures of BTK inhibitors BIIB068 (<b>1</b>), ibrutinib (<b>2</b>), acalabrutinib (<b>3</b>), and zanubrutinib (<b>4</b>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00702&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0002.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Chemical structures of novel pyrrolopyrimidine BTK hit <b>5</b> and analogs <b>6</b> and <b>7</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00702&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0003.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. An overlay of BTK cocrystal structures with compound <b>5</b> (blue, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VXQ">6VXQ</a>) and compound <b>6</b> (green, PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6W06">6W06</a>) bound in the ATP active site. H3 residues Y551, S543, and L542 are marked in orange, and structural features, binding interactions, and residues are labeled.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00702&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0004.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. X-ray cocrystal structure of compound <b>1</b> in BTK (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6W07">6W07</a>). The active site surface is shown semitransparent, and H3 residues Y551, S543, and L542 are marked in orange.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00702&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0005.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Phenotypic BioSeek study data of compound <b>1</b> at 1.1, 3.3, 10, and 30 μM. The gray area shows the 95% confidence area of each biomarker response in the absence of drug. Data points that fall outside the gray area signify inhibition (below) or augmentation (above) of the biomarker response at the indicated concentration of compound <b>1</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00702&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0009.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of BIIB068 (<b>1</b>)<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00702&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) 3 equiv of BH<sub>3</sub>, THF, 0–80 °C, 16 h, 90%; (b) 1.1 equiv of Boc<sub>2</sub>O, 3 equiv of NEt<sub>3</sub>, THF, rt, 1 h, 95%; (c) 1.2 equiv of PinB-BPin, 0.1 equiv of Pd(dppf)Cl<sub>2</sub>, 3 equiv of KOAc, 1,4-dioxane, 100 °C, 2 h, 69%; (d) 0.1 equiv of Pd(dppf)Cl<sub>2</sub>, 2 equiv of K<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane/H<sub>2</sub>O (4:1), 90 °C, 2 h, 80%; (e) 0.1 equiv of Pd<sub>2</sub>(dba)<sub>3</sub>, 0.2 equiv of S-Phos, 2 equiv of Cs<sub>2</sub>CO<sub>3</sub>, 1,4-dioxane, 120 °C, 2 h, 63%; (f) HCl/MeOH, rt, 6 h, 90%; (g) CDI, DIPEA, DMF, 30%.</p></p></figure><figure data-id="fig6" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0006.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. PK and PD analysis of BIIB068 (<b>1</b>) in the TI-2 efficacy model: (A) workflow of the TI-2 mice efficacy model; (B) pBTK % inhibition at 1 h, 4 h, and prelast dose; (C) total drug concentration at 1 h, 4 h, and prelast dose. Figure shows the mean and standard deviation of triplicate determination in one experiment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00702&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0007.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Dose–response trial of BIIB068 (<b>1</b>)-mediated inhibition of the antigen-specific antibody response to a TI-2 antigen. Figure shows the mean and standard deviation of triplicate determination in one experiment.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00702&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/medium/jm0c00702_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0008.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Dose–response of (A) pBTK inhibition, (B) CD69 expression inhibition by BIIB068, and (C) exposure of BIIB068 (<b>1</b>) in healthy human cohorts (placebo, 10 mg, 30 mg, 60 mg, 120 mg).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-21/acs.jmedchem.0c00702/20201105/images/large/jm0c00702_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.0c00702&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i50">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28828" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28828" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 47 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staudt, L. M.</span></span> <span> </span><span class="NLM_article-title">Targeting pathological B cell receptor signaling in lymphoid malignancies</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1038/nrd3937</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1038%2Fnrd3937" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=23449308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjtlamt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=229-243&author=R.+M.+Youngauthor=L.+M.+Staudt&title=Targeting+pathological+B+cell+receptor+signaling+in+lymphoid+malignancies&doi=10.1038%2Fnrd3937"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1aR"><div class="casContent"><span class="casTitleNuber">1a</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting pathological B cell receptor signalling in lymphoid malignancies</span></div><div class="casAuthors">Young, Ryan M.; Staudt, Louis M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">229-243</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Signalling through the B cell receptor (BCR) is central to the development and maintenance of B cells.  In light of the numerous proliferative and survival pathways activated downstream of the BCR, it comes as no surprise that malignant B cells would co-opt this receptor to promote their own growth and survival.  However, direct evidence for BCR signalling in human lymphoma has only come to light recently.  Roles for antigen-dependent and antigen-independent, or tonic, BCR signalling have now been described for several different lymphoma subtypes.  Furthermore, correlative data implicate antigen-dependent BCR signalling in many other forms of lymphoma.  A host of therapeutic agents targeting effectors of the BCR signalling pathway are now in clin. trials and have shown initial success against multiple forms of lymphoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVUax9riiUObVg90H21EOLACvtfcHk0ljrhbfwWtoyfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjtlamt78%253D&md5=3969aa6232508b72e03da0177ba8280e</span></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=10.1038%2Fnrd3937&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3937%26sid%3Dliteratum%253Aachs%26aulast%3DYoung%26aufirst%3DR.%2BM.%26aulast%3DStaudt%26aufirst%3DL.%2BM.%26atitle%3DTargeting%2520pathological%2520B%2520cell%2520receptor%2520signaling%2520in%2520lymphoid%2520malignancies%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2013%26volume%3D12%26spage%3D229%26epage%3D243%26doi%3D10.1038%2Fnrd3937" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bittner, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radsak, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brunner, C.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase: An emerging key player in innate immunity</span>. <i>Front. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">1454</span>, <span class="refDoi"> DOI: 10.3389/fimmu.2017.01454</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.3389%2Ffimmu.2017.01454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=29167667" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFemsLrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=1454&author=A.+N.+Weberauthor=Z.+Bittnerauthor=X.+Liuauthor=T.+Dangauthor=M.+P.+Radsakauthor=C.+Brunner&title=Bruton%E2%80%99s+tyrosine+kinase%3A+An+emerging+key+player+in+innate+immunity&doi=10.3389%2Ffimmu.2017.01454"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase: an emerging key player in innate immunity</span></div><div class="casAuthors">Weber, Alexander N. R.; Bittner, Zsofia; Liu, Xiao; Dang, Truong-Minh; Radsak, Markus Philipp; Brunner, Cornelia</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in Immunology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1454/1-1454/6</span>CODEN:
                <span class="NLM_cas:coden">FIRMCW</span>;
        ISSN:<span class="NLM_cas:issn">1664-3224</span>.
    
            (<span class="NLM_cas:orgname">Frontiers Media S.A.</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (BTK) was initially discovered as a crit. mediator of B cell receptor signaling in the development and functioning of adaptive immunity.  Growing evidence also suggests multiple roles for BTK in mononuclear cells of the innate immune system, esp. in dendritic cells and macrophages.  For example, BTK has been shown to function in Toll-like receptor-mediated recognition of infectious agents, cellular maturation and recruitment processes, and Fc receptor signaling.  Most recently, BTK was addnl. identified as a direct regulator of a key innate inflammatory machinery, the NLRP3 inflammasome.  BTK has thus attracted interest not only for gaining a more thorough basic understanding of the human innate immune system but also as a target to therapeutically modulate innate immunity.  We here review the latest developments on the role of BTK in mononuclear innate immune cells in mouse vs. man, with specific emphasis on the sensing of infectious agents and the induction of inflammation.  Therapeutic implications for modulating innate immunity and crit. open questions are also discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbuyJkEPCUhrVg90H21EOLACvtfcHk0lhDnIsI-fQvXg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFemsLrK&md5=05b5e2fa9012104f7177572f8c4a72bc</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.3389%2Ffimmu.2017.01454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffimmu.2017.01454%26sid%3Dliteratum%253Aachs%26aulast%3DWeber%26aufirst%3DA.%2BN.%26aulast%3DBittner%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DDang%26aufirst%3DT.%26aulast%3DRadsak%26aufirst%3DM.%2BP.%26aulast%3DBrunner%26aufirst%3DC.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%253A%2520An%2520emerging%2520key%2520player%2520in%2520innate%2520immunity%26jtitle%3DFront.%2520Immunol.%26date%3D2017%26volume%3D8%26spage%3D1454%26doi%3D10.3389%2Ffimmu.2017.01454" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">de
Weers, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verschuren, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraakman, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mensink, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuurman, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Dongen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span> <span> </span><span class="NLM_article-title">The Bruton’s tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages</span>. <i>Eur. J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>23</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">3109</span>– <span class="NLM_lpage">3114</span>, <span class="refDoi"> DOI: 10.1002/eji.1830231210</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1002%2Feji.1830231210" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=8258324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADyaK2cXhtVCksL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=1993&pages=3109-3114&issue=12&author=M.+de%0AWeersauthor=M.+C.+Verschurenauthor=M.+E.+Kraakmanauthor=R.+G.+Mensinkauthor=R.+K.+Schuurmanauthor=J.+J.+van+Dongenauthor=R.+W.+Hendriks&title=The+Bruton%E2%80%99s+tyrosine+kinase+gene+is+expressed+throughout+B+cell+differentiation%2C+from+early+precursor+B+cell+stages+preceding+immunoglobulin+gene+rearrangement+up+to+mature+B+cell+stages&doi=10.1002%2Feji.1830231210"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages</span></div><div class="casAuthors">de Weers, Michel; Verschuren, Martie C. M.; Kraakman, Margriet E. M.; Mensink, Rob G. J.; Schuurman, Ruud K. B.; van Dongen, Jacques J. M.; Hendriks, Rudolf W.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Immunology</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3109-14</span>CODEN:
                <span class="NLM_cas:coden">EJIMAF</span>;
        ISSN:<span class="NLM_cas:issn">0014-2980</span>.
    </div><div class="casAbstract">X-linked agammaglobulinemia (XLA) is an immunodeficiency disease in man, resulting from an arrest in early B cell differentiation.  The gene defective in XLA has recently been identified and encodes a cytoplasmic protein tyrosine kinase, named Bruton's tyrosine kinase (btk), essential for cell differentiation and proliferation at the transition from pre-B to later B cell stages.  In this study the authors investigated btk expression by Northern blotting expts. in a series of human (precursor) B cell lines, acute lymphoblastic leukemias, and plasmacytomas.  Btk was already expressed in very early stages of B cell differentiation, even prior to Ig heavy (H) or light (L) chain gene rearrangements.  Transcripts were also detected at the pre-B cell stage and in mature B cells, irresp. of the Ig H chain class expressed.  Approx. at the transition from mature B cells to plasma cells, expression of the btk gene is down-regulated.  In addn., the btk gene was expressed in myeloid cell lines and acute myeloid leukemias.  Btk expression in myeloid cells is probably not a prerequisite for myeloid differentiation, since myeloid cells in XLA patients seem not to be affected.  No btk expression was found in T-lineage cells.  The btk expression profile, i.e. from early precursor-B cell stages preceding Ig rearrangement up to mature B cells, supports the hypothesis that the XLA defect resides in a crit. step of B cell development which is independent of the Ig gene recombination machinery.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPh3BF8ebN9LVg90H21EOLACvtfcHk0ljNocw97tzUcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXhtVCksL8%253D&md5=556362bf5f73ac7c7962de1d0c7ff167</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1002%2Feji.1830231210&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Feji.1830231210%26sid%3Dliteratum%253Aachs%26aulast%3Dde%2BWeers%26aufirst%3DM.%26aulast%3DVerschuren%26aufirst%3DM.%2BC.%26aulast%3DKraakman%26aufirst%3DM.%2BE.%26aulast%3DMensink%26aufirst%3DR.%2BG.%26aulast%3DSchuurman%26aufirst%3DR.%2BK.%26aulast%3Dvan%2BDongen%26aufirst%3DJ.%2BJ.%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26atitle%3DThe%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520gene%2520is%2520expressed%2520throughout%2520B%2520cell%2520differentiation%252C%2520from%2520early%2520precursor%2520B%2520cell%2520stages%2520preceding%2520immunoglobulin%2520gene%2520rearrangement%2520up%2520to%2520mature%2520B%2520cell%2520stages%26jtitle%3DEur.%2520J.%2520Immunol.%26date%3D1993%26volume%3D23%26issue%3D12%26spage%3D3109%26epage%3D3114%26doi%3D10.1002%2Feji.1830231210" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bruton, O. C.</span></span> <span> </span><span class="NLM_article-title">Agammaglobulinemia</span>. <i>Pediatrics.</i> <span class="NLM_year" style="font-weight: bold;">1952</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">722</span>– <span class="NLM_lpage">728</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=14929630" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A280%3ADyaG38%252FlvFOnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=1952&pages=722-728&author=O.+C.+Bruton&title=Agammaglobulinemia"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Agammaglobulinemia</span></div><div class="casAuthors">BRUTON O C</div><div class="citationInfo"><span class="NLM_cas:title">Pediatrics</span>
        (<span class="NLM_cas:date">1952</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">722-8</span>
        ISSN:<span class="NLM_cas:issn">0031-4005</span>.
    </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ99IDXIc3tbqqcneEtCi92fW6udTcc2eYnhAZdY-R4e7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaG38%252FlvFOnsg%253D%253D&md5=737a40c8a7c8f591efca619f2ba894aa</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBruton%26aufirst%3DO.%2BC.%26atitle%3DAgammaglobulinemia%26jtitle%3DPediatrics.%26date%3D1952%26volume%3D9%26spage%3D722%26epage%3D728" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Islam, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vorechovsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olerup, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallin, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabbani, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baskin, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammarstrom, L.</span></span> <span> </span><span class="NLM_article-title">X-linked agammaglobulinemia and other immunoglobulin deficiencies</span>. <i>Immunol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>138</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1111/j.1600-065X.1994.tb00851.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1111%2Fj.1600-065X.1994.tb00851.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=8070814" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADyaK2cXkvVSnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=1994&pages=159-183&author=C.+I.+E.+Smithauthor=K.+B.+Islamauthor=I.+Vorechovskyauthor=O.+Olerupauthor=E.+Wallinauthor=H.+Rabbaniauthor=B.+Baskinauthor=L.+Hammarstrom&title=X-linked+agammaglobulinemia+and+other+immunoglobulin+deficiencies&doi=10.1111%2Fj.1600-065X.1994.tb00851.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">X-linked agammaglobulinemia and other immunoglobulin deficiencies</span></div><div class="casAuthors">Smith, C. I. Edvard; Islam, Khalid B.; Vorechovsky, Igor; Olerup, Olle; Wallin, Erik; Rabbani, Hodjattallah; Baskin, Berivan; Hammarstroem, Lennart</div><div class="citationInfo"><span class="NLM_cas:title">Immunological Reviews</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">159-83</span>CODEN:
                <span class="NLM_cas:coden">IMRED2</span>;
        ISSN:<span class="NLM_cas:issn">0105-2896</span>.
    </div><div class="casAbstract">A review with 123 refs. discussing Ig deficiencies, isolation of the XLA gene, structure and expression of Btk, mutation anal. in patients with XLA, the naturally occurring mouse mutant CBA/N, deletions in the IgH locus, IgA deficiency and common variable immunodeficiency, genetics of IgAD and CVID, the B-lymphocyte abnormality in IgAD, and IgG3 deficiency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpqcdUsf_XJ8LVg90H21EOLACvtfcHk0ljNocw97tzUcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXkvVSnsbk%253D&md5=90f59e592743c3baeb1531c8c0689946</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1111%2Fj.1600-065X.1994.tb00851.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1600-065X.1994.tb00851.x%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DC.%2BI.%2BE.%26aulast%3DIslam%26aufirst%3DK.%2BB.%26aulast%3DVorechovsky%26aufirst%3DI.%26aulast%3DOlerup%26aufirst%3DO.%26aulast%3DWallin%26aufirst%3DE.%26aulast%3DRabbani%26aufirst%3DH.%26aulast%3DBaskin%26aufirst%3DB.%26aulast%3DHammarstrom%26aufirst%3DL.%26atitle%3DX-linked%2520agammaglobulinemia%2520and%2520other%2520immunoglobulin%2520deficiencies%26jtitle%3DImmunol.%2520Rev.%26date%3D1994%26volume%3D138%26spage%3D159%26epage%3D183%26doi%3D10.1111%2Fj.1600-065X.1994.tb00851.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linton, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. S.</span></span> <span> </span><span class="NLM_article-title">Analysis of clinical presentations of Bruton disease: A review of 20 years of accumulated data from pediatric patients at severance hospital</span>. <i>Yonsei Med. J.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>49</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">28</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.3349/ymj.2008.49.1.28</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.3349%2Fymj.2008.49.1.28" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=18306466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BD1cXktlOgsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2008&pages=28-36&issue=1&author=J.+Chunauthor=T.+J.+Leeauthor=J.+W.+Songauthor=J.+A.+Lintonauthor=D.+S.+Kim&title=Analysis+of+clinical+presentations+of+Bruton+disease%3A+A+review+of+20+years+of+accumulated+data+from+pediatric+patients+at+severance+hospital&doi=10.3349%2Fymj.2008.49.1.28"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of clinical presentations of Bruton disease: a review of 20 years of accumulated data from pediatric patients at severance hospital</span></div><div class="casAuthors">Chun, Jin-Kyong; Lee, Taek Jin; Song, Jae Woo; Linton, John A.; Kim, Dong Soo</div><div class="citationInfo"><span class="NLM_cas:title">Yonsei Medical Journal</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">28-36</span>CODEN:
                <span class="NLM_cas:coden">YOMJA9</span>;
        ISSN:<span class="NLM_cas:issn">0513-5796</span>.
    
            (<span class="NLM_cas:orgname">Yonsei University College of Medicine</span>)
        </div><div class="casAbstract">X-linked agammaglobulinemia (XLA) is a humoral immunodeficiency disease caused by a mutation in the Bruton tyrosine kinase (BTK) gene resulting in defective B cell differentiation.  Because it is a relatively rare disorder, it is difficult for clinicians to have a comprehensive understanding of XLA due to a lack of exposure to the disease.  Clin. presentations of patients with XLA were analyzed and discussed to improve care plans.  During a 20-yr period, from Jan. 1987 to June 2006, a total of 19 patients were diagnosed as XLA in the Department of Pediatrics at Severance Hospital, Seoul, Korea.  A retrospective anal. of the clin. presentations of those patients was performed.  The mean age of the XLA patients included in the study was 4.89 years, with a range of 6 mo to 13 years.  Twelve patients were diagnosed before age 5, while the other 7 patients were diagnosed after age 5.  Recurrent infections obsd. in the patients included pneumonia, acute otitis media, septic arthritis, skin infection, sepsis, sinusitis, acute gastroenteritis, cervical lymphadenitis, epididymitis, meningitis, osteomyelitis, urinary tract infection and encephalitis.  Frequency of admissions was variable from 0 to 12 times, depending on the time at which Ig therapy was started.  Six cases had family histories pos. for XLA.  BTK gene mutations were found in 8 cases.  The overall prognosis of XLA is good as long as patients are diagnosed and treated early with regular intra venous gamma globulin therapy before the sequelae of recurrent infections appear.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1Fy7lQ2xLdbVg90H21EOLACvtfcHk0ljNocw97tzUcg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXktlOgsbs%253D&md5=65dc163066c45e56dc52d0a5af572707</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.3349%2Fymj.2008.49.1.28&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3349%252Fymj.2008.49.1.28%26sid%3Dliteratum%253Aachs%26aulast%3DChun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DT.%2BJ.%26aulast%3DSong%26aufirst%3DJ.%2BW.%26aulast%3DLinton%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DD.%2BS.%26atitle%3DAnalysis%2520of%2520clinical%2520presentations%2520of%2520Bruton%2520disease%253A%2520A%2520review%2520of%252020%2520years%2520of%2520accumulated%2520data%2520from%2520pediatric%2520patients%2520at%2520severance%2520hospital%26jtitle%3DYonsei%2520Med.%2520J.%26date%3D2008%26volume%3D49%26issue%3D1%26spage%3D28%26epage%3D36%26doi%3D10.3349%2Fymj.2008.49.1.28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saffran, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlings, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parolini, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klisak, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sparkes, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubagawa, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mohandas, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conley, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">279</span>– <span class="NLM_lpage">290</span>, <span class="refDoi"> DOI: 10.1016/0092-8674(93)90667-F</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1016%2F0092-8674%2893%2990667-F" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=8425221" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADyaK3sXkvFensro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=1993&pages=279-290&author=S.+Tsukadaauthor=D.+C.+Saffranauthor=D.+J.+Rawlingsauthor=O.+Paroliniauthor=R.+C.+Allenauthor=I.+Klisakauthor=R.+S.+Sparkesauthor=H.+Kubagawaauthor=T.+Mohandasauthor=S.+Quanauthor=J.+W.+Belmontauthor=M.+D.+Cooperauthor=M.+E.+Conleyauthor=O.+N.+Witte&title=Deficient+expression+of+a+B+cell+cytoplasmic+tyrosine+kinase+in+human+X-linked+agammaglobulinemia&doi=10.1016%2F0092-8674%2893%2990667-F"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6aR"><div class="casContent"><span class="casTitleNuber">6a</span><div class="casTitle"><span class="NLM_cas:atitle">Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia</span></div><div class="casAuthors">Tsukada, Satoshi; Saffran, Douglas C.; Rawlings, David J.; Parolini, Ornella; Allen, R. Cutler; Klisak, Ivana; Sparkes, Robert S.; Kubagawa, Hiromi; Mohandas, Thuluvancheri; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">279-90</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    </div><div class="casAbstract">We describe a novel cytoplasmic tyrosine kinase, termed BPK (B cell progenitor kinase), which is expressed in all stages of the B lineage and in myeloid cells.  BPK has classic SH1, SH2, and SH3 domains, but lacks myristylation signals and a regulatory phosphorylation site corresponding to tyrosine 527 of c-src.  BPK has a long, basic amino-terminal region upstream of the SH3 domain.  BPK was evaluated as a candidate for human X-linked agammaglobulinemia (XLA), an inherited immunodeficiency characterized by a severe deficit of B and plasma cells and profound hypogammaglobulinemia.  BPK mapped to within 100 kb of a probe defining the polymorphism most closely linked to XLA at DXS178.  Redn. in or the absence of BPK mRNA, protein expression, and kinase activity was obsd. in XLA pre-B and B cell lines.  BPK is likely the XLA gene and functions in pathways crit. to B cell expansion.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ_KGg5ilchbVg90H21EOLACvtfcHk0ljwVUPlm6jYAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXkvFensro%253D&md5=fbc5a572b91397b1e86a8640e7759c10</span></div><a href="/servlet/linkout?suffix=cit6a&amp;dbid=16384&amp;doi=10.1016%2F0092-8674%2893%2990667-F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0092-8674%252893%252990667-F%26sid%3Dliteratum%253Aachs%26aulast%3DTsukada%26aufirst%3DS.%26aulast%3DSaffran%26aufirst%3DD.%2BC.%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26aulast%3DParolini%26aufirst%3DO.%26aulast%3DAllen%26aufirst%3DR.%2BC.%26aulast%3DKlisak%26aufirst%3DI.%26aulast%3DSparkes%26aufirst%3DR.%2BS.%26aulast%3DKubagawa%26aufirst%3DH.%26aulast%3DMohandas%26aufirst%3DT.%26aulast%3DQuan%26aufirst%3DS.%26aulast%3DBelmont%26aufirst%3DJ.%2BW.%26aulast%3DCooper%26aufirst%3DM.%2BD.%26aulast%3DConley%26aufirst%3DM.%2BE.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DDeficient%2520expression%2520of%2520a%2520B%2520cell%2520cytoplasmic%2520tyrosine%2520kinase%2520in%2520human%2520X-linked%2520agammaglobulinemia%26jtitle%3DCell%26date%3D1993%26volume%3D72%26spage%3D279%26epage%3D290%26doi%3D10.1016%2F0092-8674%2893%2990667-F" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit6b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Vetrie, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vorechovsky, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideras, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holland, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Flinter, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammarstrom, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kinnon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levinsky, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bobrow, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, C. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, D. R.</span></span> <span> </span><span class="NLM_article-title">The gene involved in X-linked agammaglobulinemia is a member of the src family of protein tyrosine kinases</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>361</i></span>,  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">233</span>, <span class="refDoi"> DOI: 10.1038/361226a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1038%2F361226a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=8380905" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADyaK3sXitlajt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=1993&pages=226-233&author=D.+Vetrieauthor=I.+Vorechovskyauthor=P.+Siderasauthor=J.+Hollandauthor=A.+Daviesauthor=F.+Flinterauthor=L.+Hammarstromauthor=C.+Kinnonauthor=R.+Levinskyauthor=M.+Bobrowauthor=C.+I.+Smithauthor=D.+R.+Bentley&title=The+gene+involved+in+X-linked+agammaglobulinemia+is+a+member+of+the+src+family+of+protein+tyrosine+kinases&doi=10.1038%2F361226a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6bR"><div class="casContent"><span class="casTitleNuber">6b</span><div class="casTitle"><span class="NLM_cas:atitle">The gene involved in X-linked agammaglobulinemia is a member of the src family of protein-tyrosine kinases</span></div><div class="casAuthors">Vetrie, David; Vorechovsky, Igor; Sideras, Paschalis; Holland, Jill; Davies, Angela; Flinter, Frances; Hammarstroem, Lennart; Kinnon, Christine; Levinsky, Roland; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">6409</span>),
    <span class="NLM_cas:pages">226-33</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">X-linked agammaglobulinemia (XLA) is a human immunodeficiency caused by failure of pre-B cells in the bone marrow to develop into circulating mature B cells.  A novel gene (atk) has been isolated which maps to the XLA locus, is expressed in B cells, and shows mutations in families with the disorder.  The gene is a member of the src family of protooncogenes which encode protein-tyrosine kinases.  This is, to the authors knowledge, the first evidence that mutations in a src-related gene are involved in human genetic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrLGa0C4aUVMrVg90H21EOLACvtfcHk0ljwVUPlm6jYAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXitlajt7c%253D&md5=de1b23e0c0328d916633d0f92ddc1d68</span></div><a href="/servlet/linkout?suffix=cit6b&amp;dbid=16384&amp;doi=10.1038%2F361226a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F361226a0%26sid%3Dliteratum%253Aachs%26aulast%3DVetrie%26aufirst%3DD.%26aulast%3DVorechovsky%26aufirst%3DI.%26aulast%3DSideras%26aufirst%3DP.%26aulast%3DHolland%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DA.%26aulast%3DFlinter%26aufirst%3DF.%26aulast%3DHammarstrom%26aufirst%3DL.%26aulast%3DKinnon%26aufirst%3DC.%26aulast%3DLevinsky%26aufirst%3DR.%26aulast%3DBobrow%26aufirst%3DM.%26aulast%3DSmith%26aufirst%3DC.%2BI.%26aulast%3DBentley%26aufirst%3DD.%2BR.%26atitle%3DThe%2520gene%2520involved%2520in%2520X-linked%2520agammaglobulinemia%2520is%2520a%2520member%2520of%2520the%2520src%2520family%2520of%2520protein%2520tyrosine%2520kinases%26jtitle%3DNature%26date%3D1993%26volume%3D361%26spage%3D226%26epage%3D233%26doi%3D10.1038%2F361226a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Tsukada, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rawlings, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witte, O. N.</span></span> <span> </span><span class="NLM_article-title">Role of Bruton’s tyrosine kinase in immunodeficiency</span>. <i>Curr. Opin. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">623</span>– <span class="NLM_lpage">630</span>, <span class="refDoi"> DOI: 10.1016/0952-7915(94)90151-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1016%2F0952-7915%2894%2990151-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=7946052" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADyaK2cXlsFCqur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=1994&pages=623-630&author=S.+Tsukadaauthor=D.+J.+Rawlingsauthor=O.+N.+Witte&title=Role+of+Bruton%E2%80%99s+tyrosine+kinase+in+immunodeficiency&doi=10.1016%2F0952-7915%2894%2990151-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Bruton's tyrosine kinase in immunodeficiency</span></div><div class="casAuthors">Tsukada, Satoshi; Rawlings, David J.; Witte, Owen N.</div><div class="citationInfo"><span class="NLM_cas:title">Current Opinion in Immunology</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">623-30</span>CODEN:
                <span class="NLM_cas:coden">COPIEL</span>;
        ISSN:<span class="NLM_cas:issn">0952-7915</span>.
    </div><div class="casAbstract">A review, with 71 refs.  The genetic defect assocd. with human X-linked agammaglobulinemia and murine X-linked immunodeficiency was recently shown to result from lack of function of a new cytoplasmic tyrosine kinase, called Bruton's tyrosine kinase (Btk).  The phenotypes assocd. with these immunodeficiencies indicate that Btk plays a crit. role in B lymphocyte development.  The distinctive protein structure of Btk and preliminary functional studies suggest that Btk may act in a novel manner in a variety of signaling pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoAyW0bZjSS3rVg90H21EOLACvtfcHk0ljwVUPlm6jYAg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlsFCqur8%253D&md5=d9932cf5d56f7a77723a46cae519cbeb</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1016%2F0952-7915%2894%2990151-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0952-7915%252894%252990151-1%26sid%3Dliteratum%253Aachs%26aulast%3DTsukada%26aufirst%3DS.%26aulast%3DRawlings%26aufirst%3DD.%2BJ.%26aulast%3DWitte%26aufirst%3DO.%2BN.%26atitle%3DRole%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520immunodeficiency%26jtitle%3DCurr.%2520Opin.%2520Immunol.%26date%3D1994%26volume%3D6%26spage%3D623%26epage%3D630%26doi%3D10.1016%2F0952-7915%2894%2990151-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Satoh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizutani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Behney, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuroda, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akaogi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoshida, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacionales, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirakata, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ono, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reeves, W. H.</span></span> <span> </span><span class="NLM_article-title">X-linked immunodeficient mice spontaneously produce lupus-related anti-RNA helicase A autoantibodies but are resistant to pristane-induced lupus</span>. <i>Int. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>15</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">1117</span>– <span class="NLM_lpage">1124</span>, <span class="refDoi"> DOI: 10.1093/intimm/dxg110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1093%2Fintimm%2Fdxg110" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=12917264" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BD3sXmsVGgt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2003&pages=1117-1124&issue=9&author=M.+Satohauthor=A.+Mizutaniauthor=K.+M.+Behneyauthor=Y.+Kurodaauthor=J.+Akaogiauthor=H.+Yoshidaauthor=D.+C.+Nacionalesauthor=M.+Hirakataauthor=N.+Onoauthor=W.+H.+Reeves&title=X-linked+immunodeficient+mice+spontaneously+produce+lupus-related+anti-RNA+helicase+A+autoantibodies+but+are+resistant+to+pristane-induced+lupus&doi=10.1093%2Fintimm%2Fdxg110"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7bR"><div class="casContent"><span class="casTitleNuber">7b</span><div class="casTitle"><span class="NLM_cas:atitle">X-linked immunodeficient mice spontaneously produce lupus-related anti-RNA helicase A autoantibodies, but are resistant to pristane-induced lupus</span></div><div class="casAuthors">Satoh, Minoru; Mizutani, Akiei; Behney, Krista M.; Kuroda, Yoshiki; Akaogi, Jun; Yoshida, Hideo; Nacionales, Dina C.; Hirakata, Michito; Ono, Nobutaka; Reeves, Westley H.</div><div class="citationInfo"><span class="NLM_cas:title">International Immunology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1117-1124</span>CODEN:
                <span class="NLM_cas:coden">INIMEN</span>;
        ISSN:<span class="NLM_cas:issn">0953-8178</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">Murine lupus can occur spontaneously or be induced by hydrocarbons, such as pristane.  Spontaneous disease in MRL and NZB/W F1 mice is suppressed by the xid (X-linked immunodeficiency) mutation, which greatly diminishes T cell-independent type 2 responses as well as the no. of peritoneal B1 cells.  The present study asked whether lupus induced by i.p. injection of pristane likewise is inhibited by the xid defect.  Male CBA/N (xid) mice were refractory to the induction of autoantibodies by pristane, whereas 23% of pristane-treated male CBA/CaJ controls produced anti-nRNP/Sm, -Su and/or -OJ (isoleucyl tRNA synthetase) antibodies.  Unexpectedly, 43% (12 of 28) of the xid mice spontaneously produced anti-nuclear antibodies that proved highly specific for the lupus antigen RNA helicase A (RHA).  Strikingly, this specificity was absent in CBA/CaJ mice (none of 51).  Moreover, pristane treatment suppressed the prodn. of anti-RHA antibodies when administered prior to the onset of autoantibody prodn., but enhanced anti-RHA levels when given after the onset of autoantibody prodn., suggesting that pristane interferes with anti-RHA prodn. at an early stage.  Large amts. of IgG1 anti-RHA autoantibodies were detected in the sera of xid mice, whereas pristane-induced anti-nRNP/Sm and -Su autoantibodies were almost exclusively IgG2a.  Cytokine prodn. within the peritoneal cavity reflected the predominant isotypes: IL-12 and IFN-γ predominated in pristane-treated mice, whereas IL-4 and IL-6 were more predominant in untreated xid mice.  The spontaneous prodn. of anti-RHA by xid mice and its suppression by pristane treatment at the level of autoantibody induction supports the idea that lupus autoantibodies may be generated through a variety of mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpu9fB2XibBVbVg90H21EOLACvtfcHk0liAmVNC8zp_Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXmsVGgt74%253D&md5=e18338e223bd71f1ee0cfb65f7fd8c5c</span></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=10.1093%2Fintimm%2Fdxg110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fintimm%252Fdxg110%26sid%3Dliteratum%253Aachs%26aulast%3DSatoh%26aufirst%3DM.%26aulast%3DMizutani%26aufirst%3DA.%26aulast%3DBehney%26aufirst%3DK.%2BM.%26aulast%3DKuroda%26aufirst%3DY.%26aulast%3DAkaogi%26aufirst%3DJ.%26aulast%3DYoshida%26aufirst%3DH.%26aulast%3DNacionales%26aufirst%3DD.%2BC.%26aulast%3DHirakata%26aufirst%3DM.%26aulast%3DOno%26aufirst%3DN.%26aulast%3DReeves%26aufirst%3DW.%2BH.%26atitle%3DX-linked%2520immunodeficient%2520mice%2520spontaneously%2520produce%2520lupus-related%2520anti-RNA%2520helicase%2520A%2520autoantibodies%2520but%2520are%2520resistant%2520to%2520pristane-induced%2520lupus%26jtitle%3DInt.%2520Immunol.%26date%3D2003%26volume%3D15%26issue%3D9%26spage%3D1117%26epage%3D1124%26doi%3D10.1093%2Fintimm%2Fdxg110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Honigberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sirisawad, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verner, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loury, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thamm, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buggy, J. J.</span></span> <span> </span><span class="NLM_article-title">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B cell activation and is efficacious in models of autoimmune disease and B cell malignancy</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span>,  <span class="NLM_fpage">13075</span>– <span class="NLM_lpage">13080</span>, <span class="refDoi"> DOI: 10.1073/pnas.1004594107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1073%2Fpnas.1004594107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=20615965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=13075-13080&author=L.+A.+Honigbergauthor=A.+M.+Smithauthor=M.+Sirisawadauthor=E.+Vernerauthor=D.+Louryauthor=B.+Changauthor=S.+Liauthor=Z.+Panauthor=D.+H.+Thammauthor=R.+A.+Millerauthor=J.+J.+Buggy&title=The+Bruton+tyrosine+kinase+inhibitor+PCI-32765+blocks+B+cell+activation+and+is+efficacious+in+models+of+autoimmune+disease+and+B+cell+malignancy&doi=10.1073%2Fpnas.1004594107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy</span></div><div class="casAuthors">Honigberg, Lee A.; Smith, Ashley M.; Sirisawad, Mint; Verner, Erik; Loury, David; Chang, Betty; Li, Shyr; Pan, Zhengying; Thamm, Douglas H.; Miller, Richard A.; Buggy, Joseph J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">13075-13080, S13075/1-S13075/3</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Activation of the B-cell antigen receptor (BCR) signaling pathway contributes to the initiation and maintenance of B-cell malignancies and autoimmune diseases.  The Bruton tyrosine kinase (Btk) is specifically required for BCR signaling as demonstrated by human and mouse mutations that disrupt Btk function and prevent B-cell maturation at steps that require a functional BCR pathway.  Herein we describe a selective and irreversible Btk inhibitor, PCI-32765, that is currently under clin. development in patients with B-cell non-Hodgkin lymphoma.  We have used this inhibitor to investigate the biol. effects of Btk inhibition on mature B-cell function and the progression of B cell-assocd. diseases in vivo.  PCI-32765 blocked BCR signaling in human peripheral B cells at concns. that did not affect T cell receptor signaling.  In mice with collagen-induced arthritis, orally administered PCI-32765 reduced the level of circulating autoantibodies and completely suppressed disease.  PCI-32765 also inhibited autoantibody prodn. and the development of kidney disease in the MRL-Fas(lpr) lupus model.  Occupancy of the Btk active site by PCI-32765 was monitored in vitro and in vivo using a fluorescent affinity probe for Btk.  Active site occupancy of Btk was tightly correlated with the blockade of BCR signaling and in vivo efficacy.  Finally, PCI-32765 induced objective clin. responses in dogs with spontaneous B-cell non-Hodgkin lymphoma.  These findings support Btk inhibition as a therapeutic approach for the treatment of human diseases assocd. with activation of the BCR pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoT4OQHme7oHLVg90H21EOLACvtfcHk0liAmVNC8zp_Lg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsVCrsbk%253D&md5=196ce4a05bb9c622c49cb7e908682e63</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1004594107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1004594107%26sid%3Dliteratum%253Aachs%26aulast%3DHonigberg%26aufirst%3DL.%2BA.%26aulast%3DSmith%26aufirst%3DA.%2BM.%26aulast%3DSirisawad%26aufirst%3DM.%26aulast%3DVerner%26aufirst%3DE.%26aulast%3DLoury%26aufirst%3DD.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DPan%26aufirst%3DZ.%26aulast%3DThamm%26aufirst%3DD.%2BH.%26aulast%3DMiller%26aufirst%3DR.%2BA.%26aulast%3DBuggy%26aufirst%3DJ.%2BJ.%26atitle%3DThe%2520Bruton%2520tyrosine%2520kinase%2520inhibitor%2520PCI-32765%2520blocks%2520B%2520cell%2520activation%2520and%2520is%2520efficacious%2520in%2520models%2520of%2520autoimmune%2520disease%2520and%2520B%2520cell%2520malignancy%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D13075%26epage%3D13080%26doi%3D10.1073%2Fpnas.1004594107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hackney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramamoorthi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Austin, C. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bremer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blomgren, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeVoss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiPaolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lesch, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liimatta, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McVay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Modrusan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Townsend, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span> <span> </span><span class="NLM_article-title">Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis</span>. <i>JCI Insight.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">e90111</span>, <span class="refDoi"> DOI: 10.1172/jci.insight.90111</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1172%2Fjci.insight.90111" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=28405610" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2017&pages=e90111&author=A.+Katewaauthor=Y.+Wangauthor=J.+A.+Hackneyauthor=T.+Huangauthor=E.+Sutoauthor=N.+Ramamoorthiauthor=C.+D.+Austinauthor=M.+Bremerauthor=J.+Z.+Chenauthor=J.+J.+Crawfordauthor=K.+S.+Currieauthor=P.+Blomgrenauthor=J.+DeVossauthor=J.+A.+DiPaoloauthor=J.+Hauauthor=A.+Johnsonauthor=J.+Leschauthor=L.+E.+DeForgeauthor=Z.+Linauthor=M.+Liimattaauthor=J.+W.+Lubachauthor=S.+McVayauthor=Z.+Modrusanauthor=A.+Nguyenauthor=C.+Poonauthor=J.+Wangauthor=L.+Liuauthor=W.+P.+Leeauthor=H.+Wongauthor=W.+B.+Youngauthor=M.+J.+Townsendauthor=K.+Reif&title=Btk-specific+inhibition+blocks+pathogenic+plasma+cell+signatures+and+myeloid+cell-associated+damage+in+IFN%CE%B1-driven+lupus+nephritis&doi=10.1172%2Fjci.insight.90111"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1172%2Fjci.insight.90111&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252Fjci.insight.90111%26sid%3Dliteratum%253Aachs%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DHackney%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DSuto%26aufirst%3DE.%26aulast%3DRamamoorthi%26aufirst%3DN.%26aulast%3DAustin%26aufirst%3DC.%2BD.%26aulast%3DBremer%26aufirst%3DM.%26aulast%3DChen%26aufirst%3DJ.%2BZ.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26aulast%3DBlomgren%26aufirst%3DP.%26aulast%3DDeVoss%26aufirst%3DJ.%26aulast%3DDiPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHau%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%26aulast%3DLesch%26aufirst%3DJ.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DLiimatta%26aufirst%3DM.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMcVay%26aufirst%3DS.%26aulast%3DModrusan%26aufirst%3DZ.%26aulast%3DNguyen%26aufirst%3DA.%26aulast%3DPoon%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DTownsend%26aufirst%3DM.%2BJ.%26aulast%3DReif%26aufirst%3DK.%26atitle%3DBtk-specific%2520inhibition%2520blocks%2520pathogenic%2520plasma%2520cell%2520signatures%2520and%2520myeloid%2520cell-associated%2520damage%2520in%2520IFN%25CE%25B1-driven%2520lupus%2520nephritis%26jtitle%3DJCI%2520Insight.%26date%3D2017%26volume%3D2%26spage%3De90111%26doi%3D10.1172%2Fjci.insight.90111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boucheron, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellmeier, W.</span></span> <span> </span><span class="NLM_article-title">The role of Tec family kinases in myeloid cells</span>. <i>Int. Arch. Allergy Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>134</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">65</span>– <span class="NLM_lpage">78</span>, <span class="refDoi"> DOI: 10.1159/000078339</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1159%2F000078339" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=15133303" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktFKlsr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=134&publication_year=2004&pages=65-78&issue=1&author=U.+Schmidtauthor=N.+Boucheronauthor=B.+Ungerauthor=W.+Ellmeier&title=The+role+of+Tec+family+kinases+in+myeloid+cells&doi=10.1159%2F000078339"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">The Role of Tec Family Kinases in Myeloid Cells</span></div><div class="casAuthors">Schmidt, Uwe; Boucheron, Nicole; Unger, Bernd; Ellmeier, Wilfried</div><div class="citationInfo"><span class="NLM_cas:title">International Archives of Allergy and Immunology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">134</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">65-78</span>CODEN:
                <span class="NLM_cas:coden">IAAIEG</span>;
        ISSN:<span class="NLM_cas:issn">1018-2438</span>.
    
            (<span class="NLM_cas:orgname">S. Karger AG</span>)
        </div><div class="casAbstract">A review.  Members of the Tec kinase family (Bmx, Btk, Itk, Rlk and Tec) are primarily expressed in the hematopoietic system and form, after the Src kinase family, the second largest class of non-receptor protein tyrosine kinases.  During lymphocyte development and activation Tec kinases have important functions in signaling pathways downstream of the antigen receptors.  Tec family kinases are also expressed in cells of the myeloid lineage.  However, with the exception of mast cells and platelets, their biol. role in the myeloid system is only poorly understood.  This review summarizes the current knowledge about the function of Tec family kinases in hematopoietic cells of the myeloid lineage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpewxKP7kBxe7Vg90H21EOLACvtfcHk0lgwQm_muEjNcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktFKlsr8%253D&md5=e6e88b9b59049d9e55e95b6621a27453</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1159%2F000078339&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1159%252F000078339%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DU.%26aulast%3DBoucheron%26aufirst%3DN.%26aulast%3DUnger%26aufirst%3DB.%26aulast%3DEllmeier%26aufirst%3DW.%26atitle%3DThe%2520role%2520of%2520Tec%2520family%2520kinases%2520in%2520myeloid%2520cells%26jtitle%3DInt.%2520Arch.%2520Allergy%2520Immunol.%26date%3D2004%26volume%3D134%26issue%3D1%26spage%3D65%26epage%3D78%26doi%3D10.1159%2F000078339" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Florence, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krupa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Booshehri, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthay, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kurdowska, A. K.</span></span> <span> </span><span class="NLM_article-title">Inhibiting Bruton’s tyrosine kinase rescues mice from lethal influenza-induced acute lung injury</span>. <i>Am. J. Physiol. Lung Cell Mol. Physiol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>315</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">L52</span>– <span class="NLM_lpage">L58</span>, <span class="refDoi"> DOI: 10.1152/ajplung.00047.2018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1152%2Fajplung.00047.2018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=29516781" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2018&pages=L52-L58&issue=1&author=J.+M.+Florenceauthor=A.+Krupaauthor=L.+M.+Booshehriauthor=S.+A.+Davisauthor=M.+A.+Matthayauthor=A.+K.+Kurdowska&title=Inhibiting+Bruton%E2%80%99s+tyrosine+kinase+rescues+mice+from+lethal+influenza-induced+acute+lung+injury&doi=10.1152%2Fajplung.00047.2018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1152%2Fajplung.00047.2018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fajplung.00047.2018%26sid%3Dliteratum%253Aachs%26aulast%3DFlorence%26aufirst%3DJ.%2BM.%26aulast%3DKrupa%26aufirst%3DA.%26aulast%3DBooshehri%26aufirst%3DL.%2BM.%26aulast%3DDavis%26aufirst%3DS.%2BA.%26aulast%3DMatthay%26aufirst%3DM.%2BA.%26aulast%3DKurdowska%26aufirst%3DA.%2BK.%26atitle%3DInhibiting%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520rescues%2520mice%2520from%2520lethal%2520influenza-induced%2520acute%2520lung%2520injury%26jtitle%3DAm.%2520J.%2520Physiol.%2520Lung%2520Cell%2520Mol.%2520Physiol.%26date%3D2018%26volume%3D315%26issue%3D1%26spage%3DL52%26epage%3DL58%26doi%3D10.1152%2Fajplung.00047.2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smiljkovic, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blatt, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stefanzl, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dorofeeva, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skrabs, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Focke-Tejkl, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sperr, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaeger, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valenta, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Valent, P.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase inhibition is a potent approach to block IgE-mediated histamine release in human basophils</span>. <i>Allergy</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>72</i></span>,  <span class="NLM_fpage">1666</span>– <span class="NLM_lpage">1676</span>, <span class="refDoi"> DOI: 10.1111/all.13166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1111%2Fall.13166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=28328081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1ylsL3L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2017&pages=1666-1676&author=D.+Smiljkovicauthor=K.+Blattauthor=G.+Stefanzlauthor=Y.+Dorofeevaauthor=C.+Skrabsauthor=M.+Focke-Tejklauthor=M.+R.+Sperrauthor=U.+Jaegerauthor=R.+Valentaauthor=P.+Valent&title=Bruton%E2%80%99s+tyrosine+kinase+inhibition+is+a+potent+approach+to+block+IgE-mediated+histamine+release+in+human+basophils&doi=10.1111%2Fall.13166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">BTK inhibition is a potent approach to block IgE-mediated histamine release in human basophils</span></div><div class="casAuthors">Smiljkovic, D.; Blatt, K.; Stefanzl, G.; Dorofeeva, Y.; Skrabs, C.; Focke-Tejkl, M.; Sperr, W. R.; Jaeger, U.; Valenta, R.; Valent, P.</div><div class="citationInfo"><span class="NLM_cas:title">Allergy (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1666-1676</span>CODEN:
                <span class="NLM_cas:coden">LLRGDY</span>;
        ISSN:<span class="NLM_cas:issn">0105-4538</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Background : Recent data suggest that Bruton's tyrosine kinase (BTK) is an emerging therapeutic target in IgE receptor (IgER)-cross-linked basophils.  Methods : We examd. the effects of four BTK inhibitors (ibrutinib, dasatinib, AVL-292, and CNX-774) on IgE-dependent activation and histamine release in blood basophils obtained from allergic patients (n=11) and nonallergic donors (n=5).  In addn., we examd. the effects of these drugs on the growth of the human basophil cell line KU812 and the human mast cell line HMC-1.  Results : All four BTK blockers were found to inhibit anti-IgE-induced histamine release from basophils in nonallergic subjects and allergen-induced histamine liberation from basophils in allergic donors.  Drug effects on allergen-induced histamine release were dose dependent, with IC50 values ranging between 0.001 and 0.5 μmol/L, and the following rank order of potency: ibrutinib>AVL-292>dasatinib>CNX-774.  The basophil-targeting effect of ibrutinib was confirmed by demonstrating that IgE-dependent histamine release in ex vivo blood basophils is largely suppressed in a leukemia patient treated with ibrutinib.  Dasatinib and ibrutinib were also found to counteract anti-IgE-induced and allergen-induced upregulation of CD13, CD63, CD164, and CD203c on basophils, whereas AVL-292 and CNX-774 showed no significant effects.  Whereas dasatinib and CNX-774 were found to inhibit the growth of HMC-1 cells and KU812 cells, no substantial effects were seen with ibrutinib or AVL-292.  Conclusions : BTK-targeting drugs are potent inhibitors of IgE-dependent histamine release in human basophils.  The clin. value of BTK inhibition in the context of allergic diseases remains to be detd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5v6kgqYZUS7Vg90H21EOLACvtfcHk0lgwQm_muEjNcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1ylsL3L&md5=b912584594a8516718d443465ba2b01f</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1111%2Fall.13166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fall.13166%26sid%3Dliteratum%253Aachs%26aulast%3DSmiljkovic%26aufirst%3DD.%26aulast%3DBlatt%26aufirst%3DK.%26aulast%3DStefanzl%26aufirst%3DG.%26aulast%3DDorofeeva%26aufirst%3DY.%26aulast%3DSkrabs%26aufirst%3DC.%26aulast%3DFocke-Tejkl%26aufirst%3DM.%26aulast%3DSperr%26aufirst%3DM.%2BR.%26aulast%3DJaeger%26aufirst%3DU.%26aulast%3DValenta%26aufirst%3DR.%26aulast%3DValent%26aufirst%3DP.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibition%2520is%2520a%2520potent%2520approach%2520to%2520block%2520IgE-mediated%2520histamine%2520release%2520in%2520human%2520basophils%26jtitle%3DAllergy%26date%3D2017%26volume%3D72%26spage%3D1666%26epage%3D1676%26doi%3D10.1111%2Fall.13166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ren, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gautam, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elavazhagan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fatehchand, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stiff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reader, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Byrd, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carson, W. E.,  III</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butchar, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tridandapani, S.</span></span> <span> </span><span class="NLM_article-title">Analysis of the effects of the Bruton’s tyrosine kinase (Btk) inhibitor Ibrutinib on monocyte Fcγ receptor (FcγR) function</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>291</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">3043</span>– <span class="NLM_lpage">3052</span>, <span class="refDoi"> DOI: 10.1074/jbc.M115.687251</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1074%2Fjbc.M115.687251" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=26627823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVOqurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=291&publication_year=2016&pages=3043-3052&issue=6&author=L.+Renauthor=A.+Campbellauthor=H.+Fangauthor=S.+Gautamauthor=S.+Elavazhaganauthor=K.+Fatehchandauthor=P.+Mehtaauthor=A.+Stiffauthor=B.+F.+Readerauthor=X.+Moauthor=J.+C.+Byrdauthor=W.+E.+Carsonauthor=J.+P.+Butcharauthor=S.+Tridandapani&title=Analysis+of+the+effects+of+the+Bruton%E2%80%99s+tyrosine+kinase+%28Btk%29+inhibitor+Ibrutinib+on+monocyte+Fc%CE%B3+receptor+%28Fc%CE%B3R%29+function&doi=10.1074%2Fjbc.M115.687251"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function</span></div><div class="casAuthors">Ren, Li; Campbell, Amanda; Fang, Huiqing; Gautam, Shalini; Elavazhagan, Saranya; Fatehchand, Kavin; Mehta, Payal; Stiff, Andrew; Reader, Brenda F.; Mo, Xiaokui; Byrd, John C.; Carson, William E., III; Butchar, Jonathan P.; Tridandapani, Susheela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">291</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">3043-3052</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The irreversible Bruton's tyrosine kinase (Btk) inhibitor ibrutinib has shown efficacy against B-cell tumors such as chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma.  Fcγ receptors (FcγR) on immune cells such as macrophages play an important role in tumor-specific antibody-mediated immune responses, but many such responses involve Btk.  Here we tested the effects of ibrutinib on FcγR-mediated activities in monocytes.  We found that ibrutinib did not affect monocyte FcγR-mediated phagocytosis, even at concns. higher than those achieved physiol., but suppressed FcγR-mediated cytokine prodn.  We confirmed these findings in macrophages from Xid mice in which Btk signaling is defective.  Because calcium flux is a major event downstream of Btk, we tested whether it was involved in phagocytosis.  The results showed that blocking intracellular calcium flux decreased FcγR-mediated cytokine prodn. but not phagocytosis.  To verify this, we measured activation of the GTPase Rac, which is responsible for actin polymn.  Results showed that ibrutinib did not inhibit Rac activation, nor did the calcium chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid tetrakis(acetoxymethyl ester).  We next asked whether the effect of ibrutinib on monocyte FcγR-mediated cytokine prodn. could be rescued by IFNγ priming because NK cells produce IFNγ in response to antibody therapy.  Pretreatment of monocytes with IFNγ abrogated the effects of ibrutinib on FcγR-mediated cytokine prodn., suggesting that IFNγ priming could overcome this Btk inhibition.  Furthermore, in monocyte-natural killer cell co-cultures, ibrutinib did not inhibit FcγR-mediated cytokine prodn. despite doing so in single cultures.  These results suggest that combining ibrutinib with monoclonal antibody therapy could enhance chronic lymphocytic leukemia cell killing without affecting macrophage effector function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-NSO3o-f2tbVg90H21EOLACvtfcHk0liX0NMprwCbLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVOqurk%253D&md5=e40fc279a85f9903f06d902cf8ef8b2c</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M115.687251&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M115.687251%26sid%3Dliteratum%253Aachs%26aulast%3DRen%26aufirst%3DL.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DFang%26aufirst%3DH.%26aulast%3DGautam%26aufirst%3DS.%26aulast%3DElavazhagan%26aufirst%3DS.%26aulast%3DFatehchand%26aufirst%3DK.%26aulast%3DMehta%26aufirst%3DP.%26aulast%3DStiff%26aufirst%3DA.%26aulast%3DReader%26aufirst%3DB.%2BF.%26aulast%3DMo%26aufirst%3DX.%26aulast%3DByrd%26aufirst%3DJ.%2BC.%26aulast%3DCarson%26aufirst%3DW.%2BE.%26aulast%3DButchar%26aufirst%3DJ.%2BP.%26aulast%3DTridandapani%26aufirst%3DS.%26atitle%3DAnalysis%2520of%2520the%2520effects%2520of%2520the%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528Btk%2529%2520inhibitor%2520Ibrutinib%2520on%2520monocyte%2520Fc%25CE%25B3%2520receptor%2520%2528Fc%25CE%25B3R%2529%2520function%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2016%26volume%3D291%26issue%3D6%26spage%3D3043%26epage%3D3052%26doi%3D10.1074%2Fjbc.M115.687251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Akinleye, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mukhi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib and novel BTK inhibitors in clinical development</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>6</i></span>,  <span class="NLM_fpage">59</span>, <span class="refDoi"> DOI: 10.1186/1756-8722-6-59</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1186%2F1756-8722-6-59" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=23958373" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVagtrjI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=59&author=A.+Akinleyeauthor=Y.+I.+Chenauthor=N.+Mukhiauthor=Y.+Songauthor=D.+Liu&title=Ibrutinib+and+novel+BTK+inhibitors+in+clinical+development&doi=10.1186%2F1756-8722-6-59"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14aR"><div class="casContent"><span class="casTitleNuber">14a</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib and novel BTK inhibitors in clinical development</span></div><div class="casAuthors">Akinleye, Akintunde; Chen, Yamei; Mukhi, Nikhil; Song, Yongping; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">59</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">A review.  Small mol. inhibitors targeting dysregulated pathways (RAS/RAF/MEK, PI3K/AKT/mTOR, JAK/STAT) have significantly improved clin. outcomes in cancer patients.  Recently Bruton's tyrosine kinase (BTK), a crucial terminal kinase enzyme in the B-cell antigen receptor (BCR) signaling pathway, has emerged as an attractive target for therapeutic intervention in human malignancies and autoimmune disorders.  Ibrutinib, a novel first-in-human BTK inhibitor, has demonstrated clin. effectiveness and tolerability in early clin. trials and has progressed into phase III trials.  However, addnl. research is necessary to identify the optimal dosing schedule, as well as patients most likely to benefit from BTK inhibition.  This review summarizes preclin. and clin. development of ibrutinib and other novel BTK inhibitors (GDC-0834, CGI-560, CGI-1746, HM-71224, CC-292 and ONO-4059, CNX-774, LFM-A13) in the treatment of B-cell malignancies and autoimmune disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-fz7_rhCHvbVg90H21EOLACvtfcHk0liX0NMprwCbLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVagtrjI&md5=e5067b998c61818e2efbb62da935b490</span></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=10.1186%2F1756-8722-6-59&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1756-8722-6-59%26sid%3Dliteratum%253Aachs%26aulast%3DAkinleye%26aufirst%3DA.%26aulast%3DChen%26aufirst%3DY.%2BI.%26aulast%3DMukhi%26aufirst%3DN.%26aulast%3DSong%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DIbrutinib%2520and%2520novel%2520BTK%2520inhibitors%2520in%2520clinical%2520development%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2013%26volume%3D6%26spage%3D59%26doi%3D10.1186%2F1756-8722-6-59" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thareja, S.</span></span> <span> </span><span class="NLM_article-title">The development of Bruton’s tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>151</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">326</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.03.062</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1016%2Fj.ejmech.2018.03.062" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=29631132" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1cXnt1ehtL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=151&publication_year=2018&pages=315-326&author=C.+Liangauthor=D.+Tianauthor=X.+Renauthor=S.+Dingauthor=M.+Jiaauthor=M.+Xinauthor=S.+Thareja&title=The+development+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitors+from+2012+to+2017%3A+A+mini-review&doi=10.1016%2Fj.ejmech.2018.03.062"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14bR"><div class="casContent"><span class="casTitleNuber">14b</span><div class="casTitle"><span class="NLM_cas:atitle">The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review</span></div><div class="casAuthors">Liang, Chengyuan; Tian, Danni; Ren, Xiaodong; Ding, Shunjun; Jia, Minyi; Xin, Minhang; Thareja, Suresh</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">151</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">315-326</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (BTK) has emerged as a promising drug target for multiple diseases, particularly hematopoietic malignancies and autoimmune diseases related to B lymphocytes.  This review focuses on the diverse, small-mol. inhibitors of BTK kinase that have shown good prospects for clin. application.  Individual examples of these inhibitors, including both reversible and irreversible inhibitors and a recently developed reversible covalent inhibitor of BTK, are discussed.  Considerable progress has been made in the development of irreversible inhibitors, most of which target the SH3 pocket and the cysteine 481 residue of BTK.  The present review also surveys the pharmacol. advantages and deficiencies of both reversible and irreversible BTK drugs, with a focus on the structure-activity relationship (SARs) and binding modes of representative drugs, which could inspire crit. thinking and new ideas for developing potent BTK inhibitors with less unwanted off-target effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptNAsX0qwSHLVg90H21EOLACvtfcHk0liX0NMprwCbLQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXnt1ehtL0%253D&md5=1ea0bf36d8ebadbfba624f858911b182</span></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.03.062&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.03.062%26sid%3Dliteratum%253Aachs%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DTian%26aufirst%3DD.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DDing%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DM.%26aulast%3DXin%26aufirst%3DM.%26aulast%3DThareja%26aufirst%3DS.%26atitle%3DThe%2520development%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitors%2520from%25202012%2520to%25202017%253A%2520A%2520mini-review%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D151%26spage%3D315%26epage%3D326%26doi%3D10.1016%2Fj.ejmech.2018.03.062" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Isenberg, D. A.</span></span> <span> </span><span class="NLM_article-title">New therapies for systemic lupus erythematosus - past imperfect, future tense</span>. <i>Nat. Rev. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">403</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.1038/s41584-019-0235-5</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1038%2Fs41584-019-0235-5" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=31165780" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A280%3ADC%252BB3M3jsVCjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2019&pages=403-412&author=G.+Murphyauthor=D.+A.+Isenberg&title=New+therapies+for+systemic+lupus+erythematosus+-+past+imperfect%2C+future+tense&doi=10.1038%2Fs41584-019-0235-5"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14cR"><div class="casContent"><span class="casTitleNuber">14c</span><div class="casTitle"><span class="NLM_cas:atitle">New therapies for systemic lupus erythematosus - past imperfect, future tense</span></div><div class="casAuthors">Murphy Grainne; Isenberg David A</div><div class="citationInfo"><span class="NLM_cas:title">Nature reviews. Rheumatology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">403-412</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The failure of many new, mostly biologic, drugs to meet their primary end points in double-blind clinical trials in patients with systemic lupus erythematosus (SLE) has caused a profound sense of disappointment among both physicians and patients.  Arguably, the success of B cell depletion with rituximab in open-label clinical trials, the approval of belimumab (which blocks B cell-activating factor (BAFF)) for use in patients with lupus nephritis in the USA and in difficult-to-treat patients with SLE in the UK and the recognition that clinical trial design can be improved have given some cause for hope.  However, changes to therapies in current use and the development of new approaches are urgently needed.  The results of the latest studies investigating the use of several new approaches to treating SLE are discussed in this Review, including: fully humanized anti-CD20 and anti-CD19 monoclonal antibodies; inhibition of tyrosine-protein kinase BTK; CD40 ligand blockade; interfering with the presentation of antigen to autoreactive T cells using a peptide approach; a receptor decoy approach using an analogue of Fcγ receptor IIB; dual blockade of IL-12 and IL-23; and inhibition of Janus kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSCLtu0y2YGaOxsqfvU0ziafW6udTcc2eYREfN5qR6dF7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M3jsVCjtQ%253D%253D&md5=f978e2a3b6c87b6acafcc7195e8a5857</span></div><a href="/servlet/linkout?suffix=cit14c&amp;dbid=16384&amp;doi=10.1038%2Fs41584-019-0235-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41584-019-0235-5%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DG.%26aulast%3DIsenberg%26aufirst%3DD.%2BA.%26atitle%3DNew%2520therapies%2520for%2520systemic%2520lupus%2520erythematosus%2520-%2520past%2520imperfect%252C%2520future%2520tense%26jtitle%3DNat.%2520Rev.%2520Rheumatol.%26date%3D2019%26volume%3D15%26spage%3D403%26epage%3D412%26doi%3D10.1038%2Fs41584-019-0235-5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit14d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Pal Singh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dammeijer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span> <span> </span><span class="NLM_article-title">Role of Bruton’s tyrosine kinase in B cells and malignancies</span>. <i>Mol. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">57</span>, <span class="refDoi"> DOI: 10.1186/s12943-018-0779-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1186%2Fs12943-018-0779-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=29455639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A280%3ADC%252BC1MrivVektQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=57&issue=1&author=S.+Pal+Singhauthor=F.+Dammeijerauthor=R.+W.+Hendriks&title=Role+of+Bruton%E2%80%99s+tyrosine+kinase+in+B+cells+and+malignancies&doi=10.1186%2Fs12943-018-0779-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14dR"><div class="casContent"><span class="casTitleNuber">14d</span><div class="casTitle"><span class="NLM_cas:atitle">Role of Bruton's tyrosine kinase in B cells and malignancies</span></div><div class="casAuthors">Pal Singh Simar; Dammeijer Floris; Hendriks Rudi W; Pal Singh Simar; Pal Singh Simar; Dammeijer Floris; Dammeijer Floris</div><div class="citationInfo"><span class="NLM_cas:title">Molecular cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">57</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) is a non-receptor kinase that plays a crucial role in oncogenic signaling that is critical for proliferation and survival of leukemic cells in many B cell malignancies.  BTK was initially shown to be defective in the primary immunodeficiency X-linked agammaglobulinemia (XLA) and is essential both for B cell development and function of mature B cells.  Shortly after its discovery, BTK was placed in the signal transduction pathway downstream of the B cell antigen receptor (BCR).  More recently, small-molecule inhibitors of this kinase have shown excellent anti-tumor activity, first in animal models and subsequently in clinical studies.  In particular, the orally administered irreversible BTK inhibitor ibrutinib is associated with high response rates in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and mantle-cell lymphoma (MCL), including patients with high-risk genetic lesions.  Because ibrutinib is generally well tolerated and shows durable single-agent efficacy, it was rapidly approved for first-line treatment of patients with CLL in 2016.  To date, evidence is accumulating for efficacy of ibrutinib in various other B cell malignancies.  BTK inhibition has molecular effects beyond its classic role in BCR signaling.  These involve B cell-intrinsic signaling pathways central to cellular survival, proliferation or retention in supportive lymphoid niches.  Moreover, BTK functions in several myeloid cell populations representing important components of the tumor microenvironment.  As a result, there is currently a considerable interest in BTK inhibition as an anti-cancer therapy, not only in B cell malignancies but also in solid tumors.  Efficacy of BTK inhibition as a single agent therapy is strong, but resistance may develop, fueling the development of combination therapies that improve clinical responses.  In this review, we discuss the role of BTK in B cell differentiation and B cell malignancies and highlight the importance of BTK inhibition in cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTp0F3T0LEJd4vKgEt20y1XfW6udTcc2ebT3Cf_9-YD7Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MrivVektQ%253D%253D&md5=de1ba14dc19e6a123c21b89f1f4133f4</span></div><a href="/servlet/linkout?suffix=cit14d&amp;dbid=16384&amp;doi=10.1186%2Fs12943-018-0779-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs12943-018-0779-z%26sid%3Dliteratum%253Aachs%26aulast%3DPal%2BSingh%26aufirst%3DS.%26aulast%3DDammeijer%26aufirst%3DF.%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26atitle%3DRole%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520B%2520cells%2520and%2520malignancies%26jtitle%3DMol.%2520Cancer%26date%3D2018%26volume%3D17%26issue%3D1%26spage%3D57%26doi%3D10.1186%2Fs12943-018-0779-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span>US Food
and Drug Administration. Approved Drugs: Ibrutinib. Available at <a href="https://wayback.archive-it.org/7993/20170111231706/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm374857.htm" class="extLink">https://wayback.archive-it.org/7993/20170111231706/http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm374857.htm</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=US+Food%0Aand+Drug+Administration.+Approved+Drugs%3A+Ibrutinib.+Available+at+https%3A%2F%2Fwayback.archive-it.org%2F7993%2F20170111231706%2Fhttp%3A%2F%2Fwww.fda.gov%2FDrugs%2FInformationOnDrugs%2FApprovedDrugs%2Fucm374857.htm."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">21</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0250-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1186%2Fs13045-016-0250-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=26957112" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1eisrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=21&author=J.+Wuauthor=M.+Zhangauthor=D.+Liu&title=Acalabrutinib+%28ACP-196%29%3A+a+selective+second-generation+BTK+inhibitor&doi=10.1186%2Fs13045-016-0250-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor</span></div><div class="casAuthors">Wu, Jingjing; Zhang, Mingzhi; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21/1-21/4</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">More and more targeted agents become available for B cell malignancies with increasing precision and potency.  The first-in-class Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clin. use for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia.  More selective BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being explored.  Acalabrutinib (ACP-196) is a novel irreversible second-generation BTK inhibitor that was shown to be more potent and selective than ibrutinib.  This review summarized the preclin. research and clin. data of acalabrutinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpAU072sMxzmLVg90H21EOLACvtfcHk0liyTbYE8VsVtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1eisrw%253D&md5=a6a8f9b9236abe7ef1054a41e1c71e5a</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0250-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0250-9%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DAcalabrutinib%2520%2528ACP-196%2529%253A%2520a%2520selective%2520second-generation%2520BTK%2520inhibitor%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D21%26doi%3D10.1186%2Fs13045-016-0250-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span> <span> </span><span class="NLM_article-title">Discovery of Zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton’s tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7923</span>– <span class="NLM_lpage">7940</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00687</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00687" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref17/cit17a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsFSku7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7923-7940&issue=17&author=Y.+Guoauthor=Y.+Liuauthor=N.+Huauthor=D.+Yuauthor=C.+Zhouauthor=G.+Shiauthor=B.+Zhangauthor=M.+Weiauthor=J.+Liuauthor=L.+Luoauthor=Z.+Tangauthor=H.+Songauthor=Y.+Guoauthor=X.+Liuauthor=D.+Suauthor=S.+Zhangauthor=X.+Songauthor=X.+Zhouauthor=Y.+Hongauthor=S.+Chenauthor=Z.+Chengauthor=S.+Youngauthor=Q.+Weiauthor=H.+Wangauthor=Q.+Wangauthor=L.+Lvauthor=F.+Wangauthor=H.+Xuauthor=H.+Sunauthor=H.+Xingauthor=N.+Liauthor=W.+Zhangauthor=Z.+Wangauthor=G.+Liuauthor=Z.+Sunauthor=D.+Zhouauthor=W.+Liauthor=L.+Liuauthor=L.+Wangauthor=Z.+Wang&title=Discovery+of+Zanubrutinib+%28BGB-3111%29%2C+a+novel%2C+potent%2C+and+selective+covalent+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1021%2Facs.jmedchem.9b00687"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17aR"><div class="casContent"><span class="casTitleNuber">17a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase</span></div><div class="casAuthors">Guo, Yunhang; Liu, Ye; Hu, Nan; Yu, Desheng; Zhou, Changyou; Shi, Gongyin; Zhang, Bo; Wei, Min; Liu, Junhua; Luo, Lusong; Tang, Zhiyu; Song, Huipeng; Guo, Yin; Liu, Xuesong; Su, Dan; Zhang, Shuo; Song, Xiaomin; Zhou, Xing; Hong, Yuan; Chen, Shuaishuai; Cheng, Zhenzhen; Young, Steve; Wei, Qiang; Wang, Haisheng; Wang, Qiuwen; Lv, Lei; Wang, Fan; Xu, Haipeng; Sun, Hanzi; Xing, Haimei; Li, Na; Zhang, Wei; Wang, Zhongbo; Liu, Guodong; Sun, Zhijian; Zhou, Dongping; Li, Wei; Liu, Libin; Wang, Lai; Wang, Zhiwei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7923-7940</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Aberrant activation of Bruton's tyrosine kinase (BTK) plays an important role in pathogenesis of B-cell lymphomas, suggesting that inhibition of BTK is useful in the treatment of hematol. malignancies.  The discovery of a more selective on-target covalent BTK inhibitor is of high value.  Herein, we disclose the discovery and preclin. characterization of a potent, selective, and irreversible BTK inhibitor as our clin. candidate by using in vitro potency, selectivity, pharmacokinetics (PK), and in vivo pharmacodynamic for prioritizing compds.  Compd. BGB-3111 (31a, Zanubrutinib) demonstrates (i) potent activity against BTK and excellent selectivity over other TEC, EGFR and Src family kinases, (ii) desirable ADME, excellent in vivo pharmacodynamic in mice and efficacy in OCI-LY10 xenograft models.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgRMQ-gBKtdbVg90H21EOLACvtfcHk0liyTbYE8VsVtg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsFSku7bP&md5=5cdb551d296e60eb1e82b03b7a0384ee</span></div><a href="/servlet/linkout?suffix=cit17a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00687&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00687%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DN.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DShi%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DB.%26aulast%3DWei%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DLuo%26aufirst%3DL.%26aulast%3DTang%26aufirst%3DZ.%26aulast%3DSong%26aufirst%3DH.%26aulast%3DGuo%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DSu%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DSong%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DHong%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DZ.%26aulast%3DYoung%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DQ.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLv%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DXing%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DSun%26aufirst%3DZ.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26atitle%3DDiscovery%2520of%2520Zanubrutinib%2520%2528BGB-3111%2529%252C%2520a%2520novel%252C%2520potent%252C%2520and%2520selective%2520covalent%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D17%26spage%3D7923%26epage%3D7940%26doi%3D10.1021%2Facs.jmedchem.9b00687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit17b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsui, S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, D.</span></span> <span> </span><span class="NLM_article-title">Second-generation inhibitors of Bruton tyrosine kinase</span>. <i>J. Hematol. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">80</span>, <span class="refDoi"> DOI: 10.1186/s13045-016-0313-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1186%2Fs13045-016-0313-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=27590878" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVajtr7L" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2016&pages=80&author=J.+Wuauthor=C.+Liuauthor=S.+T.+Tsuiauthor=D.+Liu&title=Second-generation+inhibitors+of+Bruton+tyrosine+kinase&doi=10.1186%2Fs13045-016-0313-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17bR"><div class="casContent"><span class="casTitleNuber">17b</span><div class="casTitle"><span class="NLM_cas:atitle">Second-generation inhibitors of Bruton tyrosine kinase</span></div><div class="casAuthors">Wu, Jingjing; Liu, Christina; Tsui, Stella T.; Liu, Delong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Hematology & Oncology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">80/1-80/7</span>CODEN:
                <span class="NLM_cas:coden">JHOOAO</span>;
        ISSN:<span class="NLM_cas:issn">1756-8722</span>.
    
            (<span class="NLM_cas:orgname">BioMed Central Ltd.</span>)
        </div><div class="casAbstract">Bruton tyrosine kinase (BTK) is a crit. effector mol. for B cell development and plays a major role in lymphoma genesis.  Ibrutinib is the first-generation BTK inhibitor.  Ibrutinib has off-target effects on EGFR, ITK, and Tec family kinases, which explains the untoward effects of ibrutinib.  Resistance to ibrutinib was also reported.  The C481S mutation in the BTK kinase domain was reported to be a major mechanism of resistance to ibrutinib.  This review summarizes the clin. development of novel BTK inhibitors, ACP-196 (acalabrutinib), ONO/GS-4059, and BGB-3111.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpb086cwyJYLrVg90H21EOLACvtfcHk0liq8_rhuB8IhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVajtr7L&md5=b6140d9f7a24665131f5e772d55f29eb</span></div><a href="/servlet/linkout?suffix=cit17b&amp;dbid=16384&amp;doi=10.1186%2Fs13045-016-0313-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252Fs13045-016-0313-y%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DC.%26aulast%3DTsui%26aufirst%3DS.%2BT.%26aulast%3DLiu%26aufirst%3DD.%26atitle%3DSecond-generation%2520inhibitors%2520of%2520Bruton%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Hematol.%2520Oncol.%26date%3D2016%26volume%3D9%26spage%3D80%26doi%3D10.1186%2Fs13045-016-0313-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montalban, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weber, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staikov, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piasecka-Stryczynska, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Willmer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dangond, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Syed, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolinsky, J. S.</span></span> <span> </span><span class="NLM_article-title">Placebo-controlled trial of an oral BTK inhibitor in Multiple Sclerosis</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>380</i></span> (<span class="NLM_issue">25</span>),  <span class="NLM_fpage">2406</span>– <span class="NLM_lpage">2417</span>, <span class="refDoi"> DOI: 10.1056/NEJMoa1901981</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1056%2FNEJMoa1901981" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=31075187" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BB3cXnsFGqurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=380&publication_year=2019&pages=2406-2417&issue=25&author=X.+Montalbanauthor=D.+L.+Arnoldauthor=M.+S.+Weberauthor=I.+Staikovauthor=K.+Piasecka-Stryczynskaauthor=J.+Willmerauthor=E.+C.+Martinauthor=F.+Dangondauthor=S.+Syedauthor=J.+S.+Wolinsky&title=Placebo-controlled+trial+of+an+oral+BTK+inhibitor+in+Multiple+Sclerosis&doi=10.1056%2FNEJMoa1901981"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis</span></div><div class="casAuthors">Montalban, Xavier; Arnold, Douglas L.; Weber, Martin S.; Staikov, Ivan; Piasecka-Stryczynska, Karolina; Willmer, Jonathan; Martin, Emily C.; Dangond, Fernando; Syed, Sana; Wolinsky, Jerry S.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">380</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2406-2417</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Background Bruton's tyrosine kinase (BTK) regulates the functions of B cells and myeloid cells that are implicated in the pathogenesis of multiple sclerosis.  Evobrutinib is a selective oral BTK inhibitor that has been shown to inhibit B-cell activation both in vitro and in vivo. methods In this double-blind, randomized, phase 2 trial, we assigned patients with relapsing multiple sclerosis to one of five groups: placebo, evobrutinib (at a dose of 25 mg once daily, 75 mg once daily, or 75 mg twice daily), or open-label di-Me fumarate (DMF) as a ref.  The primary end point was the total (cumulative) no. of gadolinium-enhancing lesions identified on T1-weighted magnetic resonance imaging at weeks 12, 16, 20, and 24.  Key secondary end points included the annualized relapse rate and change from baseline in the score on the Expanded Disability Status Scale (EDSS). results A total of 267 patients were randomly assigned to a trial group.  The mean (±SD) total no. of gadolinium-enhancing lesions during weeks 12 through 24 was 3.85 ± 5.44 in the placebo group, 4.06 ± 8.02 in the evobrutinib 25-mg group, 1.69 ± 4.69 in the evobrutinib 75-mg once-daily group, 1.15 ± 3.70 in the evobrutinib 75-mg twice-daily group, and 4.78 ± 22.05 in the DMF group.  The baseline adjusted rate ratios for the total no. of lesions over time as compared with placebo were 1.45 in the evobrutinib 25-mg group (P = 0.32), 0.30 in the evobrutinib 75-mg once-daily group (P = 0.005), and 0.44 in the evobrutinib 75-mg twice-daily group (P = 0.06).  The unadjusted annualized relapse rate at week 24 was 0.37 in the placebo group, 0.57 in the evobrutinib 25-mg group, 0.13 in the evobrutinib 75-mg once-daily group, 0.08 in the evobrutinib 75-mg twice-daily group, and 0.20 in the DMF group.  There was no significant effect of trial group on the change from baseline in the EDSS score.  Elevations in liver aminotransferase values were obsd. with evobrutinib. conclusions Patients with relapsing multiple sclerosis who received 75 mg of evobrutinib once daily had significantly fewer enhancing lesions during weeks 12 through 24 than those who received placebo.  There was no significant difference with placebo for either the 25-mg once-daily or 75-mg twice-daily dose of evobrutinib, nor in the annualized relapse rate or disability progression at any dose.  Longer and larger trials are required to det. the effect and risks of evobrutinib in patients with multiple sclerosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBCts7AZpkC7Vg90H21EOLACvtfcHk0liq8_rhuB8IhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXnsFGqurs%253D&md5=86489e8fe1c2130c8ab46986f0b52881</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1901981&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1901981%26sid%3Dliteratum%253Aachs%26aulast%3DMontalban%26aufirst%3DX.%26aulast%3DArnold%26aufirst%3DD.%2BL.%26aulast%3DWeber%26aufirst%3DM.%2BS.%26aulast%3DStaikov%26aufirst%3DI.%26aulast%3DPiasecka-Stryczynska%26aufirst%3DK.%26aulast%3DWillmer%26aufirst%3DJ.%26aulast%3DMartin%26aufirst%3DE.%2BC.%26aulast%3DDangond%26aufirst%3DF.%26aulast%3DSyed%26aufirst%3DS.%26aulast%3DWolinsky%26aufirst%3DJ.%2BS.%26atitle%3DPlacebo-controlled%2520trial%2520of%2520an%2520oral%2520BTK%2520inhibitor%2520in%2520Multiple%2520Sclerosis%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2019%26volume%3D380%26issue%3D25%26spage%3D2406%26epage%3D2417%26doi%3D10.1056%2FNEJMoa1901981" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaur, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swami, A.</span></span> <span> </span><span class="NLM_article-title">Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib</span>. <i>Ann. Hematol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>96</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1175</span>– <span class="NLM_lpage">1184</span>, <span class="refDoi"> DOI: 10.1007/s00277-017-2973-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1007%2Fs00277-017-2973-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=28342031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC2sXltl2ht70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=96&publication_year=2017&pages=1175-1184&issue=7&author=V.+Kaurauthor=A.+Swami&title=Ibrutinib+in+CLL%3A+a+focus+on+adverse+events%2C+resistance%2C+and+novel+approaches+beyond+ibrutinib&doi=10.1007%2Fs00277-017-2973-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib</span></div><div class="casAuthors">Kaur, Varinder; Swami, Arjun</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Hematology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">96</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1175-1184</span>CODEN:
                <span class="NLM_cas:coden">ANHEE8</span>;
        ISSN:<span class="NLM_cas:issn">0939-5555</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a mediator in B cell receptor signaling has been successfully exploited as a therapeutic target in treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).  Ibrutinib is a BTK inhibitor that has shown excellent efficacy in treatment-naive, heavily pre-treated, and high-risk CLL/SLL.  With remarkable efficacy, good oral bioavailability, and modest adverse events profile, ibrutinib use is likely to continue to increase.  As data with ibrutinib use in CLL matures, concerns regarding adverse events and drug resistance have emerged.  New insights into mechanisms of ibrutinib resistance in CLL have uncovered potential therapeutic targets.  Several promising novel agents are currently in early phases of development for overcoming ibrutinib resistance in CLL/SLL.  We provide a comprehensive anal. of emerging adverse events profile of ibrutinib, summarize our current understanding of ibrutinib resistance in CLL, and review promising novel therapeutic tools to overcome this challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRsUgeFPl8N7Vg90H21EOLACvtfcHk0liq8_rhuB8IhA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXltl2ht70%253D&md5=833537673bfe80fd7931dcc132c9b5aa</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1007%2Fs00277-017-2973-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00277-017-2973-2%26sid%3Dliteratum%253Aachs%26aulast%3DKaur%26aufirst%3DV.%26aulast%3DSwami%26aufirst%3DA.%26atitle%3DIbrutinib%2520in%2520CLL%253A%2520a%2520focus%2520on%2520adverse%2520events%252C%2520resistance%252C%2520and%2520novel%2520approaches%2520beyond%2520ibrutinib%26jtitle%3DAnn.%2520Hematol.%26date%3D2017%26volume%3D96%26issue%3D7%26spage%3D1175%26epage%3D1184%26doi%3D10.1007%2Fs00277-017-2973-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ulrich, R. G.</span></span> <span> </span><span class="NLM_article-title">Idiosyncratic toxicity: A convergence of risk factors</span>. <i>Annu. Rev. Med.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1146/annurev.med.58.072905.160823</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1146%2Fannurev.med.58.072905.160823" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=16958561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BD2sXisV2jsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2007&pages=17-34&author=R.+G.+Ulrich&title=Idiosyncratic+toxicity%3A+A+convergence+of+risk+factors&doi=10.1146%2Fannurev.med.58.072905.160823"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Idiosyncratic toxicity: a convergence of risk factors</span></div><div class="casAuthors">Ulrich, Roger G.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Medicine</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">17-34</span>CODEN:
                <span class="NLM_cas:coden">ARMCAH</span>;
        ISSN:<span class="NLM_cas:issn">0066-4219</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  The therapeutic margin for any drug is based on both toxicity and efficacy.  Generally, toxicity is dose-dependent and is driven either by the therapeutic target or by an untoward target.  However, idiosyncratic toxicities are usually not obsd. until a drug has been on the market and has gained broad exposure.  Except in the case of pharmacokinetic interactions, these toxicities are not driven solely by drug exposure but rather depend on several drug- and patient-related risk factors.  Drug-related risk factors include metab., bioactivation and covalent binding, and the inhibition of key cell functions.  Patient-related risk factors include underlying disease, age, gender, comedications, nutritional status, activation of the innate immune system, phys. activity, and genetic predispositions.  Idiosyncratic toxicity can occur when a convergence of risk factors, including drug exposure, tips the risk-benefit balance away from benefit and toward risk.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4gp_C2QKITbVg90H21EOLACvtfcHk0ljeqtE9-u4C5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXisV2jsLs%253D&md5=8f2b7ffb21a38b648a83bc1a8430a17c</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1146%2Fannurev.med.58.072905.160823&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev.med.58.072905.160823%26sid%3Dliteratum%253Aachs%26aulast%3DUlrich%26aufirst%3DR.%2BG.%26atitle%3DIdiosyncratic%2520toxicity%253A%2520A%2520convergence%2520of%2520risk%2520factors%26jtitle%3DAnnu.%2520Rev.%2520Med.%26date%3D2007%26volume%3D58%26spage%3D17%26epage%3D34%26doi%3D10.1146%2Fannurev.med.58.072905.160823" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Evans, E. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tester, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aslanian, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witowski, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lounsbury, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mazdiyasni, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freed, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W. F.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>346</i></span>,  <span class="NLM_fpage">219</span>– <span class="NLM_lpage">228</span>, <span class="refDoi"> DOI: 10.1124/jpet.113.203489</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1124%2Fjpet.113.203489" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=23709115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=346&publication_year=2013&pages=219-228&author=E.+K.+Evansauthor=R.+Testerauthor=S.+Aslanianauthor=R.+Karpauthor=M.+Sheetsauthor=M.+T.+Labenskiauthor=S.+R.+Witowskiauthor=H.+Lounsburyauthor=P.+Chaturvediauthor=H.+Mazdiyasniauthor=Z.+Zhuauthor=M.+Nachtauthor=M.+I.+Freedauthor=R.+C.+Petterauthor=A.+Dubrovskiyauthor=J.+Singhauthor=W.+F.+Westlin&title=Inhibition+of+Btk+with+CC-292+provides+early+pharmacodynamic+assessment+of+activity+in+mice+and+humans&doi=10.1124%2Fjpet.113.203489"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Btk with CC-292 provides early pharmacodynamic assessment of activity in mice and humans</span></div><div class="casAuthors">Evans, Erica K.; Tester, Richland; Aslanian, Sharon; Karp, Russell; Sheets, Michael; Labenski, Matthew T.; Witowski, Steven R.; Lounsbury, Heather; Chaturvedi, Prasoon; Mazdiyasni, Hormoz; Zhu, Zhendong; Nacht, Mariana; Freed, Martin I.; Petter, Russell C.; Dubrovskiy, Alex; Singh, Juswinder; Westlin, William F.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">346</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">219-228</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Targeted therapies that suppress B cell receptor (BCR) signaling have emerged as promising agents in autoimmune disease and B cell malignancies.  Bruton's tyrosine kinase (Btk) plays a crucial role in B cell development and activation through the BCR signaling pathway and represents a new target for diseases characterized by inappropriate B cell activity.  N-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide (CC-292) is a highly selective, covalent Btk inhibitor and a sensitive and quant. assay that measures CC-292-Btk engagement has been developed.  This translational pharmacodynamic assay has accompanied CC-292 through each step of drug discovery and development.  These studies demonstrate the quantity of Btk bound by CC-292 correlates with the efficacy of CC-292 in vitro and in the collagen-induced arthritis model of autoimmune disease.  Recently, CC-292 has entered human clin. trials with a trial design that has provided rapid insight into safety, pharmacokinetics, and pharmacodynamics.  This first-in-human healthy volunteer trial has demonstrated that a single oral dose of 2 mg/kg CC-292 consistently engaged all circulating Btk protein and provides the basis for rational dose selection in future clin. trials.  This targeted covalent drug design approach has enabled the discovery and early clin. development of CC-292 and has provided support for Btk as a valuable drug target for B-cell mediated disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrN2l8ZCVqCFLVg90H21EOLACvtfcHk0ljeqtE9-u4C5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOjsbbM&md5=95fac997a246e59d943dd554af358a65</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1124%2Fjpet.113.203489&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.113.203489%26sid%3Dliteratum%253Aachs%26aulast%3DEvans%26aufirst%3DE.%2BK.%26aulast%3DTester%26aufirst%3DR.%26aulast%3DAslanian%26aufirst%3DS.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DLabenski%26aufirst%3DM.%2BT.%26aulast%3DWitowski%26aufirst%3DS.%2BR.%26aulast%3DLounsbury%26aufirst%3DH.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DMazdiyasni%26aufirst%3DH.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DFreed%26aufirst%3DM.%2BI.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DWestlin%26aufirst%3DW.%2BF.%26atitle%3DInhibition%2520of%2520Btk%2520with%2520CC-292%2520provides%2520early%2520pharmacodynamic%2520assessment%2520of%2520activity%2520in%2520mice%2520and%2520humans%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2013%26volume%3D346%26spage%3D219%26epage%3D228%26doi%3D10.1124%2Fjpet.113.203489" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span>A Study
of LY3337641 in Rheumatoid Arthritis (RAjuvenate). ClinicalTrials.gov
Identifier: NCT02628028. <a href="https://clinicaltrials.gov/ct2/show/NCT02628028" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02628028</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=A+Study%0Aof+LY3337641+in+Rheumatoid+Arthritis+%28RAjuvenate%29.+ClinicalTrials.gov%0AIdentifier%3A+NCT02628028.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02628028."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beaudoin
Bertrand, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moore, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elzinga, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westhouse, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Catlett, I. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaudhry, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pokross, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allentoff, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wallace, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Macor, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J.</span></span> <span> </span><span class="NLM_article-title">Discovery of Branebrutinib (BMS-986195): a strategy for identifying a highly potent and selective covalent inhibitor providing rapid in vivo inactivation of Bruton’s tyrosine kinase (BTK)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">3228</span>– <span class="NLM_lpage">3250</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00167</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00167" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1MXls1aks7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=3228-3250&issue=7&author=S.+H.+Wattersonauthor=Q.+Liuauthor=M.+Beaudoin%0ABertrandauthor=D.+G.+Battauthor=L.+Liauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+Chengauthor=M.+T.+Obermeierauthor=R.+Mooreauthor=Z.+Yangauthor=R.+Vickeryauthor=P.+A.+Elzingaauthor=L.+Discenzaauthor=C.+D%E2%80%99Arienzoauthor=K.+M.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicicchioauthor=Y.+Zhangauthor=E.+Heimrichauthor=K.+W.+McIntyreauthor=Q.+Ruanauthor=R.+A.+Westhouseauthor=I.+M.+Catlettauthor=N.+Zhengauthor=C.+Chaudhryauthor=J.+Daiauthor=M.+A.+Galellaauthor=A.+J.+Tebbenauthor=M.+Pokrossauthor=J.+Liauthor=R.+Zhaoauthor=D.+Smithauthor=R.+Rampullaauthor=A.+Allentoffauthor=M.+A.+Wallaceauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+E.+Macorauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+Tino&title=Discovery+of+Branebrutinib+%28BMS-986195%29%3A+a+strategy+for+identifying+a+highly+potent+and+selective+covalent+inhibitor+providing+rapid+in+vivo+inactivation+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29&doi=10.1021%2Facs.jmedchem.9b00167"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton's Tyrosine Kinase (BTK)</span></div><div class="casAuthors">Watterson, Scott H.; Liu, Qingjie; Beaudoin Bertrand, Myra; Batt, Douglas G.; Li, Ling; Pattoli, Mark A.; Skala, Stacey; Cheng, Lihong; Obermeier, Mary T.; Moore, Robin; Yang, Zheng; Vickery, Rodney; Elzinga, Paul A.; Discenza, Lorell; D'Arienzo, Celia; Gillooly, Kathleen M.; Taylor, Tracy L.; Pulicicchio, Claudine; Zhang, Yifan; Heimrich, Elizabeth; McIntyre, Kim W.; Ruan, Qian; Westhouse, Richard A.; Catlett, Ian M.; Zheng, Naiyu; Chaudhry, Charu; Dai, Jun; Galella, Michael A.; Tebben, Andrew J.; Pokross, Matt; Li, Jianqing; Zhao, Rulin; Smith, Daniel; Rampulla, Richard; Allentoff, Alban; Wallace, Michael A.; Mathur, Arvind; Salter-Cid, Luisa; Macor, John E.; Carter, Percy H.; Fura, Aberra; Burke, James R.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3228-3250</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a non-receptor tyrosine kinase, is a member of the Tec family of kinases and is essential for B cell receptor (BCR) mediated signaling.  BTK also plays a crit. role in the downstream signaling pathways for the Fcγ receptor in monocytes, the Fcε receptor in granulocytes, and the RANK receptor in osteoclasts.  As a result, pharmacol. inhibition of BTK is anticipated to provide an effective strategy for the clin. treatment of autoimmune diseases such as rheumatoid arthritis and lupus.  This article will outline the evolution of our strategy to identify a covalent, irreversible inhibitor of BTK that has the intrinsic potency, selectivity, and pharmacokinetic properties necessary to provide a rapid rate of inactivation systemically following a very low dose.  With excellent in vivo efficacy and a very desirable tolerability profile, 5a (branebrutinib, BMS-986195) has advanced into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqGr5oQEoebirVg90H21EOLACvtfcHk0ligC5RipNslTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXls1aks7w%253D&md5=2d521ec7c06d503f940cb44d381af58d</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00167%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBeaudoin%2BBertrand%26aufirst%3DM.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DMoore%26aufirst%3DR.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DElzinga%26aufirst%3DP.%2BA.%26aulast%3DDiscenza%26aufirst%3DL.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DRuan%26aufirst%3DQ.%26aulast%3DWesthouse%26aufirst%3DR.%2BA.%26aulast%3DCatlett%26aufirst%3DI.%2BM.%26aulast%3DZheng%26aufirst%3DN.%26aulast%3DChaudhry%26aufirst%3DC.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DPokross%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DSmith%26aufirst%3DD.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DAllentoff%26aufirst%3DA.%26aulast%3DWallace%26aufirst%3DM.%2BA.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DMacor%26aufirst%3DJ.%2BE.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%26atitle%3DDiscovery%2520of%2520Branebrutinib%2520%2528BMS-986195%2529%253A%2520a%2520strategy%2520for%2520identifying%2520a%2520highly%2520potent%2520and%2520selective%2520covalent%2520inhibitor%2520providing%2520rapid%2520in%2520vivo%2520inactivation%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D7%26spage%3D3228%26epage%3D3250%26doi%3D10.1021%2Facs.jmedchem.9b00167" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Caldwell, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Askew, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brugger, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camps, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dhanabal, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dutt, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eichhorn, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardberg, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goutopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenningloh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healey, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodous, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huck, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mochalkin, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyring, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Potnick, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santos, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherer, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shutes, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbahns, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Follis, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegener, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerli, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Bujalski, L.</span></span> <span> </span><span class="NLM_article-title">Discovery of Evobrutinib: an oral, potent, and highly selective, covalent Bruton’s tyrosine kinase (BTK) inhibitor for the treatment of immunological diseases</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">7643</span>– <span class="NLM_lpage">7655</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b00794</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b00794" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhsV2jtr7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=7643-7655&issue=17&author=R.+D.+Caldwellauthor=H.+Qiuauthor=B.+C.+Askewauthor=A.+T.+Benderauthor=N.+Bruggerauthor=M.+Campsauthor=M.+Dhanabalauthor=V.+Duttauthor=T.+Eichhornauthor=A.+S.+Gardbergauthor=A.+Goutopoulosauthor=R.+Grenninglohauthor=J.+Headauthor=B.+Healeyauthor=B.+L.+Hodousauthor=B.+R.+Huckauthor=T.+L.+Johnsonauthor=C.+Jonesauthor=R.+C.+Jonesauthor=I.+Mochalkinauthor=F.+Morandiauthor=N.+Nguyenauthor=M.+Meyringauthor=J.+R.+Potnickauthor=D.+C.+Santosauthor=R.+Schmidtauthor=B.+Shererauthor=A.+Shutesauthor=K.+Urbahnsauthor=A.+V.+Follisauthor=A.+A.+Wegenerauthor=S.+C.+Zimmerliauthor=L.+Liu-Bujalski&title=Discovery+of+Evobrutinib%3A+an+oral%2C+potent%2C+and+highly+selective%2C+covalent+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitor+for+the+treatment+of+immunological+diseases&doi=10.1021%2Facs.jmedchem.9b00794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton's Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases</span></div><div class="casAuthors">Caldwell, Richard D.; Qiu, Hui; Askew, Ben C.; Bender, Andrew T.; Brugger, Nadia; Camps, Montserrat; Dhanabal, Mohanraj; Dutt, Vikram; Eichhorn, Thomas; Gardberg, Anna S.; Goutopoulos, Andreas; Grenningloh, Roland; Head, Jared; Healey, Brian; Hodous, Brian L.; Huck, Bayard R.; Johnson, Theresa L.; Jones, Christopher; Jones, Reinaldo C.; Mochalkin, Igor; Morandi, Federica; Nguyen, Ngan; Meyring, Michael; Potnick, Justin R.; Santos, Dusica Cvetinovic; Schmidt, Ralf; Sherer, Brian; Shutes, Adam; Urbahns, Klaus; Follis, Ariele Viacava; Wegener, Ansgar A.; Zimmerli, Simone C.; Liu-Bujalski, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7643-7655</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) inhibitors such as ibrutinib hold a prominent role in the treatment of B cell malignancies.  However, further refinement is needed to this class of agents, particularly in terms of adverse events (potentially driven by kinase promiscuity), which preclude their evaluation in nononcol. indications.  Here, we report the discovery and preclin. characterization of evobrutinib, a potent, obligate covalent inhibitor with high kinase selectivity.  Evobrutinib displayed sufficient preclin. pharmacokinetic and pharmacodynamic characteristics which allowed for in vivo evaluation in efficacy models.  Moreover, the high selectivity of evobrutinib for BTK over epidermal growth factor receptor and other Tec family kinases suggested a low potential for off-target related adverse effects.  Clin. investigation of evobrutinib is ongoing in several autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFmL8DnlfGl7Vg90H21EOLACvtfcHk0ligC5RipNslTg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhsV2jtr7P&md5=f9711d8a18803afc356dbac848067acf</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b00794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b00794%26sid%3Dliteratum%253Aachs%26aulast%3DCaldwell%26aufirst%3DR.%2BD.%26aulast%3DQiu%26aufirst%3DH.%26aulast%3DAskew%26aufirst%3DB.%2BC.%26aulast%3DBender%26aufirst%3DA.%2BT.%26aulast%3DBrugger%26aufirst%3DN.%26aulast%3DCamps%26aufirst%3DM.%26aulast%3DDhanabal%26aufirst%3DM.%26aulast%3DDutt%26aufirst%3DV.%26aulast%3DEichhorn%26aufirst%3DT.%26aulast%3DGardberg%26aufirst%3DA.%2BS.%26aulast%3DGoutopoulos%26aufirst%3DA.%26aulast%3DGrenningloh%26aufirst%3DR.%26aulast%3DHead%26aufirst%3DJ.%26aulast%3DHealey%26aufirst%3DB.%26aulast%3DHodous%26aufirst%3DB.%2BL.%26aulast%3DHuck%26aufirst%3DB.%2BR.%26aulast%3DJohnson%26aufirst%3DT.%2BL.%26aulast%3DJones%26aufirst%3DC.%26aulast%3DJones%26aufirst%3DR.%2BC.%26aulast%3DMochalkin%26aufirst%3DI.%26aulast%3DMorandi%26aufirst%3DF.%26aulast%3DNguyen%26aufirst%3DN.%26aulast%3DMeyring%26aufirst%3DM.%26aulast%3DPotnick%26aufirst%3DJ.%2BR.%26aulast%3DSantos%26aufirst%3DD.%2BC.%26aulast%3DSchmidt%26aufirst%3DR.%26aulast%3DSherer%26aufirst%3DB.%26aulast%3DShutes%26aufirst%3DA.%26aulast%3DUrbahns%26aufirst%3DK.%26aulast%3DFollis%26aufirst%3DA.%2BV.%26aulast%3DWegener%26aufirst%3DA.%2BA.%26aulast%3DZimmerli%26aufirst%3DS.%2BC.%26aulast%3DLiu-Bujalski%26aufirst%3DL.%26atitle%3DDiscovery%2520of%2520Evobrutinib%253A%2520an%2520oral%252C%2520potent%252C%2520and%2520highly%2520selective%252C%2520covalent%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitor%2520for%2520the%2520treatment%2520of%2520immunological%2520diseases%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26issue%3D17%26spage%3D7643%26epage%3D7655%26doi%3D10.1021%2Facs.jmedchem.9b00794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krishnarajah, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nunn, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karr, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tam, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masjedizadeh, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funk, J. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gourlay, S. G.</span></span> <span> </span><span class="NLM_article-title">A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton’s tyrosine kinase, in healthy volunteers</span>. <i>Br. J. Clin. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>83</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2367</span>– <span class="NLM_lpage">2376</span>, <span class="refDoi"> DOI: 10.1111/bcp.13351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1111%2Fbcp.13351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=28636208" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslWrsLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2017&pages=2367-2376&issue=11&author=P.+F.+Smithauthor=J.+Krishnarajahauthor=P.+A.+Nunnauthor=R.+J.+Hillauthor=D.+Karrauthor=D.+Tamauthor=M.+Masjedizadehauthor=J.+O.+Funkauthor=S.+G.+Gourlay&title=A+phase+I+trial+of+PRN1008%2C+a+novel+reversible+covalent+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase%2C+in+healthy+volunteers&doi=10.1111%2Fbcp.13351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers</span></div><div class="casAuthors">Smith, Patrick F.; Krishnarajah, Janakan; Nunn, Philip A.; Hill, Ron J.; Karr, Dane; Tam, D.; Masjedizadeh, Mohammad; Funk, Jens O.; Gourlay, Steve G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Clinical Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2367-2376</span>CODEN:
                <span class="NLM_cas:coden">BCPHBM</span>;
        ISSN:<span class="NLM_cas:issn">1365-2125</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">To evaluate the safety, tolerability, and pharmacokinetics/pharmacodynamics of PRN1008, a novel Bruton's tyrosine kinase (BTK) inhibitor, in healthy volunteers, and thus det. the dose range for future clin. studies.  This was a two-part randomized, placebo controlled study in healthy volunteers using a liq. formulation.  Part I was a single ascending dose design with dose levels of 50-1200 mg (n = 6 active, two placebos per cohort); Part II was a multiple ascending dose design, with dose regimens ranging from 300 to 900 mg daily, either four times or twice daily for 10 days.  Plasma pharmacokinetics, adverse events, vital signs, electrocardiograms and lab. parameters were assessed.  BTK occupancy in peripheral blood mononuclear cells was evaluated as a marker of target engagement.  PRN1008 was rapidly absorbed following oral administration, and was safe and well tolerated in all dose regimens evaluated in both single and multiple doses.  PRN1008 demonstrated a large vol. of distribution, and a half-life of approx. 3-4 h.  BTK occupancy of >90% was obsd. within 4 h after dosing in both single and multiple dose regimens, and was closely linked to max. plasma concn.  BTK occupancy decay was slow (-1.6% h-1), and occupancy was sustained despite drug concns. being undetectable.  No severe or serious adverse events occurred, and the most common adverse events were gastrointestinal in nature.  PRN1008 was safe and well-tolerated following oral administration, and achieved high, sustained levels of BTK occupancy in peripheral blood mononuclear cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDCmAr26_VXLVg90H21EOLACvtfcHk0livcoEOj3Qqhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslWrsLnE&md5=8da03545b8beec4c50cdd95854bcad8f</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1111%2Fbcp.13351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fbcp.13351%26sid%3Dliteratum%253Aachs%26aulast%3DSmith%26aufirst%3DP.%2BF.%26aulast%3DKrishnarajah%26aufirst%3DJ.%26aulast%3DNunn%26aufirst%3DP.%2BA.%26aulast%3DHill%26aufirst%3DR.%2BJ.%26aulast%3DKarr%26aufirst%3DD.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DMasjedizadeh%26aufirst%3DM.%26aulast%3DFunk%26aufirst%3DJ.%2BO.%26aulast%3DGourlay%26aufirst%3DS.%2BG.%26atitle%3DA%2520phase%2520I%2520trial%2520of%2520PRN1008%252C%2520a%2520novel%2520reversible%2520covalent%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%252C%2520in%2520healthy%2520volunteers%26jtitle%3DBr.%2520J.%2520Clin.%2520Pharmacol.%26date%3D2017%26volume%3D83%26issue%3D11%26spage%3D2367%26epage%3D2376%26doi%3D10.1111%2Fbcp.13351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Feng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duan, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, M.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018)</span>. <i>Expert Opin. Ther. Pat.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">241</span>, <span class="refDoi"> DOI: 10.1080/13543776.2019.1594777</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1080%2F13543776.2019.1594777" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=30888232" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnt1Wrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=217-241&issue=4&author=Y.+Fengauthor=W.+Duanauthor=X.+Cuauthor=C.+Liangauthor=M.+Xin&title=Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitors+in+treating+cancer%3A+a+patent+review+%282010-2018%29&doi=10.1080%2F13543776.2019.1594777"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase (BTK) inhibitors in treating cancer: a patent review (2010-2018)</span></div><div class="casAuthors">Feng, Yifan; Duan, Weiming; Cu, Xiaochuan; Liang, Chengyuan; Xin, Minhang</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Therapeutic Patents</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">217-241</span>CODEN:
                <span class="NLM_cas:coden">EOTPEG</span>;
        ISSN:<span class="NLM_cas:issn">1354-3776</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">A review.  Bruton's tyrosine kinase (BTK) plays a crit. role in the regulation of survival, proliferation, activation and differentiation of B-lineage cells.  It participates by regulating multiple cellular signaling pathways, including B cell receptor and FcR signaling cascades.  BTK is abundantly expressed and constitutively active in the pathogenesis of B cell hematol. malignancies, as well as several autoimmune diseases.  Therefore, BTK is considered as an attractive target for treatment of B-lineage lymphomas, leukemias, and some autoimmune diseases.  Many industry and academia efforts have been made to explore small mol. BTK inhibitors.  This review aims to provide an overview of the patented BTK inhibitors for the treatment of cancer from 2010 to 2018.  BTK inhibitors attract much interest for their therapeutic potential in the treatment of cancers and autoimmune diseases, esp. for B cell hematol. malignancies.  In 2013, ibrutinib was approved by the FDA as the first-in-class BTK inhibitors for the treatment of mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL), and now it is also undergoing clin. evaluation for other indications in either single or combined therapy.  It is clear that BTK inhibitors can provide a promising clin. benefit in treating B-lineage lymphomas and leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJGOIlTJf7g7Vg90H21EOLACvtfcHk0livcoEOj3Qqhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnt1Wrsbo%253D&md5=2f31c214c46945f7818532a39430ec00</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1080%2F13543776.2019.1594777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F13543776.2019.1594777%26sid%3Dliteratum%253Aachs%26aulast%3DFeng%26aufirst%3DY.%26aulast%3DDuan%26aufirst%3DW.%26aulast%3DCu%26aufirst%3DX.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DXin%26aufirst%3DM.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitors%2520in%2520treating%2520cancer%253A%2520a%2520patent%2520review%2520%25282010-2018%2529%26jtitle%3DExpert%2520Opin.%2520Ther.%2520Pat.%26date%3D2019%26volume%3D29%26issue%3D4%26spage%3D217%26epage%3D241%26doi%3D10.1080%2F13543776.2019.1594777" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Angst, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gessier, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Janser, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vulpetti, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wälchli, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beerli, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Littlewood-Evans, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nuesslein-Hildesheim, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wieczorek, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gutmann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheufler, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hinniger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerlin, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Funhoff, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulz, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cenni, B.</span></span> <span> </span><span class="NLM_article-title">Discovery of LOU064 (remibrutinib), a potent and highly selective covalent inhibitor of Bruton’s tyrosine kinase</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>63</i></span>,  <span class="NLM_fpage">5102</span>– <span class="NLM_lpage">5118</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.9b01916</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.9b01916" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BB3cXjs1KiurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=63&publication_year=2020&pages=5102-5118&author=D.+Angstauthor=F.+Gessierauthor=P.+Janserauthor=A.+Vulpettiauthor=R.+W%C3%A4lchliauthor=C.+Beerliauthor=A.+Littlewood-Evansauthor=J.+Dawsonauthor=B.+Nuesslein-Hildesheimauthor=G.+Wieczorekauthor=S.+Gutmannauthor=C.+Scheuflerauthor=A.+Hinnigerauthor=A.+Zimmerlinauthor=E.+G.+Funhoffauthor=R.+Pulzauthor=B.+Cenni&title=Discovery+of+LOU064+%28remibrutinib%29%2C+a+potent+and+highly+selective+covalent+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase&doi=10.1021%2Facs.jmedchem.9b01916"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase</span></div><div class="casAuthors">Angst, Daniela; Gessier, Francois; Janser, Philipp; Vulpetti, Anna; Walchli, Rudolf; Beerli, Christian; Littlewood-Evans, Amanda; Dawson, Janet; Nuesslein-Hildesheim, Barbara; Wieczorek, Grazyna; Gutmann, Sascha; Scheufler, Clemens; Hinniger, Alexandra; Zimmerlin, Alfred; Funhoff, Enrico G.; Pulz, Robert; Cenni, Bruno</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">63</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5102-5118</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a cytoplasmic tyrosine kinase, plays a central role in immunity and is considered an attractive target for treating autoimmune diseases.  The use of currently marketed covalent BTK inhibitors is limited to oncol. indications based on their suboptimal kinase selectivity.  We describe the discovery and preclin. profile of LOU064 (remibrutinib, 25), a potent, highly selective covalent BTK inhibitor.  LOU064 exhibits an exquisite kinase selectivity due to binding to an inactive conformation of BTK and has the potential for a best-in-class covalent BTK inhibitor for the treatment of autoimmune diseases.  It demonstrates potent in vivo target occupancy with an EC90 of 1.6 mg/kg and dose-dependent efficacy in rat collagen-induced arthritis.  LOU064 is currently being tested in phase 2 clin. studies for chronic spontaneous urticaria and Sjoegren's syndrome.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoBR_esJ38IMrVg90H21EOLACvtfcHk0livcoEOj3Qqhg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXjs1KiurY%253D&md5=9122b310c294d6071ae7cd73cdb91b3d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.9b01916&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.9b01916%26sid%3Dliteratum%253Aachs%26aulast%3DAngst%26aufirst%3DD.%26aulast%3DGessier%26aufirst%3DF.%26aulast%3DJanser%26aufirst%3DP.%26aulast%3DVulpetti%26aufirst%3DA.%26aulast%3DW%25C3%25A4lchli%26aufirst%3DR.%26aulast%3DBeerli%26aufirst%3DC.%26aulast%3DLittlewood-Evans%26aufirst%3DA.%26aulast%3DDawson%26aufirst%3DJ.%26aulast%3DNuesslein-Hildesheim%26aufirst%3DB.%26aulast%3DWieczorek%26aufirst%3DG.%26aulast%3DGutmann%26aufirst%3DS.%26aulast%3DScheufler%26aufirst%3DC.%26aulast%3DHinniger%26aufirst%3DA.%26aulast%3DZimmerlin%26aufirst%3DA.%26aulast%3DFunhoff%26aufirst%3DE.%2BG.%26aulast%3DPulz%26aufirst%3DR.%26aulast%3DCenni%26aufirst%3DB.%26atitle%3DDiscovery%2520of%2520LOU064%2520%2528remibrutinib%2529%252C%2520a%2520potent%2520and%2520highly%2520selective%2520covalent%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2020%26volume%3D63%26spage%3D5102%26epage%3D5118%26doi%3D10.1021%2Facs.jmedchem.9b01916" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Belmont, L. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Castanedo, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coraggio, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghilardi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hau, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohli, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lubach, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McKenzie, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ortwine, D. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutt, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tay, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span> <span> </span><span class="NLM_article-title">Discovery of GDC-0853: a potent, selective, and noncovalent Bruton’s tyrosine kinase inhibitor in early clinical development</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">2227</span>– <span class="NLM_lpage">2245</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01712</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01712" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=2227-2245&author=J.+J.+Crawfordauthor=A.+R.+Johnsonauthor=D.+L.+Misnerauthor=L.+D.+Belmontauthor=G.+Castanedoauthor=R.+Choyauthor=M.+Coraggioauthor=L.+Dongauthor=C.+Eigenbrotauthor=R.+Ericksonauthor=N.+Ghilardiauthor=J.+Hauauthor=A.+Katewaauthor=P.+B.+Kohliauthor=W.+Leeauthor=J.+W.+Lubachauthor=B.+S.+McKenzieauthor=D.+F.+Ortwineauthor=L.+Schuttauthor=S.+Tayauthor=B.+Weiauthor=K.+Reifauthor=L.+Liuauthor=H.+Wongauthor=W.+B.+Young&title=Discovery+of+GDC-0853%3A+a+potent%2C+selective%2C+and+noncovalent+Bruton%E2%80%99s+tyrosine+kinase+inhibitor+in+early+clinical+development&doi=10.1021%2Facs.jmedchem.7b01712"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28aR"><div class="casContent"><span class="casTitleNuber">28a</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development</span></div><div class="casAuthors">Crawford, James J.; Johnson, Adam R.; Misner, Dinah L.; Belmont, Lisa D.; Castanedo, Georgette; Choy, Regina; Coraggio, Melis; Dong, Liming; Eigenbrot, Charles; Erickson, Rebecca; Ghilardi, Nico; Hau, Jonathan; Katewa, Arna; Kohli, Pawan Bir; Lee, Wendy; Lubach, Joseph W.; McKenzie, Brent S.; Ortwine, Daniel F.; Schutt, Leah; Tay, Suzanne; Wei, BinQing; Reif, Karin; Liu, Lichuan; Wong, Harvey; Young, Wendy B.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2227-2245</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a nonreceptor cytoplasmic tyrosine kinase involved in B-cell and myeloid cell activation, downstream of B-cell and Fcγ receptors, resp.  Preclin. studies have indicated that inhibition of Btk activity might offer a potential therapy in autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.  Here we disclose the discovery and preclin. characterization of a potent, selective, and noncovalent Btk inhibitor currently in clin. development.  GDC-0853 (29) suppresses B cell- and myeloid cell-mediated components of disease and demonstrates dose-dependent activity in an in vivo rat model of inflammatory arthritis.  It demonstrates highly favorable safety, pharmacokinetic (PK), and pharmacodynamic (PD) profiles in preclin. and Phase 2 studies ongoing in patients with rheumatoid arthritis, lupus, and chronic spontaneous urticaria.  On the basis of its potency, selectivity, long target residence time, and noncovalent mode of inhibition, 29 has the potential to be a best-in-class Btk inhibitor for a wide range of immunol. indications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqOUJgTOFJ-o7Vg90H21EOLACvtfcHk0lhIVLcYJdF3yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivFCnt7c%253D&md5=eddbd31f387fe86827a7469e8be45430</span></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01712&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01712%26sid%3Dliteratum%253Aachs%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26aulast%3DBelmont%26aufirst%3DL.%2BD.%26aulast%3DCastanedo%26aufirst%3DG.%26aulast%3DChoy%26aufirst%3DR.%26aulast%3DCoraggio%26aufirst%3DM.%26aulast%3DDong%26aufirst%3DL.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DErickson%26aufirst%3DR.%26aulast%3DGhilardi%26aufirst%3DN.%26aulast%3DHau%26aufirst%3DJ.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DKohli%26aufirst%3DP.%2BB.%26aulast%3DLee%26aufirst%3DW.%26aulast%3DLubach%26aufirst%3DJ.%2BW.%26aulast%3DMcKenzie%26aufirst%3DB.%2BS.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DSchutt%26aufirst%3DL.%26aulast%3DTay%26aufirst%3DS.%26aulast%3DWei%26aufirst%3DB.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26atitle%3DDiscovery%2520of%2520GDC-0853%253A%2520a%2520potent%252C%2520selective%252C%2520and%2520noncovalent%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%2520in%2520early%2520clinical%2520development%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D2227%26epage%3D2245%26doi%3D10.1021%2Facs.jmedchem.7b01712" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit28b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Watterson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Lucca, G. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langevine, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Batt, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yip, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Traeger, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pattoli, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obermeier, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vickery, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discenza, L. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">D’Arienzo, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimrich, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gillooly, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pulicicchio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McIntyre, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tebben, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muckelbauer, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rampulla, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salter-Cid, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrish, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fura, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burke, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tino, J. A.</span></span> <span> </span><span class="NLM_article-title">Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): a reversible inhibitor of Bruton’s tyrosine kinase (BTK) conformationally constrained by two locked atropisomers</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">9173</span>– <span class="NLM_lpage">9200</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b01088</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b01088" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsVKjsrfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=9173-9200&author=S.+H.+Wattersonauthor=G.+V.+De+Luccaauthor=Q.+Shiauthor=C.+M.+Langevineauthor=Q.+Liuauthor=D.+G.+Battauthor=M.+B.+Bertrandauthor=H.+Gongauthor=J.+Daiauthor=S.+Yipauthor=P.+Liauthor=D.+Sunauthor=D.-R.+Wuauthor=C.+Wangauthor=Y.+Zhangauthor=S.+C.+Traegerauthor=M.+A.+Pattoliauthor=S.+Skalaauthor=L.+Chengauthor=M.+T.+Obermeierauthor=R.+Vickeryauthor=L.+N.+Discenzaauthor=C.+J.+D%E2%80%99Arienzoauthor=Y.+Zhangauthor=E.+Heimrichauthor=K.+M.+Gilloolyauthor=T.+L.+Taylorauthor=C.+Pulicicchioauthor=K.+W.+McIntyreauthor=M.+A.+Galellaauthor=A.+J.+Tebbenauthor=J.+K.+Muckelbauerauthor=C.+Changauthor=R.+Rampullaauthor=A.+Mathurauthor=L.+Salter-Cidauthor=J.+C.+Barrishauthor=P.+H.+Carterauthor=A.+Furaauthor=J.+R.+Burkeauthor=J.+A.+Tino&title=Discovery+of+6-Fluoro-5-%28R%29-%283-%28S%29-%288-fluoro-1-methyl-2%2C4-dioxo-1%2C2-dihydroquinazolin-3%284H%29-yl%29-2-methylphenyl%29-2-%28S%29-%282-hydroxypropan-2-yl%29-2%2C3%2C4%2C9-tetrahydro-1H-carbazole-8-carboxamide+%28BMS-986142%29%3A+a+reversible+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+conformationally+constrained+by+two+locked+atropisomers&doi=10.1021%2Facs.jmedchem.6b01088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28bR"><div class="casContent"><span class="casTitleNuber">28b</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of 6-Fluoro-5-(R)-(3-(S)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)-2-methylphenyl)-2-(S)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1H-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton's Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers</span></div><div class="casAuthors">Watterson, Scott H.; De Lucca, George V.; Shi, Qing; Langevine, Charles M.; Liu, Qingjie; Batt, Douglas G.; Beaudoin Bertrand, Myra; Gong, Hua; Dai, Jun; Yip, Shiuhang; Li, Peng; Sun, Dawn; Wu, Dauh-Rurng; Wang, Chunlei; Zhang, Yingru; Traeger, Sarah C.; Pattoli, Mark A.; Skala, Stacey; Cheng, Lihong; Obermeier, Mary T.; Vickery, Rodney; Discenza, Lorell N.; D'Arienzo, Celia J.; Zhang, Yifan; Heimrich, Elizabeth; Gillooly, Kathleen M.; Taylor, Tracy L.; Pulicicchio, Claudine; McIntyre, Kim W.; Galella, Michael A.; Tebben, Andy J.; Muckelbauer, Jodi K.; Chang, ChiehYing; Rampulla, Richard; Mathur, Arvind; Salter-Cid, Luisa; Barrish, Joel C.; Carter, Percy H.; Fura, Aberra; Burke, James R.; Tino, Joseph A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">9173-9200</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a nonreceptor tyrosine kinase, is a member of the Tec family of kinases.  BTK plays an essential role in B cell receptor (BCR)-mediated signaling as well as Fcγ receptor signaling in monocytes and Fcε receptor signaling in mast cells and basophils, all of which have been implicated in the pathophysiol. of autoimmune disease.  As a result, inhibition of BTK is anticipated to provide an effective strategy for the clin. treatment of autoimmune diseases such as lupus and rheumatoid arthritis.  This article details the structure-activity relationships (SAR) leading to a novel series of highly potent and selective carbazole and tetrahydrocarbazole based, reversible inhibitors of BTK.  Of particular interest is that two atropisomeric centers were rotationally locked to provide a single, stable atropisomer, resulting in enhanced potency and selectivity as well as a redn. in safety liabilities.  With significantly enhanced potency and selectivity, excellent in vivo properties and efficacy, and a very desirable tolerability and safety profile, 14f (BMS-986142) was advanced into clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmpBAygRAsYrVg90H21EOLACvtfcHk0lhIVLcYJdF3yQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsVKjsrfF&md5=91098abc802521b9ad91563d20ac5893</span></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b01088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b01088%26sid%3Dliteratum%253Aachs%26aulast%3DWatterson%26aufirst%3DS.%2BH.%26aulast%3DDe%2BLucca%26aufirst%3DG.%2BV.%26aulast%3DShi%26aufirst%3DQ.%26aulast%3DLangevine%26aufirst%3DC.%2BM.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBatt%26aufirst%3DD.%2BG.%26aulast%3DBertrand%26aufirst%3DM.%2BB.%26aulast%3DGong%26aufirst%3DH.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DYip%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DP.%26aulast%3DSun%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DD.-R.%26aulast%3DWang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DTraeger%26aufirst%3DS.%2BC.%26aulast%3DPattoli%26aufirst%3DM.%2BA.%26aulast%3DSkala%26aufirst%3DS.%26aulast%3DCheng%26aufirst%3DL.%26aulast%3DObermeier%26aufirst%3DM.%2BT.%26aulast%3DVickery%26aufirst%3DR.%26aulast%3DDiscenza%26aufirst%3DL.%2BN.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%2BJ.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHeimrich%26aufirst%3DE.%26aulast%3DGillooly%26aufirst%3DK.%2BM.%26aulast%3DTaylor%26aufirst%3DT.%2BL.%26aulast%3DPulicicchio%26aufirst%3DC.%26aulast%3DMcIntyre%26aufirst%3DK.%2BW.%26aulast%3DGalella%26aufirst%3DM.%2BA.%26aulast%3DTebben%26aufirst%3DA.%2BJ.%26aulast%3DMuckelbauer%26aufirst%3DJ.%2BK.%26aulast%3DChang%26aufirst%3DC.%26aulast%3DRampulla%26aufirst%3DR.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DSalter-Cid%26aufirst%3DL.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DCarter%26aufirst%3DP.%2BH.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DBurke%26aufirst%3DJ.%2BR.%26aulast%3DTino%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25206-Fluoro-5-%2528R%2529-%25283-%2528S%2529-%25288-fluoro-1-methyl-2%252C4-dioxo-1%252C2-dihydroquinazolin-3%25284H%2529-yl%2529-2-methylphenyl%2529-2-%2528S%2529-%25282-hydroxypropan-2-yl%2529-2%252C3%252C4%252C9-tetrahydro-1H-carbazole-8-carboxamide%2520%2528BMS-986142%2529%253A%2520a%2520reversible%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520conformationally%2520constrained%2520by%2520two%2520locked%2520atropisomers%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D9173%26epage%3D9200%26doi%3D10.1021%2Facs.jmedchem.6b01088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit28c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Kawahata, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asami, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiyoi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Irie, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asamitsu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inoue, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyake, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawa, M.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of novel amino-triazine analogues as selective Bruton’s tyrosine kinase inhibitors for treatment of Rheumatoid Arthritis</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">8917</span>– <span class="NLM_lpage">8933</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b01147</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b01147" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref28/cit28c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhslaitLbK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=8917-8933&author=W.+Kawahataauthor=T.+Asamiauthor=T.+Kiyoiauthor=T.+Irieauthor=H.+Taniguchiauthor=Y.+Asamitsuauthor=T.+Inoueauthor=T.+Miyakeauthor=M.+Sawa&title=Design+and+synthesis+of+novel+amino-triazine+analogues+as+selective+Bruton%E2%80%99s+tyrosine+kinase+inhibitors+for+treatment+of+Rheumatoid+Arthritis&doi=10.1021%2Facs.jmedchem.8b01147"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28cR"><div class="casContent"><span class="casTitleNuber">28c</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Novel Amino-triazine Analogues as Selective Bruton's Tyrosine Kinase Inhibitors for Treatment of Rheumatoid Arthritis</span></div><div class="casAuthors">Kawahata, Wataru; Asami, Tokiko; Kiyoi, Takao; Irie, Takayuki; Taniguchi, Haruka; Asamitsu, Yuko; Inoue, Tomoko; Miyake, Takahiro; Sawa, Masaaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8917-8933</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) is a promising drug target for the treatment of multiple diseases, such as B-cell malignances, asthma, and rheumatoid arthritis.  A series of novel aminotriazines were identified as highly selective inhibitors of BTK by a scaffold-hopping approach.  Subsequent SAR studies of this series using two conformationally different BTK proteins, an activated form of BTK and an unactivated form of BTK, led to the discovery of a highly selective BTK inhibitor, I.  With significant efficacy in models in vivo and good ADME and safety profiles, I was advanced into preclin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_BGbFneA5HbVg90H21EOLACvtfcHk0ljZa7MbPEWQWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhslaitLbK&md5=56afc013f74a2912624c57c61a197845</span></div><a href="/servlet/linkout?suffix=cit28c&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b01147&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b01147%26sid%3Dliteratum%253Aachs%26aulast%3DKawahata%26aufirst%3DW.%26aulast%3DAsami%26aufirst%3DT.%26aulast%3DKiyoi%26aufirst%3DT.%26aulast%3DIrie%26aufirst%3DT.%26aulast%3DTaniguchi%26aufirst%3DH.%26aulast%3DAsamitsu%26aufirst%3DY.%26aulast%3DInoue%26aufirst%3DT.%26aulast%3DMiyake%26aufirst%3DT.%26aulast%3DSawa%26aufirst%3DM.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520amino-triazine%2520analogues%2520as%2520selective%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%2520for%2520treatment%2520of%2520Rheumatoid%2520Arthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D8917%26epage%3D8933%26doi%3D10.1021%2Facs.jmedchem.8b01147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuckwell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katsumoto, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Berman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Damjanov, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fedkov, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeka, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span> <span> </span><span class="NLM_article-title">OP0025 Fenebrutinib compared to placebo and adalimumab in patients with inadequate response to either methotrexate therapy or prior TNF therapy: Phase 2 study</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">80</span>– <span class="NLM_lpage">81</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2019-eular.4469</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1136%2Fannrheumdis-2019-eular.4469" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2019&pages=80-81&author=S.+Cohenauthor=K.+Tuckwellauthor=T.+R.+Katsumotoauthor=R.+Zhaoauthor=C.+Leeauthor=A.+Bermanauthor=N.+Damjanovauthor=D.+Fedkovauthor=S.+Jekaauthor=M.+C.+Genovese&title=OP0025+Fenebrutinib+compared+to+placebo+and+adalimumab+in+patients+with+inadequate+response+to+either+methotrexate+therapy+or+prior+TNF+therapy%3A+Phase+2+study&doi=10.1136%2Fannrheumdis-2019-eular.4469"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2019-eular.4469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2019-eular.4469%26sid%3Dliteratum%253Aachs%26aulast%3DCohen%26aufirst%3DS.%26aulast%3DTuckwell%26aufirst%3DK.%26aulast%3DKatsumoto%26aufirst%3DT.%2BR.%26aulast%3DZhao%26aufirst%3DR.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DBerman%26aufirst%3DA.%26aulast%3DDamjanov%26aufirst%3DN.%26aulast%3DFedkov%26aufirst%3DD.%26aulast%3DJeka%26aufirst%3DS.%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26atitle%3DOP0025%2520Fenebrutinib%2520compared%2520to%2520placebo%2520and%2520adalimumab%2520in%2520patients%2520with%2520inadequate%2520response%2520to%2520either%2520methotrexate%2520therapy%2520or%2520prior%2520TNF%2520therapy%253A%2520Phase%25202%2520study%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2019%26volume%3D78%26spage%3D80%26epage%3D81%26doi%3D10.1136%2Fannrheumdis-2019-eular.4469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chinn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Prohn, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huisman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matzuka, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanley, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuckwell, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quartino, A.</span></span> <span> </span><span class="NLM_article-title">Population pharmacokinetics, efficacy exposure-response analysis, and model-based meta-analysis of Fenebrutinib in subjects with Rheumatoid Arthritis</span>. <i>Pharm. Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>37</i></span>,  <span class="NLM_fpage">25</span>, <span class="refDoi"> DOI: 10.1007/s11095-019-2752-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1007%2Fs11095-019-2752-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=31907670" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BB3cXktVSmuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=37&publication_year=2020&pages=25&author=P.+Chanauthor=J.+Yuauthor=L.+Chinnauthor=M.+Prohnauthor=J.+Huismanauthor=B.+Matzukaauthor=W.+Hanleyauthor=K.+Tuckwellauthor=A.+Quartino&title=Population+pharmacokinetics%2C+efficacy+exposure-response+analysis%2C+and+model-based+meta-analysis+of+Fenebrutinib+in+subjects+with+Rheumatoid+Arthritis&doi=10.1007%2Fs11095-019-2752-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30aR"><div class="casContent"><span class="casTitleNuber">30a</span><div class="casTitle"><span class="NLM_cas:atitle">Population Pharmacokinetics, Efficacy Exposure-Response Analysis</span></div><div class="casAuthors">Chan, Phyllis; Yu, Jiajie; Chinn, Leslie; Prohn, Marita; Huisman, Jan; Matzuka, Brett; Hanley, William; Tuckwell, Katie; Quartino, Angelica</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutical Research</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">37</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">25</span>CODEN:
                <span class="NLM_cas:coden">PHREEB</span>;
        ISSN:<span class="NLM_cas:issn">0724-8741</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Fenebrutinib (GDC-0853), a Bruton's tyrosine kinase (BTK) inhibitor was investigated in a Phase 2 clin. trial in patients with rheumatoid arthritis (RA).  Our aim was to apply a model-informed drug development (MIDD) approach to examine the totality of available clin. efficacy data.  Methods: Population pharmacokinetics (popPK) modeling, exposure-response (E-R) anal., and model-based meta-anal. (MBMA) of fenebrutinib were performed based on the Phase 2 data.  Results: PopPK of fenebrutinib after oral administration was described using a 3-compartment model with linear elimination and a flexible absorption transit compartment model.  Healthy subjects had a 52% higher apparent clearance than patients.  E-R analyses based on longitudinal ACR20, ACR50, and ACR70 and DAS28 (CRP) data modeled fenebrutinib effect with an Emax function, and an efficacy plateau was achieved within the exposure range obtained in the Phase 2 clin. trial.  Based on literature data, a summary-level clin. efficacy database was constructed, and MBMA detd. ACR20, ACR50, and ACR70 responder rates in the placebo and adalimumab arms of the Phase 2 clin. trial were found to be consistent with historical data for these treatments.  Conclusions: Our multi-pronged approach applied MIDD to maximize knowledge extn. of efficacy data and enabled robust interpretation from a Phase 2 clin. trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4w0ut42EyLbVg90H21EOLACvtfcHk0ljZa7MbPEWQWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXktVSmuw%253D%253D&md5=9595cdee744a104468d889a049a6dd4a</span></div><a href="/servlet/linkout?suffix=cit30a&amp;dbid=16384&amp;doi=10.1007%2Fs11095-019-2752-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11095-019-2752-y%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DP.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DChinn%26aufirst%3DL.%26aulast%3DProhn%26aufirst%3DM.%26aulast%3DHuisman%26aufirst%3DJ.%26aulast%3DMatzuka%26aufirst%3DB.%26aulast%3DHanley%26aufirst%3DW.%26aulast%3DTuckwell%26aufirst%3DK.%26aulast%3DQuartino%26aufirst%3DA.%26atitle%3DPopulation%2520pharmacokinetics%252C%2520efficacy%2520exposure-response%2520analysis%252C%2520and%2520model-based%2520meta-analysis%2520of%2520Fenebrutinib%2520in%2520subjects%2520with%2520Rheumatoid%2520Arthritis%26jtitle%3DPharm.%2520Res.%26date%3D2020%26volume%3D37%26spage%3D25%26doi%3D10.1007%2Fs11095-019-2752-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit30b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Schafer, P. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kivitz, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korish, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sutherland, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Azaryan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kosek, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capone, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hur, E. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hough, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ringheim, G. E.</span></span> <span> </span><span class="NLM_article-title">Spebrutinib (CC-292) affects markers of B cell activation, chemotaxis, and osteoclasts in patients with Rheumatoid Arthritis: Results from a mechanistic study</span>. <i>Rheumatol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">101</span>– <span class="NLM_lpage">119</span>, <span class="refDoi"> DOI: 10.1007/s40744-019-00182-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1007%2Fs40744-019-00182-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=31721017" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A280%3ADC%252BB3MjosFOmtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2020&pages=101-119&author=P.+H.+Schaferauthor=A.+J.+Kivitzauthor=J.+Maauthor=S.+Korishauthor=D.+Sutherlandauthor=L.+Liauthor=A.+Azaryanauthor=J.+Kosekauthor=M.+Adamsauthor=L.+Caponeauthor=E.+M.+Hurauthor=D.+R.+Houghauthor=G.+E.+Ringheim&title=Spebrutinib+%28CC-292%29+affects+markers+of+B+cell+activation%2C+chemotaxis%2C+and+osteoclasts+in+patients+with+Rheumatoid+Arthritis%3A+Results+from+a+mechanistic+study&doi=10.1007%2Fs40744-019-00182-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30bR"><div class="casContent"><span class="casTitleNuber">30b</span><div class="casTitle"><span class="NLM_cas:atitle">Spebrutinib (CC-292) Affects Markers of B Cell Activation, Chemotaxis, and Osteoclasts in Patients with Rheumatoid Arthritis: Results from a Mechanistic Study</span></div><div class="casAuthors">Schafer Peter H; Kivitz Alan J; Ma Jianglin; Korish Shimon; Sutherland Donna; Li Li; Azaryan Ada; Kosek Jolanta; Adams Mary; Capone Lori; Hur Eun Mi; Hough Douglas R; Ringheim Garth E</div><div class="citationInfo"><span class="NLM_cas:title">Rheumatology and therapy</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">101-119</span>
        ISSN:<span class="NLM_cas:issn">2198-6576</span>.
    </div><div class="casAbstract">INTRODUCTION:  Spebrutinib (CC-292) is an orally administered, covalent, small-molecule inhibitor of Bruton's tyrosine kinase (BTK), part of the B-cell and Fc receptor signaling pathways.  This study evaluated spebrutinib pharmacology and mechanism of action over a 4-week treatment period in patients with active rheumatoid arthritis (RA).  METHODS:  Primary human B cells, T cells, natural killer cells, macrophages, dendritic cells, basophils, and osteoclasts were treated with spebrutinib in vitro.  Clinical pharmacodynamics were studied in 47 patients with active RA on background methotrexate therapy randomized to oral spebrutinib 375 mg/day or placebo.  RESULTS:  In vitro, spebrutinib inhibited B-cell proliferation more potently than T-cell proliferation and reduced both lymphoid and myeloid cytokine production and degranulation, as well as osteoclastogenesis.  Clinical efficacy trended higher in spebrutinib-treated RA patients, with 41.7% (10/24) achieving ≥ 20% improvement in ACR response criteria (ACR20) versus 21.7% (5/23) of placebo patients at week 4 (P = 0.25).  Treatment-emergent adverse events were comparable between treatment groups.  In spebrutinib-treated patients, median BTK occupancy in peripheral blood was 83%, and significant increases in total CD19(+) and mature-naive CD27(-)CD38(-)IgD(+) B cells and decreases in transitional CD27(-)CD38(+) B cells were observed.  Spebrutinib significantly reduced serum chemokines chemokine ligand 13 (CXCL13), macrophage inflammatory protein-1β (MIP-1β), and the bone resorption biomarker carboxy-terminal collagen cross-linking telopeptide (CTX-I) (P < 0.05).  Clinical response to spebrutinib was associated with lower increases in CD19(+) B cells and greater decreases in CXCL13 and MIP-1β from baseline to week 4.  High CD19(+) B cells and low CTX-I at baseline were associated with better spebrutinib clinical response.  CONCLUSIONS:  Spebrutinib inhibited various leukocyte responses in vitro, including those of B cells and osteoclasts.  In this small study in RA patients, spebrutinib was well tolerated, showed a downward trend for symptoms, significantly modulated B-cell populations, and reduced markers of chemotaxis and osteoclast activity.  TRIAL REGISTRATION:  NCT01975610.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR6nFX1j3hnRlVwdslNBF-tfW6udTcc2eZOyc9guG3HV7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MjosFOmtg%253D%253D&md5=25075a1cf6ebb264232fb345ccf77670</span></div><a href="/servlet/linkout?suffix=cit30b&amp;dbid=16384&amp;doi=10.1007%2Fs40744-019-00182-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40744-019-00182-7%26sid%3Dliteratum%253Aachs%26aulast%3DSchafer%26aufirst%3DP.%2BH.%26aulast%3DKivitz%26aufirst%3DA.%2BJ.%26aulast%3DMa%26aufirst%3DJ.%26aulast%3DKorish%26aufirst%3DS.%26aulast%3DSutherland%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DAzaryan%26aufirst%3DA.%26aulast%3DKosek%26aufirst%3DJ.%26aulast%3DAdams%26aufirst%3DM.%26aulast%3DCapone%26aufirst%3DL.%26aulast%3DHur%26aufirst%3DE.%2BM.%26aulast%3DHough%26aufirst%3DD.%2BR.%26aulast%3DRingheim%26aufirst%3DG.%2BE.%26atitle%3DSpebrutinib%2520%2528CC-292%2529%2520affects%2520markers%2520of%2520B%2520cell%2520activation%252C%2520chemotaxis%252C%2520and%2520osteoclasts%2520in%2520patients%2520with%2520Rheumatoid%2520Arthritis%253A%2520Results%2520from%2520a%2520mechanistic%2520study%26jtitle%3DRheumatol.%2520Ther.%26date%3D2020%26volume%3D7%26spage%3D101%26epage%3D119%26doi%3D10.1007%2Fs40744-019-00182-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit30c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Genovese, M. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spindler, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sagawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dudek, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kivitz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barchuk, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nirula, A.</span></span> <span> </span><span class="NLM_article-title">SAT0089 Safety and efficacy of LY3337641, a Bruton’s tyrosine kinase inhibitor in patients with Rheumatoid Arthritis: A randomized, double-blinded, placebo-controlled, 2-part phase 2 study</span>. <i>Ann. Rheum. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>78</i></span>,  <span class="NLM_fpage">1109</span>– <span class="NLM_lpage">1110</span>, <span class="refDoi"> DOI: 10.1136/annrheumdis-2019-eular.2672</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1136%2Fannrheumdis-2019-eular.2672" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=78&publication_year=2019&pages=1109-1110&author=M.+C.+Genoveseauthor=A.+Spindlerauthor=A.+Sagawaauthor=W.+Parkauthor=A.+Dudekauthor=A.+Kivitzauthor=J.+Chaoauthor=L.+Chanauthor=W.+Barchukauthor=A.+Nirula&title=SAT0089+Safety+and+efficacy+of+LY3337641%2C+a+Bruton%E2%80%99s+tyrosine+kinase+inhibitor+in+patients+with+Rheumatoid+Arthritis%3A+A+randomized%2C+double-blinded%2C+placebo-controlled%2C+2-part+phase+2+study&doi=10.1136%2Fannrheumdis-2019-eular.2672"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit30c&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2019-eular.2672&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2019-eular.2672%26sid%3Dliteratum%253Aachs%26aulast%3DGenovese%26aufirst%3DM.%2BC.%26aulast%3DSpindler%26aufirst%3DA.%26aulast%3DSagawa%26aufirst%3DA.%26aulast%3DPark%26aufirst%3DW.%26aulast%3DDudek%26aufirst%3DA.%26aulast%3DKivitz%26aufirst%3DA.%26aulast%3DChao%26aufirst%3DJ.%26aulast%3DChan%26aufirst%3DL.%26aulast%3DBarchuk%26aufirst%3DW.%26aulast%3DNirula%26aufirst%3DA.%26atitle%3DSAT0089%2520Safety%2520and%2520efficacy%2520of%2520LY3337641%252C%2520a%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitor%2520in%2520patients%2520with%2520Rheumatoid%2520Arthritis%253A%2520A%2520randomized%252C%2520double-blinded%252C%2520placebo-controlled%252C%25202-part%2520phase%25202%2520study%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2019%26volume%3D78%26spage%3D1109%26epage%3D1110%26doi%3D10.1136%2Fannrheumdis-2019-eular.2672" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bame, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bohnert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bowden-Verhoek, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cancilla, M. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conlon, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullen, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlanson, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchs-Knotts, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heumann, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marcotte, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertsching, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negrou, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otipoby, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poreci, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanowski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scott, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvian, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, M.</span></span> <span> </span><span class="NLM_article-title">Optimization of novel reversible Bruton’s tyrosine kinase inhibitors identified using tethering-fragment-based screens</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2905</span>– <span class="NLM_lpage">2913</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.05.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1016%2Fj.bmc.2019.05.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=31138459" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhtVersb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=2905-2913&author=B.+T.+Hopkinsauthor=E.+Bameauthor=N.+Bellauthor=T.+Bohnertauthor=J.+K.+Bowden-Verhoekauthor=M.+Buiauthor=M.+T.+Cancillaauthor=P.+Conlonauthor=P.+Cullenauthor=D.+A.+Erlansonauthor=J.+Fanauthor=T.+Fuchs-Knottsauthor=S.+Hansenauthor=S.+Heumannauthor=T.+J.+Jenkinsauthor=D.+Marcotteauthor=B.+McDowellauthor=E.+Mertschingauthor=E.+Negrouauthor=K.+L.+Otipobyauthor=U.+Poreciauthor=M.+J.+Romanowskiauthor=D.+Scottauthor=L.+Silvianauthor=W.+Yangauthor=M.+Zhong&title=Optimization+of+novel+reversible+Bruton%E2%80%99s+tyrosine+kinase+inhibitors+identified+using+tethering-fragment-based+screens&doi=10.1016%2Fj.bmc.2019.05.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screens</span></div><div class="casAuthors">Hopkins, Brian T.; Bame, Eris; Bell, Noah; Bohnert, Tonika; Bowden-Verhoek, Jon K.; Bui, Minna; Cancilla, Mark T.; Conlon, Patrick; Cullen, Patrick; Erlanson, Daniel A.; Fan, Junfa; Fuchs-Knotts, Tarra; Hansen, Stig; Heumann, Stacey; Jenkins, Tracy J.; Marcotte, Douglas; McDowell, Bob; Mertsching, Elisabeth; Negrou, Ella; Otipoby, Kevin L.; Poreci, Urjana; Romanowski, Michael J.; Scott, Daniel; Silvian, Laura; Yang, Wenjin; Zhong, Min</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">2905-2913</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Since the approval of ibrutinib for the treatment of B-cell malignancies in 2012, numerous clin. trials have been reported using covalent inhibitors to target Bruton's tyrosine kinase (BTK) for oncol. indications.  However, a formidable challenge for the pharmaceutical industry has been the identification of reversible, selective, potent mols. for inhibition of BTK.  Herein, we report application of Tethering-fragment-based screens to identify low mol. wt. fragments which were further optimized to improve on-target potency and ADME properties leading to the discovery of reversible, selective, potent BTK inhibitors suitable for pre-clin. proof-of-concept studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpVW3LeOScif7Vg90H21EOLACvtfcHk0lgIPJ0QoXkUJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhtVersb7P&md5=3c5471a75a4b950e417d410f9a542a95</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.05.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.05.021%26sid%3Dliteratum%253Aachs%26aulast%3DHopkins%26aufirst%3DB.%2BT.%26aulast%3DBame%26aufirst%3DE.%26aulast%3DBell%26aufirst%3DN.%26aulast%3DBohnert%26aufirst%3DT.%26aulast%3DBowden-Verhoek%26aufirst%3DJ.%2BK.%26aulast%3DBui%26aufirst%3DM.%26aulast%3DCancilla%26aufirst%3DM.%2BT.%26aulast%3DConlon%26aufirst%3DP.%26aulast%3DCullen%26aufirst%3DP.%26aulast%3DErlanson%26aufirst%3DD.%2BA.%26aulast%3DFan%26aufirst%3DJ.%26aulast%3DFuchs-Knotts%26aufirst%3DT.%26aulast%3DHansen%26aufirst%3DS.%26aulast%3DHeumann%26aufirst%3DS.%26aulast%3DJenkins%26aufirst%3DT.%2BJ.%26aulast%3DMarcotte%26aufirst%3DD.%26aulast%3DMcDowell%26aufirst%3DB.%26aulast%3DMertsching%26aufirst%3DE.%26aulast%3DNegrou%26aufirst%3DE.%26aulast%3DOtipoby%26aufirst%3DK.%2BL.%26aulast%3DPoreci%26aufirst%3DU.%26aulast%3DRomanowski%26aufirst%3DM.%2BJ.%26aulast%3DScott%26aufirst%3DD.%26aulast%3DSilvian%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DW.%26aulast%3DZhong%26aufirst%3DM.%26atitle%3DOptimization%2520of%2520novel%2520reversible%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%2520identified%2520using%2520tethering-fragment-based%2520screens%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D2905%26epage%3D2913%26doi%3D10.1016%2Fj.bmc.2019.05.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gardberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pereira, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenningloh, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haselmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Bujalski, L.</span></span> <span> </span><span class="NLM_article-title">Ability of Bruton’s tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc receptor but not B-cell receptor signaling</span>. <i>Mol. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>91</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">208</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1124/mol.116.107037</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1124%2Fmol.116.107037" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=28062735" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC2sXpsFajtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=91&publication_year=2017&pages=208-219&issue=3&author=A.+T.+Benderauthor=A.+Gardbergauthor=A.+Pereiraauthor=T.+Johnsonauthor=Y.+Wuauthor=R.+Grenninglohauthor=J.+Headauthor=F.+Morandiauthor=P.+Haselmayerauthor=L.+Liu-Bujalski&title=Ability+of+Bruton%E2%80%99s+tyrosine+kinase+inhibitors+to+sequester+Y551+and+prevent+phosphorylation+determines+potency+for+inhibition+of+Fc+receptor+but+not+B-cell+receptor+signaling&doi=10.1124%2Fmol.116.107037"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Ability of Bruton's tyrosine kinase inhibitors to sequester Y551 and prevent phosphorylation determines potency for inhibition of Fc receptor but not B-cell receptor signaling</span></div><div class="casAuthors">Bender, Andrew T.; Gardberg, Anna; Pereira, Albertina; Johnson, Theresa; Wu, Yin; Grenningloh, Roland; Head, Jared; Morandi, Federica; Haselmayer, Philipp; Liu-Bujalski, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Pharmacology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">91</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">208-219</span>CODEN:
                <span class="NLM_cas:coden">MOPMA3</span>;
        ISSN:<span class="NLM_cas:issn">1521-0111</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is expressed in a variety of hematopoietic cells.  Btk has been demonstrated to regulate signaling downstream of the B-cell receptor (BCR), Fc receptors (FcRs), and toll-like receptors.  It has become an attractive drug target because its inhibition may provide significant efficacy by simultaneously blocking multiple disease mechanisms.  Consequently, a large no. of Btk inhibitors have been developed.  These compds. have diverse binding modes, and both reversible and irreversible inhibitors have been developed.  Reported herein, we have tested nine Btk inhibitors and characterized on a mol. level how their interactions with Btk define their ability to block different signaling pathways.  By solving the crystal structures of Btk inhibitors bound to the enzyme, we discovered that the compds. can be classified by their ability to trigger sequestration of Btk residue Y551.  In cells, we found that sequestration of Y551 renders it inaccessible for phosphorylation.  The ability to sequester Y551 was an important determinant of potency against FcγR signaling as Y551 sequestering compds. were more potent for inhibiting basophils and mast cells.  This result was true for the inhibition of FcγR signaling as well.  In contrast, Y551 sequestration was less a factor in detg. potency against BCR signaling.  We also found that Btk activity is regulated differentially in basophils and B cells.  These results elucidate important determinants for Btk inhibitor potency against different signaling pathways and provide insight for designing new compds. with a broader inhibitory profile that will likely result in greater efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrN8F--ON3M7Vg90H21EOLACvtfcHk0lgIPJ0QoXkUJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXpsFajtr8%253D&md5=f869d52d6bc1aabf352988787ff1cbcf</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1124%2Fmol.116.107037&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fmol.116.107037%26sid%3Dliteratum%253Aachs%26aulast%3DBender%26aufirst%3DA.%2BT.%26aulast%3DGardberg%26aufirst%3DA.%26aulast%3DPereira%26aufirst%3DA.%26aulast%3DJohnson%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DGrenningloh%26aufirst%3DR.%26aulast%3DHead%26aufirst%3DJ.%26aulast%3DMorandi%26aufirst%3DF.%26aulast%3DHaselmayer%26aufirst%3DP.%26aulast%3DLiu-Bujalski%26aufirst%3DL.%26atitle%3DAbility%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520inhibitors%2520to%2520sequester%2520Y551%2520and%2520prevent%2520phosphorylation%2520determines%2520potency%2520for%2520inhibition%2520of%2520Fc%2520receptor%2520but%2520not%2520B-cell%2520receptor%2520signaling%26jtitle%3DMol.%2520Pharmacol.%26date%3D2017%26volume%3D91%26issue%3D3%26spage%3D208%26epage%3D219%26doi%3D10.1124%2Fmol.116.107037" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Di
Paolo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balazs, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barck, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bravo, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darrow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DeForge, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diehl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrando, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallion, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giannetti, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gribling, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hurez, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kropf, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, W. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maciejewski, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staker, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whitney, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, K. S.</span></span> <span> </span><span class="NLM_article-title">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">41</span>– <span class="NLM_lpage">50</span>, <span class="refDoi"> DOI: 10.1038/nchembio.481</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1038%2Fnchembio.481" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=21113169" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2011&pages=41-50&author=J.+A.+Di%0APaoloauthor=T.+Huangauthor=M.+Balazsauthor=J.+Barbosaauthor=K.+H.+Barckauthor=B.+J.+Bravoauthor=R.+A.+Caranoauthor=J.+Darrowauthor=D.+R.+Daviesauthor=L.+E.+DeForgeauthor=L.+Diehlauthor=R.+Ferrandoauthor=S.+L.+Gallionauthor=A.+M.+Giannettiauthor=P.+Griblingauthor=V.+Hurezauthor=S.+G.+Hymowitzauthor=R.+Jonesauthor=J.+E.+Kropfauthor=W.+P.+Leeauthor=P.+M.+Maciejewskiauthor=S.+A.+Mitchellauthor=H.+Rongauthor=B.+L.+Stakerauthor=J.+A.+Whitneyauthor=S.+Yehauthor=W.+B.+Youngauthor=C.+Yuauthor=J.+Zhangauthor=K.+Reifauthor=K.+S.+Currie&title=Specific+Btk+inhibition+suppresses+B+cell-+and+myeloid+cell-mediated+arthritis&doi=10.1038%2Fnchembio.481"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis</span></div><div class="casAuthors">Di Paolo, Julie A.; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai H.; Bravo, Brandon J.; Carano, Richard A. D.; Darrow, James; Davies, Douglas R.; DeForge, Laura E.; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven L.; Giannetti, Anthony M.; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah G.; Jones, Randall; Kropf, Jeffrey E.; Lee, Wyne P.; Maciejewski, Patricia M.; Mitchell, Scott A.; Rong, Hong; Staker, Bart L.; Whitney, J. Andrew; Yeh, Sherry; Young, Wendy B.; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">41-50</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (Btk) is a therapeutic target for rheumatoid arthritis, but the cellular and mol. mechanisms by which Btk mediates inflammation are poorly understood.  Here we describe the discovery of CGI1746, a small-mol. Btk inhibitor chemotype with a new binding mode that stabilizes an inactive nonphosphorylated enzyme conformation.  CGI1746 has exquisite selectivity for Btk and inhibits both auto- and transphosphorylation steps necessary for enzyme activation.  Using CGI1746, we demonstrate that Btk regulates inflammatory arthritis by two distinct mechanisms.  CGI1746 blocks B cell receptor-dependent B cell proliferation and in prophylactic regimens reduces autoantibody levels in collagen-induced arthritis.  In macrophages, Btk inhibition abolishes FcγRIII-induced TNFα, IL-1β and IL-6 prodn.  Accordingly, in myeloid- and FcγR-dependent autoantibody-induced arthritis, CGI1746 decreases cytokine levels within joints and ameliorates disease.  These results provide new understanding of the function of Btk in both B cell- or myeloid cell-driven disease processes and provide a compelling rationale for targeting Btk in rheumatoid arthritis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoegiZYoitP57Vg90H21EOLACvtfcHk0liDuejuL1dLIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVOrsLjP&md5=99d925c71bc1b201191ebde0f1c0b50f</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.481&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.481%26sid%3Dliteratum%253Aachs%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%2BA.%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DBalazs%26aufirst%3DM.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DBarck%26aufirst%3DK.%2BH.%26aulast%3DBravo%26aufirst%3DB.%2BJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%26aulast%3DDarrow%26aufirst%3DJ.%26aulast%3DDavies%26aufirst%3DD.%2BR.%26aulast%3DDeForge%26aufirst%3DL.%2BE.%26aulast%3DDiehl%26aufirst%3DL.%26aulast%3DFerrando%26aufirst%3DR.%26aulast%3DGallion%26aufirst%3DS.%2BL.%26aulast%3DGiannetti%26aufirst%3DA.%2BM.%26aulast%3DGribling%26aufirst%3DP.%26aulast%3DHurez%26aufirst%3DV.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DJones%26aufirst%3DR.%26aulast%3DKropf%26aufirst%3DJ.%2BE.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DMaciejewski%26aufirst%3DP.%2BM.%26aulast%3DMitchell%26aufirst%3DS.%2BA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DStaker%26aufirst%3DB.%2BL.%26aulast%3DWhitney%26aufirst%3DJ.%2BA.%26aulast%3DYeh%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DCurrie%26aufirst%3DK.%2BS.%26atitle%3DSpecific%2520Btk%2520inhibition%2520suppresses%2520B%2520cell-%2520and%2520myeloid%2520cell-mediated%2520arthritis%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2011%26volume%3D7%26spage%3D41%26epage%3D50%26doi%3D10.1038%2Fnchembio.481" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Obach, R. S.</span></span> <span> </span><span class="NLM_article-title">Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol</span>. <i>Drug Metab. Dispos.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">1359</span>– <span class="NLM_lpage">1369</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=9394025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADyaK2sXotVymt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=1997&pages=1359-1369&issue=12&author=R.+S.+Obach&title=Nonspecific+binding+to+microsomes%3A+impact+on+scale-up+of+in+vitro+intrinsic+clearance+to+hepatic+clearance+as+assessed+through+examination+of+warfarin%2C+imipramine%2C+and+propranolol"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34aR"><div class="casContent"><span class="casTitleNuber">34a</span><div class="casTitle"><span class="NLM_cas:atitle">Nonspecific binding to microsomes: impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine, and propranolol</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1359-1369</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">Williams & Wilkins</span>)
        </div><div class="casAbstract">The nonspecific, noncovalent binding of three drugs, imipramine, warfarin, and propranolol, to pooled human and animal liver microsomes has been detd. using equil. dialysis in conditions where no cofactor (NADPH) was included in the incubation.  The binding of warfarin was dependent upon both protein and drug concn., whereas the binding of propranolol and imipramine was also dependent upon protein concn. but generally independent of drug concn.  At a microsomal protein concn. of 1.0 mg/mL and a warfarin concn. of 10 μM, the free fraction (fu(mic)) was 0.85.  The corresponding values for propranolol and imipramine were 0.41 and 0.16, resp.  Thus, although all three drugs exhibit high binding in plasma (fu <0.1) the acidic drug warfarin differs from the basic drugs propranolol and imipramine in the extent to which each binds to microsomal protein.  The binding of all three drugs to liver microsomes obtained from commonly studied animal species (rat, dog, and monkey) was almost identical to that obsd. in human.  Addnl., the binding of warfarin and propranolol to microsomes obtained from insect cells used in baculovirus cytochrome P 450 expression systems was similar to that exhibited in liver microsomes, when equal protein concns. were compared.  The enzyme kinetics of propranolol, imipramine; and warfarin oxidative metab. were detd. in pooled human liver microsomes, and the intrinsic clearance values obtained were used in scaling up to project human in vivo clearance.  The values obtained by incorporating microsomal binding were compared with those in which this factor is ignored.  The findings suggest that the parameter fu(mic) is important to obtain when attempting to relate in vitro intrinsic clearance to in vivo clearance.  Also, this value is important to consider when comparing substrates with respect to enzyme specificity, since measured apparent KM values should be converted to true "free KM" values by correcting for the free fraction in the in vitro incubation.  Furthermore, the extent of nonspecific binding to microsomes is likely an important parameter to consider when attempting to relate Ki values measured in vitro to observations of drug-drug interactions (or the lack thereof) in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTI5meSXnqbrVg90H21EOLACvtfcHk0liDuejuL1dLIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXotVymt74%253D&md5=b8c792b5c477d7eb653c2d0f9ef77e49</span></div><a href="/servlet/linkout?suffix=cit34a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DNonspecific%2520binding%2520to%2520microsomes%253A%2520impact%2520on%2520scale-up%2520of%2520in%2520vitro%2520intrinsic%2520clearance%2520to%2520hepatic%2520clearance%2520as%2520assessed%2520through%2520examination%2520of%2520warfarin%252C%2520imipramine%252C%2520and%2520propranolol%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1997%26volume%3D25%26issue%3D12%26spage%3D1359%26epage%3D1369" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit34b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, H.</span></span> <span> </span><span class="NLM_article-title">Interpretation of non-clinical data for prediction of human pharmacokinetic parameters: in vitro-in vivo extrapolation and allometric scaling</span>. <i>Pharmaceutics</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">168</span>, <span class="refDoi"> DOI: 10.3390/pharmaceutics11040168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.3390%2Fpharmaceutics11040168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVSrtbzK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2019&pages=168&author=G.+Choiauthor=Y.+Leeauthor=H.+Cho&title=Interpretation+of+non-clinical+data+for+prediction+of+human+pharmacokinetic+parameters%3A+in+vitro-in+vivo+extrapolation+and+allometric+scaling&doi=10.3390%2Fpharmaceutics11040168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34bR"><div class="casContent"><span class="casTitleNuber">34b</span><div class="casTitle"><span class="NLM_cas:atitle">Interpretation of non-clinical data for prediction of human pharmacokinetic parameters: in vitro-in vivo extrapolation and allometric scaling</span></div><div class="casAuthors">Choi, Go-Wun; Lee, Yong-Bok; Cho, Hea-Young</div><div class="citationInfo"><span class="NLM_cas:title">Pharmaceutics</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">168</span>CODEN:
                <span class="NLM_cas:coden">PHARK5</span>;
        ISSN:<span class="NLM_cas:issn">1999-4923</span>.
    
            (<span class="NLM_cas:orgname">MDPI AG</span>)
        </div><div class="casAbstract">Extrapolation of pharmacokinetic (PK) parameters from in vitro or in vivo animal to human is one of the main tasks in the drug development process.  Translational approaches provide evidence for go or no-go decision-making during drug discovery and the development process, and the prediction of human PKs prior to the first-in-human clin. trials.  In vitro-in vivo extrapolation and allometric scaling are the choice of method for projection to human situations.  Although these methods are useful tools for the estn. of PK parameters, it is a challenge to apply these methods since underlying biochem., math., physiol., and background knowledge of PKs are required.  In addn., it is difficult to select an appropriate methodol. depending on the data available.  Therefore, this review covers the principles of PK parameters pertaining to the clearance, vol. of distribution, elimination half-life, absorption rate const., and prediction method from the original idea to recently developed models in order to introduce optimal models for the prediction of PK parameters.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7QdeHYCk3oLVg90H21EOLACvtfcHk0lgGm2QVfx4H8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVSrtbzK&md5=9757266a6e6cda7cdcb4a2add87f2007</span></div><a href="/servlet/linkout?suffix=cit34b&amp;dbid=16384&amp;doi=10.3390%2Fpharmaceutics11040168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fpharmaceutics11040168%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DG.%26aulast%3DLee%26aufirst%3DY.%26aulast%3DCho%26aufirst%3DH.%26atitle%3DInterpretation%2520of%2520non-clinical%2520data%2520for%2520prediction%2520of%2520human%2520pharmacokinetic%2520parameters%253A%2520in%2520vitro-in%2520vivo%2520extrapolation%2520and%2520allometric%2520scaling%26jtitle%3DPharmaceutics%26date%3D2019%26volume%3D11%26spage%3D168%26doi%3D10.3390%2Fpharmaceutics11040168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Copeland, R. A.</span></span> <i>Evaluation of Enzyme Inhibitors in Drug Discovery</i>; <span class="NLM_publisher-name">John Wiley & Sons, Inc.</span>: <span class="NLM_publisher-loc">Hoboken, NJ</span>, <span class="NLM_year">2005</span>; pp  <span class="NLM_fpage">141</span>– <span class="NLM_lpage">177</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2005&pages=141-177&author=R.+A.+Copeland&title=Evaluation+of+Enzyme+Inhibitors+in+Drug+Discovery"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DCopeland%26aufirst%3DR.%2BA.%26btitle%3DEvaluation%2520of%2520Enzyme%2520Inhibitors%2520in%2520Drug%2520Discovery%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26date%3D2005%26spage%3D141%26epage%3D177" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Berg, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Polokoff, M. A.</span></span> <span> </span><span class="NLM_article-title">Building predictive models for mechanism-of-action classification from phenotypic assay data sets</span>. <i>J. Biomol. Screening</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">1260</span>– <span class="NLM_lpage">1269</span>, <span class="refDoi"> DOI: 10.1177/1087057113505324</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1177%2F1087057113505324" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=24088371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhslWjsLvP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2013&pages=1260-1269&author=E.+L.+Bergauthor=J.+Yangauthor=M.+A.+Polokoff&title=Building+predictive+models+for+mechanism-of-action+classification+from+phenotypic+assay+data+sets&doi=10.1177%2F1087057113505324"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Building predictive models for mechanism-of-action classification from phenotypic assay data sets</span></div><div class="casAuthors">Berg, Ellen L.; Yang, Jian; Polokoff, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Screening</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1260-1269, 10 pp.</span>CODEN:
                <span class="NLM_cas:coden">JBISF3</span>;
        ISSN:<span class="NLM_cas:issn">1087-0571</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Compd. mechanism-of-action information can be crit. for drug development decisions but is often challenging for phenotypic drug discovery programs.  One concern is that compds. selected by phenotypic screening will have a previously known but undesirable target mechanism.  Here we describe a useful method for assigning mechanism class to compds. and bioactive agents using an 84-feature signature from a panel of primary human cell systems (BioMAP systems).  For this approach, a ref. data set of well-characterized compds. was used to develop predictive models for 28 mechanism classes using support vector machines.  These mechanism classes encompass safety and efficacy-related mechanisms, include both target-specific and pathway-based classes, and cover the most common mechanisms identified in phenotypic screens, such as inhibitors of mitochondrial and microtubule function, histone deacetylase, and cAMP elevators.  Here we describe the performance and the application of these predictive models in a decision scheme for triaging phenotypic screening hits using a previously published data set of 309 environmental chems. tested as part of the Environmental Protection Agency's ToxCast program.  By providing quantified membership in specific mechanism classes, this approach is suitable for identification of off-target toxicity mechanisms as well as enabling target deconvolution of phenotypic drug discovery hits.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqSbGfCpuChA7Vg90H21EOLACvtfcHk0lgGm2QVfx4H8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhslWjsLvP&md5=1177a3a1dbae60621bbc2249f0e8e0ac</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1177%2F1087057113505324&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F1087057113505324%26sid%3Dliteratum%253Aachs%26aulast%3DBerg%26aufirst%3DE.%2BL.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DPolokoff%26aufirst%3DM.%2BA.%26atitle%3DBuilding%2520predictive%2520models%2520for%2520mechanism-of-action%2520classification%2520from%2520phenotypic%2520assay%2520data%2520sets%26jtitle%3DJ.%2520Biomol.%2520Screening%26date%3D2013%26volume%3D18%26spage%3D1260%26epage%3D1269%26doi%3D10.1177%2F1087057113505324" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Haselmayer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Camps, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu-Bujalski, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morandi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Head, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Mahony, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerli, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bruns, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schroeder, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grenningloh, R.</span></span> <span> </span><span class="NLM_article-title">Efficacy and pharmacodynamic modeling of the BTK inhibitor Evobrutinib in autoimmune disease models</span>. <i>J. Immunol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>202</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">2888</span>– <span class="NLM_lpage">2906</span>, <span class="refDoi"> DOI: 10.4049/jimmunol.1800583</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.4049%2Fjimmunol.1800583" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=30988116" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1MXpvF2ntLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=202&publication_year=2019&pages=2888-2906&issue=10&author=P.+Haselmayerauthor=M.+Campsauthor=L.+Liu-Bujalskiauthor=N.+Nguyenauthor=F.+Morandiauthor=J.+Headauthor=A.+O%E2%80%99Mahonyauthor=S.+C.+Zimmerliauthor=L.+Brunsauthor=A.+T.+Benderauthor=P.+Schroederauthor=R.+Grenningloh&title=Efficacy+and+pharmacodynamic+modeling+of+the+BTK+inhibitor+Evobrutinib+in+autoimmune+disease+models&doi=10.4049%2Fjimmunol.1800583"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy and pharmacodynamic modeling of the BTK inhibitor evobrutinib in autoimmune disease models</span></div><div class="casAuthors">Haselmayer, Philipp; Camps, Montserrat; Liu-Bujalski, Lesley; Nguyen, Ngan; Morandi, Federica; Head, Jared; O'Mahony, Alison; Zimmerli, Simone C.; Bruns, Lisa; Bender, Andrew T.; Schroeder, Patricia; Grenningloh, Roland</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Immunology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">202</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2888-2906</span>CODEN:
                <span class="NLM_cas:coden">JOIMA3</span>;
        ISSN:<span class="NLM_cas:issn">0022-1767</span>.
    
            (<span class="NLM_cas:orgname">American Association of Immunologists</span>)
        </div><div class="casAbstract">Because of its role in mediating both B cell and Fc receptor signaling, Bruton's tyrosine kinase (BTK) is a promising target for the treatment of autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).  Evobrutinib is a novel, highly selective, irreversible BTK inhibitor that potently inhibits BCR- and Fc receptor-mediated signaling and, thus, subsequent activation and function of human B cells and innate immune cells such as monocytes and basophils.  We evaluated evobrutinib in preclin. models of RA and SLE and characterized the relationship between BTK occupancy and inhibition of disease activity.  In mouse models of RA and SLE, orally administered evobrutinib displayed robust efficacy, as demonstrated by redn. of disease severity and histol. damage.  In the SLE model, evobrutinib inhibited B cell activation, reduced autoantibody prodn. and plasma cell nos., and normalized B and T cell subsets.  In the RA model, efficacy was achieved despite failure to reduce autoantibodies.  Pharmacokinetic/pharmacodynamic modeling showed that mean BTK occupancy in blood cells of 80% was linked to near-complete disease inhibition in both RA and SLE mouse models.  In addn., evobrutinib inhibited mast cell activation in a passive cutaneous anaphylaxis model.  Thus, evobrutinib achieves efficacy by acting both on B cells and innate immune cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLVxS4palhvbVg90H21EOLACvtfcHk0lgGm2QVfx4H8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXpvF2ntLg%253D&md5=9a339003f40e52527127ac12a2593ae9</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.4049%2Fjimmunol.1800583&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4049%252Fjimmunol.1800583%26sid%3Dliteratum%253Aachs%26aulast%3DHaselmayer%26aufirst%3DP.%26aulast%3DCamps%26aufirst%3DM.%26aulast%3DLiu-Bujalski%26aufirst%3DL.%26aulast%3DNguyen%26aufirst%3DN.%26aulast%3DMorandi%26aufirst%3DF.%26aulast%3DHead%26aufirst%3DJ.%26aulast%3DO%25E2%2580%2599Mahony%26aufirst%3DA.%26aulast%3DZimmerli%26aufirst%3DS.%2BC.%26aulast%3DBruns%26aufirst%3DL.%26aulast%3DBender%26aufirst%3DA.%2BT.%26aulast%3DSchroeder%26aufirst%3DP.%26aulast%3DGrenningloh%26aufirst%3DR.%26atitle%3DEfficacy%2520and%2520pharmacodynamic%2520modeling%2520of%2520the%2520BTK%2520inhibitor%2520Evobrutinib%2520in%2520autoimmune%2520disease%2520models%26jtitle%3DJ.%2520Immunol.%26date%3D2019%26volume%3D202%26issue%3D10%26spage%3D2888%26epage%3D2906%26doi%3D10.4049%2Fjimmunol.1800583" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Miyaura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, A.</span></span> <span> </span><span class="NLM_article-title">Palladium-catalyzed cross-coupling reactions of organoboron compounds</span>. <i>Chem. Rev.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>95</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">2457</span>– <span class="NLM_lpage">2483</span>, <span class="refDoi"> DOI: 10.1021/cr00039a007</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cr00039a007" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1995&pages=2457-2483&issue=7&author=N.+Miyauraauthor=A.+Suzuki&title=Palladium-catalyzed+cross-coupling+reactions+of+organoboron+compounds&doi=10.1021%2Fcr00039a007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Palladium-Catalyzed Cross-Coupling Reactions of Organoboron Compounds</span></div><div class="casAuthors">Miyaura, Norio; Suzuki, Akira</div><div class="citationInfo"><span class="NLM_cas:title">Chemical Reviews (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2457-83</span>CODEN:
                <span class="NLM_cas:coden">CHREAY</span>;
        ISSN:<span class="NLM_cas:issn">0009-2665</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review with >250 refs. including title reactions and their mechanisms, prepn. of organoboron reagents, alkoxycarbonylation and dimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHwupBJT1UCbVg90H21EOLACvtfcHk0lgGm2QVfx4H8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXoslGiurg%253D&md5=d127b414a75161652876eebc3ed0c486</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1021%2Fcr00039a007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcr00039a007%26sid%3Dliteratum%253Aachs%26aulast%3DMiyaura%26aufirst%3DN.%26aulast%3DSuzuki%26aufirst%3DA.%26atitle%3DPalladium-catalyzed%2520cross-coupling%2520reactions%2520of%2520organoboron%2520compounds%26jtitle%3DChem.%2520Rev.%26date%3D1995%26volume%3D95%26issue%3D7%26spage%3D2457%26epage%3D2483%26doi%3D10.1021%2Fcr00039a007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Anderson, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tundel, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buchwald, S. L.</span></span> <span> </span><span class="NLM_article-title">Monodentate phosphines provide highly active catalysts for Pd-catalyzed CN bond-forming reactions of heteroaromatic halides/amines and (H)N-heterocycles</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>45</i></span> (<span class="NLM_issue">39</span>),  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6527</span>, <span class="refDoi"> DOI: 10.1002/anie.200601612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1002%2Fanie.200601612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtFWgsrnP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2006&pages=6523-6527&issue=39&author=K.+W.+Andersonauthor=R.+E.+Tundelauthor=T.+Ikawaauthor=R.+A.+Altmanauthor=S.+L.+Buchwald&title=Monodentate+phosphines+provide+highly+active+catalysts+for+Pd-catalyzed+CN+bond-forming+reactions+of+heteroaromatic+halides%2Famines+and+%28H%29N-heterocycles&doi=10.1002%2Fanie.200601612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Monodentate phosphines provide highly active catalysts for Pd-catalyzed C-N bond-forming reactions of heteroaromatic halides/amines and (H)N-heterocycles</span></div><div class="casAuthors">Anderson, Kevin W.; Tundel, Rachel E.; Ikawa, Takashi; Altman, Ryan A.; Buchwald, Stephen L.</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">39</span>),
    <span class="NLM_cas:pages">6523-6527</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Highly reactive catalysts based on palladium and dialkylbiarylphosphino ligands provide unprecedented reactivity and selectivity in C-N bond-forming processes.  The bulky monophosphine catalyst system Pd2(dba)3/I is effective for the reaction of aryl/heteroaryl halides bearing primary amides and 2-aminoheterocycles, thus showing that monodentate phosphines are viable alternatives to, and sometimes superior to, chelating ligands.  E.g., amination of 3-chlorobenzamide by morpholine gave 81% II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwitHXua7pPbVg90H21EOLACvtfcHk0lj5cadonm4xVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtFWgsrnP&md5=5958e76b262517af3527cea57573210a</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1002%2Fanie.200601612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.200601612%26sid%3Dliteratum%253Aachs%26aulast%3DAnderson%26aufirst%3DK.%2BW.%26aulast%3DTundel%26aufirst%3DR.%2BE.%26aulast%3DIkawa%26aufirst%3DT.%26aulast%3DAltman%26aufirst%3DR.%2BA.%26aulast%3DBuchwald%26aufirst%3DS.%2BL.%26atitle%3DMonodentate%2520phosphines%2520provide%2520highly%2520active%2520catalysts%2520for%2520Pd-catalyzed%2520CN%2520bond-forming%2520reactions%2520of%2520heteroaromatic%2520halides%252Famines%2520and%2520%2528H%2529N-heterocycles%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2006%26volume%3D45%26issue%3D39%26spage%3D6523%26epage%3D6527%26doi%3D10.1002%2Fanie.200601612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Khan, W. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alt, F. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerstein, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malynn, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larsson, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rathbun, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davidson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muller, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kantor, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herzenberg, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosen, F. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideras, P.</span></span> <span> </span><span class="NLM_article-title">Defective B cell development and function in Btk-deficient mice</span>. <i>Immunity</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">283</span>– <span class="NLM_lpage">299</span>, <span class="refDoi"> DOI: 10.1016/1074-7613(95)90114-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1016%2F1074-7613%2895%2990114-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=7552994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADyaK2MXosVygu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=1995&pages=283-299&author=W.+N.+Khanauthor=F.+W.+Altauthor=R.+M.+Gersteinauthor=B.+A.+Malynnauthor=I.+Larssonauthor=G.+Rathbunauthor=L.+Davidsonauthor=S.+Mullerauthor=A.+B.+Kantorauthor=L.+A.+Herzenbergauthor=F.+S.+Rosenauthor=P.+Sideras&title=Defective+B+cell+development+and+function+in+Btk-deficient+mice&doi=10.1016%2F1074-7613%2895%2990114-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40aR"><div class="casContent"><span class="casTitleNuber">40a</span><div class="casTitle"><span class="NLM_cas:atitle">Defective B cell development and function in Btk-deficient mice</span></div><div class="casAuthors">Khan, Wasif N.; Alt, Frederick W.; Gerstein, Rachel M.; Malynn, Barbara A.; Larsson, Irene; Rathbun, Gary; Davidson, Laurie; Mueller, Sussane; Kantor, Aaron B.; et al.</div><div class="citationInfo"><span class="NLM_cas:title">Immunity</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">283-99</span>CODEN:
                <span class="NLM_cas:coden">IUNIEH</span>;
        ISSN:<span class="NLM_cas:issn">1074-7613</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the Bruton's tyrosine kinase (Btk) gene have been linked to severe early B cell developmental blocks in human X-linked agammaglobulinemia (XLA), and to milder B cell activation deficiencies in murine X-linked immune deficiency (Xid).  To elucidate unequivocally potential Btk functions in mice, we generated mutations in embryonic stem cells, which eliminated the ability to encode Btk pleckstrin homol. or kinase domains, and assayed their effects by RAG2-deficient blastocyst complementation of introduction into the germline.  Both mutations block expression of Btk protein and lead to reduced nos. of mature conventional B cells, severe B1 cell deficiency, serum IgM and IgG3 deficiency, and defective responses in vitro to various B cell activators and in vivo by immunization with thymus-independent type II antigens.  These results prove that lack of Btk function results in an Xid phenotype and further suggest a differential requirement for Btκ during the early stages of murine vs. human B lymphocyte development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5A-ze-ib1c7Vg90H21EOLACvtfcHk0lj5cadonm4xVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXosVygu7o%253D&md5=fdae8fd170f35068b44a0475568c3d95</span></div><a href="/servlet/linkout?suffix=cit40a&amp;dbid=16384&amp;doi=10.1016%2F1074-7613%2895%2990114-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F1074-7613%252895%252990114-0%26sid%3Dliteratum%253Aachs%26aulast%3DKhan%26aufirst%3DW.%2BN.%26aulast%3DAlt%26aufirst%3DF.%2BW.%26aulast%3DGerstein%26aufirst%3DR.%2BM.%26aulast%3DMalynn%26aufirst%3DB.%2BA.%26aulast%3DLarsson%26aufirst%3DI.%26aulast%3DRathbun%26aufirst%3DG.%26aulast%3DDavidson%26aufirst%3DL.%26aulast%3DMuller%26aufirst%3DS.%26aulast%3DKantor%26aufirst%3DA.%2BB.%26aulast%3DHerzenberg%26aufirst%3DL.%2BA.%26aulast%3DRosen%26aufirst%3DF.%2BS.%26aulast%3DSideras%26aufirst%3DP.%26atitle%3DDefective%2520B%2520cell%2520development%2520and%2520function%2520in%2520Btk-deficient%2520mice%26jtitle%3DImmunity%26date%3D1995%26volume%3D3%26spage%3D283%26epage%3D299%26doi%3D10.1016%2F1074-7613%2895%2990114-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit40b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Goess, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murdock, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sampson, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Twomey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mathieu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mario, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goedken, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, A. J.</span></span> <span> </span><span class="NLM_article-title">ABBV-105, a selective and irreversible inhibitor of Bruton’s tyrosine kinase, is efficacious in multiple preclinical models of inflammation</span>. <i>Mod. Rheumatol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">510</span>– <span class="NLM_lpage">522</span>, <span class="refDoi"> DOI: 10.1080/14397595.2018.1484269</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1080%2F14397595.2018.1484269" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=29862859" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVSmsr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=510-522&author=C.+Goessauthor=C.+M.+Harrisauthor=S.+Murdockauthor=R.+W.+McCarthyauthor=E.+Sampsonauthor=R.+Twomeyauthor=S.+Mathieuauthor=R.+Marioauthor=M.+Perhamauthor=E.+R.+Goedkenauthor=A.+J.+Long&title=ABBV-105%2C+a+selective+and+irreversible+inhibitor+of+Bruton%E2%80%99s+tyrosine+kinase%2C+is+efficacious+in+multiple+preclinical+models+of+inflammation&doi=10.1080%2F14397595.2018.1484269"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40bR"><div class="casContent"><span class="casTitleNuber">40b</span><div class="casTitle"><span class="NLM_cas:atitle">ABBV-105, a selective and irreversible inhibitor of Bruton's tyrosine kinase, is efficacious in multiple preclinical models of inflammation</span></div><div class="casAuthors">Goess, Christian; Harris, Christopher M.; Murdock, Sara; McCarthy, Richard W.; Sampson, Erik; Twomey, Rachel; Mathieu, Suzanne; Mario, Regina; Perham, Matthew; Goedken, Eric R.; Long, Andrew J.</div><div class="citationInfo"><span class="NLM_cas:title">Modern Rheumatology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">510-522</span>CODEN:
                <span class="NLM_cas:coden">MROHA4</span>;
        ISSN:<span class="NLM_cas:issn">1439-7595</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) is a non-receptor tyrosine kinase required for intracellular signaling downstream of multiple immunoreceptors.  We evaluated ABBV-105, a covalent BTK inhibitor, using in vitro and in vivo assays to det. potency, selectivity, and efficacy to validate the therapeutic potential of ABBV-105 in inflammatory disease.  ABBV-105 potency and selectivity were evaluated in enzymic and cellular assays.  The impact of ABBV-105 on B cell function in vivo was assessed using mechanistic models of antibody prodn.  Efficacy of ABBV-105 in chronic inflammatory disease was evaluated in animal models of arthritis and lupus.  Measurement of BTK occupancy was employed as a target engagement biomarker.  ABBV-105 irreversibly inhibits BTK, demonstrating superior kinome selectivity and is potent in B cell receptor, Fc receptor, and TLR-9-dependent cellular assays.  Oral administration resulted in rapid clearance in plasma, but maintenance of BTK splenic occupancy.  ABBV-105 inhibited antibody responses to thymus-independent and thymus-dependent antigens, paw swelling and bone destruction in rat collagen induced arthritis, and reduced disease in an IFNα-accelerated lupus nephritis model.  BTK occupancy in disease models correlated with in vivo efficacy.  ABBV-105, a selective BTK inhibitor, demonstrates compelling efficacy in pre-clin. mechanistic models of antibody prodn. and in models of rheumatoid arthritis and lupus.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRiXhHbdCpgbVg90H21EOLACvtfcHk0lj5cadonm4xVw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVSmsr%252FP&md5=27a6e678e069976360dc9f2893c39c61</span></div><a href="/servlet/linkout?suffix=cit40b&amp;dbid=16384&amp;doi=10.1080%2F14397595.2018.1484269&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F14397595.2018.1484269%26sid%3Dliteratum%253Aachs%26aulast%3DGoess%26aufirst%3DC.%26aulast%3DHarris%26aufirst%3DC.%2BM.%26aulast%3DMurdock%26aufirst%3DS.%26aulast%3DMcCarthy%26aufirst%3DR.%2BW.%26aulast%3DSampson%26aufirst%3DE.%26aulast%3DTwomey%26aufirst%3DR.%26aulast%3DMathieu%26aufirst%3DS.%26aulast%3DMario%26aufirst%3DR.%26aulast%3DPerham%26aufirst%3DM.%26aulast%3DGoedken%26aufirst%3DE.%2BR.%26aulast%3DLong%26aufirst%3DA.%2BJ.%26atitle%3DABBV-105%252C%2520a%2520selective%2520and%2520irreversible%2520inhibitor%2520of%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%252C%2520is%2520efficacious%2520in%2520multiple%2520preclinical%2520models%2520of%2520inflammation%26jtitle%3DMod.%2520Rheumatol.%26date%3D2019%26volume%3D29%26spage%3D510%26epage%3D522%26doi%3D10.1080%2F14397595.2018.1484269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Drabek, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raguz, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Wit, T. P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dingjan, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Savelkoul, H. F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosveld, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hendriks, R. W.</span></span> <span> </span><span class="NLM_article-title">Correction of the X-linked immunodeficiency phenotype by transgenic expression of human Bruton tyrosine kinase under the control of the class II major histocompatibility complex Ea locus control region</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>94</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">610</span>– <span class="NLM_lpage">615</span>, <span class="refDoi"> DOI: 10.1073/pnas.94.2.610</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1073%2Fpnas.94.2.610" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=9012832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADyaK2sXnslOktQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=94&publication_year=1997&pages=610-615&issue=2&author=D.+Drabekauthor=S.+Raguzauthor=T.+P.+M.+De+Witauthor=G.+M.+Dingjanauthor=H.+F.+J.+Savelkoulauthor=F.+Grosveldauthor=R.+W.+Hendriks&title=Correction+of+the+X-linked+immunodeficiency+phenotype+by+transgenic+expression+of+human+Bruton+tyrosine+kinase+under+the+control+of+the+class+II+major+histocompatibility+complex+Ea+locus+control+region&doi=10.1073%2Fpnas.94.2.610"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Correction of the X-linked immunodeficiency phenotype by transgenic expression of human Bruton tyrosine kinase under the control of the class II major histocompatibility complex Ea locus control region</span></div><div class="casAuthors">Drabek, Dubravka; Raguz, Selina; De Wit, Ton P. M.; Dingjan, Gemma M.; Savelkoul, Huub F.; Grosveld, Frank; Hendriks, Rudolf W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">94</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">610-615</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Bruton tyrosine kinase (Btk) is essential for the development of pre-B cells to mature B cell stages.  Btk-deficient mice manifest an X-linked immunodeficiency (xid) defect characterized by a redn. of peripheral IgMlow IgDhigh B cells, a lack of peritoneal CD5+ B cells, low serum levels of IgM and IgG3, and impaired responses to T cell independent type Ii (TI-II) antigens.  We have generated transgenic mice in which expression of the human Btk genes is driven by the murine class II major histocompatibility complex Ea gene locus control region, which provides gene expression from the pre-B cell stage onwards.  When these transgenic mice were mated onto a Btk- background, correction of the xid B cell defects was obsd.: B cells differentiated to mature IgMlowIgDhigh stages, peritoneal CD5+ B cells were present, and serum Ig levels and in vivo responses to TI-II antigens were in the normal ranges.  A comparable rescue by transgenic Btk expression was also obsd. in heterozygous Btk+/- female mice in those B-lineage cells that were Btk-deficient as a result of X chromosome inactivation.  These findings indicate that the Btk- phenotype in the mouse can be cor. by expression of human Btk from the pre-B cell stage onwards.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGocQdhQ4ERPwbVg90H21EOLACvtfcHk0ljoMbozBNcHiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnslOktQ%253D%253D&md5=2f4e1543f97a6f72198ed8eb31cbced5</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1073%2Fpnas.94.2.610&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.94.2.610%26sid%3Dliteratum%253Aachs%26aulast%3DDrabek%26aufirst%3DD.%26aulast%3DRaguz%26aufirst%3DS.%26aulast%3DDe%2BWit%26aufirst%3DT.%2BP.%2BM.%26aulast%3DDingjan%26aufirst%3DG.%2BM.%26aulast%3DSavelkoul%26aufirst%3DH.%2BF.%2BJ.%26aulast%3DGrosveld%26aufirst%3DF.%26aulast%3DHendriks%26aufirst%3DR.%2BW.%26atitle%3DCorrection%2520of%2520the%2520X-linked%2520immunodeficiency%2520phenotype%2520by%2520transgenic%2520expression%2520of%2520human%2520Bruton%2520tyrosine%2520kinase%2520under%2520the%2520control%2520of%2520the%2520class%2520II%2520major%2520histocompatibility%2520complex%2520Ea%2520locus%2520control%2520region%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1997%26volume%3D94%26issue%3D2%26spage%3D610%26epage%3D615%26doi%3D10.1073%2Fpnas.94.2.610" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, K.</span></span> <i>Janeway’s Immunobiology</i>; <span class="NLM_edition">8</span>th ed.; <span class="NLM_publisher-name">Garland Science</span>: <span class="NLM_publisher-loc">London</span>, <span class="NLM_year">2012</span>; xix, 868 s.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2012&author=K.+Murphy&title=Janeway%E2%80%99s+Immunobiology"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DK.%26btitle%3DJaneway%25E2%2580%2599s%2520Immunobiology%26pub%3DGarland%2520Science%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43a"><span><span class="NLM_label">(a) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Brenneman, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaiah, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rohde, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Messing, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Neil, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gauthier, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, Z. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mantena, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shevlin, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leonard, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sokolowski, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carraher, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jesson, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomlinson, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bobrowski, W. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bailey, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vogel, W. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morris, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteley, L. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. W.,  II</span></span> <span> </span><span class="NLM_article-title">Mechanistic investigations of test article–induced pancreatic toxicity at the endocrine–exocrine interface in the rat</span>. <i>Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">229</span>– <span class="NLM_lpage">242</span>, <span class="refDoi"> DOI: 10.1177/0192623313508851</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1177%2F0192623313508851" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=24226507" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43a&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1OmsrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2014&pages=229-242&author=K.+A.+Brennemanauthor=S.+K.+Ramaiahauthor=C.+M.+Rohdeauthor=D.+M.+Messingauthor=S.+P.+O%E2%80%99Neilauthor=L.+M.+Gauthierauthor=Z.+S.+Stewartauthor=S.+R.+Mantenaauthor=K.+M.+Shevlinauthor=C.+G.+Leonardauthor=S.+A.+Sokolowskiauthor=H.+Linauthor=D.+C.+Carraherauthor=M.+I.+Jessonauthor=L.+Tomlinsonauthor=Y.+Zhanauthor=W.+F.+Bobrowskiauthor=S.+A.+Baileyauthor=W.+M.+Vogelauthor=D.+L.+Morrisauthor=L.+O.+Whiteleyauthor=J.+W.+Davis&title=Mechanistic+investigations+of+test+article%E2%80%93induced+pancreatic+toxicity+at+the+endocrine%E2%80%93exocrine+interface+in+the+rat&doi=10.1177%2F0192623313508851"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43aR"><div class="casContent"><span class="casTitleNuber">43a</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanistic investigations of test article-induced pancreatic toxicity at the endocrine-exocrine interface in the rat</span></div><div class="casAuthors">Brenneman, Karrie A.; Ramaiah, Shashi K.; Rohde, Cynthia M.; Messing, Dean M.; O'neil, Shawn P.; Gauthier, Lauren M.; Stewart, Zachary S.; Mantena, Srinivasa R.; Shevlin, Kimberly M.; Leonard, Christopher G.; Sokolowski, Sharon A.; Lin, Hungyun; Carraher, Deborah C.; Jesson, Michael I.; Tomlinson, Lindsay; Zhan, Yutian; Bobrowski, Walter F.; Bailey, Steven A.; Vogel, W. Mark; Morris, Dale L.; Whiteley, Laurence O.; Davis, John W.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">229-242, 14</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Pancreatic toxicity commonly affects the endocrine or exocrine pancreas.  However, it can also occur at the endocrine-exocrine interface (EEI), where the capillary network of the islet merges with the capillaries of the surrounding acinar tissue, i.e., the insulo-acinar portal system.  The goal of this article is to describe a novel, test article-induced pancreatic toxicity that originated at the EEI and to summarize investigations into the mechanistic basis of the injury.  This injury was initially characterized by light microscopy in 7/14 day-toxicity studies in Sprague-Dawley (Crl: CD[SD]) rats with undisclosed test articles.  Microvascular injury at the interface resulted in peri-islet serum exudation, fibrin deposition, hemorrhage, inflammation, and secondary degeneration/necrosis of surrounding exocrine tissue.  More chronic injury presented as islet fibrosis and lobular atrophy.  Direct cytotoxicity affecting the capillary endothelium at the EEI was confirmed ultrastructurally on day 4.  Endothelial microparticle and blood flow studies further confirmed endothelial involvement.  Similar lesions occurred less frequently in 2 other rat strains and not in the mouse, dog, or cynomolgus macaque.  In summary, in vivo and investigative study data confirmed primary endothelial cytotoxicity in the pathogenesis of this lesion and suggested that the lesion may be rat/rat strain-specific and of uncertain relevance for human safety risk assessment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpXHld_SeCbYrVg90H21EOLACvtfcHk0ljoMbozBNcHiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1OmsrrJ&md5=da42f344ccd6ae6d4d6ed0d58bc12afe</span></div><a href="/servlet/linkout?suffix=cit43a&amp;dbid=16384&amp;doi=10.1177%2F0192623313508851&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623313508851%26sid%3Dliteratum%253Aachs%26aulast%3DBrenneman%26aufirst%3DK.%2BA.%26aulast%3DRamaiah%26aufirst%3DS.%2BK.%26aulast%3DRohde%26aufirst%3DC.%2BM.%26aulast%3DMessing%26aufirst%3DD.%2BM.%26aulast%3DO%25E2%2580%2599Neil%26aufirst%3DS.%2BP.%26aulast%3DGauthier%26aufirst%3DL.%2BM.%26aulast%3DStewart%26aufirst%3DZ.%2BS.%26aulast%3DMantena%26aufirst%3DS.%2BR.%26aulast%3DShevlin%26aufirst%3DK.%2BM.%26aulast%3DLeonard%26aufirst%3DC.%2BG.%26aulast%3DSokolowski%26aufirst%3DS.%2BA.%26aulast%3DLin%26aufirst%3DH.%26aulast%3DCarraher%26aufirst%3DD.%2BC.%26aulast%3DJesson%26aufirst%3DM.%2BI.%26aulast%3DTomlinson%26aufirst%3DL.%26aulast%3DZhan%26aufirst%3DY.%26aulast%3DBobrowski%26aufirst%3DW.%2BF.%26aulast%3DBailey%26aufirst%3DS.%2BA.%26aulast%3DVogel%26aufirst%3DW.%2BM.%26aulast%3DMorris%26aufirst%3DD.%2BL.%26aulast%3DWhiteley%26aufirst%3DL.%2BO.%26aulast%3DDavis%26aufirst%3DJ.%2BW.%26atitle%3DMechanistic%2520investigations%2520of%2520test%2520article%25E2%2580%2593induced%2520pancreatic%2520toxicity%2520at%2520the%2520endocrine%25E2%2580%2593exocrine%2520interface%2520in%2520the%2520rat%26jtitle%3DToxicol.%2520Pathol.%26date%3D2014%26volume%3D42%26spage%3D229%26epage%3D242%26doi%3D10.1177%2F0192623313508851" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit43b"><span><span class="NLM_label">(b) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spolverato, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawlik, T. M.</span></span> <span> </span><span class="NLM_article-title">Long-term therapy with sorafenib is associated with pancreatic atrophy</span>. <i>J. Surg. Res.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>199</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">314</span>– <span class="NLM_lpage">321</span>, <span class="refDoi"> DOI: 10.1016/j.jss.2015.04.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43b&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1016%2Fj.jss.2015.04.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43b&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=26115806" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43b&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtVKmt7nF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=199&publication_year=2015&pages=314-321&issue=2&author=L.+Xuauthor=D.+Zhouauthor=J.+Zhaoauthor=G.+Spolveratoauthor=Y.+Zhangauthor=S.+Liauthor=M.+Chenauthor=T.+M.+Pawlik&title=Long-term+therapy+with+sorafenib+is+associated+with+pancreatic+atrophy&doi=10.1016%2Fj.jss.2015.04.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43bR"><div class="casContent"><span class="casTitleNuber">43b</span><div class="casTitle"><span class="NLM_cas:atitle">Long-term therapy with sorafenib is associated with pancreatic atrophy</span></div><div class="casAuthors">Xu, Li; Zhou, Dong-Sheng; Zhao, Jing; Spolverato, Gaya; Zhang, Yao-Jun; Li, Sheng-Ping; Chen, Min-Shan; Pawlik, Timothy M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Surgical Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">199</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">314-321</span>CODEN:
                <span class="NLM_cas:coden">JSGRA2</span>;
        ISSN:<span class="NLM_cas:issn">0022-4804</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Although the short-term adverse effects of sorafenib are well known, few data exist on long-term toxicity.  The objective of the present study was to investigate the prevalence of pancreatic atrophy among a cohort of patients with hepatocellular carcinoma (HCC) who were treated with sorafenib for ≥2 y.  Between March 2007 and Dec. 2013, 31 patients with HCC who were treated with sorafenib for ≥2 y were identified.  The effect of pancreatic atrophy and enhancement on incidence of adverse events, tumor response, and overall survival (OS) were assessed.  Thirty-one patients with HCC were treated with sorafenib for ≥2 y and met inclusion criteria; 11 patients (35.5%) were Barcelona-clinic liver cancer stage B, whereas 20 patients (64.5%) were Barcelona-clinic liver cancer stage C.  Median duration of treatment with sorafenib was 35.2 mo.  Pancreatic atrophy and a decrease in pancreatic enhancement occurred in 24 patients (77.4%) and 15 patients (48.4%), resp.  On the basis of the modified response evaluation criteria in solid tumors, four patients (12.9%) had a complete response, 10 patients (32.3%) had a partial response, and 17 patients (54.8%) had stable disease.  Patients treated with sorafenib with pancreatic atrophy had a median OS of 49.4 mo (95% confidence interval, 41.2-57.5 mo) compared with 31.2 mo (95% confidence interval, 25.7-36.7 mo) among patients who did not develop pancreatic atrophy (P = 0.009).  In contrast, survival was not assocd. with decreased vs. normal enhancement of the pancreas (OS, 47.7 mo vs. 41.7 mo, resp.; P = 0.739).  Pancreatic atrophy occurred in many HCC patients after 2 y of treatment with sorafenib.  Patients who experienced pancreatic atrophy had a better tumor response and OS.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFi1PX3aL37LVg90H21EOLACvtfcHk0li_RY2yrggLLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtVKmt7nF&md5=ab4757b6bddaa63070a268156f71421c</span></div><a href="/servlet/linkout?suffix=cit43b&amp;dbid=16384&amp;doi=10.1016%2Fj.jss.2015.04.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jss.2015.04.035%26sid%3Dliteratum%253Aachs%26aulast%3DXu%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DSpolverato%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DPawlik%26aufirst%3DT.%2BM.%26atitle%3DLong-term%2520therapy%2520with%2520sorafenib%2520is%2520associated%2520with%2520pancreatic%2520atrophy%26jtitle%3DJ.%2520Surg.%2520Res.%26date%3D2015%26volume%3D199%26issue%3D2%26spage%3D314%26epage%3D321%26doi%3D10.1016%2Fj.jss.2015.04.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit43c"><span><span class="NLM_label">(c) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Erickson, R. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schutt, L. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarrant, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDowell, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewin-Koh, S.-C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hedehus, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carano, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Staflin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Katewa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, W. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dambach, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Misner, D. L.</span></span> <span> </span><span class="NLM_article-title">Bruton’s tyrosine kinase small molecule inhibitors induce a distinct pancreatic toxicity in rats</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>360</i></span>,  <span class="NLM_fpage">226</span>– <span class="NLM_lpage">238</span>, <span class="refDoi"> DOI: 10.1124/jpet.116.236224</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43c&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1124%2Fjpet.116.236224" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43c&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=27821712" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43c&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC2sXptVOjtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=360&publication_year=2017&pages=226-238&author=R.+I.+Ericksonauthor=L.+K.+Schuttauthor=J.+M.+Tarrantauthor=M.+McDowellauthor=L.+Liuauthor=A.+R.+Johnsonauthor=S.-C.+Lewin-Kohauthor=M.+Hedehusauthor=J.+Rossauthor=R.+A.+Caranoauthor=K.+Staflinauthor=F.+Zhongauthor=J.+J.+Crawfordauthor=S.+Zhongauthor=K.+Reifauthor=A.+Katewaauthor=H.+Wongauthor=W.+B.+Youngauthor=D.+M.+Dambachauthor=D.+L.+Misner&title=Bruton%E2%80%99s+tyrosine+kinase+small+molecule+inhibitors+induce+a+distinct+pancreatic+toxicity+in+rats&doi=10.1124%2Fjpet.116.236224"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43cR"><div class="casContent"><span class="casTitleNuber">43c</span><div class="casTitle"><span class="NLM_cas:atitle">Bruton's tyrosine kinase small molecule inhibitors induce a distinct pancreatic toxicity in rats</span></div><div class="casAuthors">Erickson, Rebecca I.; Schutt, Leah K.; Tarrant, Jacqueline M.; McDowell, Michelle; Liu, Lichuan; Johnson, Adam R.; Lewin-Koh, Sock-Cheng; Hedehus, Maj; Ross, Jed; Carano, Richard A. D.; Staflin, Karin; Zhong, Fiona; Crawford, James J.; Zhong, Shelly; Reif, Karin; Katewa, Arna; Wong, Harvey; Young, Wendy B.; Dambach, Donna M.; Misner, Dinah L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">360</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">226-238</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">1521-0103</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) is a member of the Tec family of cytoplasmic tyrosine kinases involved in B-cell and myeloid cell signaling.  Small mol. inhibitors of BTK are being investigated for treatment of several hematol. cancers and autoimmune diseases.  GDC-0853 ((S)-2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4'-bipyridin]-2'-yl)-7,7-dimethyl-3,4,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one) is a selective and reversible oral small-mol. BTK inhibitor in development for the treatment of rheumatoid arthritis and systemic lupus erythematosus.  In Sprague-Dawley (SD) rats, administration of GDC-0853 and other structurally diverse BTK inhibitors for 7 days or longer caused pancreatic lesions consisting of multifocal islet-centered hemorrhage, inflammation, fibrosis, and pigment-laden macrophages with adjacent lobular exocrine acinar cell atrophy, degeneration, and inflammation.  Similar findings were not obsd. in mice or dogs at much higher exposures.  Hemorrhage in the peri-islet vasculature emerged between four and seven daily doses of GDC-0853 and was histol. similar to spontaneously occurring changes in aging SD rats.  This suggests that GDC-0853 could exacerbate a background finding in younger animals.  Glucose homeostasis was dysregulated following a glucose challenge; however, this occurred only after 28 days of administration and was not directly assocd. with onset or severity of pancreatic lesions.  There were no changes in other common serum biomarkers assessing endocrine and exocrine pancreatic function.  Addnl., these lesions were not readily detectable via Doppler ultrasound, computed tomog., or magnetic resonance imaging.  Our results indicate that pancreatic lesions in rats are likely a class effect of BTK inhibitors, which may exacerbate an islet-centered pathol. that is unlikely to be relevant to humans.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgiBmsDhUKIbVg90H21EOLACvtfcHk0li_RY2yrggLLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXptVOjtLo%253D&md5=15b2ef2030ed978d81cec5be5e0a74c8</span></div><a href="/servlet/linkout?suffix=cit43c&amp;dbid=16384&amp;doi=10.1124%2Fjpet.116.236224&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.116.236224%26sid%3Dliteratum%253Aachs%26aulast%3DErickson%26aufirst%3DR.%2BI.%26aulast%3DSchutt%26aufirst%3DL.%2BK.%26aulast%3DTarrant%26aufirst%3DJ.%2BM.%26aulast%3DMcDowell%26aufirst%3DM.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DLewin-Koh%26aufirst%3DS.-C.%26aulast%3DHedehus%26aufirst%3DM.%26aulast%3DRoss%26aufirst%3DJ.%26aulast%3DCarano%26aufirst%3DR.%2BA.%26aulast%3DStaflin%26aufirst%3DK.%26aulast%3DZhong%26aufirst%3DF.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DZhong%26aufirst%3DS.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DKatewa%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DH.%26aulast%3DYoung%26aufirst%3DW.%2BB.%26aulast%3DDambach%26aufirst%3DD.%2BM.%26aulast%3DMisner%26aufirst%3DD.%2BL.%26atitle%3DBruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520small%2520molecule%2520inhibitors%2520induce%2520a%2520distinct%2520pancreatic%2520toxicity%2520in%2520rats%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2017%26volume%3D360%26spage%3D226%26epage%3D238%26doi%3D10.1124%2Fjpet.116.236224" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div>. </div><div class="NLM_citation" id="rightTab-cit43d"><span><span class="NLM_label">(d) </span> <span class="NLM_contrib-group"><span class="NLM_string-name">Bhaskaran, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cornwell, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorden, S. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elwell, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Russell, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritt, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vahle, J. L.</span></span> <span> </span><span class="NLM_article-title">Pancreatic effects of a Bruton’s tyrosine kinase small-molecule inhibitor in rats are strain-dependent</span>. <i>Toxicol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>46</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">460</span>– <span class="NLM_lpage">472</span>, <span class="refDoi"> DOI: 10.1177/0192623318770163</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43d&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1177%2F0192623318770163" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43d&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=29699458" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43d&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1agtrjO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2018&pages=460-472&issue=4&author=M.+Bhaskaranauthor=P.+D.+Cornwellauthor=S.+D.+Sordenauthor=M.+R.+Elwellauthor=N.+R.+Russellauthor=M.+L.+Prittauthor=J.+L.+Vahle&title=Pancreatic+effects+of+a+Bruton%E2%80%99s+tyrosine+kinase+small-molecule+inhibitor+in+rats+are+strain-dependent&doi=10.1177%2F0192623318770163"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43dR"><div class="casContent"><span class="casTitleNuber">43d</span><div class="casTitle"><span class="NLM_cas:atitle">Pancreatic Effects of a Bruton's Tyrosine Kinase Small-molecule Inhibitor in Rats Are Strain-dependent</span></div><div class="casAuthors">Bhaskaran, Manoj; Cornwell, Paul D.; Sorden, Steven D.; Elwell, Michael R.; Russell, Natalie R.; Pritt, Michael L.; Vahle, John L.</div><div class="citationInfo"><span class="NLM_cas:title">Toxicologic Pathology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">460-472</span>CODEN:
                <span class="NLM_cas:coden">TOPADD</span>;
        ISSN:<span class="NLM_cas:issn">0192-6233</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications</span>)
        </div><div class="casAbstract">Inhibitors of Bruton's tyrosine kinase (BTK) are under development as potential therapies for various autoimmune diseases.  In repeat-dose toxicity studies, small-mol. BTK inhibitors (BTKi) have been reported to cause a constellation of histol. effects at the pancreatic endocrine-exocrine interface in male rats; however, similar findings were not reported in other species.  Since the BTKi-induced pancreatic effect is morphol. similar to well-documented spontaneous changes (predominantly characterized by insular/peri-insular hemorrhage, pigment deposition, chronic inflammation, and fibrosis) that are known to vary by rat strain, we investigated potential strain-dependent differences in the pancreatic effects of a small-mol. BTKi, LY3337641.  Following 13 wk of LY3337641 treatment, Crl:CD(SD) rats were most sensitive, Crl:WI(Han) rats were of intermediate sensitivity, and Hsd:SD rats were least sensitive.  These strain differences appear to be related to differences in rate of wt. gain across strains and sexes; however, a definitive mechanism was not detd.  This study demonstrated that BTKi-induced pancreatic effects were highly dependent on rat strain and correlated with differences in the incidence and severity of the spontaneous background change.  When considered with the lack of pancreas effects in nonrat species, these changes in rats are unlikely predictive of similar changes in humans administered a BTK inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqENYhd4tz4wLVg90H21EOLACvtfcHk0li_RY2yrggLLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1agtrjO&md5=fd64740a984a2adacd3debce4dadc335</span></div><a href="/servlet/linkout?suffix=cit43d&amp;dbid=16384&amp;doi=10.1177%2F0192623318770163&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0192623318770163%26sid%3Dliteratum%253Aachs%26aulast%3DBhaskaran%26aufirst%3DM.%26aulast%3DCornwell%26aufirst%3DP.%2BD.%26aulast%3DSorden%26aufirst%3DS.%2BD.%26aulast%3DElwell%26aufirst%3DM.%2BR.%26aulast%3DRussell%26aufirst%3DN.%2BR.%26aulast%3DPritt%26aufirst%3DM.%2BL.%26aulast%3DVahle%26aufirst%3DJ.%2BL.%26atitle%3DPancreatic%2520effects%2520of%2520a%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520small-molecule%2520inhibitor%2520in%2520rats%2520are%2520strain-dependent%26jtitle%3DToxicol.%2520Pathol.%26date%3D2018%26volume%3D46%26issue%3D4%26spage%3D460%26epage%3D472%26doi%3D10.1177%2F0192623318770163" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Paolo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbosa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rong, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, H.</span></span> <span> </span><span class="NLM_article-title">Antiarthritis effect of a novel Bruton’s tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy</span>. <i>J. Pharmacol. Exp. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>338</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">154</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1124/jpet.111.181545</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1124%2Fjpet.111.181545" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=21521773" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosFCiu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=338&publication_year=2011&pages=154-163&issue=1&author=L.+Liuauthor=J.+Di+Paoloauthor=J.+Barbosaauthor=H.+Rongauthor=K.+Reifauthor=H.+Wong&title=Antiarthritis+effect+of+a+novel+Bruton%E2%80%99s+tyrosine+kinase+%28BTK%29+inhibitor+in+rat+collagen-induced+arthritis+and+mechanism-based+pharmacokinetic%2Fpharmacodynamic+modeling%3A+relationships+between+inhibition+of+BTK+phosphorylation+and+efficacy&doi=10.1124%2Fjpet.111.181545"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy</span></div><div class="casAuthors">Liu, Lichuan; Di Paolo, Julie; Barbosa, Jim; Rong, Hong; Reif, Karin; Wong, Harvey</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacology and Experimental Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">338</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">154-163</span>CODEN:
                <span class="NLM_cas:coden">JPETAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3565</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK) plays a crit. role in the development, differentiation, and proliferation of B-lineage cells, making it an attractive target for the treatment of rheumatoid arthritis.  The objective of this study was to evaluate the antiarthritis effect of GDC-0834 [R-N-(3-(6-(4-(1,4-dimethyl-3-oxopiperazin-2-yl)phenylamino)-4-methyl-5-oxo-4,5-dihydropyrazin-2-yl)-2-methylphenyl)-4,5,6,7-tetrahydrobenzo[b]thiophene-2-carboxamide], a potent and selective BTK inhibitor, and characterize the relationship between inhibition of BTK phosphorylation (pBTK) and efficacy.  GDC-0834 inhibited BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochem. and cellular assays, resp., and in vivo IC50 of 1.1 and 5.6 μM in mouse and rat, resp.  Administration of GDC-0834 (30-100 mg/kg) in a rat collagen-induced arthritis (CIA) model resulted in a dose-dependent decrease of ankle swelling and redn. of morphol. pathol.  An integrated disease progression pharmacokinetic/pharmacodynamic model where efficacy is driven by pBTK inhibition was fit to ankle-diam. time-course data.  This model incorporated a transit model to characterize nondrug-related decreases in ankle swelling occurring at later stages of disease progression in CIA rats.  The time course of ankle swelling in vehicle animals was described well by the base model.  Simultaneous fitting of data from vehicle- and GDC-0834-treated groups showed that overall 73% inhibition of pBTK was needed to decrease the rate const. describing the ankle swelling increase (kin) by half.  These findings suggest a high degree of pBTK inhibition is required for maximal activity of the pathway on inflammatory arthritis in rats.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUtceutx0oDrVg90H21EOLACvtfcHk0li9z9cGyaj0Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosFCiu7w%253D&md5=52ec6f33d9fc743036baea87a2d6bce1</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1124%2Fjpet.111.181545&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fjpet.111.181545%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DDi%2BPaolo%26aufirst%3DJ.%26aulast%3DBarbosa%26aufirst%3DJ.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DReif%26aufirst%3DK.%26aulast%3DWong%26aufirst%3DH.%26atitle%3DAntiarthritis%2520effect%2520of%2520a%2520novel%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520%2528BTK%2529%2520inhibitor%2520in%2520rat%2520collagen-induced%2520arthritis%2520and%2520mechanism-based%2520pharmacokinetic%252Fpharmacodynamic%2520modeling%253A%2520relationships%2520between%2520inhibition%2520of%2520BTK%2520phosphorylation%2520and%2520efficacy%26jtitle%3DJ.%2520Pharmacol.%2520Exp.%2520Ther.%26date%3D2011%26volume%3D338%26issue%3D1%26spage%3D154%26epage%3D163%26doi%3D10.1124%2Fjpet.111.181545" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span>SLE:
A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic
(PK), and Pharmacodynamic (PD) Study of BIIB068 in Healthy Participants.
ClinicalTrials.gov Identifier: NCT02829541. <a href="https://clinicaltrials.gov/ct2/show/NCT02829541" class="extLink">https://clinicaltrials.gov/ct2/show/NCT02829541</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=SLE%3A%0AA+Phase+1%2C+Single-Ascending-Dose%2C+Safety%2C+Tolerability%2C+Pharmacokinetic%0A%28PK%29%2C+and+Pharmacodynamic+%28PD%29+Study+of+BIIB068+in+Healthy+Participants.%0AClinicalTrials.gov+Identifier%3A+NCT02829541.+https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02829541."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweblink%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marcotte, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arduini, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hession, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miatkowski, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wildes, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cullen, P. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mertsching, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romanowski, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silvian, L. F.</span></span> <span> </span><span class="NLM_article-title">Structures of human Bruton’s tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases</span>. <i>Protein Sci.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">429</span>– <span class="NLM_lpage">439</span>, <span class="refDoi"> DOI: 10.1002/pro.321</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1002%2Fpro.321" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=20052711" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC3cXisFOhtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2010&pages=429-439&issue=3&author=D.+J.+Marcotteauthor=Y.-T.+Liuauthor=R.+M.+Arduiniauthor=C.+A.+Hessionauthor=K.+Miatkowskiauthor=C.+P.+Wildesauthor=P.+F.+Cullenauthor=V.+Hongauthor=B.+T.+Hopkinsauthor=E.+Mertschingauthor=T.+J.+Jenkinsauthor=M.+J.+Romanowskiauthor=D.+P.+Bakerauthor=L.+F.+Silvian&title=Structures+of+human+Bruton%E2%80%99s+tyrosine+kinase+in+active+and+inactive+conformations+suggest+a+mechanism+of+activation+for+TEC+family+kinases&doi=10.1002%2Fpro.321"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases</span></div><div class="casAuthors">Marcotte, Douglas J.; Liu, Yu-Ting; Arduini, Robert M.; Hession, Catherine A.; Miatkowski, Konrad; Wildes, Craig P.; Cullen, Patrick F.; Hong, Victor; Hopkins, Brian T.; Mertsching, Elisabeth; Jenkins, Tracy J.; Romanowski, Michael J.; Baker, Darren P.; Silvian, Laura F.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Science</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">429-439</span>CODEN:
                <span class="NLM_cas:coden">PRCIEI</span>;
        ISSN:<span class="NLM_cas:issn">1469-896X</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Bruton's tyrosine kinase (BTK), a member of the TEC family of kinases, plays a crucial role in B-cell maturation and mast cell activation.  Although the structures of the unphosphorylated mouse BTK kinase domain and the unphosphorylated and phosphorylated kinase domains of human ITK are known, understanding the kinase selectivity profiles of BTK inhibitors has been hampered by the lack of availability of a high resoln., ligand-bound BTK structure.  Here, we report the crystal structures of the human BTK kinase domain bound to either Dasatinib (BMS-354825) at 1.9 Å resoln. or to 4-amino-5-(4-phenoxyphenyl)-7H-pyrrolospyrimidin-7-yl-cyclopentane at 1.6 Å resoln.  This data provides information relevant to the development of small mol. inhibitors targeting BTK and the TEC family of nonreceptor tyrosine kinases.  Anal. of the structural differences between the TEC and Src families of kinases near the Trp-Glu-Ile motif in the N-terminal region of the kinase domain suggests a mechanism of regulation of the TEC family members.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqBETS8unO82rVg90H21EOLACvtfcHk0li9z9cGyaj0Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXisFOhtbs%253D&md5=8c2dae6949f8bdb627d68ee14edc8d4f</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1002%2Fpro.321&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fpro.321%26sid%3Dliteratum%253Aachs%26aulast%3DMarcotte%26aufirst%3DD.%2BJ.%26aulast%3DLiu%26aufirst%3DY.-T.%26aulast%3DArduini%26aufirst%3DR.%2BM.%26aulast%3DHession%26aufirst%3DC.%2BA.%26aulast%3DMiatkowski%26aufirst%3DK.%26aulast%3DWildes%26aufirst%3DC.%2BP.%26aulast%3DCullen%26aufirst%3DP.%2BF.%26aulast%3DHong%26aufirst%3DV.%26aulast%3DHopkins%26aufirst%3DB.%2BT.%26aulast%3DMertsching%26aufirst%3DE.%26aulast%3DJenkins%26aufirst%3DT.%2BJ.%26aulast%3DRomanowski%26aufirst%3DM.%2BJ.%26aulast%3DBaker%26aufirst%3DD.%2BP.%26aulast%3DSilvian%26aufirst%3DL.%2BF.%26atitle%3DStructures%2520of%2520human%2520Bruton%25E2%2580%2599s%2520tyrosine%2520kinase%2520in%2520active%2520and%2520inactive%2520conformations%2520suggest%2520a%2520mechanism%2520of%2520activation%2520for%2520TEC%2520family%2520kinases%26jtitle%3DProtein%2520Sci.%26date%3D2010%26volume%3D19%26issue%3D3%26spage%3D429%26epage%3D439%26doi%3D10.1002%2Fpro.321" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Adams, P. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Afonine, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bunkóczi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, V. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Echols, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Headd, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hung, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kapral, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grosse-Kunstleve, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCoy, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moriarty, N. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oeffner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Read, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richardson, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terwilliger, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zwart, P. H.</span></span> <span> </span><span class="NLM_article-title">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span>. <i>Acta Crystallogr., Sect. D: Biol. Crystallogr.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>66</i></span>,  <span class="NLM_fpage">213</span>– <span class="NLM_lpage">221</span>, <span class="refDoi"> DOI: 10.1107/S0907444909052925</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=10.1107%2FS0907444909052925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=20124702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=213-221&author=P.+D.+Adamsauthor=P.+V.+Afonineauthor=G.+Bunk%C3%B3cziauthor=V.+B.+Chenauthor=I.+W.+Davisauthor=N.+Echolsauthor=J.+J.+Headdauthor=L.+Hungauthor=G.+J.+Kapralauthor=R.+W.+Grosse-Kunstleveauthor=A.+J.+McCoyauthor=N.+W.+Moriartyauthor=R.+Oeffnerauthor=R.+J.+Readauthor=D.+C.+Richardsonauthor=J.+S.+Richardsonauthor=T.+C.+Terwilligerauthor=P.+H.+Zwart&title=PHENIX%3A+a+comprehensive+Python-based+system+for+macromolecular+structure+solution&doi=10.1107%2FS0907444909052925"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">PHENIX: a comprehensive Python-based system for macromolecular structure solution</span></div><div class="casAuthors">Adams, Paul D.; Afonine, Pavel V.; Bunkoczi, Gabor; Chen, Vincent B.; Davis, Ian W.; Echols, Nathaniel; Headd, Jeffrey J.; Hung, Li Wei; Kapral, Gary J.; Grosse-Kunstleve, Ralf W.; McCoy, Airlie J.; Moriarty, Nigel W.; Oeffner, Robert; Read, Randy J.; Richardson, David C.; Richardson, Jane S.; Terwilliger, Thomas C.; Zwart, Peter H.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">213-221</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">A review.  Macromol. X-ray crystallog. is routinely applied to understand biol. processes at a mol. level.  However, significant time and effort are still required to solve and complete many of these structures because of the need for manual interpretation of complex numerical data using many software packages and the repeated use of interactive three-dimensional graphics.  PHENIX has been developed to provide a comprehensive system for macromol. crystallog. structure soln. with an emphasis on the automation of all procedures.  This has relied on the development of algorithms that minimize or eliminate subjective input, the development of algorithms that automate procedures that are traditionally performed by hand and, finally, the development of a framework that allows a tight integration between the algorithms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpm_HgKRpa-ObVg90H21EOLACvtfcHk0li9z9cGyaj0Xw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1Sisbc%253D&md5=67b439ff4bd61c659cae37ca4209b7bc</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1107%2FS0907444909052925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909052925%26sid%3Dliteratum%253Aachs%26aulast%3DAdams%26aufirst%3DP.%2BD.%26aulast%3DAfonine%26aufirst%3DP.%2BV.%26aulast%3DBunk%25C3%25B3czi%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DV.%2BB.%26aulast%3DDavis%26aufirst%3DI.%2BW.%26aulast%3DEchols%26aufirst%3DN.%26aulast%3DHeadd%26aufirst%3DJ.%2BJ.%26aulast%3DHung%26aufirst%3DL.%26aulast%3DKapral%26aufirst%3DG.%2BJ.%26aulast%3DGrosse-Kunstleve%26aufirst%3DR.%2BW.%26aulast%3DMcCoy%26aufirst%3DA.%2BJ.%26aulast%3DMoriarty%26aufirst%3DN.%2BW.%26aulast%3DOeffner%26aufirst%3DR.%26aulast%3DRead%26aufirst%3DR.%2BJ.%26aulast%3DRichardson%26aufirst%3DD.%2BC.%26aulast%3DRichardson%26aufirst%3DJ.%2BS.%26aulast%3DTerwilliger%26aufirst%3DT.%2BC.%26aulast%3DZwart%26aufirst%3DP.%2BH.%26atitle%3DPHENIX%253A%2520a%2520comprehensive%2520Python-based%2520system%2520for%2520macromolecular%2520structure%2520solution%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%253A%2520Biol.%2520Crystallogr.%26date%3D2010%26volume%3D66%26spage%3D213%26epage%3D221%26doi%3D10.1107%2FS0907444909052925" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VXQ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VXQ','PDB','6VXQ'); return false;">PDB: 6VXQ</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6W06" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6W06','PDB','6W06'); return false;">PDB: 6W06</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6W07" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=6W07','PDB','6W07'); return false;">PDB: 6W07</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i38"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00702">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_63713"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c00702?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c00702</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthetic methods, characterization of key compounds, assay conditions, kinase selectivity data, receptor panel data, BioSeek data, and table of protein crystal data collection and refinement statistics (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00702/suppl_file/jm0c00702_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c00702/suppl_file/jm0c00702_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00702/suppl_file/jm0c00702_si_001.pdf">jm0c00702_si_001.pdf (1.21 MB)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.0c00702/suppl_file/jm0c00702_si_002.csv">jm0c00702_si_002.csv (1.94 kb)</a></li></ul></div></div><span class="author-information-subsection-header">Accession Codes</span><p class="last">Structure data associated with this study have been deposited to the RCSB Protein Data Bank (<a href="http://www.rcsb.org" class="extLink">http://www.rcsb.org</a>) and can be accessed with the following codes: BTK bound to <b>1</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6W07">6W07</a>, to <b>5</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6VXQ">6VXQ</a>, and to <b>6</b> is <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=6W06">6W06</a>. Authors will release the atomic coordinates and experimental data upon article publication.</p><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.0c00702&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.0c00702%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-21" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.0c00702" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                5MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-b425991822a79ada59b3.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-fb88834b824b41b135ad.js"></script>

<script type="text/javascript" src="/wro/ke1q~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"66797d2f3a2f1252","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.6.0","si":10}'></script>
</body>
</html>
